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Abstract
A small fraction of mammalian genes exhibit parent-of-origin specific monoallelic 
expression. They are expressed from only one allele and this is determined by 
modifications established in the germline. Approximately 100 imprinted genes 
have been identified to date. Most imprinted genes are located in discrete 
clusters and are controlled by shared regulatory elements. Imprinted genes play 
important roles in regulating embryonic and placental development, with overt 
growth phenotypes resulting both from loss of expression and from over­
expression of imprinted genes.
The maternally expressed Phlda2 gene has been implicated in placental 
development. Loss of expression leads to placentomegaly as a consequence of 
the disproportionate expansion of the spongiotrophoblast layer. In this study, the 
consequences of over-expressing Phlda2 and the adjacent Slc22a18 were 
investigated in four independent lines of transgenic mice driving incrementally 
increasing doses of the two genes and on two genetic backgrounds. In all cases, 
transgenic placentae were significantly lighter throughout gestation, which was 
entirely due to a reduction in the spongiotrophoblast layer. There was also a 
reduction in glycogen staining and a progressive mislocalisation of cells from the 
spongiotrophoblast layer. These phenotypes were essentially restored by 
restored by normalising Phlda2 gene dosage in a single copy line.
In addition, transgenic embryos were significantly lighter than wild type 
littermates from E16.5 onwards and were born 13% lighter. These embryos were 
asymmetrically growth restricted and displayed rapid post-natal catch up growth 
within two weeks of birth. Adult transgenic females that had undergone 
embryonic growth restriction also displayed increased adiposity and reduced 
glucose tolerance at one year of age. These data suggest that altered expression 
of Phlda2 and possibly Slc22a18 drive IUGR and program adult disease 
susceptibility. Recent human studies have found an association between 
elevated placental PHLDA2 and low birth weight or IUGR infants. This mouse 
model may thus provide a genetic tool that recapitulates a known human 
condition for further investigation of the fetal programming of metabolic 
syndrome.
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Chapter 1: 
General Introduction
1
1.1 Gene expression and genomic imprinting
Diploid animals possess two homologous copies of each autosomal 
chromosome, inheriting an entire haploid set from each parent at fertilisation. 
Autosomal genes are thus represented by two alleles, which can both be 
transcriptionally active for most genes (reviewed in Watanabe and Barlow 1996). 
Such biallelic expression from a diploid genome is proposed to be advantageous 
by protecting against the potential consequences of genetic mutations (Orr 1995; 
Otto and Goldstein 1992). Haploid organisms possess a single copy of each 
gene, with mutations potentially resulting in the complete loss of functional gene 
product. In a diploid organism, the same mutation will generally result in only a 
reduction in the amount of functional gene product, with the homologous allele 
remaining functional.
Despite the benefit of possessing two actively expressed alleles for each 
gene, several types of mammalian genes are expressed from only one allele, 
with the other allele rendered inactive (reviewed in Goldmit and Bergman 2004). 
Such monoallelically-expressed genes can be classified according to the 
mechanisms involved in their regulation. The most extensively studied of these is 
X-inactivation, which results in the random inactivation of an entire X- 
chromosome in somatic cells of females (reviewed in Avner and Heard 2001; 
Lyon 1961). This dosage compensation ensures that the expression level of X- 
linked genes is comparable between males and females, which possess only one 
X chromosome. Another mechanism that results in monoallelic expression is 
termed “random allelic exclusion”. This method is important for ensuring the 
expression of a single cell surface receptor molecule in B-lymphocytes. Allelic 
exclusion has also been observed in the regulation of odorant receptor 
expression in olfactory neurones for a similar reason (Chess et al. 1994; 
Corcoran 2005; Efstratiadis 1995; Mostoslavsky et al. 2004). A third mechanism 
associated with monoallelic gene expression is “genomic imprinting”. This 
describes the expression of imprinted genes in a parent-of-origin specific manner 
(see Fig 1.1) (Surani et al. 1984). The activity of a particular imprinted gene is 
always inherited through the same germline. For example, the gene encoding 
insulin-like growth factor 2 (Igf2) is expressed from the paternally inherited allele 
in both mice and humans (DeChiara et al. 1991).
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Imprinted genes are often defined as genes that exhibit parent-of-origin 
specific, monoallelic expression (Ferguson-Smith and Surani 2001; Mochizuki et 
al. 1996; Pfeifer 2000; Reik and Walter 2001b). However, some imprinted genes 
do not exhibit the strict monoallelic expression pattern suggested by this 
definition, and instead display preferential allelic expression (Schulz et al. 2006). 
A recent review of the literature concluded that of 27 maternally expressed 
imprinted genes, 21 displayed preferential expression of the maternal allele, 
whereas 18 of 23 paternally expressed genes exhibit strict monoallelic 
expression (Khatib 2007). Furthermore, some imprinted genes are expressed 
monoallelically in all cell types, whereas others exhibit monoallelic expression in 
only a subset of tissues. For instance, the gene encoding the mouse insulin-like 
growth factor 2 receptor (Igf2r) exhibits monoallelic expression in peripheral 
tissues, such as liver and kidney, but is expressed biallelically in the central 
nervous system (CNS) (Hu et al. 1998). Thus an imprinted gene is more 
accurately defined as a gene that exhibits differential expression of parental 
alleles in one or more tissues (Moore 2001).
Monoallelic expression of imprinted genes eliminates the protection 
afforded by the presence of two active alleles. Deletions affecting the active allele 
of an imprinted gene are often associated with human disease. The human 
neurological disorders Prader-Willi syndrome (PWS) and Angelman syndrome 
(AS) are characterised by distinct clinical symptoms, but are both associated with 
deletion of the chromosomal region 15q11-13. This region contains several 
imprinted genes, including the paternally expressed SNRPN and NDN  and the 
maternally expressed UBE3A (reviewed in Glenn et al. 1997). Paternal 
inheritance of the q11 -13 deletion can cause PWS implicating loss of SNRPN 
and NDN  in PWS (Jay et al. 1997; Ozcelik et al. 1992). Inheriting the deletion on 
the maternally inherited chromosome is causative of AS implicating loss of 
UBE3A expression in AS (Kishino et al. 1997; Knoll et al. 1989; Nicholls et al. 
1989). Loss of imprinting (LOI) is also associated with human disease, and is 
particularly prevalent in various cancers (reviewed in Falls et al. 1999; Jelinic and 
Shaw 2007; Lalande 1997; and Rainier et al. 1993).
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Figure 1.1: Inheritance and expression of biallelic and imprinted genes
Imprinted genes are inherited in accordance with the rules of Mendelian 
genetics, with one allele inherited from each parent. Expression of imprinted 
genes however does not conform to the rules of Mendelian genetics, with 
one parental allele exhibiting preferential expression over the other. 
Expression of most autosomal genes is biallelic; both alleles are transcribed 
equally (green). Imprinted genes however, are expressed in a parent-of- 
origin dependent manner, with preferential expression resulting from either 
the paternal allele (blue) (e.g. Igf2) or the maternal allele (red) (e.g. Igf2r).
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In contrast to X-inactivation in embryonic cells and allelic exclusion, in 
which the repressed allele is randomly selected, imprinting is a parent-of-origin 
specific process, with the actively expressed allele expressed from only the 
maternal or paternal chromosome. This method of gene regulation requires an 
“imprint”, by which the parental origin of each allele is identified. The differential 
methylation of a transgene arising from passage through the paternal and 
maternal germline in mice suggested a role for DNA methylation in the imprinting 
process (Hadchouel et al. 1987; Reik et al. 1987; Sapienza et al. 1987; Swain et 
al. 1987). This role was subsequently confirmed in mice deficient for DNA 
methyltransferase, which exhibit LOI of several genes due to a lack of CpG 
dinucleotide methylation (Hata et al. 2002; Kaneda et al. 2004; Li et al. 1993; 
Okano et al. 1999).
Imprinted loci acquire methylation on passage through either the maternal 
or paternal germline, generating differentially methylated regions (DMRs), which 
are now a recognised characteristic of imprinted genes (Constancia et al. 1998; 
Mann 2001; Smith et al. 2003). The maternal genome acquires the majority of 
imprinting-associated methylation, although this does not necessarily correspond 
with gene repression (Delaval and Feil 2004; Reik and Walter 2001a, b). The 
methylation of imprinted genes acts to mark the parental alleles in the germline 
(Surani 1998). The “interpretation” of this imprint is performed by more complex 
mechanisms, which include histone modifications and additional DNA methylation 
that ensures differential allelic expression (reviewed in Reik and Walter 2001b; 
and Surani 1998).
The methylation imprint is established in the germline (Tucker et al. 1996), 
the time at which the two parental genomes exist in isolation, enabling a 
differential methylation pattern to be established. Methylated regions are 
established by members of the Dnmt3 family of methyltransferases (Kato et al.
2007), including Dnmt3a (Kaneda et al. 2004), Dnmt3b (Okano et al. 1999) and 
Dnmt3l (Hata et al. 2002). These methylation marks must be maintained through 
successive cycles of cell division in somatic cells, and during the global 
demethylation of the parental genomes following fertilisation. This imprint 
maintenance is performed by the methyltransferase Dnmtl (Branco et al. 2008; Li 
et al. 1993), which specifically recognises and methylates the newly synthesised 
strand during DNA replication (Bestor 2000; Branco et al. 2008; Hirasawa et al.
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2008). Methylation of imprinted loci is erased in the germline and re-established 
according to the individual’s sex, thus completing a cycle of establishment, 
maintenance, erasure and re-establishment, as depicted in Fig 1.2 (reviewed in 
Constancia et al. 1998; Reik et al. 2001; and Szabo and Mann 1995).
Maintenance of ^  
imprint in 
somatic cells
Establishment of 
appropriate imprint
c? /  \  Z
or
Fertilisation
Development to adult
/
Erasure of 
imprint in 
germline
Figure 1.2: Dynamic imprinting
Imprinted genes are identified by differential methylation of the two parental 
alleles established in the germline. This pattern of methylation is maintained 
in somatic cells by the DNA methyltransferase Dnmtl. In subsequent 
generations, the imprint is erased in germline cells prior to re-establishment 
of the appropriate methylation mark according to the sex of the individual. At 
fertilisation, two haploid genomes with the appropriate methylation marks 
combine to give a diploid genome, with the correct dosage of imprinted 
genes. Blue = paternally active, red = maternally active, grey = inactive allele.
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1.2 Parthenogenesis and genomic imprinting
Genomic imprinting was first identified in the early 1980s from investigations into 
the failure of parthenogenesis (embryogenesis of an unfertilised oocyte) in mice 
(Mann and Lovell-Badge 1984; McGrath and Solter 1984; Surani et al. 1984). 
Parthenogenetic reproduction is common in invertebrates, occurs more rarely in 
vertebrate species such as reptiles, birds and fish, yet has not been reported to 
occur naturally in mammals (Chapman et al. 2007; Kaufman et al. 1977; Rougier 
and Werb 2001; Watts et al. 2006). Mouse oocytes in which embryogenesis was 
experimentally induced were not viable. These parthenogenetic embryos 
generally died soon after implantation at embryonic day 4.5 (E4.5), although a 
few developed to the 25-somite stage (~E10.5). Parthenogenetic embryos that 
survived to these advanced developmental stages appeared growth restricted but 
otherwise relatively normal, in contrast to extraembryonic development, which 
was severely restricted and disorganised (Kaufman et al. 1977; Sturm et al. 1994; 
Tarkowski etal. 1970).
The failure of parthenogenetic embryos to survive to term was initially 
suggested to be due to either the absence of a cytoplasmic contribution from 
sperm or a consequence of homozygosity of recessive lethal mutations resulting 
in the uniparental genome (Graham 1974). The need for a cytoplasmic 
contribution from sperm was excluded following the generation of viable embryos 
from normal genetic material transplanted into enucleated parthenogenetic eggs 
(Mann and Lovell-Badge 1984; Surani et al. 1984). Furthermore, Surani and 
colleagues reported that haploid parthenogenetic eggs that receive a second 
female pronucleus fail to develop to term, whereas those that received a male 
pronucleus were viable (Surani et al. 1984). The viability of a heterozygous bi- 
parental genome compared with the developmental failure of a uniparental 
heterozygous maternal genome led to the conclusion that the both parental 
genomes are essential for embryonic development (Surani et al. 1984). Support 
for this came from the observation that androgenetic conceptuses, consisting of 
two paternal genomes, also fail to support normal embryogenesis (Barton et al. 
1984; McGrath and Solter 1984)
Gynogenetic and parthenogenetic embryos exhibit a similar fate, 
generating relatively normal, albeit growth restricted embryos that die soon after
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implantation, with approximately 20% surviving until around E10.5. The 
associated extraembryonic tissue is almost non-existent, and may be a 
contributing factor to embryonic lethality. Androgenetic embryos exhibit a 
contrasting phenotype with severe developmental retardation of the embryo and 
death at around E8.5, with an abundance hyperplastic extraembryonic tissue 
(Barton et al. 1984; Kaufman et al. 1977; McGrath and Solter 1984; Surani et al. 
1986). Gynogenetic, parthenogenetic and androgenetic embryogenesis is 
summarised in Table 1.1. The reciprocal phenotypes associated with 
gynogenetic/parthenogenetic and androgenetic conceptuses suggested 
complementary roles for the two parental genomes in the development of the 
embryo and placenta. These non-equivalent functions of the parental genomes 
were proposed to be the result of genomic imprinting, whereby specific genes are 
expressed from only one parental genome (Surani et al. 1984). This theory was 
confirmed by the findings that both Igf2 and Igf2r exhibit parental specific patterns 
of expression in the mouse. The paternally expressed Igf2 gene encodes a 
potent growth-promoting factor (DeChiara et al. 1990), whereas the maternally 
expressed Igf2r gene encodes a receptor that binds and sequesters Igf2, thus 
acting in a growth inhibitory role (Barlow et al. 1991). In uniparental embryos, 
imprinted gene expression is disrupted such that some genes are expressed at 
twice the normal level whereas others are not expressed at all. For example, in 
androgenetic embryos, the paternally expressed Igf2 gene is expressed at two­
fold normal levels, whereas expression of the maternally expressed Igf2r is 
completely ablated (Walsh et al. 1994).
The substantial extraembryonic tissue development in androgenetic 
embryos suggested that genes required for placental development were 
expressed only from the paternal genome, whereas those controlling stages of 
embryonic development were expressed from the maternal genome (Barton et al. 
1984). Later experiments using chimeric mice generated from a mixture of 
parthenogenetic/gynogenetic and androgenetic cells revealed a striking pattern of 
segregation of the two cell types, with trophoblast tissue tending to consist of 
androgenetic cells and the embryo being formed largely from 
parthenogenetic/gynogenetic cells (Surani et al. 1987; Thomson and Solter 
1988). Such chimeras still failed to survive to term indicating that there was an 
incomplete complement of gene expression, and that some placental-specific
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genes are maternally expressed and some embryo-specific genes are paternally
expressed.
Genomic
content
Embryonic
development
Placental
development
Parthenogenetic
Two maternal 
genomes 
(homozygous)
Growth retarded 
Death by -E10.5
Poor
Gynogenetic
Two maternal 
genomes 
(heterozygous)
Growth retarded 
Death by ~E10.5
Poor
Androgenetic
Two paternal 
genomes 
(heterozygous)
Disorganised 
Death by ~E8.5
Hyperplastic
Table 1.1: Developmental phenotypes of parthenogenetic, gynogenetic and
androgenetic conceptuses
Development of the embryo is relatively normal, although delayed where two 
maternal genomes are present; extraembryonic development is severely 
disrupted. In androgenetic conceptuses, extraembryonic tissue develops 
relatively normally, however embryonic development is severely affected.
The creation of a parthenogenetic mouse that survived to adulthood and 
gave birth to viable offspring was recently reported. However, this was only 
achieved following genetic manipulation to yield monoallelic expression of the 
H19 domain (Kono et al. 2004; Kono et al. 2002). Correct dosage of the growth 
factor Igf2 thus appears to be at least one critical factor for successful 
embryogenesis. Furthermore, only two of nearly 400 such conceptuses that were 
implanted survived, with one yielding viable offspring, indicating that expression 
levels of other imprinted genes may also be a factor in determining embryonic 
survival (Kono 2006; Kono et al. 2004). Normalised expression of several 
imprinted genes independent of the H19 region was observed in these 
parthenogenetic embryos. The authors postulate that corrected expression of the 
maternally expressed Meg3 (Dlk2) and the paternally expressed DJk1 genes in 
some parthenogenetic conceptuses may contribute to enhanced viability. 
However, it remains unclear how expression of these unrelated genes is 
normalised in such parthenogenetic conceptuses (Kono et al. 2004).
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1.3 Imprinted gene clusters and their regulation
The reciprocal growth phenotypes of gynogenetic/parthenogenetic and 
androgenetic embryos revealed that the two parental genomes perform 
complementary roles during development potentially as a consequence of 
parental imprinting of the genome (Surani et al. 1984). The initial nuclear 
transplantation experiments however did not yield any indication as to the extent 
or location of imprinting in the genome. Phenotypes observed in mice with 
maternal or paternal duplication (MatDp or PatDp respectively) of specific 
chromosomal regions, led to the identification of a number of imprinted regions in 
mice. Conceptuses with MatDp or PatDp for chromosomal regions including 2, 6, 
7, 11 and 17 resulted in embryonic and/or placental growth defects, indicating 
parental imprinting of these regions (Cattanach and Beechey 1990). For instance, 
MatDp of mouse distal chromosome 7 results in small placentae and growth 
restricted embryos that die at ~E16.5 (Searle and Beechey 1990). PatDp of the 
same region is associated with loss of the spongiotrophoblast layer from the 
placenta and embryonic death at approximately E10.5 (McLaughlin et al. 1996; 
Searle and Beechey 1990). In contrast, conceptuses with MatDp or PatDp of 
chromosomes 1,4,  5, 9, 13, 14 or 15 are phenotypically normal, suggesting the 
absence of imprinting of these chromosomes (Cattanach and Kirk 1985).
The first imprinted genes to be described were discovered from the 
phenotypic analysis of knockout mouse models. The growth deficiency 
associated with paternal transmission of an Igf2 null allele was not observed 
when this same allele was transmitted through the maternal germline (DeChiara 
et al. 1990; DeChiara et al. 1991). Likewise, the embryonic lethality associated 
with maternal deletion of Igf2r was not observed in embryos with a paternal 
deletion of this gene (Barlow et al. 1991). Analysis of mouse uniparental disomy 
(UPD) phenotypes led to the identification of 11 imprinted regions located on 
seven chromosomes in the mouse (reviewed in Cattanach and Beechey 1997; 
Cattanach and Kirk 1985). However, identification of imprinted genes in this 
manner assumes that inheritance of both copies of an imprinted gene from one 
parent will yield overt embryonic or placental defects. Further to the analysis of 
UPD growth phenotypes, additional approaches have been undertaken to identify 
imprinted genes within the genome (reviewed in Maeda and Hayashizaki 2006;
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Oakey and Beechey 2002; and Peters and Beechey 2004). One such approach 
is to specifically search for DMRs, which are often associated with imprinted 
regions (reviewed in Constancia et al. 1998). The paternally expressed genes 
Nap1l5, Peg13 and Slc38a4 were identified utilising this technique (Smith et al.
2003). Another approach is to compare the expression profiles of PatDp and 
MatDp tissue by “subtraction hybridisation”. The expression of a maternally 
expressed gene would be two-fold wild type levels in MatDp and completely lost 
in PatDp, whereas the opposite would be true for paternally expressed genes. 
Biallelically expressed genes would show no change in expression levels. 
Several imprinted genes have been identified in this way, including the paternally 
expressed genes Peg1 and Peg5 and the maternally expressed Grb10 (Kagitani 
et al. 1997; Kaneko-lshino et al. 1995; Miyoshi et al. 1998). A similar approach 
utilising microarray analysis of uniparental disomies identified imprinted 
expression of Dhcr7, Th and Ampd3 in the mouse placenta (Schulz etal. 2006).
To date, imprinted genes have been identified on twelve different 
chromosomes in the mouse, including chromosomes 9, 14 and 15, which did not 
result in growth phenotypes when inherited from only one parent (Cattanach and 
Kirk 1985). The position of imprinted genes identified through a variety of 
approaches have been collated to generate an “imprinting map” of the mouse 
genome, depicting the chromosomal location of all known imprinted genes (see 
Fig 1.3) (Cattanach et al. 2004; Cattanach and Kirk 1985). A total of 
approximately 100 imprinted genes have been identified to date, of which 
approximately one quarter are non-coding RNA molecules (ncRNA) (Morison et 
al. 2005; Peters and Beechey 2004). Estimates for the total number of imprinted 
genes range from around 100 to over 600, with the most realistic expectations 
generally considered to be at the lower end of this range (Barlow 1995; Luedi et 
al. 2005; Morison et al. 2005; Wang et al. 2008).
The imprinting map revealed a tendency for imprinted genes to localise in 
discrete clusters within the genome. Approximately 80% of imprinted genes are 
physically linked in these “imprinted regions” or “imprinted domains” (Reik and 
Walter 2001b), three of which are located on mouse chromosome 7 (see Fig 1.3). 
The clustered organisation of imprinted genes suggested the co-ordinated control 
of imprinted expression. Investigations using mouse models demonstrate that c/s- 
acting sequences known as imprinting control regions (ICRs) or imprinting
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centres (ICs) establish domain-wide allele-specific gene expression (Edwards 
and Ferguson-Smith 2007; Lewis and Reik 2006; Spahn and Barlow 2003). ICs 
acquire germline-specific DNA methylation, with mutation or deletion of these 
regions resulting in LOI of surrounding genes (Lewis and Reik 2006).
Imprinted clusters generally consist of a number of protein-coding genes in 
addition to at least one ncRNA gene (Edwards and Ferguson-Smith 2007; Pauler 
et al. 2007). The ncRNA is generally expressed from the domain on which the 1C 
is unmethylated, whereas the protein-coding genes tend to be expressed from 
the domain on which the 1C is methylated (O'Neill 2005; Pauler and Barlow 2006; 
Pauler et al. 2007; Spahn and Barlow 2003). In contrast to situations such as the 
direct silencing of transposable elements by DNA methylation (Bird 1992), 
imprinted gene repression is instead often associated with transcription of the 
ncRNA molecule in c/'s. Indeed, two mechanisms have been described that are 
involved in the control of imprinted domains. One mechanism involves the 
expression of the ncRNA transcript from one parental allele, which acts in cis to 
prevent the expression of adjacent imprinted genes. Methylation of the other 
parental allele silences expression of the ncRNA, thus permitting expression of 
the protein-coding genes (reviewed in O'Neill 2005). The “insulator” or “enhancer 
blocking” mechanism involves competition for shared enhancer sequences, and 
is exemplified by the Igf2/H19 locus. Binding of the zinc-finger protein CTCF to 
the unmethylated maternal allele prevents interaction of the Igf2 promoter with
the downstream enhancer, thus repressing the maternal Igf2 allele. Methylation
of the paternal allele prevents CTCF binding and thus enables Igf2 to interact 
with the promoter (see section 1.7.1 for further detail).
The genetic organisation of imprinted domains is generally well conserved 
between humans and mice, however the imprinting status of some genes is not 
always maintained between the species (Khatib et al. 2007; Morison et al. 2005). 
For instance, the organisation of mouse distal 7 and the syntenic human region
on chromosome 11 p15.5 are generally well conserved, with most genes
exhibiting the same pattern of imprinting in both species (Paulsen et al. 1998; 
Paulsen et al. 2000). Two genes for which imprinting is not conserved are 
Tssc4/TSSC4, which is imprinted in the mouse but not human, and 
Ltrpc5/LTRPC5, which is imprinted in human but not mouse (Paulsen et al. 
2000).
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Figure 1.3: Mouse imprinting map
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1.4 Imprinted genes in growth and development
The developmental abnormalities associated with gynogenetic, parthenogenetic 
and androgenetic conceptuses clearly demonstrated a role for imprinted genes in 
the regulation of growth and development of the embryo and placenta. Indeed, 
the majority of protein coding imprinted genes for which a function has been 
assigned are expressed in the embryo and/or the placenta (reviewed in Coan et 
al. 2005a; Isles and Holland 2005; Morison and Reeve 1998; Reik et al. 2003; 
and Tycko and Morison 2002). However, imprinted genes have recently been 
identified that are involved in neonatal growth, namely the maternally expressed 
Gnas and Atp10a and the paternally expressed Gnasxl and Rasgrfl (Dhar et al. 
2004; Font de Mora et al. 2003; Xie et al. 2006; Yu et al. 2000).
In mice, the majority of imprinted genes are expressed in the placenta 
where they sometimes exhibit a more stringent pattern of allele-specific 
expression compared to embryonic tissues (Coan et al. 2005a; Tycko 2006). 
Imprinted genes are involved in numerous aspects of placental development and 
function, including the regulation trophoblast differentiation and nutrient transfer 
(reviewed in Coan et al. 2005a). Most imprinted genes that act in the placenta 
control aspects of placental development, for instance the maternally expressed 
Ascl2 (achaete-scute complex homolog 2; formerly Mash2) is essential for the 
differentiation of spongiotrophoblast cells. Interestingly, loss of the paternally 
expressed Peg10 also causes a loss of spongiotrophoblast although giant cell 
number was unaffected; Peg10 null embryos die by E10.5 (Ono et al. 2006). 
Additionally, some placental nutrient transporters are encoded by imprinted 
genes, including the maternally expressed Slc22a18 (Dao et al. 1998), Slc22a2 
and Slc22a3 (Zwart et al. 2001), and the paternally expressed Slc38a4 (Smith et 
al. 2003).
Some imprinted genes are expressed in both embryo and placenta, with 
the reciprocally imprinted Igf2 and Igf2r genes representing classic examples. 
The paternally expressed lgf2 is essential for embryonic and placental 
development, with paternal inheritance of an lgf2 null allele resulting in small 
placenta and growth-retarded offspring, which are viable and remain small into 
adulthood (Baker et al. 1993; DeChiara et al. 1990). The maternally expressed 
Igf2r encodes a signalling antagonist to Igf2; maternal inheritance of a mutant
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Igf2r allele causes fetal overgrowth and early post-natal lethality due to cardiac 
defects (Lau etal. 1994).
Further to the finding that imprinted genes affect neonatal growth; a 
recently emerging field is the discovery that some imprinted genes affect the 
behaviour of the mother and/or offspring in the neo-natal period. For instance 
mutation of the paternally expressed gene Peg3 adversely affects suckling in 
pups and the maternal care exhibited by these animals in adulthood (Curley et al.
2004). The maternally expressed imprinted gene Nesp has also been implicated 
in affecting behavioural traits. Nesp deficient mice display increased exploratory 
behaviour when exposed to a novel environment, although this effect is 
diminished following acclimatisation of the animal to the environment (Plagge et 
al. 2005).
Imprinted genes in humans perform similar functions in regulating 
embryonic and placental development, with aberrant expression or mutation of 
imprinted genes associated with a variety of growth abnormalities, including 
Beckwith-Wiedemann Syndrome (BWS) (Hatada et al. 1996), PWS/AS (Jay et al. 
1997; Knoll et al. 1989; Nicholls et al. 1989; Ozcelik et al. 1992), Silver-Russell 
Syndrome (Yoshihashi et al. 2000) and cancer (Rainier et al. 1993). Mouse 
models have been generated for a number of these diseases by targeting the 
gene(s) concerned, giving rise to similar phenotypes to the human conditions, 
and supporting a role for imprinted genes in human disease. For instance, many 
of the characteristics of human BWS patients are recapitulated in a mouse model 
possessing a Cdknlc null allele in addition to LOI of Igf2 (Caspary etal. 1999).
1.5 The evolution of imprinting
In the context of this investigation, genomic imprinting refers to the parent-of- 
origin specific monoallelic expression of specific autosomal genes. However, the 
term has historically been used in reference to similar regulatory mechanisms in 
a variety of species. Genomic imprinting was first used to describe the parent-of- 
origin specific elimination of sex chromosomes in the insect species Sciara 
(Crouse 1960). The term was subsequently used to describe the epigenetic 
silencing of the entire paternal genome in male mealybugs, thus apparently 
fulfilling a role in sex determination (Brown and Nur 1964). Parent-of-origin 
dependent phenotypes have also been observed in plants; for instance, differing
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pigmentation patterns in maize depend upon the parental inheritance of a 
particular allele (Kermicle 1970). Imprinted genes are also expressed during 
endosperm development in some flowering plant species (Kinoshita et al. 1999; 
Vinkenoog et al. 2003). In animals, imprinted genes are observed in placental 
mammals (eutheria and marsupials), but not in monotremes or invertebrate 
species (John and Surani 2000). Interestingly, in addition to the imprinting of 
autosomal genes, the X chromosome is imprinted in the extraembryonic tissue of 
mice with the paternally inherited X chromosome preferentially inactivated 
(Takagi and Sasaki 1975; West et al. 1977).
The evolution of imprinting has occurred independently in plants and 
animals, although similar mechanisms of gene regulation are observed, thus 
representing a case of convergent evolution (Feil and Berger 2007). The 
selection of monoallelic expression over biallelic expression, and the parental- 
specific allele expression of imprinted genes has generated much debate, and 
the development of a number of theories attempting to explain the evolution of 
imprinting in mammals (reviewed in Hurst 1997; Hurst and McVean 1998), some 
of which are discussed below.
1.5.1 Ovarian time-bomb hypothesis
Imprinted genes represent the primary preventative factor of parthenogenetic 
development in mammals (Kono 2006). The “ovarian time-bomb hypothesis” 
purports that this was the driving force of imprinting, suggesting that imprinting 
arose as a mechanism to prevent unfertilised oocytes from implanting and 
developing into malignant trophoblast disease (Varmuza and Mann 1994).
Benign ovarian tumours resulting from parthenogenetically activated 
oocytes occur in around 1-2% of women, whereas germ-cell derived testicular 
cancer in males occurs at a rate approximately 1000-fold lower (Varmuza and 
Mann 1994). Trophoblast is an inherently invasive tissue type, and this level of 
spontaneous tumour development could have potentially serious consequences 
for the reproductive success and survival of an individual. The authors proposed 
that ovarian tumours are prevented from becoming invasive by imprinting and 
silencing of specific genes that promote trophoblast proliferation and invasion 
(Varmuza and Mann 1994). Consequently, maternally expressed imprinted genes 
would tend to restrict extraembryonic tissue growth, with genes promoting growth
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and invasion of the placenta expressed only from the paternal genome. Support 
for this theory is provided by phenotypic characterisation of complete 
hydatidiform molar pregnancies. Such conceptuses result from fertilisation of an 
enucleated egg and duplication of the paternal genome, and thus are entirely 
androgenetic in origin. The result is the development of a large mass of 
potentially highly invasive extraembryonic tissue (Kajii and Ohama 1977). In 
contrast, partial hydatidiform moles, which contain an additional maternal genetic 
contribution, exhibit some embryonic development with generally less invasive 
extraembryonic tissue (Devriendt 2005; Lawler et al. 1982). Furthermore, 
parthenogenetic reproduction and genomic imprinting are phylogentically 
mutually exclusive, as discussed in Section 1.2. The ovarian time-bomb 
hypothesis does not offer an explanation for either the presence of imprinting in 
the male genome, or the imprinting of genes that are not involved in trophoblast 
development, suggesting instead that such genes are “bystanders” of the 
imprinting mechanism (Varmuza and Mann 1994), and has been largely rejected 
as a consequence (Haig 1994; Moore 1994; Solter 1994).
1.5.2 Adaptation of host defence
Approximately half of the human genome is thought to have arisen from the 
insertion of transposable elements, the majority of which are no longer active 
(Lander et al. 2001). Integration of such transposable elements poses significant 
risk to the host organism, occasionally through the effect of integration into 
endogenous genes, but primarily due to the effect of the translated gene-product 
(reviewed in Yoder et al. 1997). The mammalian genome protects itself by 
inactivating these transposable elements by methylation and chromatin 
modifications (Birchler et al. 2000; Yoder et al. 1997) - the same mechanisms 
that control expression of imprinted genes (Li et al. 1993). The common usage of 
methylation and chromatin remodelling in these two processes led some to 
predict that imprinting of some genes evolved as a consequence of these host 
defence mechanisms (Barlow 1993; Ono et al. 2001). Although some imprinted 
genes exhibit retrotransposon-like features, for instance Peg10 (Ono et at. 2001), 
many other imprinted genes bear no resemblance to transposable DNA 
sequences, although the presence of such sequences within non-coding regions 
of imprinted domains cannot be excluded.
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1.6.4 Placentation hypothesis
Mammals are divided into three broad groups: monotremes, marsupials and 
eutheria. Monotremes are egg-laying mammals, whereas marsupials and 
eutheria (collectively referred to as theria) are viviparous, giving birth to live, well- 
developed young. Therians diverged from monotreme ancestors approximately 
170 million years ago, whereas eutheria diverged from marsupials around 150 
million years ago (Figure 1.4) (Bininda-Emonds et al. 2007). The viviparous 
reproduction exhibited by the two groups of therian mammals is possible due to 
the appearance of the placenta around the time of divergence from monotremes. 
Although they share a common placental ancestor, the eutherian and marsupial 
placentae subsequently evolved independently. Marsupials have a relatively non- 
invasive placenta, which supports only short gestation periods, with gestation 
completed in the pouch. In contrast, eutherian mammals generally possess more 
advanced and invasive placental structures, and thus can support longer 
gestation periods, allowing the birth of more advanced young (reviewed in John 
and Surani 2000).
Genomic imprinting emerged in the same evolutionary time-period as 
placentation. Over 100 imprinted genes have been identified in eutheria, the 
majority of which are expressed in the placenta. A subset of which are also 
imprinted in marsupials, although the imprinting status is not conserved for all 
genes between marsupials and eutheria. For example, although the paternal 
expression of Peg 1 is conserved in marsupials, Cdknlc does not exhibit parental- 
specific expression in this order (Suzuki et al. 2005). Imprinting has thus far not 
been described in monotremes or other vertebrates such as birds or reptiles, with 
the reciprocally imprinted Igf2 and Igf2r exhibiting biallelic expression in chickens 
and monotremes, whereas Igf2 is paternally expressed and Igf2r is maternally 
expressed in eutheria and marsupials (Killian et al. 2000; Nolan et al. 2001; 
Suzuki et al. 2005).
The “placenta hypothesis” suggests that imprinting of specific genes was 
driven by the evolution of the placenta, which exerted selective pressure on 
genes that regulate embryonic growth and development (Hall 1990; Kaneko- 
Ishino et al. 2003). Following the divergence of marsupials and eutheria, co­
evolution of the placenta and imprinting resulted in the distinct placental
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structures and reproductive strategies of the two groups. This hypothesis 
accounts for the phylogenetic distribution of imprinting and the role of such genes 
in regulating embryonic growth and development.
~170 Mya ~150Mya
. .  x No placentation
----------------------------------------------- Monotremes No imprinting
---------------  -----------------------  Marsupials Non-invasive placenta
Limited imprinting
A
I-----------------------  Eutheria Lnvasive PlacentaExtensive imprinting
Evolution of 
placentation
Figure 1.4: Co-evolution of placentae and imprinting
Marsupials and eutherian mammals shared a common placental ancestor 
around 170 Mya. Placentation co-evolved with genomic imprinting, with 
imprinting of specific genes enabling the subsequent evolution and increased 
invasiveness of the eutherian placenta following divergence from marsupials 
around 150 Mya. Mya = Million years ago.
1.5.3 Parental conflict hypothesis
Perhaps the most widely debated theory regarding genomic imprinting in 
mammals is the “parental conflict hypothesis”, first proposed by Moore and Haig 
(1991). The conflict hypothesis predicts that imprinting arose in placental 
mammals due to the “conflicting interests of maternal and paternal genes in 
relation to the transfer of nutrients from the mother to her offspring. Both parents 
are invested in producing large, viable offspring that will successfully reproduce, 
but the mother must additionally preserve resources for herself and future 
progeny. This hypothesis suggests that paternally expressed imprinted genes 
tend to be growth promoting, whereas maternally expressed imprinted genes 
tend to be growth restrictive (Moore and Haig 1991). The reciprocally imprinted 
Igf2/lgf2r genes provided the first evidence in support of the parental conflict 
hypothesis. The growth promoting Igf2 gene is paternally expressed whereas the
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growth restrictive Igf2r, which encodes a signalling antagonist of Igf2, is 
maternally expressed (Barlow et al. 1991; DeChiara et al. 1991; Haig and 
Graham 1991). Indeed, expression patterns for the majority of imprinted genes 
for which a function has been assigned correlate with these predictions (Isles and 
Holland 2005; Tycko and Morison 2002).
The importance of imprinting in the placenta is further support for the 
parental conflict hypothesis (Tycko 2006). The placenta mediates the maternal 
supply and fetal demand for nutrients during gestation, and thus directly 
influences embryonic growth (Reik et al. 2003). According to the conflict 
hypothesis, paternally expressed imprinted genes would be expected to enhance 
placental function, whereas maternally expressed imprinted genes would be 
expected to restrict placental capacity. This is true for Igf2, with loss of 
expression of the paternal transcript in the placenta causing reduced placental 
size; conversely, loss of the maternally expressed Cdknlc causes 
placentomegaly (Constancia et al. 2002; DeChiara et al. 1990; DeChiara et al. 
1991; Takahashi et al. 2000a).
In addition to explaining the common functions of imprinted genes, the 
conflict hypothesis also attempts to explain the phylogenetic distribution of 
imprinting to placental mammals. Monoallelic expression of specific genes in the 
placenta achieved by imprinting effectively restricts the effects of these gene 
products, thus providing an optimal environment for nutrient delivery to the 
embryo whilst maintaining sufficient resources for maternal health. Vertebrate 
species such as reptiles and birds, which reproduce by laying eggs, are not 
subject to the same continued nutritional demands as those experienced by 
placental mammals, and thus would not be expected to exhibit imprinting.
The conflict hypothesis is not however without its limitations (reviewed in 
Hurst and McVean 1998); for instance the imprint status of some genes does not 
correlate with the pattern predicted by the hypothesis. Most notable of these is 
the maternally expressed Ascl2 gene. Ascl2 null mice have small placenta, with a 
complete loss of the spongiotrophoblast region, causing embryonic lethality due 
to placental failure (Guillemot et al. 1994). According to the conflict hypothesis, 
maternally expressed genes should be growth-restrictive and thus loss of 
expression would be predicted to result in some form of placentomegaly, 
whereas over-expression would restrict placental growth. However, loss of
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expression does not model imprinting since it tests the function of the gene and 
not the consequences of altered expression. It will be of particular interest to 
determine whether over-expression of Ascl2 in the mouse placenta has a 
consequence.
1.6 The placenta
The placenta is a transient organ that is essential for mammalian embryogenesis, 
developing early in pregnancy before being discarded at birth. Comprised largely 
of extraembryonic trophoblast cells, the placenta is permeated by embryo-derived 
blood vessels from the umbilical cord and maternal blood vessels from the 
uterus. Growth, development and ultimate survival of the embryo depends upon 
this organ, as exemplified by many mouse models of disrupted placentation, in 
which embryonic growth is impaired and often associated with embryonic lethality 
(reviewed in Cross etal. 2003a; and Rossant and Cross 2001).
The primary role of the placenta is to provide sufficient nutrients for fetal 
growth, achieved through the formation of intimate feto-maternal interfaces. The 
functions of the placenta can be broadly categorised as “transport and barrier” 
and “invasive and endocrine” functions (Cross et al. 2003a; Georgiades et al. 
2002). Transport and barrier functions include the supply of nutrients to and the 
removal of waste products from the embryo, and the protection of the embryo 
from potential maternal immune response (Georgiades et al. 2002; Koch and 
Platt 2007). Invasive and endocrine functions include the invasion of placental 
cells into the uterus wall to anchor the placenta in place, and the secretion of 
hormones into maternal blood that alter maternal metabolism to favour embryonic 
growth and increase blood flow to the placenta (Cross et al. 2003a; Malassine et 
al. 2003).
The vital role that the placenta plays in nourishing the embryo means that 
placental defects may have serious consequences for embryonic growth. In 
humans, placental defects are associated with pregnancy complications including 
pre-eclampsia and intrauterine growth restriction (IUGR). Mouse models provide 
useful tools for gaining further understanding of such conditions and for 
understanding placental development in general.
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1.6.1 Development of the mouse placenta
The trophoblast cell lineage is the first to differentiate during embryogenesis, 
occurring at around embryonic day 3 (E3.0) (Gilbert 2003; Pedersen 1986). At 
this stage the zygote has proliferated to form a ball of approximately 16 cells (the 
morula), comprising a monolayer of trophoblast cells, called the trophectoderm, 
surrounding the inner cell mass (ICM) (Gilbert 2003). The ICM forms the entire 
embryo, with the trophectoderm contributing solely to the extraembryonic tissue 
(Cross 2005; Rossant and Cross 2001; Watson and Cross 2005). Cell fate can 
be experimentally manipulated at this stage by altering cell position, indicating 
that cells of the morula remain totipotent (Ziomek et al. 1982). As embryogenesis 
progresses to the 32-cell blastocyst stage, the ICM is characterised by 
expression of the transcription factors Oct4 and Nanog. Expression of these 
genes is repressed by Cdx2, which is specifically expressed by cells of the 
trophectoderm (Hart et al. 2004; Kunath et al. 2004; Palmieri et al. 1994; Strumpf 
et al. 2005). Deletion of Cdx2 causes implantation failure due to loss of the 
extraembryonic cell lineage (Strumpf et al. 2005).
Prior to implantation, water enters the blastocyst under osmotic flow 
forming the blastocoelic cavity, to one side of which lies the ICM (Fig 1.5A) 
(Gilbert 2003; Pedersen 1986). Trophectoderm cells lying directly above the ICM 
are referred to as polar trophectoderm, whereas those cells not in contact with 
the ICM are designated mural trophectoderm (Pedersen 1986). The ICM 
comprises a heterogeneous population of epiblast and primitive endoderm cell 
lineages (Chazaud et al. 2006). Epiblast cells segregate closest to the 
trophoblast cells and contain precursors to all embryonic cell types. Epiblast cells 
are surrounded by a monolayer of primitive endoderm cells, called the visceral 
endoderm. These primitive endoderm cells spread across the inner surface of the 
blastocoelic cavity, beneath the primary trophoblast cell layer forming the parietal 
endoderm (Lawson and Pedersen 1987). Together, the parietal endoderm and 
giant cell layer form the parietal yolk sac, while the visceral endoderm combines 
with the embryonic-derived extraembryonic mesoderm to form the visceral yolk 
sac (Jollie 1990). The parietal and visceral yolk sacs facilitate nutrient uptake to 
the embryo, prior to the establishment of the mature placenta.
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A E3.5 blastocyst
Polar trophectoderm 
Epiblast
Primitive endoderm
Blastocoelic cavity
Mural trophectoderm
B E6.5 egg cylinder stage
Ectoplacental cone
Extraembryonic ectoderm
Primitive endoderm
Epiblast
Primary giant cells
Figure 1.5: Early differentiation of trophoblast lineages
A: At E3.5 the blastocyst comprises a monolayer of trophectoderm cells 
surrounding a blastocoelic cavity. The ICM is attached to one side of the 
trophectoderm and consists of cells of the epiblast and primitive 
endoderm lineages. B: Polar trophectoderm cells directly above the ICM 
proliferate outwards to form the ectoplacental cone and inwards to form 
the extraembryonic ectoderm. The remaining mural trophectoderm 
undergo endoreduplication to form primary giant cells, which together 
with the primitive endoderm forms the parietal yolk sac.
23
Following implantation of the blastocyst into the uterine wall at E4.5, polar 
trophectoderm cells proliferate inwards to form the extraembryonic ectoderm and 
divide outwards to form the ectoplacental cone (Copp 1979). In contrast, mural 
trophectoderm cells cease proliferating, instead undergoing repeated rounds of 
DNA replication resulting in the formation of large, polyploid primary trophoblast 
giant cells through the process of endoreduplication (Rossant and Cross 2001; 
Watson and Cross 2005). This stage of embryogenesis is referred to the egg- 
cylinder stage, and corresponds to approximately E6.5 (Fig 1.5B). Continued 
proliferation of polar trophectoderm cells is maintained by the release of the 
growth factor Fgf4 from the ICM, acting through Fgf2r receptors of trophectoderm 
cells (Haffner-Krausz et al. 1999; Niswander and Martin 1992). Consequently, 
Fgf4 and Fgf2r mutant mice exhibit similar phenotypes, dying soon after 
implantation due to a failure of trophectoderm development (Arman et al. 1998; 
Feldman et al. 1995). Fgf4 signals are transmitted downstream by Erk2/Mapk1, 
mutation of which also results in a failure of ectoplacental cone and 
extraembryonic ectoderm formation (Saba-EI-Leil et al. 2003).
Expansion and differentiation of the ectoplacental cone forms a compact 
layer of cells called the spongiotrophoblast. Similar to mural trophectoderm cells, 
cells at the maternal edge the spongiotrophoblast undergo endoreduplication 
becoming secondary trophoblast giant cells (Cross 2000; Cross et al. 1994). 
Meanwhile, the extraembryonic ectoderm proliferates to generate the chorionic 
epithelium, initially forming a flat “chorionic plate” at the base of the placenta. 
Simultaneously the allantois (umbilical cord) develops from the posterior end of 
the embryo (Rossant and Cross 2001; Watson and Cross 2005). At E8.5, the 
allantois and chorionic epithelium fuse in an event termed chorioallantoic 
attachment (Downs and Gardner 1995; Watson and Cross 2005). Following 
chorioallantoic attachment, the chorionic epithelium begins to undergo branching 
morphogenesis, forming primary villi at regularly spaced intervals. Fetal blood 
vessels from the allantois begin to grow into the primary villi, which elongate and 
branch further to form the characteristic maze-like structure of the murine 
labyrinth (Cross etal. 2003b).
Simultaneous with branching morphogenesis of the chorionic epithelium, 
trophoblast cells of the extraembryonic ectoderm differentiate to form the 
trilaminar arrangement of the labyrinth layer (Fig 1.6). In addition to the epithelial
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lining of fetal blood vessels, the maternal and fetal blood flows are separated by 
three layers of trophoblast cells. A single layer of mononuclear sinusoidal 
trophoblast giant cells (S-TGCs) replaces the endothelial lining of maternal 
vasculature. A bilayer of multinucleated syncytiotrophoblast formed by cell fusion 
surrounds the fetal vasculature, which maintains its endothelial cell lining, unlike 
maternal vessels (Coan et al. 2005b; Simmons and Cross 2005; Simmons et al. 
2008). The S-TGCs primarily perform a secretory function, releasing hormones 
into maternal blood, whereas the syncytiotrophoblast layers are involved in 
nutrient transport (Georgiades et al. 2002; Simmons and Cross 2005; Watson 
and Cross 2005).
Fetal
capillary Maternalblood
sinus
Syncytiotrophoblast 
Fetal vascular layer II layer I Sinusoidal trophoblast
endothelium 9 |ant 06118
Figure 1.6: Trilaminar arrangement of labyrinth
The fetal and maternal blood flows are separated by a trilaminar 
arrangement of trophoblast cells in the labyrinth layer of the mouse 
placenta. The endothelial lining of maternal vasculature is replaced by 
sinusoidal trophoblast giant cells. A bilayer of syncytiotrophoblast cells 
formed by cell fusion separates maternal blood sinuses from fetal 
capillaries. Fetal capillaries maintain their endothelial lining, thus 
separating maternal and fetal blood by four cell layers.
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Mouse models of defective placentation indicate that of the genes 
examined that are involved in placental development, the majority appear to 
control development of the labyrinth region (see Tables 2 and 3 in Watson and 
Cross 2005). Perhaps one of the most crucial genes required for development of 
the labyrinth region is Gcm1. Expression is first detected at around E7.5 in 
distinct clusters of cells in the extraembryonic ectoderm, and regulates the 
process of branching morphogenesis in the labyrinth region, with expression 
restricted to cells at the tip of branching villi (Basyuk et al. 1999). Loss of Gcm1 
expression results in failure of branching morphogenesis with the chorionic plate 
remaining flat and undifferentiated. As a consequence of this placental failure, 
Gcm1-null embryos die at ~E10.5 (Anson-Cartwright et al. 2000).
The definitive mouse placenta is formed by ~E12.5 and comprises three 
layers, namely the labyrinth, spongiotrophoblast (junctional zone) and outer 
monolayer of giant cells in addition to the maternal decidua into which the 
placenta embeds (Fig 1.7). A sub-population of spongiotrophoblast cells called 
glycogen cells begin to accumulate their characteristic glycogen stores at this 
stage. Glycogen cells are characterised by a large, glycogen-filled cytoplasm and 
expression of the spongiotrophoblast-specific marker Tpbpa (4311), suggesting 
that they are a direct sub-type of the spongiotrophoblast (Adamson et al. 2002). 
However, the actual origin of these cells remains elusive, with expression of the 
glycogen cell-specific marker protocadherin 12 (Pcdh12) detected in the 
ectoplacental cone as early as E7.5 (Bouillot et al. 2005), prior to the 
differentiation of spongiotrophoblast and appearance of the morphological 
characteristics of glycogen cells. Furthermore, the placentae of Cdknfc-null mice 
possess approximately twice the normal number of spongiotrophoblast cells, 
whereas the number of glycogen cells remains similar to wild-type (Takahashi et 
al. 2000a). Between E14.5 and term, glycogen cells migrate into the decidua 
where they tend to cluster around maternal blood vessels. In addition to the large 
glycogen stores, these cells are also characterised by synthesis of the growth 
factor Igf2. Interestingly, both glycogen cell number and glycogen content are 
greatly reduced in Igf2-null placenta, indicating that glycogen cell differentiation 
and glycogen synthesis/uptake are /g/2-dependent processes (Lopez et al.
1996). The function of glycogen cells remains unclear, although a role in 
parturition has been proposed (Coan et al. 2006).
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Figure 1.7: Structure and blood circulation of the mature mouse placenta
The mature mouse placenta comprises three main regions; the labyrinth, spongiotrophoblast and maternal 
decidua. Separating the spongiotrophoblast from the maternal decidua is a discontinuous layer of invasive 
trophoblast giant cells. Glycogen cells first arise at E12.5 in the spongiotrophoblast and migrate to the 
decidua until term. Fetal and maternal blood flow in a counter-current direction. Maternal blood is delivered 
to the base of the placenta through arterial canals and drains back to the maternal side through blood 
sinuses. Fetal blood enters at the base of the placenta, traverses the labyrinth in small arterioles and 
returns back to the embryo through capillaries.
Fetal circulation J  Maternal circulation
In addition to the S-TGC subtype described previously, a further three sub- 
types of trophoblast giant cell (TGC) have been described in the mouse placenta. 
The secondary giant cell layer separating the spongiotrophoblast and maternal 
decidua is comprised of parietal giant cells (P-TGCs). Spiral artery-associated 
trophoblast giant cells (SpA-TGCs) surround the maternal spiral arteries in the 
decidua, whereas canal-associated trophoblast giant cells (C-TGCs) surround the 
maternal blood canals that traverse the spongiotrophoblast and enter the 
labyrinth layer of the placenta (summarised in Figure 1.8). All giant cell subtypes 
are characterised by a large, polyploid nucleus and are identified by specific gene 
expression markers and their spatial localisation in the placenta (reviewed in 
Hemberger 2008).
SpA-TGC
P-TGC
C-TGC
S-TGC
Figure 1.8: Trophoblast giant cell subtypes in the mouse placenta
Four sub-types of trophoblast giant cell exist in the mouse placenta. The parietal 
trophoblast giant cells (P-TGCs) form the boundary between the maternal 
decidua and spongiotrophoblast. Spiral arteries entering the decidua are 
surrounded by spiral artery associated trophoblast giant cells (SpA-TGCs), 
whereas canal-associated trophoblast giant cells (C-TGCs) surround the blood 
canals that traverse the spongiotrophoblast and deliver maternal blood to the 
labyrinth. The endothelial lining of maternal vasculature in the labyrinth is 
eroded and replaced by sinusoidal trophoblast giant cells (S-TGCs). Diagram 
adapted from Flemberger (2008).
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Prior to the completion of placental development ~E12.5 the developing 
fetus is nourished by the uptake of nutrients across the yolk sac (Cross et al. 
1994; Georgiades et al. 2002). Between E10.5 and E12.5, the maternal and fetal 
blood supplies to the placenta are complete, with the fetus subsequently 
obtaining all required nutrients by transfer across the placenta. This is a critical 
stage in placental development, as exemplified by the significant number of 
mouse models of defective placentation that are embryonic lethal at this stage, 
including mice deficient for Ascl2 (Guillemot et al. 1994), Gcm1 (Anson- 
Cartwright et al. 2000), and Vhl in which the fetal placental vasculature fails to 
form correctly (Gnarra etal. 1997).
Effective placental function requires that maternal and fetal blood 
circulations be brought into close proximity such that exchange of nutrients, 
wastes and gases can take place. Maternal blood enters the placenta from the 
uterine radial artery, which splits into numerous spiral arteries in the decidua, 
before converging at the giant cell layer to form between one and four arterial 
canals (Adamson et al. 2002). The endothelial lining of these central canals, 
which cross the spongiotrophoblast layer, is eroded away and replaced with 
trophoblast giant cells (Rossant and Cross 2001). Maternal blood is carried 
directly to the base of the placenta where it flows into the trophoblast-lined 
maternal blood sinuses, and subsequently drains back to the decidua (Adamson 
et al. 2002). Fetal blood enters at the base of the placenta through a single 
artery, subsequently branching into a number of smaller arterioles, which 
penetrate the labyrinth and upon reaching the spongiotrophoblast, form 
capillaries that direct fetal blood out of the placenta (Adamson et al. 2002). 
Maternal and fetal blood thus flows in a counter-current direction, with maternal 
blood draining towards the decidua through trophoblast-lined maternal sinuses as 
fetal blood is carried back to the fetus through endothelial-lined capillaries.
1.6.2 Comparison of human and mouse placenta
Practical and ethical considerations prevent the direct investigation of human 
placental development, and thus a suitable model organism must be used in 
which to undertake comparative studies. The mouse is a well-established model 
organism in numerous fields, and provides an ideal model in which to study the 
placenta. A key advantage of the mouse is the relatively short gestation time, in
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addition to the ability to give birth to multiple pups in the same litter. This enables 
a direct comparison of wild type and mutant individuals in the same litter. In order 
to relate findings from mouse models to the human placenta, it is important to 
understand the similarities and differences between placenta of the two 
organisms, and thus the potential limitations of mouse studies.
Human and mouse placentae are described as discoid, as they are 
generally dome shaped with a flat surface facing the embryo to which the 
allantois attaches (Georgiades et al. 2002). Both human and mouse placentae 
comprise three distinct layers. The labyrinth region of the mouse placenta is 
analogous to the “fetal placenta” in humans. In the human placenta, a single layer 
of syncytiotrophoblast cells separates maternal blood from fetal capillaries, in 
comparison to the trilaminar arrangement in the mouse. Both human 
“monochorial” and mouse “trichorial” placentae possess “haemochorial 
interfaces”, with fetal capillaries bathed directly in maternal blood (Georgiades et 
al. 2002). Differences exist in the branching of fetal vasculature between the two 
species, with the human “villous” structure resembling a tree, with progressive 
branching and sub-branching, whereas the branches of the murine vasculature 
are interconnected to form a complex “labyrinth” arrangement. Maternal blood 
sinuses in the human placenta are thus relatively larger than their counterparts in 
the mouse (Georgiades etal. 2002; Kingdom et al. 2000).
Lying directly above the fetal placenta/labyrinth is a compact region of 
cytotrophoblast cells called the basal plate in humans and the spongiotrophoblast 
in mice. Glycogen cells are observed in this layer in both humans and mice, and 
although this region does not contain fetal vasculature, trophoblast-lined maternal 
arterial and venous channels dissect this zone. The function of this region is 
unclear, although it is suggested to fulfil an endocrine/secretory role in both 
species. A third layer, consisting of polyploid secondary giant cells, surrounds the 
spongiotrophoblast in mice and invades the uterine wall. The extravillous 
cytotrophoblast cells in humans, which are polyploid although to a lesser extent, 
appear to perform a similar invasive role (Georgiades et al. 2002; Rossant and 
Cross 2001). The primary differences between mouse and human placental 
structure are summarised in Tables 1.2 and 1.3.
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Mouse Human
Labyrinth Fetal placenta
Maternal blood space/lacunae Intervillous space
Spongiotrophoblast/Junctional zone 
comprised of: 
spongiotrophoblast cells 
glycogen cells
Basal plate 
comprised of: 
cytotrophoblast cell columns 
glycogen cells
Giant cells Giant cells*
Decidua Placental bed
Table 1.2: Comparison of human and mouse placental structure
The above table compares the nomenclature for the major regions of the mouse 
and human placenta. *Although giant cells are observed in human placenta, they 
are morphologically distinct. An analogous cell type to the murine giant cells thus 
appears to be the invasive extravillous trophoblast.
Structure Mouse Human
Chorionic plate
Maze-like and interconnected 
Small maternal blood spaces
Tree-like with branches and 
sub-branches 
Larger intervillous space
Ultrastructure
Trichorial:
Three trophoblast layers 
separate fetal and maternal 
blood
Monochorial:
A single trophoblast layer 
separate fetal and maternal 
blood
Table 1.3: Comparison of structure of labyrinth/fetal placenta
The table summarises the two major differences between the organisation of the 
labyrinth layer of the mouse placenta and the analogous fetal placental layer of 
the human placenta.
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1.6.3 Imprinted gene expression in the mouse placenta
The majority of imprinted genes are expressed in the placenta (reviewed in Coan 
et al. 2005a). This pattern of expression is consistent with their role in regulating 
fetal growth by controlling mediating the supply of nutrients to the embryo during 
gestation. Imprinted genes are involved in both the control of placental 
development (Ascl2 , Peg10, Grb10) and the transport of nutrients (Slc22a2, 
Slc22a3 and Slc38a4). Although placental expression has been reported for the 
majority of imprinted genes, the spatial expression pattern has been reported for 
only a small number of these genes. Table 1.4 summarises the expression 
pattern of the most extensively studied of these genes.
Gene Spatial expression
Ascl2
Diploid trophoblast of labyrinth and spongiotrophoblast 
layers until E12.5, declining thereafter
Cdknlc
Labyrinth, spongiotrophoblast, 
glycogen cells, giant cells
Dlk1 Fetal endothelium of labyrinth region
Igf2
Labyrinth, spongiotrophoblast, glycogen cells, 
giant cells and fetal endothelium
lgf2P0 Labyrinth
Mest/Peg1
Chorionic plate and fetal endothelium 
(not expressed in trophoblast cells)
Peg3
Spongiotrophoblast, giant cells and weak expression in
labyrinth
Phlda2
Ectoplacental cone (at -E5.5), 
thereafter restricted to labyrinth
Table 1.4: Summary of imprinted gene expression in the mouse placenta
The table summarises the reported spatial expression pattern of autosomal 
imprinted genes in the mouse placenta. For many imprinted genes, although 
placental expression has been reported at high levels, the spatial expression 
pattern has not yet been described. Table adapted from Coan et al. (2005a) 
and references therein. Red = maternally expressed; Blue = paternally 
expressed.
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1.7 Mouse distal 7 and human 11p15.5
A major imprinted domain implicated in placental development is located on 
mouse distal chromosome 7, a region that is homologous to the human BWS- 
associated cluster at 11 p15.5. Mouse distal 7 is approximately 1 megabase (Mb) 
in length and contains thirteen protein-coding genes, eleven of which exhibit 
imprinted expression to varying degrees. The domain also contains three 
imprinted genes from which non-coding antisense RNA is transcribed (reviewed 
in Ainscough et al. 1998). In comparison, the human region is 40% longer, 
orientated in the opposite direction with respect to the centromere and contains 
an additional two imprinted genes that encode antisense RNA transcripts 
(Cooper et al. 1998; Paulsen et al. 1998; Paulsen et al. 2000; Xin et al. 2000). 
The non-imprinted genes Cars and Mrpl23 approximately demarcate the 
telomeric and centromeric extents of the mouse domain respectively (Engemann 
et al. 2000; Zubair et al. 1997). Due to the reverse orientation of the domain in 
human, MRPL23 marks the telomeric extent, whereas NAP1L4, which is 
imprinted in mouse but not human, marks the centromeric extent of 11 p15.5 (Hu 
et al. 1996; Tsang et al. 1995). Although the imprinting status is conserved for 
most genes in the domain, some are imprinted only in humans and others only in 
the mouse (summarised in Fig 1.9).
Two imprinted sub-domains have been described within mouse distal 7, 
each controlled by an independent regulatory element (Lee etal. 1999b). The IC1 
domain is located at the centromeric end of distal 7, and incorporates the 
maternally expressed antisense H19 and the paternally expressed Ins2, Igf2 and 
its associated antisense transcript Igf2as. The IC2 domain encompasses the 
genes between Ascl2 and Nap1l4, with the biallelically-expressed Th forming a 
boundary between the two sub-domains. Interestingly, TSSC4, CD81 and 
TSPAN32 are expressed biallelically in humans, but are maternally expressed in 
the mouse (Lee et al. 1999a; Monk et al. 2006). Furthermore, there is conflicting 
data as to whether ASCL2 is imprinted (Alders et al. 1997) or not (Miyamoto et al. 
2002; Monk et al. 2006; Westerman et al. 2001) in humans. In addition, 
Trpm5/TRPM5, which is not imprinted in the mouse, is preferentially expressed 
from the paternal allele in human (Paulsen etal. 1998; Prawitt et al. 2000).
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Figure 1.9: Domain structure of mouse distal 7 and human 11p15.5
The imprinting status of genes located within the syntenic mouse distal 7 (A) 
and human chromosome 11 p15.5 (B) imprinted domains are depicted. In the 
mouse, the imprinted region consists of two sub-domains, IC1 (spanning 
Ins2 to H19), and IC2, encompassing Ascl2 to genes several hundred-kb 
upstream. The human and mouse domains share similar organisation and 
regulation, but are orientated in opposite directions, with the human domain 
around 40% longer. Red = maternally expressed genes; blue = paternally 
expressed genes; white = biallelically expressed genes. Direction of 
transcription is denoted by arrows. Diagram not to scale.
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1.7.1 Control of imprinting at the mouse IC1 sub-domain
The IC1 sub-domain is one of the most extensively studied imprinted regions in 
the mouse and comprises the paternally expressed genes Ins2, Igf2 and Igf2as in 
addition to the maternally expressed H19 antisense RNA transcript. Igf2 and H19 
share a common enhancer element, with imprinting mediated through the 
paternally methylated IC1 DMR (also called IC1 or H19-DMR) located between 
the Igf2 and H19 genes (Ferguson-Smith et al. 1993; Leighton et al. 1995b; 
Thorvaldsen et al. 1998; Tremblay et al. 1997). IC1 contains several recognition 
motifs for the zinc-finger DNA-binding protein CTCF, which acts as a functional 
insulator to block the effect of enhancer elements (Bell et al. 1999; Szabo et al. 
2000) (summarised in Fig 1.10). Binding of CTCF to the hypomethylated 
maternal IC1 prevents interaction of the Igf2 promoter with downstream 
enhancers, thus inactivating the maternal Igf2 allele (Bell and Felsenfeld 2000; 
Kanduri et al. 2000; Szabo et al. 2000). Binding of CTCF also maintains the 
differential methylation of the domain and further acts to promote transcription of 
H19 (Engel et al. 2006; Schoenherr et al. 2003). In contrast, CTCF is unable to 
bind to the methylated paternal allele, thus in theory allowing the Igf2 promoter to 
interact with enhancer elements and so enabling its transcription. The absence of 
CTCF permits methylation of the paternal chromosomal region, which renders the 
paternal H19 allele inactive. In addition, the different epigenetic modifications at 
IC1 result in altered chromatin arrangements of the two parental alleles, such that 
Igf2 is located in an active chromatin structure on the paternal allele, but in a 
silent chromatin loop on the maternal copy (Murrell et al. 2004). Imprinting at IC1 
is often described as a “boundary” or “insulator” model due to the action of the 
H19-DMR as a boundary element between H19 and Igf2.
In addition to the differential methylation of IC1, a post-fertilisation 
paternally methylated DMR (DMR1) is located upstream of Igf2 (Eden etal. 2001; 
Feil et al. 1994). The unmethylated maternal allele interacts with the repressor 
protein GCF2, which prevents transcription of Igf2. Methylation of the paternal 
DMR1 prevents binding of GCF2, thus allowing transcription of Igf2 from the 
paternal allele (Eden et al. 2001). This mechanism acts independently of IC1, 
with maternal inheritance of DMR1 deletion resulting in biallelic expression of 
Igf2, whereas H19 expression remains monoallelic (Constancia etal. 2000).
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Figure 1.10: Control of imprinting at IC1
Imprinting at IC1 is regulated by the “enhancer blocking” or “insulator” 
mechanism. The DNA binding protein CTCF binds to the unmethylated 
maternal IC1 sequence, preventing interaction of Igf2 with upstream 
enhancer elements and thus allowing maternal transcription of H19. CTCF 
cannot bind to the paternally methylated IC1 sequence, thus allowing Igf2 to 
interact with enhancer elements. A second /gf2-specific level of control is 
provided by binding of the repressor protein GCF2 at the maternally 
unmethylated DMR1. Paternal methylation of this sequence prevents GCF2 
binding, thus allowing Igf2 transcription. Diagram not to scale
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1.7.2 Control of imprinting at the mouse IC2 sub-domain
Transcription of H19 is associated with repression of IC1 sub-domain genes on 
the same chromosome. H19 expression is not however involved in the regulation 
of gene expression at the IC2 sub-domain. Maternal inheritance of a H19 null 
allele results in biallelic expression of Igf2 (Leighton et al. 1995a; Ripoche et al. 
1997), whereas expression of Ascl2, Cdknlc and Kcnql remains monoallelic 
(Caspary et al. 1998). Monoallelic expression of genes within the telomeric IC2 
sub-domain of mouse distal 7 is regulated by a mechanism independent of H19.
The mouse IC2 domain contains at least 11 genes that exhibit preferential 
expression of the maternal allele to varying degrees, including Ascl2 (Guillemot et 
al. 1995), Cdknlc (Hatada and Mukai 1995), Phlda2 (Qian et al. 1997) and 
Slc22a18 (Dao et al. 1998), all of which exhibit strong expression in the placenta. 
The domain also contains a paternally expressed ~60-kb ncRNA, Kcnqlot1, 
which is transcribed from a promoter within intron 10 of Kcnql. The Kcnqlot1 
promoter is methylated on the maternal chromosome, forming a differentially 
methylated region referred to as Kvdmrl. Methylation of Kvdmrl prevents 
expression of Kcnq1ot1, whereas paternal expression of Kcnq1ot1 is associated 
with silencing of the protein-coding genes in the domain (Smilinich et al. 1999) 
(summarised in Fig 1.11).
Two regions have been identified as essential for Kcnq1ot1 expression: a 
~1.9-kb region of Kvdmrl and a 244-bp region of the Kcnq1ot1 promoter. 
Deletion of either of these regions causes loss of expression of Kcnq1ot1 and 
biallelic expression of genes, including Ascl2, Cdknlc, Phlda2 and Slc22a18 
(Fitzpatrick et al. 2002; Mancini-Dinardo et al. 2006). Transcription initiation is 
insufficient for maintenance of monoallelic gene expression, with a truncated 
Kcnq1ot1 transcript also associated with LOI of adjacent imprinted genes, 
indicating that a full-length Kcnq1ot1 transcript is required for complete imprinting 
at the IC2 sub-domain (Mancini-Dinardo et al. 2006; Thakur et al. 2004). 
Additionally, Cdknlc acquires Kvdmrl-dependent methylation of the paternal 
Cdknlc promoter between E6.5 and E7.5. This post-fertilisation methylation is 
not required for initiation of the imprint, although it is probably required to 
maintain monoallelic expression of Cdknlc, with Dnmt deficient mice exhibiting 
biallelic expression of Cdknlc (Bhogal et al. 2004; Caspary et al. 1998).
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Kcnql ot1
Figure 1.11: Imprinting at the mouse IC2 domain
Imprinting at the mouse IC2 domain is regulated by transcription of the 
ncRNA Kcnq1ot1 from the paternal allele, which prevents transcription of 
adjacent genes from the paternal chromosome. Methylation of the maternal 
Kcnq1ot1 promoter prevents transcription of the ncRNA and thus allows 
maternal expression of genes both up and downstream. Monoallelic 
expression of Cdknlc is maintained by paternal methylation of the promoter 
in a Kcnq1ot1 dependent manner. Diagram not to scale. M = Maternal allele; 
P = Paternal allele
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Although classified as an imprinted gene, Nap1l4/NAP1L4 only exhibits 
monoallelic expression in the mouse placenta (Engemann et al. 2000), with 
biallelic expression observed in the embryo (Paulsen et al. 1998) and all human 
tissues (Hu et al. 1996). Initially Nap1l4 was presumed to mark the telomeric 
extent of the mouse IC2 sub-domain, with biallelic expression of the adjacent 
Cars/CARS in both mouse and human appearing to support this (Engemann et 
al. 2000). However, Tnfrsf23, which is located approximately 150-kb upstream of 
Nap1l4 displays weak imprinting, with preferential expression of the maternal 
allele in some mouse tissues including the placenta (Clark et al. 2002). 
Additionally, expression analysis of Kvdmrl mutant mice revealed imprinted 
expression of Osbpl5, which is located adjacent to Tnfrsf23 (Mancini-Dinardo et 
al. 2006). Thus, Kvdmrl controls the imprinting of genes that lie at least 200-kb 
outside of the previously defined IC2 region. Imprinted expression has not been 
reported for the three genes that lie between Nap1l4 and Tnfrsf23.
1.7.3 Phenotypes associated with human 11p15.5 and mouse distal 7
The human overgrowth syndrome BWS is associated with aberrant expression of 
imprinted genes from 11 p15.5 (Ping et al. 1989). BWS results from a variety of 
genetic and epigenetic alterations within this region, including paternal UPD of 
11 p15.5 (Henry et al. 1991), LOI of IGF2 (Weksberg et al. 1993) and mutation of 
CDKN1C (Hatada et al. 1996). The most common alteration associated with 
BWS is loss of methylation at the maternal KCNQ10T1 promoter, which is 
predicted to result in biallelic expression of KCNQ10T1 and silencing of normally 
maternally expressed genes (Lee et al. 1999b). In contrast, maternal UPD of
11 p15.5 (resulting in biallelic expression of genes including CDKN1C) and loss of 
methylation at IC1 (resulting in loss of IGF2 expression) are associated with the 
growth restriction disorder Silver-Russell Syndrome (Fisher et al. 2002; Gicquel 
etal. 2005).
Uniparental disomy of two separate chromosomal regions is associated 
with embryonic lethality in the mouse due to the altered dosage of imprinted gene 
expression (reviewed in Cattanach and Beechey 1997). Paternal uniparental 
disomy of chromosome 12 (pUPD12) results in placentomegaly and late 
gestation embryonic death, whereas maternal uniparental disomy of chromosome
12 (mUPD12) is associated with perinatal lethality (Georgiades et al. 2000).
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Similarly, mUPD7 causes placental deficiency, embryonic growth retardation and 
death by E16.5, whereas pUPD7 results in placental deficiency and restricted 
embryonic growth, with embryonic death by around E10.5 (McLaughlin et al. 
1996; Searle and Beechey 1990). The altered dosage of several imprinted genes 
in these UPD models, with both loss of expression and over-expression, makes it 
impossible to determine the contribution of each gene to the phenotype. 
Investigations using single gene knockout mice have enabled the role of some 
genes to be investigated.
Embryonic lethality of pUPD7 conceptuses appears to be primarily 
associated with loss of Ascl2. Ascl2 acts to prevent the differentiation of 
spongiotrophoblast cells into secondary giant cells, with Ascl2 null placentae 
exhibiting an expanded giant cell layer and a complete loss of spongiotrophoblast 
(Guillemot et al. 1995; Guillemot et al. 1994; Scott et al. 2000). Similar to pUPD7 
conceptuses, Ascl2 null embryos die at -E10.5 due to a similar placental defect 
(Guillemot et al. 1994; McLaughlin et al. 1996). The embryonic lethality 
associated with Ascl2 null conceptuses was rescued by generating chimeras with 
tetraploid wild type embryos. The tetraploid wild type cells form extraembryonic 
tissue only, with viable embryos derived from diploid Ascl2 null cells, confirming 
that the embryonic lethality is due to the lack of spongiotrophoblast and 
subsequent placental failure (Guillemot et al. 1994). The embryonic lethality of 
mUPD7 conceptuses has not been attributed to a single gene. Loss of the 
paternally expressed growth factor Igf2 appears to contribute to the reduced 
embryonic and placental growth of mUPD7 embryos, with Igf2-null mice 
exhibiting smaller placentae and reduced birth weights (DeChiara et al. 1990; 
Ferguson-Smith et al. 1991). However, Igf2 null mice are healthy and viable 
indicating a role for other genes in the lethality of mUPD7 (DeChiara et al. 1990). 
We recently reported that excess Cdknlc in only a subset of tissues that 
endogenously express Cdknlc is associated with embryonic lethality in BAC 
transgenic mice (Andrews et al. 2007). Thus, a combination of excess Cdknlc 
and loss of lgf2 expression may be causative of embryonic lethality in mUPD7 
embryos. Interestingly, the opposite scenario of loss of Cdknlc and LOI of Igf2 
generates a mouse model of BWS (Caspary et al. 1999).
Examination of the phenotype resulting from the loss of an imprinted gene 
is useful for assigning a function to a particular gene product. These models are
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often found to represent useful tools for investigating human disease. In the case 
of imprinted genes, knockout models provide a useful indication of gene function, 
but provide less insight as to the advantage of acquiring an imprint at a specific 
gene or locus. Particular interest thus lies in generating models in which the 
effect of biallelic expression can be investigated. Not only will these models be 
useful for investigating human diseases such as BWS, they may enable a better 
understanding as to the function of imprinting.
Mice that inherit a paternal deletion of Kvdmr display biallelic expression of 
six maternally expressed genes, including Cdknlc, Phlda2, Slc22a18 and Ascl2. 
These mice have significantly lighter placentae, and are born up to 25% lighter 
than wild type littermates (Fitzpatrick et al. 2002; Salas et al. 2004). Maternal 
inheritance of the same deletion has no effect on gene expression or birth weight 
(Fitzpatrick et al. 2002). In contrast, maternal inheritance of a H19 deletion results 
in excess Igf2 and Ins2, and subsequent overgrowth of progeny that persists into 
adulthood (Leighton etal. 1995a). Similar to the UPD conceptuses however, such 
models result in the deregulation of several genes. One way to gain greater 
understanding of an individual imprinted gene is to generate single gene over­
expression models. However, generation of such models is significantly more 
difficult than creating a knockout model, with no approach able to reactivate the 
silent allele of a single imprinted gene. In general, two approaches can be taken 
to generate mouse models for over-expression of imprinted genes. One is to 
directly disrupt the IC, resulting in LOI of all imprinted genes that are under the 
control of this element. Such mice have been generated for both the IC1 and IC2 
sub-domains of mouse distal 7. An alternative approach is to introduce additional 
copies of imprinted gene(s), for example using BAC transgenes.
1.7.4 Cdknlc
Cdknlc (p57Kip2) (cyclin dependent kinase inhibitor 1C) encodes a cyclin- 
dependent kinase inhibitor that is localised within the nucleus and inhibits Gi 
cyclin-dependent kinases (CDKs), and prevents cell proliferation (Lee et al. 1995; 
Matsuoka et al. 1995). In the mouse, Cdknlc is expressed in a range of tissues 
during embryogenesis, including skeletal muscle, neural tissue, lung, kidney, 
heart and the placenta (Nagahama et al. 2001; Westbury et al. 2001). Expression 
in adult tissues is restricted to the kidney and the cortex of the adrenal gland
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(Nagahama et al. 2001). Tissue specific expression of the mouse Cdknlc gene is 
controlled by a number of c/s-elements, with embryonic enhancer elements 
located up to 225-kb downstream of Cdknlc. Placental specific enhancers are 
yet to be identified, but are located at least either 50-kb upstream of Cdknlc or 
over 225-kb downstream (John et al. 2001). Human Cdknlc transcripts exist as 
either a 1.5-kb or a 7-kb mRNA transcript, with the 1.5-kb mRNA expressed at 
high levels in the placenta, at lower levels in skeletal muscle, heart, kidney and 
pancreas, and very low levels in the brain. The 7-kb transcript is observed only in 
skeletal muscle and the heart (Lee et al. 1995). In both humans and mice, 
Cdknlc is generally expressed in cells as they enter terminal differentiation.
Cdknlc null mice exhibit placentomegaly, with approximately twice the 
number of spongiotrophoblast and labyrinthine cells, although the number of both 
giant cells and glycogen cells remains unaffected (Takahashi et al. 2000a). 
Embryonic development in the absence of Cdknlc expression was investigated 
in three separate mouse models, with variable reported phenotypes, potentially 
due to genetic background differences (Hagan et al. 2004). Zhang et al. (1997) 
deleted exons 1 and 2 of the Cdknlc gene and reported phenotypes 
characteristic of BWS in humans, including cleft palate, with all mutant animals 
dying within 24 hours of birth. Yan et al. (1997) deleted exon 1 and around 50% 
of exon 2, resulting in various developmental defects including a shortened small 
intestine in all mutants and cleft palate in approximately 50% of mutants. 
Approximately 10% of these mutant animals survived to adulthood and did not 
display any developmental or growth abnormalities. Takahashi et al. (2000b) 
deleted the entire Cdknlc coding region (exons 2 and 3), and also reported the 
survival of 10% of mutants. However, these animals displayed severe growth 
retardation and defective development of the male and female reproductive 
organs. We have recently reported that over-expression of Cdknlc in a subset of 
embryonic tissues causes embryonic growth retardation that persists into 
adulthood. The placental phenotype could not be investigated in these animals as 
the enhancer for Cdknlc placental expression is not present on the transgene 
(Andrews etal. 2007).
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1.7.5 Igf2
One of the first imprinted genes to be described in mice was Igf2 (Insulin-like 
growth factor 2), which encodes a potent mitogenic growth factor that regulates 
fetal and placental growth (DeChiara et al. 1990; DeChiara et al. 1991). Igf2 is 
widely expressed in embryonic and placental tissues during gestation, with levels 
declining towards term (reviewed in Fowden 2003). In the mouse, Igf2 is 
transcribed from four promoters; embryo-specific transcripts are expressed from 
promoters P1, P2 and P3, with placental Igf2 transcribed from the P0 promoter 
(Feil etal. 1994; Moore etal. 1997).
Imprinting of Igf2 was initially discovered through the observation that an 
Igf2 null allele only caused a growth phenotype when inherited through the male 
germline (DeChiara etal. 1990; DeChiara etal. 1991). Maternal inheritance of the 
same disrupted allele had no growth consequences, whereas paternal 
inheritance resulted in a ~40% reduction in both embryonic and placental 
weights, from which adult mice did not recover. Cell number and content of 
glycogen cells was significantly reduced in Igf2 null placentae, indicating a role of 
Igf2 in glycogen cell differentiation and/or the synthesis of glycogen by this 
trophoblast sub-type (Lopez et al. 1996). Despite accounting for only 
approximately 10% of total placental Igf2 transcripts (Moore et al. 1997), loss of 
placenta-specific lgf2P0 transcripts resulted in a comparable placental phenotype 
to Igf2 null mice, with a 30% reduction in placental weight throughout mid to late 
gestation. In contrast, Igf2 null embryos were growth restricted from early 
gestation and into adulthood, whereas lgf2P0 null embryos displayed progressive 
growth restriction from approximately E15.5, and caught up in weight compared 
to wild type animals by three months of age. The late gestation embryonic growth 
restriction of lgf2P0 null embryos seemingly occurs due to placental insufficiency 
(Constancia et al. 2002). The delayed growth restriction may also be partially 
attributed to upregulation of nutrient transporter expression in lgf2P0 null 
placentae at E15.5. The mutant placenta was seemingly able to respond to the 
nutrient demands of the embryo by upregulating expression of Slc2a3, which 
encodes a glucose transporter, and Slc38a4, which encodes a member of the 
system A amino acid transporter family. The altered gene expression was 
associated with a compensatory increase in nutrient transport efficiency at E15.5,
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although this compensatory effect was absent at E18.5. Embryonic growth 
restriction therefore occurred because the placenta was unable to continue to 
supply the necessary nutrients for normal growth. In contrast, such altered gene 
expression was not observed in Igf2 null conceptuses, which possess similarly 
small placenta but with inherently smaller embryos also. It was proposed that the 
mutant placenta was able to supply the mutant embryo with sufficient nutrients to 
reach its genetic growth potential, without the need to increase nutrient transport 
(Constancia et al. 2005; Constancia et al. 2002; Sibley et al. 2004).
Over-expression of Igf2, either due to maternal inheritance of a disrupted 
H19 allele or over-expression of the endogenous locus due to the presence of 
Igf2 transgenes, resulted in placentomegaly and embryonic overgrowth of 
between 30% and 60%, which persists into adulthood (Eggenschwiler et al. 1997; 
Leighton et al. 1995a; Sun et al. 1997). Furthermore, deletion of the reciprocally 
imprinted Igf2r gene, which encodes an antagonist of Igf2 signalling, also results 
in placentomegaly and embryonic overgrowth, although Igf2r-null mice die soon 
after birth (Lau etal. 1994).
1.7.6 Phlda2
The maternally expressed gene Phlda2 (Pleckstrin homology-like domain family a 
member 2) encodes a small, cytoplasmic protein of the specific function of which 
remains unknown (Frank et al. 2002; Qian et al. 1997). Phlda2 is highly 
expressed in extraembryonic tissue, with the highest level of expression reported 
in the extraembryonic membranes and relatively lower expression in the 
placenta. Moderate levels of expression were reported in fetal liver and lower 
levels in fetal lung, kidney and limb buds. In the adult mouse, expression is only 
observed in the kidney. Expression of Phlda2 in the placenta is detected in the 
ectoplacental cone following implantation, becoming restricted to the labyrinth 
layer by E10.5 (Frank et al. 1999). Between E12.5 and E14.5, the number of 
P/?/da2-expressing cells declines significantly, restricted to the type II trophoblast 
cells and at lower levels in type III trophoblast cells. Phlda2 is not expressed in 
the spongiotrophoblast or giant cells (Frank et al. 2002; Frank et al. 1999). 
Expression of human PHLDA2 is more restricted, with high expression detectable 
only in extraembryonic tissue, and background expression observed in lung and
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kidney of embryos and adults (Dunwoodie and Beddington 2002; Qian et al.
1997)
The mouse Phlda2 protein is 144 amino acids in length (152 in humans), 
comprising a single pleckstrin homology (PH)-like domain enclosed by short isl­
and C-termini (Frank et al. 1999; Qian et al. 1997). The PH domain is an amino 
acid sequence of between 100-120 amino acids that was first identified in the 
protein Pleckstrin (Haslam et al. 1993). Over 100 proteins have since been 
identified with homologous PH domains, most of which are implicated in signal 
transduction due to their affinity for various phosphatidyl inositol phosphate (PIP) 
molecules (reviewed inLemmon and Ferguson 2000). Similar to many PH-domain 
proteins, Phlda2 binds a wide range of PIP molecules with moderate affinity but 
low specificity, indicating a potential role in PIP signalling, but suggesting that this 
is either a broad role, or that the PIP molecule to which Phlda2 is specific is yet to 
be identified (Saxena et al. 2002). The presence of only a single functional 
domain within the protein suggests a role of Phlda2 as a signalling antagonist.
Phlda2 null mice exhibit placentomegaly with a disproportionate expansion 
of the spongiotrophoblast and an increased abundance of glycogen cells. 
However, no growth advantage was conferred to the embryo as a result of the 
larger placenta (Frank et al. 2002). Over-expression of Phlda2 and Slc22a18 
results in smaller placenta, and a subsequent reduction in embryonic growth. 
Restoration of Phlda2 gene dosage to normal in Kvdmrl null mice revealed that 
the reduced placental weight in this model was due in part to excess Phlda2 
(Salas et al. 2004).
1.7.7 Slc22a18
The maternally expressed Slc22a18 (solute carrier family 22 (organic cation 
transporter), member 18) (formerly Imptl) encodes an organic cation transporter 
molecule that is highly expressed in the mouse placenta (Dao et al. 1998). The 
mouse Slc22a18 gene encompasses 11 exons and encodes a protein of 410 
amino acids in length, with a similar organisation existing in the human 
SLC22A18 gene, which encodes a protein of 424 amino acids. Expression of 
Slc22a18 is restricted to tissues with transport function, with high expression 
levels in the placenta yolk sac, fetal kidney, liver and intestine (Dao et al. 1998). 
Although only a general role of Slc22a18 has been described in organic cation
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transport, reduced levels of Slc22a18 expression are associated with impaired 
kidney function in Ap/t-deficient mice (Tzortzaki et al. 2003).
1.8 Intrauterine growth restriction and fetal programming
Birth weight is routinely used to assess the general health of a newborn baby at 
delivery. Full-term infants with a birth weight below the 10th centile are generally 
referred to as small for gestational age (SGA), and by definition account for 10% 
of all births (Lubchenco et al. 1963). SGA infants can however be further 
classified according to the cause of their small size. Some SGA infants are 
inherently small, having achieved their predetermined, genetic growth potential 
(reviewed in Bamberg and Kalache 2004). However, a significant proportion, 
estimated at between 3% to 7% of all infants fail to achieve their genetic growth 
potential as a consequence of a variety of genetic or environmental factors. Such 
infants are said to have undergone intrauterine growth restriction (IUGR) 
(reviewed in Brodsky and Christou 2004). Furthermore, there are some infants 
whose birth weight falls in the normal range, but are nonetheless growth 
restricted, having failed to achieve their genetic growth potential (Blair 1994; 
Monk and Moore 2004). The terms IUGR and SGA are sometimes used 
synonymously in the literature, however they are not interchangeable, with IUGR 
referring to a failure to achieve the genetic growth potential and SGA describing 
an infant with birth weight below the 10th centile for its gestational age (Monk and 
Moore 2004). Thus, not all SGA infants have undergone IUGR, likewise, not all 
IUGR infants are SGA (Sifianou 2006).
IUGR may result from a variety of fetal, placental or maternal factors. 
Despite a significant proportion of IUGR cases remaining idiopathic, fetal factors, 
such as chromosomal abnormalities or multiple gestations (i.e. twins or triplets) 
are predicted to account for approximately 20% of cases. Maternal factors, 
including general health, drug or alcohol consumption, and in particular placental 
factors generally referred to as “utero-placental insufficiency” account for the 
remaining 80% of cases (reviewed in Brodsky and Christou 2004; and Lin and 
Santolaya-Forgas 1998). In the Western world, placental insufficiency is the most 
common cause of IUGR (Henriksen and Clausen 2002), resulting from 
insufficient trophoblast invasion, poor maternal or fetal blood flow, or other 
defects with placental structure or function (reviewed in Mandruzzato et al. 2008).
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IUGR can be classified as either type I (symmetric), or type II 
(asymmetric), assessed by the ratio of head circumference to abdominal 
circumference (HC:AC) (Campbell and Thoms 1977). Around 20-30% of IUGR 
infants are symmetrically growth restricted, characterised by a proportional 
growth restriction of the head and body, with a HC:AC ratio in the normal range. 
Symmetric IUGR is frequently associated with fetal chromosomal abnormalities 
with the onset of fetal growth restriction during the first or second trimester. The 
remaining 70-80% of IUGR cases are asymmetric, exhibiting an increased 
HC:AC ratio due to a relative sparing of brain growth in comparison to the body. 
Such asymmetric growth restriction tends to result from placental insufficiency 
affecting embryonic growth during the third trimester (Lin et al. 1991; Lumbers et 
al. 2001; Monk and Moore 2004; and reviewed in Platz and Newman 2008). Post­
natal catch up growth is observed in 70-90% of IUGR infants, and is generally 
complete by two years of age (Hokken-Koelega et al. 1995; Leger et al. 1997; 
Ong et al. 2000). Such catch up growth tends to be associated with 
asymmetrically growth restricted infants, resulting from a return to normal growth 
kinetics following removal of the growth restrictive factor acting in utero (Adair 
1989; Fay and Ellwood 1993; Villar et al. 1984).
IUGR is associated with a 10 to 20-fold increased risk of perinatal lethality 
(Buck et al. 1989; Dobson et al. 1981; Kok et al. 1998; Mclntire et al. 1999; 
Richardus et al. 2003). Epidemiological studies in human populations have 
reported increased occurrence of the “metabolic syndrome” in individuals that 
were born with a low birth weight. Metabolic syndrome is a multifactorial condition 
characterised by the presence of at least three key factors, including central (or 
visceral) obesity, insulin resistance, hypertension, dyslipidemia, elevated plasma 
triglyceride levels and elevated HDL levels, all of which are risk factors for 
cardiovascular disease (CVD) and Type 2 Diabetes (reviewed in Alberti et al. 
2005). Low birth weight has been associated with increased rates of CVD (Barker 
et al. 1993; Barker and Osmond 1986; Osmond et al. 1993), hypertension 
(Barker et al. 1990) and impaired glucose tolerance (Hales et al. 1991). There is 
conflicting data as to whether low birth weight is also associated with increased 
obesity in human studies. Some studies report no association (McNeely et al. 
2007), whereas others suggest a positive correlation between low birth weight 
and central adiposity in both adults (Law et al. 1992; Loos et al. 2001) and
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children (Barker et al. 1997; Ong et al. 2000). Additional studies have reported 
reduced lean mass, although with no effect on fat mass in individuals that were 
born small, resulting in a relative increase of body fat proportion (Gale et al. 2001; 
Hediger et al. 1998). Further studies and a re-evaluation of existing data 
identified post-natal catch up growth as an additional risk factor for metabolic 
syndrome. Data from the “Helsinki cohort”, consisting of over 7,000 men and 
women born in Helsinki between 1934-44, indicated that the risk of developing 
metabolic syndrome was increased in low birth weight infants that displayed post­
natal catch up growth (Eriksson et al. 2000; Eriksson et al. 1999; Forsen et al. 
2000; Forsen et al. 1999). In an independent study, low birth weight infants that 
displayed catch up growth by two years of age were more likely to be obese at 
five years of age (Ong et al. 2000).
1.8.1 Rodent models of IUGR
A number of animal models of IUGR exist, which demonstrate components of 
metabolic syndrome to varying degrees. Uterine artery ligation of the rat during 
late gestation results in IUGR, with a 15% reduction in birth weight. IUGR animals 
displayed catch up growth and became obese and developed glucose intolerance 
by 6 months of age (Simmons et al. 2001). Dietary induced models of IUGR 
include the maternal low protein model, in which pregnant dams are fed an 
isocaloric diet containing less than 50% of the protein in standard diet during 
pregnancy and lactation. Pups born to protein-restricted mothers have a 
significantly reduced birth weight, with catch up growth displayed by those pups 
suckled by standard chow fed dams (Desai et al. 1996). Male offspring born to 
protein restricted dams developed insulin resistance by 17 months of age (Petry 
et al. 2001). Similarly, female offspring born to protein restricted dams displayed 
hyperinsulinaemia at 21 months, possibly indicative of the development of insulin 
resistance (Fernandez-Twinn et al. 2005).
Similar to the protein restriction model, a calorie-restricted diet during 
gestation induces a low birth weight, although animals did not exhibit catch up 
growth when suckled by ad libitum fed dams. Subsequent weaning onto a 
hypercaloric resulted in development of hypertension and hyperinsulinaemia. 
Although the body weight of calorie-restricted animals remained lower than 
control animals, the retroperitoneal fat pad mass relative to body weight was
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significantly increased in both standard chow fed and hypercaloric diet fed IUGR 
rats (Vickers et al. 2000).
The importance of catch up growth for the programming of adult obesity 
was subsequently demonstrated in both the calorie and protein restricted rat 
models. Whereas protein or calorie restriction during gestation and lactation 
yielded growth-restricted offspring that did not display catch up growth or obesity, 
over-feeding during lactation induced obesity in both models. Exposure to a 
hypercaloric diet from weaning further exacerbated the weight gain, with calorie- 
restricted animals gaining significantly more weight than protein restricted 
animals (Bieswal etal. 2006).
A similar model of IUGR has been applied to mice, with pregnant dams fed 
an 8% protein diet during gestation and offspring cross-fostered to dams fed 
either a standard 20% protein diet (recuperated) or the 8% protein diet (low 
protein diet). Recuperated mice were born significantly lighter but exhibit rapid 
catch-up growth whereas the low protein fed offspring were born small and 
remain small throughout their lives (Ozanne et al. 2004). Feeding recuperated 
animals a highly palatable “cafeteria” diet from weaning exacerbated weight gain 
and reduced average longevity. Longevity was improved by maintaining IUGR 
pups on a low protein diet during lactation (Ozanne and Hales 2004; Ozanne et 
al. 2004).
1.8.2 The “Thrifty Phenotype” hypothesis
The relationship between birth weight and adult health and disease led David 
Barker and colleagues to propose the “thrifty phenotype hypothesis”, 
suggesting that poor fetal and neonatal nutrition leads to permanent alterations 
to organs including the pancreas (Hales and Barker 1992). This so-called “fetal 
programming” is proposed to occur in response to nutrient deprivation during 
critical developmental windows, primarily late gestation and during suckling 
(reviewed in McMillen and Robinson 2005). Exposure to a nutrient restricted 
environment in utero results in an adaptive metabolic response in organs such as 
the pancreas and an increased blood flow to the brain at the expense of other 
organs (Hales and Barker 1992; Lumbers et al. 2001). Such adaptations are 
irreversible but essential for the immediate survival of the fetus. The hypothesis 
proposes that these alterations would continue to be advantageous if nutrient
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restriction persisted in the post-natal environment, as predicted by exposure in 
utero. However, in instances when the post-natal environment is nutrient rich in 
comparison to the in utero environment, the “programmed” metabolism is unable 
to respond adequately, eventually resulting in diabetes and obesity (Hales and 
Barker 1992, 2001).
Despite an established link between IUGR and metabolic syndrome, the 
mechanisms of fetal programming that underlie this association are only now 
beginning to be understood. Epigenetic alterations are proposed to play a key 
role in the adaptive mechanism through regulation of gene expression in 
response to metabolic needs (Burdge et al. 2007; Gluckman et al. 2007; Godfrey 
et al. 2007). Imprinted genes, which are epigenetically regulated and control 
embryonic and placental growth, are potential candidates in both IUGR and fetal 
programming. Indeed, several imprinted genes have been implicated in IUGR in 
mice, including Igf2 (Constancia et al. 2002; DeChiara et al. 1990) and Cdknlc 
(Andrews et al. 2007). Loss of Igf2 and over-expression of Cdknlc result in 
symmetric growth restriction from which adult animals do not recover, whereas 
loss of Igf2 in the placenta only, causes embryonic growth restriction with post­
natal catch up growth. Phlda2 is another imprinted gene in the same imprinted 
domain and has been implicated in IUGR in mouse models, with over-expression 
causing reduced placental growth resulting in embryonic growth restriction at 
E16.5 (Salas et al. 2004). PHLDA2 has recently been reported to be upregulated 
in human placentae of IUGR and lower birth weight infants, although no alteration 
was reported for IGF2 (Antonazzo et al. 2008; Apostolidou et al. 2007; McMinn et 
al. 2006). Over-expression of Phlda2 in the mouse placenta may thus represent a 
model for a known human scenario, which can be used to further investigate 
IUGR and fetal programming.
1.9 Aims and objectives
Two approaches have been undertaken to investigate the function of imprinted 
genes. The first is to generate knockout mouse models by specifically targeting 
the actively expressed allele. The mutant allele is subsequently transmitted 
through the appropriate germline such that progeny inherit a disrupted allele on 
the normally active chromosome. The disrupted allele would be silenced by 
transmission through the alternative germline and would thus not be associated
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with any phenotype. Such knockout models are useful in identifying gene 
function, but provide less insight as to the advantage of monoallelic expression 
over biallelic expression. To investigate the potential rationale for actively 
reducing the amount of gene product produced, an alternative model in which 
expression levels are restored to biallelic levels or above can be used. Such 
models can be generated for some genes of an imprinted domain by targeting the 
ICR, thus resulting in altered expression of all genes under its control. However, 
this would result in two-fold expression of some genes with loss of expression of 
others. Thus, there is no direct mechanism to generate biallelic expression of a 
single gene in a complex imprinted domain. One approach that has been utilised 
is the generation of mice that possess additional copies of the imprinted gene on 
transgenes. Such an approach relies upon the availability of appropriate genomic 
constructs that contain an intact copy of the gene of interest in addition to any 
elements essential for transcription. Furthermore, the resulting transgenic mice 
may possess multiple copies of the transgene, or exhibit de-regulated expression 
of the transgene, and thus may still not represent true models of LOI.
The transgenic mouse model that was primarily utilised during this 
investigation (line 10-15) possesses three copies of a modified BAC transgene 
that spans the genes Phlda2, Slc22a18 and Cdknlc, but with Cdknlc inactivated 
by insertion of a /3-galactosidase reporter (John et al. 2001), thus isolating the 
role of Phlda2 and Slc22a18 in development. Preliminary investigations into this 
transgenic model identified a significant reduction in placental weight at E14.5 
and E16.5, with a subsequent reduction in embryonic weight at E16.5. This 
reduced placental weight was indirectly attributed to a reduction in the 
spongiotrophoblast component (Salas et al. 2004).
Further to the initial observation that over expression of Phlda2 results in a 
placental defect, the primary aims of this investigation were to perform a detailed 
characterisation of the placental phenotype associated with over expression of 
Phlda2 and to determine any associated post-natal consequences. The 
investigation focused primarily on characterising the phenotype on a pure 129/Sv 
genetic background using BAC transgenic mice that over express the imprinted 
genes Phlda2 and Slc22a18. The effect of genetic background on placental 
phenotype was examined on a 129/Sv x C57BL/6 background. Additionally, as 
part of this study a second independent transgenic line was generated and
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utilised to confirm the observed placental phenotypes on a 129/Sv x C57BL/6 
genetic background. The effect of transgene copy number was examined on two 
additional transgenic lines that possess either one or two copies of the transgene.
The placental phenotype was characterised by utilising a number of 
approaches and techniques. Gene expression levels in transgenic placentae 
were compared to those of wild type by microarray and Quantitative Reverse 
Transcription PCR (qPCR). The gross placental morphology was examined by 
Haematoxylin and Eosin (H&E) staining of midline placental sections, from which 
spongiotrophoblast and labyrinth areas were measured. Furthermore, the relative 
abundance of glycogen cells was assessed by using periodic acid-Schiff (PAS) 
staining. The spatial expression pattern of various placental markers was 
examined using in situ hybridisation. Probes were utilised for genes including 
Phida2 and Slc22a18, which are expressed from the transgene, Tpbpa, which 
specifically marks spongiotrophoblast and the giant cell markers PH and PI2. The 
primary placental phenotypes identified in transgenic placentae from line 10-15 
on a pure 129/Sv background were also examined on the 129/Sv x C57BL/6 
genetic background and in additional independent transgenic lines.
Post-natal characterisation was performed entirely on mice from line 10-15 
on a pure 129/Sv genetic background. Organ weights were analysed from 
neonatal animals, and a cohort of animals was weighed over the course of a 
year. Subsets of male and female mice from this cohort were subjected to 
glucose tolerance tests at 10 weeks, 6 months and 1 year of age. Furthermore, 
additional animals were dissected at these same ages to examine adiposity at 
two defined depots. Gross organ morphology was examined by H&E staining of 
organs from neonatal and adult animals, with specific measurements of some 
organs performed using computer software. A separate cohort of animals was 
also subjected to MRI scanning to investigate the potential for the use of this 
technique in future longitudinal studies of fat deposition.
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Chapter 2: 
Materials and Methods
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2.1 Transgenic mouse lines
Several transgenic mouse lines were utilised during the course of this 
investigation. The majority of placental and post-natal characterisation studies 
were performed using mice from line 10-15(Phlda2) (henceforth line 10-15) 
maintained on a pure 129/Sv genetic background. These mice possess three 
copies of a BAC transgene that encompasses a discrete region of the mouse 
distal 7 imprinted region (Fig 2.1 A). The transgene contains intact copies of the 
imprinted genes Phlda2 and Slc22a18. A third gene, Cdknlc, is inactivated by 
the insertion of a /3-galactosidase reporter construct (John et al. 2001) (Fig 2.1B). 
Transgenic mice from line 10-15 were also maintained on a C57BL/6 
background, and utilised for the characterisation of the placental phenotype on a 
129/Sv x C57BL/6 genetic background. In all such instances, the genetic 
background of the female is first, followed by the genetic background of the male. 
An independent line named 10-10(Phlda2) (henceforth line 10-10), containing an 
undetermined number of the same modified BAC transgene, was generated as 
part of this study and used to examine the placental phenotype in an independent 
transgenic line to 10-15. Transgenic mice were maintained on the C57BL/6 
background, with placental characterisation performed on a 129/Sv x C57BL/6 
genetic background.
The placental phenotype was also examined in a single copy transgenic 
line (5D3) and on a two-copy transgenic line (5A4). Both lines 5D3 and 5A4 
possess an unmodified version of the BAC transgene, with an intact copy of the 
Cdknlc gene (Fig 2.1C). Placenta-specific enhancer elements for Cdknlc are not 
present on the transgene, thus Cdknlc is not expressed from the transgene in 
the placenta (John et al. 2001). Cdknlc is however expressed from the transgene 
in a subset of embryonic tissues that normally express Cdknlc, including the lung 
epithelium and kidney, but not muscle or cartilage (John etal. 2001). Lines 10-15, 
10-10, 5D3 and 5A4 thus differ only in the gene dosage of Phlda2 and Slc22a18 
in the placenta, with Cdknlc not expressed in the placenta of any line. Due to the 
previously reported embryonic lethality associated with maintaining lines 5D3 and 
5A4 on the 129/Sv background (Andrews et al. 2007), both lines were maintained 
on the C57BL/6 background and placental phenotype examined on a 129/Sv x 
C57BL/6 genetic background.
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To analyse the individual contribution of Slc22a18 over-expression to the 
placental phenotype, transgenic males from the single copy transgenic line 5D3 
were mated with females of the Phlda2ioxp (henceforth Phlda2 null or Phlda2'l+) 
line to generate “double transgenics”. Such conceptuses possess a single copy 
of the unmodified transgene and a maternally inherited Phlda2 null allele, such 
that Phlda2 gene dosage was returned to normal, whereas Slc22a18 remains 
over-expressed. Generation of the Phlda2 null line was described by Frank et al. 
(2002), with homozygous stud males maintained on the C57BL/6 background.
A: Human 11 p15.5 / Mouse Distal Chromosome 7
Nap1l4 Phlda2 Slc22a18 Cdknlc
M   ► 4
Kcnql
B: Modified BAC 144D14: Lines 10-15 and 10-10 Kcnql ot1
C: Unmodified BAC 144D14: Lines 5D3 and 5A4
3
Figure 2.1: Structure of modified and unmodified BAC transgenes
A: Organisation of imprinted genes at mouse distal 7. B: Unmodified 85-kb BAC 
transgene containing the intact Phlda2, Slc22a18 and Cdknlc  genes. C: 
Modified version of the 85-kb BAC transgene, including reporter gene LacZ 
(blue). Cdkn 1c expression is disrupted by insertion of a /3-galactosidase reporter 
gene. Maternally expressed genes are in red, the paternally expressed non­
coding RNA transcript Kcnqlo t is shown by a blue arrow. Non-imprinted genes 
are green. The transgene does not undergo imprinting and thus transgenic 
copies of Phlda2, Slc22a18 and Cdknlc  are shown in green.
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2.1.1 Generation 10-15, 5D3 and 5A4 transgenic mouse lines
Generation of lines 10-15, 5D3 and 5A4 was described in John et al. (2001). 
Briefly, a 129/Sv gridded pBeloBAC library (Genome Systems, St Louis) was 
hybridised with a probe for Cdknlc, resulting in the identification of the clone 
144D14. This fragment extends 65-kb upstream of Cdknlc and 20-kb 
downstream, encompassing the genes Slc22a18, Phlda2 and part of Nap1l4 in 
addition to Cdknlc (Fig 2.1 C). BAC DNA was linearised and ES stem cell lines 
were generated by co-electroporation with PGK-neo. Transgene copy number 
was determined by Southern blotting of genomic DNA from independent lines, 
with comparison of band intensity to the endogenous locus by phosphorimaging. 
Lines containing 1-6 copies of the BAC transgene were used to ultimately 
generate several lines, including 5D3 (single copy) and 5A4 (two copy).
The BAC clone was modified by homologous recombination of a fi- 
galactosidase reporter construct (p57Kip2-IRES/3geoloxPalkP) into the Cdknlc 
locus to report transgenic Cdknlc expression. This modification also inactivated 
Cdknlc on the BAC. Line 10-15 was generated from this construct by pronuclear 
injection into Fi C57BL/6 x CBA embryos. Lines 10-15, 5D3 and 5A4 were 
generated at Cambridge University by Dr John.
2.1.1 Generation 10-10 transgenic mouse line
Transgenic line 10-10 was generated at Cardiff University using the same 
modified BAC transgene present in line 10-15. BAC DNA was prepared by Dr 
John and transgenic founder animals generated by pronuclear injection of 
linearised BAC DNA into C57BL/6 x CBA Fi hybrid eggs. Pronuclear injection 
was performed at the Cardiff Transgenic Production Facility.
A single transgenic male was identified from 76 live born pups following 
pronuclear injection. This male was mated with a wild type C57BL/6 female by 
the Transgenic Production Facility to generate G2 C57BL/6 progeny, of which 
one male (of three) and two females (of four) were transgenic. The transgenic 
animals were returned to the conventional transgenic facility, where the male was 
mated with a wild type C57BL/6 female to generate G3 C57BL/6 progeny. The 7 
progeny from this mating consisted of five females, which were culled prior to 
genotyping and two males, of which one was transgenic. Line 10-10 was further
56
backcrossed onto the C57BL/6 background as described in Section 2.2.1 until 
transgenic males from at least G6 were obtained.
2.2 Maintenance and mating of transgenic mice
All animals were maintained on a 12-hour light-dark cycle, under non-barrier 
conditions according to Home Office regulations, and fed ad libitum with standard 
rodent feed (Harlan, Oxfordshire) and tap water. Five transgenic mouse lines 
maintained on two genetic backgrounds were utilised during the course of this 
investigation. All over-expression transgenic lines were maintained by 
transmission of the transgene(s) from hemizygous males in a mating with wild 
type females. Transgenic males for line 10-15 were maintained separately on 
both the 129/Sv and C57BL/6 genetic backgrounds. Transgenic males for lines 
10-10, 5A4 and 5D3 were maintained only on a C57BL/6 background. The 
Phlda2 null line was maintained on a pure C57BL/6 background. Stocks of wild 
type C57BL/6 and 129/Sv females were maintained in the conventional 
transgenic facility at Cardiff University. An outline of the maintenance of 
transgenic lines is presented in Section 2.2.2.
2.2.1 Backcross to C57BL/6 background
Line 10-15 was maintained on the 129/Sv background for greater than 15 
generations, and was thus considered pure 129/Sv. Lines 5D3 and 5A4 were 
previously maintained on the 129/Sv x MF1 background. Embryonic lethality was 
observed on both lines as the contribution of the 129/Sv background increased 
(Andrews et al. 2007). For this work, lines 5D3 and 5A4 were backcrossed to the 
C57BL/6 background until no lethality was observed. Line 10-10 was generated 
by pronuclear injection of BAC DNA into C57BL/6 x CBA Fi hybrid eggs, and 
backcrossed to the C57BL/6 background.
To backcross each transgenic line, confirmed transgenic males were 
mated with a wild type C57BL/6 female, to yield live born pups. Male progeny 
were earmarked and genotyped as described in Section 2.3.1, with wild type 
males and all females killed prior to weaning. At four weeks of age, transgenic 
males were weaned to separate cages, and at six weeks of age were mated with 
a wild type C57BL/6 female. This procedure was repeated for at least six cycles, 
to establish transgenic males of at least generation 6 C57BL/6 (G6).
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Backcrossing to the C57BL/6 background was continued beyond G6, although 
experimental conceptuses were generated using animals from G6 and beyond. 
Table 2.1 shows the relative genetic contribution of each genetic background at 
each generation.
Mai
Male
ing
Female
Progeny
generation
Genetic co 
129/Sv
ntribution
C57BL/6
129/Sv C57BL/6 G1 50% 50%
G1 C57BL/6 C57BL/6 G2 25% 75%
G2 C57BL/6 C57BL/6 G3 12.5% 87.5%
G3 C57BL/6 C57BL/6 G4 6.2% 93.8%
G4 C57BL/6 C57BL/6 G5 3.1% 96.9%
G5 C57BL/6 C57BL/6 G6 1.6% 98.4%
G6 C57BL/6 C57BL/6 G7 0.8% 99.2%
G7 C57BL/6 C57BL/6 G8 0.4% 99.6%
Table 2.1: Relative contribution of genetic background after successive
generations of backcrossing
The table shows the relative contribution of 129/Sv and C57BL/6 genetic 
backgrounds over the course of eight generations of backcrossing from a 
pure 129/Sv background to the C57BL/6 background.
2.2.2 Maintenance of stock animals
Stock animals for all transgenic lines were kept to an absolute minimum, with up 
to six transgenic males maintained for each line, dependent upon the level of 
usage. Stud males were used for breeding up to approximately one year of age, 
or until breeding efficiency became noticeably reduced. Stud males were 
renewed by mating a transgenic male with a wild type 129/Sv or C57BL/6 female 
as required, genotyping male progeny (see Section 2.3.1) and selecting 
transgenic animals for subsequent breeding. Wild type females were mated from 
6 weeks of age until 6 months or until average litter size fell below five. All 
transgenic lines yielded transgenic over-expression animals in approximate 
Mendelian ratios, with 50% wild type and 50% transgenic animals born.
The primary use of the Phlda2 null line was to cross with line 5D3 to 
observe the effect of returning Phlda2 gene dosage to normal. Due to the
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imprinted nature of Phlda2, female transmission of the Phlda2 null allele was 
essential in experimental conceptuses. To minimise animal numbers, 
heterozygous Phlda2 null females were generated from matings between 
homozygous Phlda2 null males with wild type C57BL/6 females. Two 
homozygous C57BL/6 Phlda2 null males were kindly provided by Miguel 
Constancia of the University of Cambridge. All progeny of the first litter born to 
each stud were genotyped to confirm 100% transmission of the null allele; 
subsequently, no genotyping was performed on progeny from confirmed stud 
animals. All male progeny were culled, except when required to mate with a 
Phlda2 null female to generate replacement homozygous stud males. Female 
progeny were weaned at four weeks of age, and mated with 5D3 stud males 
between 6 and 10 weeks of age as required.
2.2.3 Generation of conceptuses and experimental mice
Placental and embryonic phenotype characterisation was performed using mice 
from five transgenic lines on both pure 129/Sv and 129/Sv x C57BL/6 genetic 
backgrounds. Conceptuses on a pure 129/Sv background were generated by 
mating a transgenic male on the 129/Sv background with a wild type female also 
on the 129/Sv background. Conceptuses on a 129/Sv x C57BL/6 genetic 
background were generated by mating a transgenic male from at least G6 
C57BL/6 with a wild type female on the 129/Sv background thus generating F1 
129/Sv x C57BL/6 progeny. Transgenic male mice were mated with a wild type 
(or Phlda2 null) female and females checked each morning for the presence of a 
vaginal plug. The day of plug discovery was recorded as embryonic day 0.5 
(E0.5). Females were killed and embryos dissected at the appropriate stage as 
described in Section 2.4.
Post-natal characterisation was performed using mice from line 10-15 on a 
pure 129/Sv background. These mice were generated from mating hemizygous 
stud males with wild type 129/Sv females, allowing the birth of progeny, 
performing genotyping as described in Section 2.3.1 and weaning offspring at 
four weeks of age. A maximum of five animals were co-housed, with no 
experimental animals housed alone. All cages contained a mixture of both wild 
type and transgenic animals, restricted where possible to animals from the same
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litter. Male animals from different litters were not mixed, and litters that contained 
only one male were not used for experimental purposes.
To investigate the relative contribution of Slc22a18 and Phlda2 to the 
observed placental phenotype, Phlda2 gene dosage was restored to normal by 
crossing the Phlda2 null line with the single copy over-expression line 5D3. A 
hemizygous 5D3 male was mated with a heterozygous PhldaZl+ female, which 
was expected to yield four potential genotypes in equal Mendelian ratios, as 
depicted by the Punnett square in Table 2.2. Both 5D3 males and Phlda2 null 
females were maintained on the C57BL/6 background, and thus all conceptuses 
were at least G7 C57BL/6.
Matern. 
Wild type
al alleles
Phlda2 null
Paternal Wild type Wild type Phlda2 null
alleles Transgene Transgenic Phlda2 null&Tg
Table 2.2: Punnett square for mating 5D3 male with Phlda2 null female
The Punnett square shows the four expected genotypes and ratios of 
progeny generated from a cross between transgenic males of line 5D3 with 
Phlda2 null females. Each genotype would be expected to occur with a 25% 
frequency.
A summary of all breeding scenarios utilised during the course of this 
investigation is presented in Table 2.3. The first two rows show the use of wild 
type male and female mice from lines 129/Sv and C57BL/6 to produce wild type 
females for mating with transgenic males. Wild type males were occasionally 
retained from these litters to replenish stud males in maintaining these colonies. 
The table is subsequently organised according to the transgenic line, followed by 
the genetic background of transgenic males used for breeding from each line. 
These transgenic males were mated with wild type females of the designated 
genetic background to generate experimental animals either at various 
gestational stages (“embryos and placentae” in table), or for adult animals 
(“experimental adults”). Mating scenarios used for backcrossing specific 
transgenic lines are designated by the purpose of “stud males”.
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Line
Genetic
Transgenic
male
background of: 
Wild type female
Usage
129/Sv 129/Sv 129/Sv Wild type females
C57BL/6 C57BL/6 C57BL/6 Wild type females
10-15
129/Sv 129/Sv
Embryos and placentae 
Neonate weights 
Experimental adults 
Stud males
C57BL/6
129/Sv Embryos and placentae
C57BL/6 Stud males
10-10
129/Sv 129/Sv Stud males
C57BL/6
129/Sv Embryos and placentae
C57BL/6 Stud males
5A4 C57BL/6
129/Sv Embryos and placentae
C57BL/6 Stud males
5D3 C57BL/6
129/Sv
Embryos and placentae
Neonate weights
C57BL/6
Embryos and placentae 
Stud males
C57BL/6 (Phlda2 null) Embryos and placentae
Phlda2 null C57BL/6 C57BL/6 (P/j/cfa2null) Homozygous stud males
Table 2.3: Summary of mouse breeding and usage
The table summarises all matings that were set up for each transgenic line 
according to genetic background and intended usage. The genetic 
background of the stud male is listed under “Stud” and the genetic 
background of the female is listed under “female”. All females were wild type, 
unless stated otherwise. The broad intended purpose of the breeding is 
listed under the column “Usage”.
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2.3 Genotyping of transgenic mice
Two methods were utilised in order to determine the genotype of stock or 
experimental animals. All transgenic lines could be genotyped by Polymerase 
Chain Reaction (PCR) amplification of specific sequences from either tail 
biopsies or yolk sac DNA. Additionally, the presence of the p-galactosidase 
reporter construct in lines 10-15 and 10-10 allowed conceptuses from these 
transgenic lines to be genotyped by p-galactosidase staining of the embryo. All 
experimental animals were genotyped prior to weaning and genotype confirmed 
from a second tail biopsy post-mortem.
2.3.1 Genotyping by Polymerase Chain Reaction
PCR is routinely used to genotype genetically modified mice. Primers are 
designed to amplify a specific sequence of DNA, the size of which (or 
alternatively the presence or absence of a product) is used to determine 
genotype. Two PCR protocols were utilised to genotype animals used in this 
investigation. Lines 10-15, 10-10, 5D3 and 5A4 were genotyped using primers 
that specifically amplify a region of the pBeloBAC vector sequence that is 
common to both the modified and unmodified transgene (Fig 2.2 A). Phlda2 null 
animals were genotyped using primers that span the deleted region of Phlda2, 
thus producing wild type and KO products of distinct sizes (Fig 2.2 B).
From two weeks of age, mice were ear marked and up to 5 mm of tail 
removed under local anaesthetic. For embryonic stages, the yolk sac was 
separated from the embryo and placenta during dissection (Section 2.4) and 
used for genotyping. The tail biopsy or yolk sac was lysed in a shaking incubator 
at 55°C overnight in 500 i^l of lysis buffer (50 mM Tris (pH 8.0), 100 mM EDTA 
(pH 8.0), 100 mM NaCI and 0.5 % SDS in water) containing proteinase K (400 
i^g/ml). Tissue lysate was diluted 20-fold in 10 mM Tris (pH 8.0) and heated to 
95°C for twenty minutes to denature proteinase K. Genotyping was performed in 
a total reaction volume of 25 pJ (Table 2.4), using 1 i^l of diluted lysate as 
template. Reactions were incubated at the relevant temperatures for the desired 
times in an MJ Research PTC-200 thermocycler.
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Volume (\i\)
dH20 16.7
Buffer (1 OX) (Sigma) 2.5
MgCE (25 mM) (Sigma) 2.0
dNTPs (10 mM each) (Roche) 0.8
Primers (Sigma Genosys) 1.0
Genomic Red Taq (Sigma) 1.0
Template DNA 1.0
Table 2.4: Reaction constituents for PCR genotyping
The table shows the volumes of each constituent required for a single PCR 
genotyping reaction. For multiple reactions a master mix was made.
BAC transgenic mice were genotyped using primers R85 and R86 (see 
Table 2.5 for sequences), designed using the Primer3 program (hosted at 
http://frodo.wi.mit.edu/primer3/input.htm). Thermocycler conditions were; 94°C for 
3 minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds, then 72°C for 3 minutes. Approximately half of each 
reaction was loaded on a 1% 1X Tris-acetate EDTA (TAE) agarose gel containing 
0.5 pig/ml Ethidium Bromide (EtBr) (Sigma) (later SafeView (NBS Biologicals)) 
and visualised using a transilluminator (BioRad). Transgenic animals were 
identified by the presence of a -575 bp product; with no product generated from 
wild type genomic DNA. Technical problems encountered with this genotyping 
protocol led to the design of a new set of primers. Primer set R85v2/R86v2 also 
amplifies a region of pBeloBAC vector sequence, with transgenic animals 
identified by the presence of a 314 bp product (Fig 2.2 C).
Genotyping of Phlda2 null animals was performed using primers R293 and 
R294 (for sequences see Table 2.5). A touchdown PCR program was used in 
order to amplify both the 2,025 bp wild type and 479 bp KO products. 
Thermocycler conditions were; 94°C for 5 minutes, followed by 10 cycles of 94°C 
for 30 seconds, 62°C for 30 seconds, 72°C for 1 minute. A further 20 cycles were 
performed at 94°C for 30 seconds, 56°C for 30 seconds, 72°C for 1 minute, then 
a final 72°C elongation step for 3 minutes. Primer sequences and thermocycler 
protocol were provided by Professor Ben Tycko. Products were resolved on a 1% 
TAE agarose gel as described above, with KO animals identified by the presence
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of a -500 bp product and wild type animals by a product of -2-kb; the presence 
of both products identified heterozygous animals (Fig 2.2 D).
Primer Sequence (5’ -  3’) Tm (Primer3)
R85 ATT CTG CTT ACA CAC GAT GC 56.4
R86 TTC CGC AGA GGT CAA TCC 59.7
R85v2 GGG CAC CAA TAA CTG CCT TA 60.0
R86v2 GCG TGT TAC GGT GAA AAC CT 60.0
R293 CGA GAG CCT GCT TGG GAT TG 65.5
R294 GGG GCT TGT CCT CCA ATA AAA C 63.0
Table 2.5: Primer sequences for genotyping of transgenic mice
The table shows the sequences of primers used for genotyping transgenic 
lines. Primers R85 and R86 (later R85v2 and R86v2) were used for BAC- 
specific PCR, whereas R293 and R294 were used for Phlda2 KO genotyping.
2.3.2 Genotyping by fi-galactosidase staining
The p-galactosidase reporter gene is expressed from the modified transgene in 
neural tissue during embryonic development (John et al. 2001). This allows 
transgenic animals to be identified by the development of an intense blue stain in 
the neural cord and brain stem when embryos are incubated with the |3- 
galactosidase substrate X-Gal (Promega). This method of genotyping was 
utilised to ascertain the genotype of embryos from lines 10-10 and 10-15 when 
the embryo was not required for further investigation.
Staining of embryonic stages E14.5 and earlier was performed on whole 
embryos. At developmental stages later than E14.5, embryos were decapitated 
according to Schedule 1, and development of colour assessed in the severed 
brain stem. Entire embryos or embryo heads were fixed in “LacZ fix” (2% 
formaldehyde, 0.2% glutaraldehyde, 0.02% NP-40, 1 mM MgCI2 in phosphate 
buffered saline (PBS)) for one hour at 4°C on a rocking platform, washed in two 
changes of 1X PBS and then placed in ltLacZ stain” (0.4 mg/ml X-Gal, 4 mM 
potassium ferrocyanide, 4 mM potassium ferricyanide, 1 mM MgCI2) 0.02% NP- 
40 in PBS). Colour was allowed to develop in a lightproof box at room 
temperature for several hours. Transgenic conceptuses were identified by the 
development of an intense blue colouration; wild type embryos exhibit no such 
stain (Fig 2.2 E).
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Figure 2.2: Genotyping of BAC transgenic and Phlda2 KO mice
A: Position of primers R85 and R86 used for genotyping of lines 10-10. 10-15, 
5D3 and 5A4, which amplify the same product from both unmodified (above) 
and modified (below) transgene. B: Result of genotyping reaction; transgenic 
animals were identified by a 314 bp (previously ~575 bp) product; wild type 
animals produce no product. C: Position of primers used to genotype Phlda2 
null KO mice. Primer R293 binds upstream of exon 1, with primer R294 
binding downstream of exon 2. Both exons are excised in KO mice, however 
primer-binding sites remain intact. D: Result of genotyping reaction; wild type 
animals were identified by the presence of a 2025 bp product, Phlda2 null 
animals were identified by the presence if a 479 bp product. The presence of 
both products indicated heterozygous animals. E: Development of
characteristic blue colouration of neural tissue following LacZ staining of wild 
type and transgenic embryos from line 10-15 at E14.5.
2.4 Dissection and fixation of embryos and placentae
Transgenic males were mated with wild-type female 129/Sv mice, which were 
monitored for the presence of vaginal plugs, with the day of plug discovery 
recorded as day E0.5. At the required stages of gestation, pregnant females were 
killed by cervical dislocation, as per Schedule 1 and the uterus dissected out and 
placed into cold PBS. Embryos and placentae were dissected free of the uterus 
and placed separately into fresh, cold PBS in a 24-well plate. Yolk sacs were 
separated and placed into microfuge tubes, and stored at -20°C prior to lysis as 
described in Section 2.3.1. Embryos were killed by methods approved under 
Schedule 1 of the Animals (Scientific Procedures) Act 1986, including immediate 
decapitation or immersion in ice-cold fixative. Embryo and placental weights were 
ascertained after removing excess PBS/fixative by drying on a paper towel.
In order to preserve the integrity of tissue structure for histology and to 
prevent degradation of protein and nucleic acids, placentae were fixed in 4% 
paraformaldehyde (PFA) (4% PFA (Sigma) w/v in 1X PBS) at 4°C overnight. 
Fixative was removed and tissue washed three times for 10 minutes in cold PBS, 
once for 10 minutes in 50% EtOH and stored in 70% ethanol prior to embedding 
and sectioning. All solutions were made using diethyl pyrocarbonate (DEPC) 
treated sterile distilled water. In instances where embryos and/or placentae were 
required for subsequent extraction of RNA, tissue was immediately frozen in a 
24-well plate placed directly onto dry ice, and stored at -80°C until required.
To assess relative organ size of transgenic animals, pups were dissected 
on the day of birth (P0). The entire litter was removed from the cage and 
maintained at a warm temperature in ample bedding under a lamp. Individual 
pups were weighed and decapitated as per Schedule 1. Brain, liver, heart, 
kidneys, lungs and pancreas were separated from the carcass and fixed in 4% 
PFA overnight at 4°C. Organs were subsequently washed in PBS and 50% EtOH 
as described for placentae above, and stored in 70% EtOH. After equilibrating in 
70% EtOH for two days, organs were weighed and weights recorded.
2.5 Embedding and sectioning of placentae
Following fixation in PFA overnight, washing and transfer to 70% EtOH, 
placentae were processed, embedded and sectioned by the Histology Unit
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(Cardiff School of Biosciences). Placentae were dehydrated for 1 hour 
sequentially in 70% EtOH, 95% EtOH, 100% EtOH (twice), xylene (twice), and 
passed through three changes of molten paraffin at 55°C for two hours each prior 
to being orientated and paraffin embedded. Midline sagittal sections of 10 p,m 
thickness were cut and floated onto slides in a 37°C water bath. Slides were dried 
by incubating at 50°C overnight, and stored at room temperature in sealed slide 
boxes.
For in situ hybridisation, placentae were processed immediately following 
fixation. Placentae were dehydrated for two hours sequentially in 70% EtOH, 
95% EtOH, 100% EtOH (twice), xylene (twice), and passed through three 
changes of molten paraffin at 55°C for two hours each prior to being orientated 
and paraffin embedded. Paraffin blocks were stored at 4°C in sealed containers 
prior to sectioning. Sections were prepared and stored at 4°C on the day prior to 
beginning the in situ protocol.
To measure the absolute volume of the spongiotrophoblast and labyrinth 
layers, placentae were PFA fixed as described previously and paraffin embedded 
by Histology Unit. Subsequently, sections of 10 ^m thickness were cut 
throughout the entire depth of the placenta using a Microm HM310 microtome. 
The first and every tenth section thereafter was retained and placed onto slides in 
a known order prior to H&E staining. Cross-sectional area was measured as 
described in Section 2.10.
2.6 Haematoxylin and eosin staining
Haematoxylin and Eosin (H&E) staining of placental midline sections was used to 
assess placental structure and determine the relative contribution of 
spongiotrophoblast and labyrinth regions. The protocol used for H&E staining 
was provided by Katrina Varanou from the University of Cambridge.
Slides were deparaffinised in two changes of xylene for 10 minutes, and 
rehydrated through graded ethanol solutions for 2 minutes each; 100% (twice), 
95%, 70%, 50%, and 30% EtOH, followed by five minutes in dH20. Slides were 
immersed in Mayer's haematoxylin (Sigma) for two minutes and washed in 
running tap water for 5 minutes. Slides were dipped in acid alcohol solution (0.5% 
HCI in 70% EtOH) for 10 seconds, and rinsed again in running tap water for 5 
minutes. Acid alcohol treatment was repeated, and slides washed first in running
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tap water, then in dH20  for five minutes each. Slides were immersed in Eosin Y 
Solution (Sigma) for 5 - 10 seconds and immediately dehydrated through graded 
ethanol solutions of 30%, 50%, 70%, and 95% each for 5 - 10 seconds, then 
100% EtOH for 2 minutes. Slides were fixed in xylene for 5 minutes and mounted 
using DPX mounting medium (Sigma).
2.7 Detection o f glycogen cells
Glycogen cells are a unique subtype of trophoblast found in the murine placenta, 
characterised by large glycogen-filled vacuoles (Georgiades et al. 2002). Two 
main techniques have been previously used to identify these cells, the first to be 
used was Best’s Carmine staining, which results in the staining of glycogen a 
bright pink colour, with some mucins also staining a less intense colour (Lopez et 
al. 1996). More recently, periodic acid Schiff (PAS) staining has been widely used 
to identify such cells (including Bouillot et al. 2005; Coan et al. 2006). Both 
techniques were employed in this investigation in order to compare the relative 
effectiveness of each technique, and to assess the relative extent of glycogen 
staining in wild type and transgenic placentae.
In addition to staining for glycogen in PFA fixed placentae, the use of an 
alternative method of fixation was also investigated. Placentae were dissected as 
described previously and placed directly into Tellyesniczky/Fekete (Telly’s) 
fixative (20 parts 70% EtOH, 2 parts 40% Formalin, 1 part glacial acetic acid), as 
recommended by the Jackson Laboratory for the preservation of glycogen 
(http://jaxservices.jax.org/histology-fixatives.html). Following overnight fixation at 
4°C, placentae were washed and stored in 85% EtOH prior to processing and 
embedding as described for PFA fixed placentae, but omitting the dehydration 
step through 70% EtOH. Midline sections of 10 pirn thickness were cut and 
floated onto slides as described in Section 2.5.
2.7.1 Periodic acid Schiff staining
Periodic acid Schiff (PAS) staining is based upon two chemical reactions, the first 
is an oxidation of glycogen by periodic acid to form aldehyde groups, and the 
second involves the reaction of these aldehyde groups with Schiffs reagent to 
develop an intense pink colouration.
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Slides were deparaffinised as described in section 2.6, and rehydrated 
through 100% (twice), 95% and 70% EtOH. Sections were circled using a PAP- 
pen (Dako), and incubated with 1 ml of 1% (w/v) periodic acid (Sigma) in dH20 
for 5 minutes at room temperature. Slides were washed in running water for 5 
minutes and incubated in 1 ml Schiffs reagent (Sigma) for 10 minutes at room 
temperature. Slides were rinsed in running tap water for a further 10 minutes, 
counterstained with haematoxylin for 1 minute and excess stain cleared by 
washing in tap water. Slides were dehydrated by reversing the rehydration steps 
and mounted using DPX mounting medium.
2.7.2 Best’s Carmine staining
Slides were deparaffinised and rehydrated to water as described in section 2.6. 
Sections were stained in Mayer's haematoxylin (Sigma) for two minutes and 
washed in running tap water for 5 minutes. Slides were dipped in acid alcohol 
solution (0.5% HCI in 70% EtOH) for up to 10 seconds, and rinsed briefly in 
running tap water. Slides were stained in Best’s Carmine solution (Sigma) for 6 
minutes, washed in Best’s differentiator (40% EtOH, 20% MeOH in dH20) for 2 
minutes and 100% EtOH for 2 minutes. Slides were cleared in xylene for 5 
minutes and mounted using DPX medium.
2.7.3 Comparison of glycogen staining techniques
A comparison of the four possible combinations for fixation and glycogen staining 
was performed in order to determine the method that would yield the best results. 
Initial observations suggested that Best’s Carmine staining of PFA fixed placental 
sections yielded appropriate staining with good distinction between glycogen and 
other cell types (Fig 2.3A). However, PAS staining is more extensively utilised in 
recent publications, and yielded good results with both PFA-fixed sections and 
Telly’s fixed sections, resulting in intense pink staining of glycogen cells (Fig 2.3B 
and D respectively). Best’s Carmine staining displayed poor reproducibility, with 
colour not developing for either PFA or Telly’s fixed placentae in some instances 
(Fig 2.3C and E respectively). PAS staining of PFA-fixed tissue was subsequently 
used to detect glycogen cells because of the ability to use PFA-fixed placentae 
for other histological techniques, including in situ hybridisation and the 
reproducibility of PAS staining over Best’s Carmine.
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Figure 2.3: Comparison of glycogen staining techniques
Fixation and staining method combinations were compared to determine the 
optimum conditions for visualisation of glycogen cells. A: Best’s Carmine 
staining of a PFA fixed section. B and C: PAS and Best’s Carmine staining 
respectively of adjacent PFA-fixed sections. D and E: PAS and Best’s Carmine 
staining respectively of adjacent PFA-fixed sections. Scale bar =100 pm.
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2.8 In situ hybridisation
In situ hybridisation was used to examine the spatial and temporal expression of 
mRNA for a number of key placental markers. The technique utilises digoxigenin 
(DIG) labelled RNA probes (riboprobes) that are complementary (anti-sense) to 
and thus specifically bind the target mRNA sequence. An anti-digoxigenin 
alkaline phosphatase-conjugated antibody was subsequently used to detect 
probe binding by development of a purple stain. DIG labelled sense RNA probes 
of the same sequence as the mRNA molecules were used as a negative control. 
Probes were transcribed from a vector containing a full-length or partial cDNA 
fragment of the appropriate mRNA in the multiple cloning site (MCS), flanked on 
each side by a promoter sequence for T3, T7 or SP6 RNA polymerase (Fig 2.4 
A). The RNA polymerase promoters were used to sequence the cDNA insert in 
order to ascertain its orientation within the vector. The vector was then linearised 
by two separate restriction enzymes, one cutting on each side of the insert, such 
that the appropriate RNA polymerase could be used to transcribe “run-off’ probes 
of consistent length (Fig 2.3 B).
Riboprobes for Phlda2 and Slc22a18 were designed and generated 
specifically for this investigation. In addition to these, a number of previously 
published probes were also utilised to assess the relative expression of various 
placental markers. The junctional zone marker Tpbpa is only expressed by 
spongiotrophoblast and glycogen cells (Lescisin et al. 1988). Ascl2 is expressed 
in the pre-implantation embryo, becoming restricted to the trophoblast lineage at 
implantation. High levels of expression are observed in the ectoplacental cone 
and chorionic epithelium at E7.5, with stronger expression seen in the 
ectoplacental cone at E8.5. From ~E10.5, expression patterns in both 
spongiotrophoblast and labyrinth regions becomes patchy and begins to decline, 
with little Ascl2 expression at E18.5 (Guillemot et al. 1994; Rossant et al. 1998). 
Cdknlc mRNA is detected in cells of both the spongiotrophoblast and labyrinth 
layers, but was not detected in glycogen cells or giant cells (Takahashi et al. 
2000). In contrast, others have found high levels of Cdknlc protein localised to 
glycogen cells (Coan et al. 2006; Georgiades et al. 2001). Labyrinth development 
was examined by assessment of the expression pattern of Gcm1, which is 
expressed at the branch-points of the dividing epithelium (Altshuller et al. 1996;
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Basyuk et al. 1999). Handl is expressed in cells of the spongiotrophoblast and 
labyrinth, and acts to promote giant cell differentiation in opposition to the effect 
of Ascl2 (Cross et al. 1995; Riley et al. 1998; Scott et al. 2000). During early 
gestation, giant cells were examined by expression of prolactin family 3, 
subfamily d, member 1 (Prl3d1, formerly placental lactogen 1 (PI1)), which is 
expressed from at least E6.5 until approximately E11.5 (Carney et al. 1993; 
Simmons et al. 2008; Yamaguchi et al. 1992). From E12.5, giant cells were 
examined by expression of prolactin family 3, subfamily b, member 1 (Prl3b1, 
formerly placental lactogen 2 (PI2)), which is expressed in all giant cell sub-types 
except the spiral artery associated giant cells in addition to the 
spongiotrophoblast cells (Simmons et al. 2008). Fetal capillaries in the labyrinth 
were detected by expression of the VEGF receptor Kdr (Flk1) (Breier et al. 1995; 
Dumont etal. 1995).
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Figure 2.4: Schematic of in situ “run-off” probe transcription
Sense and antisense run-off riboprobes were transcribed from a linearised 
plasmid construct containing an appropriate cDNA. A) Full length or partial 
cDNA fragments were cloned into appropriate vectors with an MCS flanked by 
RNA polymerase promoter sequences (T3 and T7 or T7 and SP6). The 
orientation of the cDNA was determined by sequencing using promoters specific 
to the RNA polymerase promoter sites. The primer that resulted in a 
complementary sequence to the mRNA transcript is the anti-sense probe. B) 
Plasmid DNA was linearised in two separate reactions on each side of the 
cDNA insert, and run-off riboprobes were transcribed with the appropriate RNA 
polymerase. In this example the cDNA fragment was cloned into a vector 
containing promoters for the RNA polymerases T3 and T7. Probe was 
transcribed using T7 RNA polymerase from plasmid linearised with restriction 
enzyme 1, and using T3 RNA polymerase from plasmid linearised with 
restriction enzyme 2.
73
2.8.1 Generation of Phlda2  and Slc22a8  cDNA constructs
Primer sets R356/357 and R358/359 were designed using Primer3 to amplify 
fragments of the Phlda2 and Slc22a18 coding regions respectively (see Table 2.6 
for sequences). Primer set R356/357 amplifies a 546 bp region of the Phlda2 
spliced transcript, between nucleotides 120 and 666 inclusive (NCBI accession 
number NM009434). Primer set R358/359 amplifies an 858 bp region of the 
Slc22a18 spliced transcript, between nucleotides 440 and 1297 inclusive (NCBI 
accession number NM008767).
Primer Sequence (5’ -  3’) Tm (Primer3)
R356 ACA GCC TGT TCC AGG TAT GG 60.0
R357 GGT TGG AAG CAG GTA ACC AA 60.0
R358 AGA GCG GCA CTC TCA CTC TC 60.0
R359 GGT CAA TGG TTG CAC AGA TG 60.0
Table 2.6: Primer sequences for amplification of Phlda2 and Slc22a18 cDNA
Primer3 was used to design primers to amplify fragments of Phlda2 and 
Slc22a18 transcripts in order to generate riboprobes for in situ hybridisation.
Target sequences were amplified from wild type E12.5 placental cDNA 
(see Sections 2.11.1 and 2.11.2 for generation of cDNA) in separate reactions. 
For each target, four separate reactions were set up according to Table 2.7, 
using 2 \i\ of diluted cDNA as template. Thermocycler conditions were 94°C for 3 
minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds, then a 72°C final elongation step for 3 minutes. For each 
target, the four reactions were combined in a single microfuge tube and 10 \i\ 
analysed on a 1.5% 1X TAE gel, using a 100 bp ladder (NEB) to quantify product 
size. PCR-amplified products were purified using a PCR purification kit (Qiagen) 
according to the manufacturer’s instructions and resuspended in 50 pil 10 mM 
Tris (pH8.0). Concentration was determined from 1 using a NanoDrop 1000 
(Thermo Scientific) and DNA stored at -20°C.
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Volume (p-l)
dH20 33.4
Buffer (10X) (Sigma) 5.0
MgCI2 (25 mM) (Sigma) 4.0
dNTPs (10 mM each) (Roche) 1.6
Primers (Sigma Genosys) 2.0
Genomic Red Taq (Sigma) 2.0
Template DNA 2.0
Table 2.7: Reaction constituents for PCR amplification of Phlda2 and
Slc22a18 cDNA
The table shows the constituent volumes for PCR amplification of cDNA 
fragments of Phlda2 and Slc22a18. Gene fragments were amplified in four 
separate reactions each containing the above constituents.
Amplified cDNA fragments were ligated into the pGEM-T Easy Vector 
System (Promega). The pGEM-T Easy Vector contains a single 3’ 
deoxythymidine overhang, which is complementary to the additional 
deoxyadenosine that is added to the 3’ end of PCR products by most Taq 
polymerase enzymes. Two separate ligation reactions were set up for each 
target, with either a 3:1 or a 5:1 insert to vector molar ratio, calculated using the 
formula below:
Amount of insert (ng) = amount of vector (ng) x insert size (kb) x insert ratio
vector size (ng) vector
Ligation reactions were incubated overnight at 4°C. Following brief 
centrifugation, 2 pi of ligation mixture was mixed with 50 i^l of high efficiency 
JM109 cells (Promega) in a 1.5 ml microfuge tube. Cells were incubated on ice 
for 20 minutes, heat shocked at 42°C for 45 seconds to facilitate uptake of 
plasmid and immediately placed on ice for 2 minutes. Room temperature SOC 
medium (950 ^l) was added to each tube and incubated at 37°C in a shaking 
incubator for 90 minutes. Each culture was plated onto two agar plates containing 
carbenicillin (Sigma), IPTG (Sigma) and X-Gal (Promega). One plate was 
inoculated with 100 pi and the other with 900 pi of culture, and incubated at 37°C 
overnight. The pGEM-T Easy Vector contains a /3-galactosidase reporter gene, 
which is inactivated following successful ligation of a DNA fragment into the
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vector, thus allowing positive transformants (white colonies) to be selected over 
negative colonies (blue).
Five white colonies were selected from each of the 100 pj plates and used 
to inoculate 5 ml of LB medium containing carbenicillin, which was incubated 
overnight at 37°C in a shaking incubator. Plasmid DNA was purified from 4.5 ml 
of each culture using a mini prep kit (Qiagen), according to the manufacturer’s 
instructions, with DNA eluted in 50 \x\ dh^O. The remaining 0.5 ml of each culture 
was used to generate a “glycerol stock” by mixing with an equal volume of 50% 
glycerol in a sterile screw cap tube, labelled appropriately and stored at -80°C. 
Plasmid DNA was quantified using a NanoDrop, and an EcoRI analytical digest, 
designed to excise the cloned fragment, performed on approximately 500 ng of 
DNA from each culture. DNA from cultures exhibiting the expected fragment size 
was sent for sequencing at the Cardiff Sequencing Core utilising the SP6 and T7 
promoter sites that flank the multiple cloning site (MCS) of the pGEM-T Easy 
Vector. Insert sequences were aligned with published mRNA sequences 
available from NCBI (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene). Insert 
orientation with respect to SP6 and T7 promoters was determined and any 
mismatches present in the cloned sequence were noted. Only constructs with 
sequences identical to the published mRNA sequence were retained for future 
use. Glycerol stocks of transformants that did not display 100% sequence identity 
were discarded, whereas glycerol stocks of those colonies that met this criterion 
were stored at -80°C until required, with riboprobes prepared as described in 
Sections 2.8.3 and 2.8.4.
2.8.2 Transformation of competent cells with cDNA vectors
In addition to the constructs created for Phlda2 and Slc22a18 riboprobes, several 
previously published in situ probes were also utilised. Constructs for these probes 
were supplied as either a small volume (-5  pil) of purified plasmid DNA in Tris, or 
“spotted” on a piece of 3MM paper, outlined in pencil and sealed in a sterile bag. 
Plasmids that were supplied in Tris were stored at -20°C until required, whereas 
those that were spotted on 3MM paper were placed in a sterile microfuge tube, 
covered with the minimum amount of 10 mM Tris (pH 8.0), incubated at room 
temperature for 5 minutes, and stored at -20°C.
76
In order to facilitate large-scale purification of plasmid DNA, each construct 
was transfected into chemically competent JM109 Escherichia coli (Promega), 
which were subsequently cultured and plasmid DNA extracted by midi prep. 
Competent cells (50 pi) were mixed with ~1 pg plasmid DNA (approximately 1-2 
pi) and incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 45 
seconds and placed on ice for 2 minutes. Room temperature SOC medium (950 
pi) was added and the culture incubated for 90 minutes at 37°C in a shaking 
incubator. Cultures were plated onto two agar plates containing the relevant 
antibiotic as described in Section 2.8.1, and plates incubated at 37°C overnight.
A single colony from the 100 pi plate was used to streak a second agar 
plate containing antibiotic and incubated overnight at 37°C. Four well-isolated 
individual colonies were selected from the second plate and grown overnight in a 
shaking incubator at 37°C in 5 ml of LB medium containing the appropriate 
antibiotic. Plasmid DNA was isolated from 4.5 ml of culture using a mini prep kit 
(Qiagen), following the manufacturers instructions and DNA eluted in 50 pi sterile 
H2O. A glycerol stock for each culture was prepared as described in Section 2.8.1 
and stored at -80°C.
In order to confirm that the correct construct had been transfected and 
purified, an appropriate analytical digest was performed on approximately 500 ng 
of plasmid DNA. Each analytical digest was designed to excise the cloned insert, 
thus generating two products, representing the vector backbone and the insert. 
Table 2.8 shows the expected size of the cDNA fragment for each construct 
when digested with the restriction enzyme shown. Restriction enzyme digests 
were performed in reaction volumes of 10 pi (Table 2.9) and incubated at the 
appropriate temperature for 4 hours prior to being analysed on a 1.5% TAE 
agarose gel. One sample exhibiting the correct insert size was selected for each 
construct and sequenced to ensure the correct cDNA fragment had been inserted 
and to confirm its orientation with respect to the RNA Polymerase promoters. 
Sequencing was performed from both promoters using 300 ng of DNA per 
reaction and carried out at the Cardiff Sequencing Core, and sequences 
compared with published mRNA sequences available from NCBI.
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Target Vector Resistance Analytical Digest Fragment Size
Ascl2 pBlueScript Ampicillin EcoRI 1,700 bp
C dknlc pBlueScript Ampicillin Xho\ 1,400 bp
Kdr pCDNA3 Ampicillin EcoRI 1,500 bp
Gcm1 Topoll Ampicillin EcoRI 400 bp
H andl pBlueScript Ampicillin Sa/I and Not\ 1,700 bp
Phlda2 pGEM T-Easy Ampicillin EcoRI 550 bp
PI1 pGEM2 Ampicillin Hind\\\ and Pst\ 800 bp
PI2 pGEM1 Ampicillin Hind\\\ and Sacl 800 bp
Slc22a18 pGEM T-Easy Ampicillin EcoRI 850 bp
Tpbpa pBlueScript Ampicillin EcoRI 750 bp
Table 2.8: Constructs used for generation of riboprobes
The table depicts the vector, antibiotic resistance, restriction enzyme used for 
analytical digest and size of insert for each riboprobes construct. All restriction 
enzymes were from New England Biolabs (NEB).
Volume (\i\)
H20 to 10
Buffer (1 OX) 1.0
BSA (100X) 0.1
Enzyme 1 (0.5 each for double digest)
Plasmid DNA 0.5 -1  ng
Table 2.9: Reaction constituents for analytical digests
Analytical restriction enzyme digests were performed to confirm the isolation of 
the anticipated construct. The table shows the constituent volumes for a single 
restriction enzyme digest reaction of mini or midi prep plasmid DNA.
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2.8.3 Midi prep of plasmid DNA and linearisation of probe constructs
Agar plates containing the appropriate antibiotic were inoculated using the 
glycerol stock of the required construct and incubated overnight at 37°C. A single, 
well-isolated colony was used to inoculate a second agar plate, and incubated 
overnight at 37°C. A single colony from the second agar plate was used to 
inoculate 5 ml of LB medium containing antibiotic and grown for 8 hours at 37°C 
in a shaking incubator at 200  rpm. 100 pi of this culture was used to inoculate 
200 ml LB medium, from which plasmid DNA was purified using a midi prep kit 
(Qiagen) following the manufacturer’s instructions, with DNA resuspended in 200 
pi 10 mM Tris (pH 8.0), and stored at -20°C. Analytical digests were performed 
on plasmid DNA preps as described in Section 2.8.2.
Two separate reactions were set up using the restriction enzymes shown 
in Table 2.10 to linearise each construct either side of the insert thus allowing the 
independent transcription of sense and anti-sense probes. A total of 30 pg of 
DNA was linearised in each reaction, with constituents as shown in Table 2.11. 
Restriction digests were incubated overnight at the appropriate temperature, and 
5 pi of reaction was run on an agarose gel alongside undigested vector to confirm 
complete linearisation.
Linearised plasmid DNA was phenol/chloroform extracted by first adjusting 
the volume to 500 pi with 10 mM Tris (pH 8.0), then adding an equal volume (500 
pi) of phenol and mixing. The mixture was centrifuged at 13,000 rpm for 10 
minutes at room temperature, and the upper aqueous phase was removed to a 
clean microfuge tube to which an equal volume of chloroform was added and 
mixed. The mixture was centrifuged as above, and the aqueous phase removed 
to another microfuge tube. A volume of 3 M NaOAc (pH 5.2) equal to one-tenth of 
the total volume of the aqueous phase was added in addition to 2.5 volumes of 
100% EtOH. DNA was precipitated overnight at -20°C, and centrifuged for 20 
minutes at 13,000 rpm at 4°C. The pellet was washed with 1 ml of 70% EtOH, 
allowed to air dry and resuspended in 25 pi of 10 mM Tris (pH 8.0). DNA 
concentration was determined using a NanoDrop as before, and adjusted to 1 
pg/pl using 10 mM Tris (pH 8.0) as required.
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Anti-sense probe Sense probe
Ascl2 Sma\ C/a I
Cdknlc Sacl Kpnl1
Kdr C/a I BamH\
Gcm1 Hind\\\ Xho\
Handl Sa/I Not\
Phlda2 Pst\ SacW
PI1 Hind\\\ Pst\
PI2 Hind\\\ Sacl
Slc22a18 Pst\ Sacll
Tpbpa Xba\ Kpnl1
Table 2.10: Restriction enzymes for plasmid linearisation
Constructs were linearised in two separate reactions using the restriction 
enzymes stated above. All restriction enzymes were obtained from NEB except 
1 from Promega.
Volume
RNase Free H2O to 200 pi
Buffer (1 OX) (NEB) 20 pi
BSA (1X) (NEB) 1 ptl
Enzyme 10 pi
DNA 30 pg
Table 2.11: Reaction constituents for linearisation
The table shows the constituent volumes for a single reaction to linearise a 
construct containing a cDNA fragment from which run-off DIG labelled 
riboprobes were generated.
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2.8.4 DIG labelling of riboprobes
The linearised plasmid DNA prepared in Section 2.8.3 was used as a template for 
the transcription of Digoxigenin-labelled riboprobes using SP6 , T3 or T7 RNA 
polymerase (Roche) as detailed in Table 2.12. Reaction constituents for DIG- 
labelling of riboprobes are shown in Table 2.13.
Anti-sense probe Sense probe
Ascl2 T3 T7
Cdknlc T3 T7
Kdr T7 T3
Gcm1 T7 SP6
Handl T7 T3
Phlda2 T7 SP6
PH T7 SP6
PI2 T7 SP6
Slc22a18 T7 SP6
Tpbpa T3 T7
Table 2.12: RNA Polymerase enzymes for probe transcription
Run-off DIG-labelled riboprobes were transcribed from linearised plasmid DNA 
using the appropriate RNA polymerase enzyme from Roche.
Volume
RNase Free H2O 12 pi
Transcription Buffer (10X) (Roche) 2 pi
DIG RNA Labelling mix (Roche) 2 pi
RNasin (Promega) 1 pi
RNA Polymerase (Roche) 2 pi
DNA 1 pi (1 pg/pl)
Table 2.13: Reaction constituents for DIG labelling
The table shows the constituent volumes for a single reaction for the generation 
of a DIG labelled run-off riboprobe.
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The DIG RNA labelling mix contains the nucleotide triphosphates ATP, 
CTP and GTP at a concentration of 10 mM. UTP is present at a concentration of
6.5 mM and is supplemented with 3.5 mM DIG-11-UTP, to make a total 
concentration of 10 mM. In this way, as the riboprobes are transcribed, 
approximately one in every three UTP molecules contains the DIG label.
Transcription reactions were incubated for 2 hours at 37°C, and DNA 
template digested by incubation with 20 units of DNasel (Ambion) for 15 minutes 
at 37°C. Probes were precipitated by addition of 2 i^l 3 M NaOAc (pH 5.2) and 
100 [i\ 100% EtOH, and incubated at -20°C overnight. RNA was pelleted by 
centrifugation at 13,000 rpm at 4°C for 20 minutes, the pellet washed with 70% 
EtOH, and allowed to air dry for a few minutes. The pellet was resuspended in 
100 l^ of DEPC treated H20  and divided into 10 \i\ aliquots, which were stored at 
-80°C.
2.8.5 Probe hybridisation
Slides were dewaxed in two changes of xylene for 10 minutes each, and 
rehydrated through graded ethanols of 100% (twice), 95%, 85%, 75%, 50% and 
30% for 1 minute each. Slides were incubated in 1X saline followed by 1X PBS 
for 5 minutes each and incubated in 6% hydrogen peroxide (in 1X PBS) for 30 
minutes at room temperature in order to inactivate endogenous alkaline 
phosphatase activity. Slides were washed twice in 1X PBS for 5 minutes each, 
fixed in ice cold 4% PFA (in 1X PBS) for 20 minutes and washed twice in 1X PBS 
for 5 minutes each. Slides were incubated for 5 minutes in Proteinase K 
(Melfords) (20 i^g/ml Proteinase K, 50 mM Tris, 5 mM EDTA in H20 ) at room 
temperature, washed in 1X PBS for 5 minutes, post-fixed in 4% PFA for 5 
minutes and washed in DEPC treated H20  for 2 minutes.
To reduce non-specific probe binding, slides were treated with acetic 
anhydride (0.01 M in 0.1 M triethanolamine hydrochloride), by incubating at room 
temperature for 10 minutes. Slides were washed with 1X PBS and 1X saline each 
for five minutes at room temperature. Slides were rehydrated through 30%, 50%, 
70%, 85%, 95% and 100% (twice) EtOH solutions, each for 1 minute, except for 
70%, in which slides were left for five minutes to prevent salt precipitation. Slides 
were air dried for 30 minutes, and placed into sealable boxes lined with 
absorbent paper soaked in moisture buffer (5X SSC, 50% (v/v) formamide in
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DEPC H2O). Probe was heated at 80°C for 3 minutes, and stored on ice, whilst 
hybridisation buffer (5X SSC, 50% formamide, 1% SDS, 0.05 mg/ml heparin, 
0.05 mg/ml calf liver tRNA in DEPC H20 ) was thawed at 80°C. An appropriate 
amount of probe and hybridisation buffer were mixed (per slide: 1 \x\ probe per 
100 i^l hybridisation buffer), and applied to relevant slides. A piece of parafilm 
was placed on top of the probe mixture, the box sealed with electrical tape and 
incubated at 62°C overnight in a water bath.
2.8.6 Post-hybridisation treatment
Slides were incubated in pre-warmed 5X SSC at 65°C for 30 minutes, and 
parafilm removed from solution using forceps. Slides were washed twice in pre­
warmed solution I (50% formamide, 5X SSC, 1% (v/v) SDS in DEPC H20 ) at 
65°C for 30 minutes each, and then washed three times in solution II (0.5 M 
NaCI, 0.01 Tris (pH 7.5), 0.1% Tween 20 in DEPC H20 ) at room temperature for 
10 minutes each. Slides were treated with RNase (0.02 mg/ml in solution II) to 
digest unhybridised probe, by incubation at 37°C for 45 minutes, followed by a 
final 10 minute was in solution II at room temperature. Slides were washed twice 
at 65°C in solution III (50% formamide, 5X SSC in DEPC H20 ) for 30 minutes 
each. Slides were washed twice in PBT (0.1% Tween 20 in 1X PBS) for 10 
minutes each and pre-blocked in 10% heat-inactivated sheep serum in PBT for 3 
hours, covered with a piece of parafilm as before. Anti-digoxigenin alkaline 
phosphatase conjugated antibody (Roche) was pre-absorbed for 3 hours at 4°C 
in 1% heat inactivated sheep serum in PBT containing 6 mg/ml dried, 
homogenised wild type placenta. Parafilm was removed from slides by washing 
in PBT for 5 minutes, and the pre-absorbed antibody diluted to a final 
concentration of 1:2000 in 1% sheep serum in PBT. Antibody solution (100 pil) 
was applied to each slide, covered with a piece of parafilm, and incubated 
overnight at 4°C.
2.8.7 Signal detection
Parafilm was removed from slides by washing in PBT for 5 minutes, followed by a 
further two five minute washes in PBT, and a subsequent three washes for 30 
minutes in PBT. Slides were preconditioned in three washes of NTMT (0.1 M 
NaCI, 0.1 M Tris (pH 9.5), 0.05 M MgCI2, 0.1% Tween 20) containing 2 mM
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Levamisole (Sigma) for five minutes each. BM Purple substrate (Roche) was 
applied directly onto each slide to completely cover sections. Slides were sealed 
in a dark box and incubated at room temperature until signal of the desired 
intensity developed. Slides were washed in PBT for 10 minutes, dhhO for 30 
minutes, and counterstained in Eosin Y Solution (Sigma) for up to 10 seconds. 
Excess eosin was washed in running tap water and slides air dried for 30 
minutes. Slides were cleared briefly in xylene, air dried and mounted in DPX 
mounting medium (Sigma).
2.8.8 Optimisation of in situ hybridisation
A number of steps were optimised during the development of the in situ 
hybridisation protocol. An important consideration was to prevent the slides from 
drying out following application of the probe. For this reason, slides were 
incubated in a water bath during the probe hybridisation step. Initially this step 
was performed in an incubator, which resulted in slides drying out and poor signal 
intensity after staining. Similarly, parafilm was used to prevent the slides drying 
out during hybridisation, pre-blocking and incubation with secondary antibody. 
Initially parafilm was only used during the hybridisation step, with the secondary 
antibody solution tending to drain from the slides during the overnight incubation.
Following these adjustments to the protocol the signal intensity and 
section integrity were determined to be suitable for experimental use. A number 
of slides were subjected to the in situ protocol using various probes. These slides 
were mounted using VectaMount Permanent Mounting Medium (Vector 
Laboratories). However, after several months the majority of slides developed a 
precipitate in the mounting medium that occasionally obscured the section. 
Furthermore, the intensity of the eosin counterstain had dramatically reduced. 
Subsequently all slides that were subjected to in situ hybridisation were mounted 
using DPX mounting medium and to date no such precipitate or de-staining has 
been observed. Due to the large number of slides that had been subjected to in 
situ hybridisation at this stage it was not feasible to repeat all experiments. In 
most instances a representative section could be found that was not obscured by 
the precipitate, and which demonstrated the pattern of staining appropriately. A 
comparison of the effects of the two mounting media used is shown in Figure 2.5.
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Figure 2.5: Effect of mounting medium on in situ hybridised section
integrity
Two mounting media were used for in situ hybridisation. A) Slides that were 
hybridised with riboprobes were initially mounted with VectaMount, which 
resulted in the development of a precipitate in the mounting medium of some 
sections (not shown) and decolouration of eosin staining. B) Subsequent 
slides were mounted in DPX mounting medium, which preserved the 
intensity of eosin staining and did not result in any precipitate formation. 
Scale bar = 1 mm.
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2.9 Digital photographs of placental sections
Photographs of placental sections were taken at varying degrees of magnification 
both for visualisation and presentation of the placental phenotype and in order to 
quantify the relative proportion of spongiotrophoblast and labyrinth regions. 
Photographs of entire placental midline sections from which spongiotrophoblast 
and labyrinth regions were measured were taken under low magnification using a 
Nikon SMZ1000 dissection microscope mounted with a Nikon CoolPix digital 
camera. Presentation quality photographs of all tissues including placentae were 
taken under various degrees of magnification between 2X and 20X using an 
Olympus BX41 light microscope mounted with a ColorView III Soft Imaging 
System digital camera operated through analySIS computer software.
2.10 Measurement of placental areas and volumes
Spongiotrophoblast and labyrinth areas were directly measured from H&E 
stained placental sections (Section 2.6) using the ImageJ freeware developed by 
NIH and downloaded from http://rsb.info.nih.gov/ij. Calibration was achieved by 
measuring a known distance on a photograph of a ruler and setting the measured 
length in pixels to equal the known distance. Photographs taken as described in 
Section 2.9 were opened in ImageJ and the “Freehand Selection” tool used to 
outline the relevant regions and derive their respective area. Spongiotrophoblast 
and labyrinth regions were measured both separately and together (total area).
Spongiotrophoblast and labyrinth volumes were measured from E14.5 
placenta. Whole placentae were sectioned end-to-end as described in Section 
2.5, photographed as in Section 2.9 and areas measured from each section as 
described above. Each area measured corresponded to every tenth section 
throughout the placenta, at a known distance of 100 (im apart. The measured 
areas together with the distance between sequential sections allowed the volume 
to be determined by the trapezium rule, using the formula below:
Volume (mm3) *  50 ( A0 + An + 2 (2Ar) )
Where Ao is the area of the first section; An is the area of the final section; 
and Ar represents the areas of all sections in between.
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2.11 Analysis of gene expression by qPCR
Expression of Phlda2, Slc22a18 and Cdknlc was assessed in placentae of lines 
10-15, 10-10 and 5D3 at E12.5 and E16.5. The relative expression of other 
genes of interest in the placenta, including nutrient transporters, was also 
assessed at E16.5 in lines 10-15 and 5D3. Quantitative reverse transcription 
polymerase chain reaction (qPCR) was utilised to examine gene expression in 
wild type and transgenic placenta. Expression levels were compared between 
two wild type and two transgenic placentae from the same litter at each time 
point, and confirmed by repeating the analysis on samples from a second litter. 
Total RNA was isolated from the tissue to be analysed, complementary DNA 
(cDNA) generated by reverse transcription of mRNA, and used as the template 
for qPCR.
2.11.1 Isolation of RNA from tissue samples
Conceptuses were dissected as described in Section 2.4, with tissue from which 
RNA was to be extracted frozen on dry ice and stored at -80°C until genotypes 
were ascertained (Section 2.3). Whole tissue (up to ~100 mg) was homogenised 
in 1 ml RNA-Bee (Ams Biotechnology) with an RNase-Free pestle (VWR 
International) in a 1.5 ml microfuge tube. Chloroform (200 jxl) was added to the 
homogenate, mixed vigorously and incubated on ice for five minutes. Tubes were 
centrifuged at 13,000 rpm for 15 minutes at 4°C, the aqueous phase removed to 
a fresh tube and 500 i^l isopropanol added. The isopropanol precipitation was 
incubated at room temperature for between 5 and 10 minutes and tubes 
centrifuged at 13,000 rpm for 5 minutes at 4°C to pellet RNA. The RNA pellet was 
washed in 75% EtOH (1 ml), and subsequently allowed to air dry prior to being 
resuspended in 10 mM Tris (pH 8.0).
RNA-Bee is designed to isolate only RNA, and thus prevent DNA or 
protein contamination. As a precaution to avoid potential genomic DNA 
contamination, all RNA extracts were DNase-treated prior to use in generating 
cDNA. Approximately 30 ^g of RNA was DNase-treated in a 1.5 ml microfuge 
tube as detailed in Table 2.14. RNA was incubated with RQ DNasel (Promega) at 
37°C for 45 minutes and RNA purified by phenol/chloroform extraction and 
NaOAc precipitation. Reaction volume was increased to 500 i^ l by addition of
87
RNase-free H2O, and an equal volume (500 pi) of phenol added. Tubes were 
centrifuged at 13,000 rpm for 10 minutes at room temperature and the aqueous 
phase transferred to a fresh tube. An equal volume of chloroform was added and 
tubes centrifuged as before. The aqueous phase was removed to a separate tube 
and RNA precipitated in 10% of aqueous phase volume 3 M NaOAc (pH 5.2) and 
2.5X aqueous phase volume 100% EtOH. Tubes were incubated at -20°C 
overnight and RNA pelleted by centrifugation at 13,000 rpm for 20 minutes at 
4°C. The pellet was washed with 70% EtOH, allowed to air dry and resuspended 
in 25 pi of 10 mM Tris (pH 8.0). RNA quality was assessed by running 1 pi on a 
2% TAE agarose gel, concentration determined using a NanoDrop as described 
previously, and adjusted to a concentration of 1 pg/pl in 10 mM Tris (pH 8.0).
Volume (pi)
dH20 to 100
RQ DNase I 10X Buffer (Promega) 10
RNasin 1
RQ DNase I (Promega) 10
RNA 30 pg
Table 2.14: Reaction constituents for DNase treatment of RNA
Total RNA was DNase treated to remove potential DNA contamination prior 
to reverse transcription. The table shows constituent volumes for a single 
DNase treatment reaction.
2.11.2 Reverse transcription of cDNA from total RNA
Single stranded RNA cannot be used as template material for a PCR reaction. To 
enable relative transcript levels to be determined, cDNA was generated by 
reverse transcription of mRNA. First strand cDNA representing the entire mRNA 
transcriptome was synthesised from DNase treated total RNA, using random 
primers (also known as random hexamers) of 6 nucleotides length (Promega), 
and the Moloney Murine Leukemia Virus Reverse Transcriptase enzyme (M-MLV 
RT) (H-) (Promega). For each sample, two reactions were performed; one in the 
presence of the reverse transcriptase (RT+) and one without reverse 
transcriptase (RT-).
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For each reaction, total RNA (5 pg) was incubated at 70°C for 10 minutes 
with 1 pi of random hexamers (0.5 pig/^ xl) (Promega) in a total reaction volume of 
11 pi in RNase-Free water (Ambion). First strand cDNA transcription master mix 
(8 pi) (Table 2.15) was added to each reaction, and incubated at 37°C for 2 
minutes. M-MLV (1 pil; 200 units) was then added to each RT+ reaction, 
transcription allowed to proceed for 1 hour at 37°C, with a final 15-minute 
incubation period at 70°C to denature the reverse transcriptase.
Volume (pi)
dH20 2.5
5X First strand synthesis buffer 4
RNasin 0.5
10 mM dNTPs 1
Table 2.15: Reaction constituents for reverse transcription of cDNA
DNase treated total RNA was used as the template for the reverse 
transcription of cDNA. The table shows the constituent volumes for a single 
reverse transcription reaction.
RT+ and RT- reactions were diluted 1:19 in 10 mM Tris (pH 8). The purity 
of cDNA was assessed by PCR amplification of fi-Actin or Gapdh (see Table 2.17 
for primer sequences). Separate PCR reactions using RT+ and RT- reactions as 
template material were set up as outlined in Table 2.16. Thermocycler conditions 
were 94°C for 3 minutes, followed by 35 cycles of 94°C for 30 seconds, 60°C for 
30 seconds, 72°C for 30 seconds, then a 72°C final elongation step for 3 minutes. 
Half of the volume of each reaction was loaded on a 1.5% TAE agarose gel 
containing Ethidum Bromide (later SafeView) and visualised under UV. 
Successful reverse transcription resulted in the generation of the correct sized 
product from RT+ cDNA. The absence of genomic DNA contamination in the 
DNase-treated RNA was shown by the lack of product in RT- reactions; the 
presence of a band of any intensity indicated the presence of genomic DNA 
contamination. In such instances, RNA was incubated with DNase for an 
increased time, and the process of cDNA transcription repeated until RT- 
reactions were clean. Diluted cDNA was further diluted 1:4 in 10 mM Tris (pH 8 ) 
and stored at -20°C until required for qPCR.
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Volume (pi)
dH20 16.7
Buffer (10X) (Sigma) 2.5
MgCl2(25 mM) (Sigma) 2.0
dNTPs (10 mM each) (Roche) 0.8
Primers (Sigma Genosys) 1.0
Genomic Red Taq (Sigma) 1.0
Template cDNA (1:19 dilution) 1.0
Table 2.16: Reaction constituents for PCR analysis of cDNA
Quality and purity of cDNA was assessed from RT+ and RT- reactions in 
separate PCR reactions. The table shows constituent volumes for a single 
PCR reaction utilised to assess cDNA quality.
2.11.3 Design of prim ers for qPC R
Quantitative PCR is based on the same principle as standard PCR, except with 
product amplification directly and quantitatively measured after each cycle rather 
than a semi-quantitative analysis at the end of the entire procedure. The 
generation of PCR product was analysed by measuring the incorporation of the 
fluorescent dye “SYBR Green” (Finnzymes) into the PCR amplified product. Due 
to the increased sensitivity required for qPCR, primers were designed to generate 
a product of between 100- and 250 bp. When possible, forward and reverse 
primers were designed to anneal within adjacent exons, thus providing an 
additional level of control over potential genomic DNA contamination. Primers 
were designed to amplify from mRNA sequences available through NCBI using 
Primer3 (http://www.ncbi.nlm.nih.gov/sites/entrez). These mRNA sequences 
were first aligned to the associated genomic DNA sequence (also from NCBI) 
using the Spidey mRNA-to-genomic alignment program 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/index.html). The mRNA 
sequences were then annotated with exon-exon boundaries before being entered 
into Primer3 to design appropriate primers. Previously published primers were 
used for the reference genes fi-actin (Ogawa et al., 2003) and Gapdh (Wu et al. 
2004). A summary of all qPCR primer sequences and their melting temperature is 
shown in Table 2.17, and their associated products in Table 2.18.
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Target ID Sequence Tm
Ascl2
R277 GAG CAG GAG CTG CTT GAC TT 59.9
R278 CAG TCA GCA CTT GGC ATT TG 60.5
/3-Actin
R150 CCT GTA TGC CTC TGG TCG TA 58.8
R151 CCA TCT CCT GCT CGA AGT CT 59.6
Cdknlc
R161 AGA GAA CTG CGC AGG AGA AC 60.0
R162 TCT GGC CGT TAG CCT CTA AA 60.0
Kdr
R327 GGC GGT GGT GAC AGT ATC TT 60.0
R328 GTC ACT GAC AGA GGC GAT GA 60.0
Gapdh
R148 CAC AGT CAA GGC CGA GAA TG 61.8
R149 TCT CGT GGT TCA CAC CCA TC 62.0
Gcm1
R283 AGC CTG TGT TGA GCA GAC CT 60.1
R284 TGT CGT CCG AGC TGT AGA TG 60.0
Handl
R287 CGC CTG GCT ACC AGT TAC AT 60.2
R288 GCG CCC TTT AAT CCT CTT CT 59.8
Igf2
R168 GTC GAT GTT GGT GCT TCT CA 59.8
R169 AAG CAG CAC TCT TCC ACG AT 60.0
Phlda2
EG36 TCA GCG CTC TGA GTC TGA AA 60.0
EG37 TCC TGG GCT CCT GTC TGA T 60.8
Slc2a3
R309 GAT CGG CTC TTT CCA GTT TG 59.8
R310 CAA TCA TGC CAC CAA CAG AG 60.1
Slc3a2
R259 TGA TGA ATG CAC CCT TGT ACT TG 62.2
R260 GCT CCC CAG TGA AAG TGG A 61.2
Slc22a18
EG84 TGA TGT CCA GTG TGC TCC AT 60.1
EG85 AGA GTT CGG GTC AAT GGT TG 60.0
Slc38a2
R331 ACT CAT ACC CCA CCA AGC AG 60.0
R332 CAC AAT CGC ATT GCT CAG AT 59.8
Slc38a4 
(4-kb specific)
R323 TGA TTG GGA TGT TAG TCT GAG G 59.1
R324 GGC CTG GGT TAA AAT GTG TG 60.2
Tpbpa
R285 TGA AGA GCT GAA CCA CTG GA 59.6
R286 CTT GCA GTT CAG CAT CCA AC 59.5
Table 2.17: List of primers used for qPCR analysis of gene expression
The table summarises the sequences and melting temperature (Tm) of 
primer sets used in qPCR analysis of gene expression.
Target
mRNA accession 
number (NCBI)
Nucleotides
amplified
Prod 
Size (bp)
luct
Tm
Ascl2 NM 008554 1 0 0 7 - 1182 176 84
/3-Actin NM 007393 502 -  761 260 85
C dkn lc NM 009876 1 0 4 7 - 1187 141 86
Kdr NM 010612 498 -  659 162 81
Gapdh NM 008084 2 1 8 -4 5 9 242 84
Gcm1 NM 008103 1 6 5 -3 3 6 172 81
H andl NM 008213 770 -  967 198 85
Igf2 NM 010514 468 -  662 195 86
Phlda2 NM 009434 409 -  532 124 86
Slc2a3 NM 011401 1 8 3 -3 5 8 176 81
Slc3a2 NM 008577 8 6 7 -  1049 183 81
Slc22a18 NM 008767 1 1 4 0 - 1305 166 82
Slc38a2 NM 175121 10 37 -11 6 3 126 79
Slc38a4 NM 027052 1 8 2 9 - 1995 167 77
Tpbpa NM 009411 2 5 -1 7 4 150 82
Table 2.18: Summary of qPCR products
The table shows the amplicon size and melting temperature for qPCR 
products. Approximate product Tm was determined from melting curves from 
Opticon Monitor and is provided for reference only. Anti primer-dimer steps 
were performed at least 2 degrees below the melting temperature of the 
product.
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2.11.4 Determination of relative gene expression
Gene expression was compared between wild type and transgenic tissue 
samples by qPCR. Relative transcript abundance was determined by measuring 
the incorporation of SYBR Green (DyNAmo HS SYBR Green qPCR kit) 
(Finnzymes) into the product detected by a Chromo4 Continuous Fluorescence 
Detector mounted on a PTC 200 Thermocycler (MJ Research). Thermocycler 
conditions were: 95°C for 15 min, followed by 35 cycles of 95°C for 30 sec, 60°C 
for 30 sec, 72°C for 30 sec and an anti primer-dimer step performed at between 
75°C to 82°C for 30 seconds. The anti-primer dimer step was performed to 
denature potential primer dimers, which may contribute to the measured 
fluorescence. The temperature of this step was set at least two degrees below 
the pre-determined melting temperature of the PCR product, to prevent 
denaturation of the specific product. Melting curve analysis was performed 
between 70°C and 95°C, at 0.5°C intervals. Fluorescence and melting curves 
were analysed using Opticon 3 software. Melting curves were examined to detect 
non-specific amplification or the presence of primer-dimers, evidenced by 
multiple peaks. A threshold fluorescence level was set in the early exponential 
phase for each assay. The point at which the fluorescence for each amplicon 
passed through this level was the cycle threshold (Ct), and was used to quantify 
relative transcript abundance.
Each assay consisted of a comparison between two wild type and two 
transgenic placentae from the same litter. Each sample was run in triplicate for 
each gene of interest (GOI) and reference genes fi-Actin and Gapdh. The fold 
change of gene expression in transgenic placentae compared to wild type was 
calculated according to the 2-M method (Livak and Schmittgen 2001). In each 
assay, the mean Ct for each sample was determined for all genes of interest and 
reference genes. The ACj for each gene of interest was determined by 
subtracting the mean C j for each reference gene from the mean Ct of each gene 
of interest. Separate ACj values were calculated for each wild type and 
transgenic sample, and for each of the two reference genes, as below.
CT WT GOI -  CT WT fi-Actin and CT WT GOI -  CT WT Gapdh
Ct Tg GOI -  Ct Tg fi-Actin and Ct Tg GOI -  Ct Tg Gapdh
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The AACt value was then determined for each combination of wild type 
and transgenic sample comparisons, by subtracting the ACT of the wild type from
r*-r-
the ACy of the transgenic sample. Fold change was determined by the 2'AA 
method relative to both reference genes as shown below:
2  -  [Ct Tg GOI -  C t Tg p-Actin] -  [Ct WT GOI -  C t WT p-Actin]
2  -  [Ct Tg GOI -  C t Tg Gapdh] -  [Ct WT GOI -  C t WT Gapdh]
For each assay, the mean fold change relative to the two reference genes 
was calculated, and the procedure repeated on the same samples to confirm the 
value. The same procedure was subsequently repeated on independent samples 
such that a total of four wild type and four transgenic samples were compared.
2.15 Investigating the post-natal phenotype
2.15.1 Weighing and dissection of adult mice
Adult mice were weighed weekly between P7 and 10 weeks of age, and 
subsequently every fifth week until one year of age. All mice weighed as part of 
this study were born within three weeks of each other, weaned at P28 and were 
co-housed with littermates of the same sex irrespective of genotype. No singly 
housed mice were included in this study. Mice were selected from this cohort at
10 weeks, 6 months and 1 year of age for fat pad and tibia measurements, thus
accounting for the decreasing value of n over the course of the year. Mice were 
selected based on genotype, with at least four wild type and four transgenic mice 
dissected at each time point. Dissections were performed blind, with the identity 
and genotype of animals unknown until all animals had been dissected and 
weights collected.
Mice were killed by CO2 inhalation at 10 weeks, 6 months and one year of 
age. Death was confirmed by the absence of response to pressure applied to the 
limbs. Blood was removed immediately following death by piercing the heart with 
a needle and removing blood into a syringe. Whole blood was immediately 
ejected into a heparinised tube, spun at 5,000 rpm for 5 minutes at room 
temperature and the serum removed and stored at -80°C until required.
Adipose tissue surrounding the intestines (mesenteric) and located behind 
the kidney (retroperitoneal) was dissected and weighed under advice from Dr Tim
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Wells of Cardiff University. Adipose tissue was either fixed overnight in 4% PFA 
at 4°C or frozen immediately on dry ice and stored at -80°C. Kidneys, liver and 
pancreas were also dissected and weighed, with kidneys either fixed as above or 
frozen and stored at -80°C, and liver and pancreas PFA-fixed. RNA was 
extracted from frozen tissue as described in Section 2.11.1, cDNA generated as 
described in Section 2.11.2 and gene expression assessed by qPCR (Section 
2.11.4). PFA-fixed tissue was washed in PBS and stored in 70% EtOH as 
described in Section 2.4, prior to embedding and sectioning by Derek 
Scarborough, and H&E staining as detailed in Section 2.6. The tibia from the rear 
left leg of each mouse was dissected under advice from Dr Tim Wells and the 
length measured.
2.15.2 Measurement of adipocyte cell diameter
Adipocyte size was estimated according to the method of Ashwell and colleagues 
(1976). Cell number was counted from three regions of H&E stained midline 
retroperitoneal adipose tissue sections viewed under a light microscope at 20X 
magnification. The “Touch Count” feature of analysis software was utilised to 
count cell number by marking counted cells such that no cell was included twice 
or excluded from the analysis. In contrast to the published method, whereby cells 
were included if at least half of their area was contained in the region, in this case 
cells were included if they crossed the left or lower boundaries, but excluded if 
they crossed the right or upper boundary of the field of view. The effect of such 
an alteration is minimal, but excludes the need for a subjective decision as to 
which cells to include and which to exclude. For each animal the three cell counts 
were individually converted to a calculated cell diameter (see formula below), and 
the mean value for each animal determined. Overall wild type and transgenic 
mean estimated cell diameters were calculated from these values. Cell diameter 
was calculated according to the formula:
Where of is the calculated average cell diameter, A is the defined area of 
the region from which cells were counted (in i^m2) m is the final magnification of 
the section and n is the number of cells counted in the region. The value for A 
was calculated using the scale bar in the analysis window, instead of from
d 2 x VA  
m x V(n x jt)
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photographs as described in the original method. Thus, as the defined area was 
equal to the actual area of the region, the final magnification was effectively 1X. 
Three regions were measured from three wild type and three transgenic animals 
at each age. An average calculated cell diameter was then determined for each 
individual, which was then used to calculate the mean cell diameter for wild type 
and transgenic animals at each stage.
2.16 Glucose tolerance testing
Glucose tolerance tests (GTT) were performed as described in Ma et al., (2004). 
Mice were removed to a clean cage and fasted overnight (approximately 16 
hours), with ad libitum access to water. Each mouse was weighed and a short (1- 
2 mm) piece of tail removed with a sterile sharp razor blade. The tail tip was 
gently bled by applying pressure from the base of the tail towards the tip, and 
blood collected in a HemoCue 201+ microcuvette (HemoCue) by capillary action. 
Excess blood was cleaned from the surface of the cuvette, which was placed in a 
HemoCue 201+ Glucose Analyser (HemoCue) to determine blood glucose 
concentration. Following determination of fasting baseline glucose levels, each 
mouse was injected with 2 mg/g filter-sterilised 2 M D-Glucose (Sigma) in dH2 0 . 
Blood glucose concentration was measured every 30 minutes for two hours by 
gently removing coagulated blood from the tail tip and following the same 
procedure described above. A maximum of eight mice were subjected to the 
procedure on any single day. Following the procedure, animals were placed in a 
fresh cage, and closely monitored for at least 24 hours to ensure no adverse 
effects ensued. Throughout the procedure animals were handled with care to 
prevent undue distress being caused, which may adversely affect subsequent 
measurements. Glucose tolerance tests were performed on the same cohort of 
animals at 10 weeks, 6 months and 1 year of age.
2.17 Magnetic Resonance Imaging (MR!)
Mice were killed by C 0 2-asphyxiation and scanned in a Bruker Biospec 94/20 
(9.4T) scanner, equipped with a 72 mm internal diameter quadrature coil. 
Multislice spin echo scans with a TR of 3000 ms, TE of 12 ms and a flip angle of 
180 degrees were performed. Sixty-four slices of 0.5 mm thickness were 
generated from a field of view of 8 cm by 4 cm, using a matrix size of 512 x 256,
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giving a resolution of 156 jxm/pixel. MRI scans were performed by Pawel 
Tokarczuk and Stephen Paisey at the EMRIC facility (Experimental MRI centre) 
within Cardiff School of Biosciences.
Two scans were performed on each mouse, one with fat suppression off 
and a second with fat suppression on. Fat suppressed scan images were 
subsequently subtracted from the non-suppressed scan images to generate a set 
of “fat-only” images from which total fat volumes were determined using Analyze 
MRI analysis software (Biomedical Imaging Resource, Mayo Clinic, Rochester 
MN). Whole animal volumes were determined from non-suppressed scan images, 
thus enabling a fat to body volume ratio to be determined for each mouse.
2.18 Enzyme-Linked ImmunoSorbent Assay (ELISA)
Serum concentration of insulin, leptin, and glucagon was determined by Enzyme- 
Linked ImmunoSorbent Assay (ELISA). Concentration of all three hormones was 
determined in the same reaction using 10 pil of serum (collected as described in 
Section 2.15.1) and the Mouse Endocrine Lincoplex Kit (Millipore). Each reaction 
was performed in duplicate on a 96-well microtitre plate alongside known 
standards. Absorbance was measured using a Luminex 100 plate reader, 
concentration of standards confirmed and used to determine the concentration of 
each hormone in each sample.
2.19 Statistical analysis of data
2.19.1 Choice of statistical test
Throughout the course of this investigation, data was collected from wild type and 
transgenic mice in order to compare a number of different variables, such as 
weight, area or volume. Appropriate statistical tests were chosen and applied to 
data sets to determine the probability that the two data sets (wild type and 
transgenic) were different. In each instance, two hypotheses were formulated; the 
null hypothesis (Ho) states that there is no difference between the two sets of 
data, whereas the alternative hypothesis (Hi) states that there is a difference 
between the two sets of data. The chosen statistical analysis tests whether or not 
the null hypothesis is true, by generating a probability value between 0 and 1.
97
The closer this value is to 0, the less likely the null hypothesis is to be true 
(Dytham 2003a).
Generally, one of two statistical tests was selected in order to compare the 
two data sets, dependent upon the distribution of the data. The Student’s two- 
tailed f-test (henceforth the t-test) was used in instances where the spread of 
data followed a normal, or Gaussian distribution (Dytham 2003d). Alternatively, 
for data that did not follow a normal distribution, statistical analysis was 
performed using the Mann-Whitney U test (henceforth the Mann-Whitney test) 
(Dytham 2003d). The choice of statistical analysis was critical in order to arrive at 
the correct conclusion regarding the data.
To determine whether the f-test or Mann-Whitney test was used, data was 
first analysed using the one-sample Kolmogorov-Smirnov test (henceforth the 
Kolmogorov-Smirnov test), which tests whether the data is from a normal 
distribution with the same mean and variance (Dytham 2003d). As for the f-test 
and Mann-Whitney test, two hypotheses were formulated. Ho states that the data 
follows a normal distribution with the same mean and variance as the sample 
data, whereas Hi states that the data does not follow a normal distribution as 
described above. The Kolmogorov-Smirnov test tests whether or not the null 
hypothesis was true, by calculating a probability value as described above. As 
this test has low sensitivity when sample sizes are low (Dytham 2003c), it was 
used only when sample size was sufficiently large (in this instance, more than 
approximately 20 observations). When fewer than around 20 observations were 
made, the Kolmogorov-Smirnov test could not be applied, and thus the spread of 
data could not be tested. Neither could the data be assumed to follow a normal 
distribution. In such instances, data were analysed using the Mann-Whitney test, 
which makes no assumption as to the spread of data.
2.19.2 The p-value
All three statistical analyses calculate a probability, or p value, which relates to 
the probability of the null hypothesis being correct. The smaller this value is, the 
less likely Ho is to be true, and thus the more likely we are to reject Ho in favour of 
Hi. Generally, the minimum level at which Ho was rejected (called the critical 
value) was 5%, such that Ho was rejected when p < 0.05. The critical value is 
also referred to as the significance level of a test. Smaller p values are
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associated with greater confidence in the conclusion for example, when p < 0 .0 1 , 
there is a 1% chance that Ho is true. Thus, for the Kolmogorov-Smirnov test, if p > 
0.05, the null hypothesis was not rejected, and the data was assumed to follow a 
normal distribution. Likewise, for both the f-test and Mann Whitney test, if p < 
0.05, the null hypothesis was rejected, and the two data sets were said to be 
“significantly different”.
The choice of statistical test was critical, as selection of the wrong type of 
analysis could result in the incorrect conclusion being drawn. Generally, two 
types of error are possible: a type I error results when the null hypothesis is 
incorrectly rejected, whereas a type II error occurs when the null hypothesis fails 
to be rejected (Dytham 2003b). A type I error results in the “false positive” 
identification of a statistically significant difference, where in fact there is no 
difference between data sets. At the 5% significance level, there is a 5% chance 
of making a type I error; using a lower significance level reduces the chance of a 
type I error, but increases the likelihood of a type II error. In general, the p value 
of each statistical test is given in the text and summarised on figures by the use 
of asterisks, the value to which they refer is defined in the figure legend.
2.19.3 The Chi-squared (x2) test
Genetic manipulation may directly or indirectly result in a varying degree of 
embryonic or post-natal lethality. The rules of Mendelian genetics dictate that by 
mating a transgenic male with a wild type female, transgenic and wild type 
progeny should be observed at equal frequencies at all stages. Further, as the 
transgene is not linked to a sex chromosome, transgenic and wild type animals 
should be present in a 1:1 ratio in both males and females. At all gestational 
stages examined, the observed number of wild type and transgenic animals was 
compared to the expected number using the Chi-squared test. The Chi-squared 
test tests the two hypotheses, Ho; that the observed number of animals is not 
significantly different to the expected number, and H-i; that there is a difference 
between the observed and expected numbers (Dytham 2003d). In all instances, 
the significance level was 5% and there was 1 degree of freedom, such that Ho 
was not rejected if the calculated p value was < 3.841.
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2.19.4 Normalisation of data
A number of environmental factors affect the growth of both embryo and 
placenta, which cannot be controlled for. Such factors result in a natural variation 
of weights of animals of the same genotype both within a litter (e.g. due to 
position in the uterus) and between litters (e.g. differences in litter size; slight 
variations in precise gestational age) (McLaren 1965). Initially raw data was 
analysed to identify any potential trends however, to account for the variation 
between individual weights, which may potentially mask or even introduce 
differences, all individual weights were “normalised”. The individual weight of both 
wild type and transgenic embryos and placentae were adjusted by the ratio of 
wild type mean at that gestational age to the wild type mean of the appropriate 
litter.
Mean of wild type x Individual value
Mean of wild types from litter 
This method does not affect the overall wild type mean, but individual 
values were adjusted according to the above ratio thus reducing the standard 
deviation of both wild type and transgenic data sets. Data were presented in 
graphical form throughout this investigation, with graphs for both raw and 
normalised data, with error bars representing the standard deviation. As the 
standard deviation does not take into account the sample size, no conclusions 
can be drawn regarding statistical significance from whether or not standard 
deviation error bars overlap. Error bars representing standard deviation are used 
in favour of those representing standard error as they portray the actual variance 
of the data more accurately.
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Chapter 3:
Characterising the placental phenotype of over­
expressing Phlda2 and Slc22a18
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3.1 Overview
Over 100 imprinted genes have been identified in the mouse, of which a 
significant number are expressed in the placenta (Coan et al. 2005; Tycko 2006). 
The role of some of these genes in the placenta has been examined through 
knockout mouse models, the phenotypes of which are summarised in Table 3.1. 
Of the three genes located on the transgene used in this investigation, knockout 
models have been generated for Cdknlc and Phlda2. Cdknlc exhibits 
widespread, low level expression in the spongiotrophoblast and labyrinth. Cdknlc 
null mice develop placentomegaly as a result of a proportional expansion of 
spongiotrophoblast and labyrinth layers, although there was no effect on giant 
cell or glycogen cell number (Takahashi et al. 2000). In contrast, Phlda2 
expression is restricted to the syncytiotrophoblast cells of the labyrinth. Loss of 
Phlda2 causes placentomegaly as a consequence of an expanded 
spongiotrophoblast layer and increased glycogen cell abundance (Frank et al. 
2002). Slc22a18 mRNA is detected in E12.5 and E14.5 placenta (Dao et al. 
1998), although the cell type(s) that express this gene have not yet been 
determined. The phenotype of Slc22a18 null mice is yet to be reported.
Examination of the phenotype resulting from the loss of an imprinted gene 
is useful for assigning a function to a particular protein. Such knockout models 
however, provide little insight as to the advantage of acquiring an imprint at a 
specific gene or locus. Additionally, a number of human diseases result from 
over-expression of imprinted gene due to their loss of imprinting. Thus, over­
expression animal models are vital in gaining a complete understanding of the 
role of imprinted genes in development of the embryo and placenta. Generation 
of such LOI models is significantly more difficult than creating a knockout model, 
with no approach able to reactivate the silent allele of a single imprinted gene. 
One approach involves the targeted deletion of the imprinting centre resulting in 
LOI of all genes in the domain. Consequently, there is loss of expression of some 
genes and two-fold expression of others making it difficult to assign a specific 
phenotype to a particular gene in the domain. Such mice have been generated 
for both the IC1 and IC2 sub-domains of mouse distal 7.
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Gene Null phenotype Reference
A sc 12
Loss of spongiotrophoblast 
Disruption of labyrinth 
Expansion of giant cell layer
(Guillemot et al. 1994) 
(Tanaka et al. 1997)
Cdknlc
Proportionate expansion of 
spongiotrophoblast and labyrinth
(Takahashi et al. 2000)
Cited 1 
(X-linked)
Irregular expansion of 
spongiotrophoblast 
Reduction and disruption of labyrinth
(Rodriguez et al. 2004)
Esx1
(X-lined)
Expansion of spongiotrophoblast 
Increased glycogen cell number 
Mislocalisation of spongiotrophoblast 
Disrupted vascularisation of labyrinth
(Li and Behringer 1998)
Grb10 Placentomegaly
(Charalambous et al. 
2003)
igf2
Disproportionate loss of labyrinth 
Disproportionate loss of glycogen 
cells from junctional zone
(Lopez et al. 1996) 
(Coan et al. 2008)
lgf2P0
Proportionate reduction of 
spongiotrophoblast and labyrinth
(Constancia et al. 2002)
Igf2r Placentomegaly (Lau et al. 1994)
Mest/Peg1
Proportionate reduction of 
spongiotrophoblast and labyrinth
(Lefebvre et al. 1998)
Peg 10
Complete loss of spongiotrophoblast 
Disrupted labyrinth development
(Ono et al. 2006)
Rt 11/Peg 11
Impaired passive transport due to 
phagocytic attack of fetal capillaries
(Sekita et al. 2008)
Phlda2
Expansion of spongiotrophoblast 
Increased glycogen cell number
(Frank et al. 2002)
Table 3.1: Placental phenotype of imprinted gene knockout mice
The table shows the placental phenotype(s) associated with targeted disruption 
of specific imprinted genes. Maternally expressed genes are in red, paternally 
expressed genes are in blue, X-linked imprinted genes are in black. The 
paternally inherited X chromosome is preferentially inactivated in the 
extraembryonic tissue of female mice.
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A mouse model of LOI at IC2 was generated by paternal inheritance of a 
disrupted Kvdmrl, resulting in expression of Cdknlc, Ascl2, Phlda2 and 
Slc22a18 from both paternal and maternal alleles. Transgenic embryos exhibited 
symmetric growth restriction, which persisted into adulthood (Fitzpatrick et al. 
2002). Furthermore, transgenic placentae were approximately 20% lighter than 
wild type (Salas et al. 2004). The Kvdmrl null mouse clearly demonstrates a role 
for Kvdmrl in suppressing paternal expression of a number of adjacent imprinted 
genes, and a role for these genes in placental and embryonic growth. However, 
the model is limited by an inability to accurately determine the relative 
contribution of each gene to the phenotype.
The contribution of Phlda2 to the Kvdmrl*1' phenotype was examined by 
analysing the effect of restoring Phlda2 gene dosage to normal. Mice that inherit 
a paternal Kvdmrl null allele in addition to a maternal Phlda2 null allele possess 
a single active Phlda2 allele, albeit on the paternal allele, whereas all other genes 
under the control of Kvdmrl remain biallelic. Kvdmrl null placentae were -20%  
lighter than wild type. Restoration of Phlda2 gene dosage to normal resulted in a 
-10%  reduction in placental weight compared to wild type and a -50%  rescue of 
embryonic growth. Kvdmrl null placentae also exhibit a reduced 
spongiotrophoblast region, which was restored to within the normal range by 
normalising Phlda2 expression (Salas et al. 2004). Such comparative phenotypic 
analysis demonstrated a role for Phlda2 in limiting expansion of the 
spongiotrophoblast, reciprocal to the Phlda2 null mouse (Frank et al. 2002). 
However, the biallelic expression of other imprinted genes complicates a more 
detailed phenotypic analysis, particularly the investigation of adult phenotypes. 
Despite a partial rescue of embryonic growth restriction, restoring Phlda2 gene 
dosage to normal did not rescue the symmetric growth restriction observed at 
P14 (Salas et al. 2004), which may to be due to over-expression of Cdknlc 
(Andrews et al. 2007).
The aim of the work presented in this chapter was to further characterise 
the effect of over-expressing Phlda2 and Slc22a18 in the mouse placenta. 
Transgenic mice from line 10-15, which possess three copies of a modified BAC 
transgene from which Phlda2 and Slc22a18 are expressed were used to 
investigate the effect of over-expressing these genes in the placenta. Although
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not necessarily an optimal model for LOI due to the presence of an additional 
three copies of the genes, such a transgenic model may allow the phenotypes 
associated with Kvdmrl null mice to be assigned to one or other of these genes. 
Furthermore, the excess expression from the transgene may amplify any 
associated phenotype. Gene expression was first examined using qPCR and in 
situ hybridisation with probes specific for Phlda2 and Slc22a18. Placental weights 
were measured from E12.5 to E18.5 coupled with an examination of gross 
placental morphology from midline placental sections stained with haematoxylin 
and eosin staining. Labyrinth and spongiotrophoblast regions were directly 
measured from H&E stained sections from mid-late gestation placentae. 
Glycogen cell number was increased in Phlda2 null placentae; glycogen content 
was assessed in transgenic placentae using periodic acid Schiff staining. Markers 
for several trophoblast cell types were analysed by in situ hybridisation, including 
those for giant cells, spongiotrophoblast and labyrinth.
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3.2 Results
3.2.1 Appropriate spatial and temporal expression of Phlda2 and 
Slc22a18 in transgenic placentae
Southern blotting previously identified the presence of three copies of the 
modified BAC transgene in line 10-15 (John et al. 2001). Expression of both 
genes was reported to be at least 10-fold greater than endogenous levels in 
transgenic placentae at E14.5 and E16.5 on a mixed genetic background (Salas 
et al. 2004). Furthermore, in Kvdmrl null placenta, despite the presence of only 
two active copies of Phlda2, transcript levels were reported to be approximately 
four-fold the level of wild type placentae (Salas et al. 2004). Microarray analysis 
performed by Professor Tycko reported a 6.6  fold increase in Phlda2 transcript 
levels in a comparison of three wild type and three transgenic placentae from line 
10-15 on a mixed genetic background. Analysis of Slc22a18 expression on this 
same microarray showed that expression was upregulated 5.4-fold in transgenic 
placentae. Previous analysis of expression of Slc22a18 and in particular of 
Phlda2 therefore suggested that transcript level was not correlated with the 
number of active gene copies present. Expression of these two genes in addition 
to Cdknlc was further analysed by qPCR and in situ hybridisation.
Expression levels of Phlda2, Slc22a18 and the inactivated Cdknlc were 
first assessed in line 10-15 by qPCR at E12.5, when Phlda2 levels are at their 
peak, and at E16.5, at which point only a few Phlda2-express\ng cells remain in 
the labyrinth (Frank et al. 2002). The relative fold change for each gene in 
transgenic placentae compared to wild type at E12.5 and E16.5 is shown in 
Figure 3.1. Fold changes represent the mean fold change observed between a 
total of four wild type and four transgenic placentae, from two litters normalised to 
two reference genes, as described in Section 2.11. Phlda2 was expressed at 
3.70-fold (± 0.53) wild type levels at E12.5 and 3.33-fold (± 0.49) wild type levels 
at E16.5. Similarly, Slc22a18 was expressed at 3.39-fold (± 0.87) the level of wild 
type at E12.5 and 2.73-fold (± 0.49) wild type at E16.5. Consistent with 
inactivation of Cdknlc by insertion of the fi-galactosidase reporter, Cdknlc 
expression was comparable in wild type and transgenic placentae at E12.5 (1.18 
±0.26) and E16.5 (1.03 ± 0.26).
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Figure 3.1: Relative expression levels of Phlda2, Slc22a18 and Cdknlc
Expression of Phlda2, Slc22a18 and Cdknlc was examined by qPCR to 
determine if expression levels correlated with transgene copy number. 
Relative expression levels were compared for the three genes located on the 
transgene at E12.5 and E16.5. Graph shows the relative fold change in gene 
expression determined by qPCR in transgenic placentae compared to wild 
type from line 10-15 on a pure 129/Sv background. Error bars represent 
standard deviation of fold change from four repeats.
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The critical difference between the previously reported expression levels 
and the more recently generated data was the genetic background of the tissue. 
Expression of Phlda2 was more than 10-fold endogenous levels on a mixed 
genetic background, with four-fold expression observed on a pure 129/Sv 
background. Intermediate levels of expression were observed in tissue collected 
from conceptuses between these two stages. Expression was next examined by 
in situ hybridisation. Visualisation of mRNA expression enabled the spatial 
expression pattern of both genes to be examined. Additionally, the Cdknlc 
spatial expression pattern was assessed by in situ hybridisation. Phlda2 and 
Slc22a18 riboprobes were designed as described in Section 2.8.1, and 
hybridised to midline placental sections of appropriate gestational stages as 
detailed in Section 2.8.5 and 2.8.6.
Phlda2 is highly expressed during early gestation, with the number of 
P/?/da2-expressing cells declining dramatically by E14.5, although a small 
number of labyrinth trophoblast cells continue to express the gene until late 
gestation (Frank et al. 2002; Frank et al. 1999; Qian et al. 1997). Expression of 
Phlda2 was examined at E10.5 and E12.5 to compare relative expression levels 
during early gestation and to confirm that the number of cells expressing Phlda2 
is comparable in transgenic and wild type placentae. In contrast, little is known 
about the temporal or spatial expression of Slc22a18, and thus expression was 
initially assessed at E12.5.
Phlda2 expression in wild type and transgenic placentae was assessed by 
in situ hybridisation at E10.5 and E12.5. At both stages signal was only detected 
on slides hybridised with anti-sense probe, with no signal observed on slides 
hybridised with the sense probe and stain developed for the same duration. At 
E10.5, Phlda2 expression was widespread in cells of the extraembryonic 
ectoderm of both wild type and transgenic placentae (Fig 3.2 A and B). By E12.5, 
expression became more restricted, with signal detected only in discrete cell 
clusters of the labyrinth of both wild type and transgenic placentae (Fig 3.2 C and
D). There was no overt difference in the number of cells expressing Phlda2 in 
transgenic placentae compared to wild type, although signal intensity was 
noticeably greater in transgenic placentae.
The localisation of Slc22a18 expression in the mouse placenta has not 
previously been described, although placental expression has been reported at
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E12.5 and E14.5, (Dao et al. 1998). As an organic cation transporter, expression 
would be expected in cells of the labyrinth. In situ hybridisation was utilised to 
observe the expression pattern of Slc22a18 at E12.5 in both wild type and 
transgenic placentae, with widespread signal detected in the labyrinth and 
increased signal intensity in transgenic placentae compared to wild type (Fig 3.2 
E and F). As predicted by qPCR analysis of Cdknlc expression, no overt 
difference was observed in spatial expression between wild type and transgenic 
placentae at E14.5 (Fig 3.2 G and H).
To confirm that elevated expression of Phlda2 resulted in increased 
translation and production of Phlda2 protein, immunohistochemical staining using 
an antibody specific for mouse Phlda2 was performed by Ben Tycko (Colombia 
University, New York). At both E10.5 and E12.5, Phlda2 protein signal was 
overtly increased in transgenic placentae and similarly localised in the anticipated 
regions (Fig 3.3).
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Figure 3.2: Expression of Phlda2, Slc22a18 and Cdknlc  during early
gestation
Spatial expression patterns for the three genes located on the transgene 
were assessed by in situ hybridisation. Midline placental sections from line 
10-15 on a pure 129/Sv background were hybridised with an anti-sense 
probe specific for Phlda2 (A-D), Slc22a18 (E and F) and Cdknlc (G and H). 
Sections from wild type placentae (left panels) and transgenic placenta (right 
panels) are at E10.5 (A and B), E12.5 (C-F) and E14.5 (G and H). Broken 
line indicates boundary between labyrinth (lower) and spongiotrophoblast 
(upper). Scale bar = 200 p irn .
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Figure 3.3: Immunohistochemical localisation of Phlda2 at E10.5 and E12.5
To confirm that elevated expression of Phlda2 was associated with 
increased translation, immunohistochemical staining using an antibody 
specific to mouse Phlda2 was performed at E10.5 and E12.5. H&E stained 
midline placental sections (left panels) and Phlda2 IHC sections (right 
panels) from line 10-15 on a pure 129/Sv background. Figure shows wild 
type (A, B, E, F) and transgenic (C, D, G, H) at E10.5 (A-D) and E12.5 (E-H). 
Phlda2 protein signal was more intense in transgenic placentae, with no 
overt effect on number of positive cells. Broken line indicates boundary 
between labyrinth (lower) and spongiotrophoblast (upper). Scale bar = 200 
[xm.
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3.2.2 Reduced weight of transgenic placentae
Targeted deletion of Phlda2 in the mouse placenta causes placentomegaly, with 
a 22% increase in mean placental weight observed at E12.5 and a 27% increase 
at E16.5. Both Phlda2neo and Phlda2ioxP null lines displayed a comparable 
increase in placental size, which was further enhanced when crossed onto a pure 
C57BL/6 background (Frank et al. 2002). Initial characterisation of line 10-15 on a 
mixed genetic background revealed a reciprocal phenotype to the Phlda2 KO, 
with a 25% reduction in placental weight at E14.5 and a 17% reduction at E16.5 
(Salas et al. 2004).
Placental weights were gathered throughout gestation on a pure 129/Sv 
genetic background. Placental weight was examined from E12.5 until E18.5, in 
order to characterise the effect of Phlda2 over-expression on early placental 
development and the extent of the placental phenotype prior to birth at E19. The 
earliest time-point at which accurate weight data could be obtained was E12.5, 
and thus placenta were weighed at E12.5, E13.5, E14.5, E16.5 and E18.5, 
generating a set of weight data representing stages between mid gestation and 
birth. At least six litters were collected at each stage, with data only utilised if at 
least two wild type and two transgenic embryos were in the same litter. Raw 
weight data was analysed and is presented in Figure 3.4A. Transgenic placentae 
were 15.4% lighter than wild type at E12.5 (51.1 mg ± 8.4 versus 42.3 mg ± 9.7; 
9 litters; n = 74; p = 7.8 x 10"5), increasing to a 25.3% weight deficit at E13.5 
(54.8 mg ± 9.0 versus 41.0 mg ± 9.6; 6 litters; n = 41; p = 2.9 x 10'5). At E14.5, 
transgenic placentae were 14.8% lighter (78.7 mg ± 12.5 versus 67.0 mg ± 11.5; 
9 litters; n = 53; p = 1.1 x 10"3) , and 17.6% lighter at E16.5 (82.3 mg ± 10.1 
versus 67.8 mg ± 10.1; 8 litters; n = 58; p = 1.05 x 10‘6). Prior to birth at E18.5, 
transgenic placentae were only 6.5% lighter than wild type, without achieving 
statistical significance (79.2 mg ± 11.4 versus 75.5 mg ± 18.3; 10 litters; n = 6 8 ; p 
= 0.310).
Individual raw weights of wild type placentae exhibited a standard 
deviation of up to 17% the mean weight for each gestational stage, with greater 
variation observed in transgenic placentae. Such variations in weight may be 
caused by a number of factors that could not be controlled for, such as litter size, 
exact gestational age, position of the conceptus in the uterine horn, maternal
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health and other environmental factors (McLaren 1965). To prevent such factors 
from potentially disguising or influencing apparent weight phenotypes, individual 
weights of both wild type and transgenic embryos were adjusted by the ratio of 
the mean wild type weight for the gestational stage to the mean wild type weight 
for the litter, as described in Section 2.19.4. Such manipulation did not alter the 
mean wild type weight, but reduces the standard deviation of both wild type and 
transgenic data sets. Mean normalised embryonic weights of wild type and 
transgenic embryos are presented in Figure 3.4B, with error bars representing 
standard deviation of normalised data. The mean transgenic weight is presented 
as a percentage of mean wild type weight for each gestational stage.
Following normalisation of placental weight data, transgenic placenta were 
15.4% lighter than wild type at E12.5 (51.1 mg ± 6.5 versus 43.2 mg ±9.7;  9 
litters; n = 74; p = 9.1 x 10'5), increasing to a 26.2% difference at E13.5 (54.8 mg 
± 6.2 versus 40.5 mg ± 8 .6 ; 6 litters; n = 41; p = 5.5 x 10'7). Transgenic placentae 
were 14.9% lighter at E14.5 (78.7 mg ± 6.5 versus 66.9 mg ± 6.4; 9 litters; n = 53; 
p = 3.1 x 10'8), and 16.6% lighter at E16.5 (82.3 mg ± 6.3 versus 68.7 mg ± 11.3; 
8 litters; n = 58; p = 3.99 x 10'7). At E18.5, transgenic placentae were observed to 
be only 9% lighter than wild type (79.2 mg ± 7.2 versus 72.5 mg ± 11.6; 10 litters; 
n = 6 8 ; p = 0.0018).
Wild type placentae reached their maximum weight at E14.5, exhibiting an 
increase of approximately 50% between E12.5 and E14.5, with the majority of 
this weight gain occurring from E13.5. Wild type placental weight did not 
significantly alter between E14.5 and E18.5. Transgenic placentae exhibited a 
similar growth pattern, with a rapid gain in weight between E13.5 and E14.5. In 
contrast to wild type placental growth, the weight of transgenic placentae 
increased by approximately 10% between E16.5 and E18.5, such that the extent 
of the weight difference at E18.5 was considerably less than at E14.5. 
Furthermore, the weight of individual transgenic placenta was considerably more 
variable than that of wild type, particularly at later gestational stages.
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Figure 3.4: Placental weights from line 10-15 between E12.5 and E18.5
Placental weight was examined throughout gestation to examine the effect of 
over-expressing Phlda2 and Slc22a18 in the placenta. Graphs show A) raw 
and B) normalised mean weight of wild type and transgenic placenta at the 
indicated stages during gestation from line 10-15 on a pure 129/Sv 
background. Error bars show standard deviation. Significance level according 
to the Student’s f-test indicated by asterisks: ** p < 0.01 ;*** p < 0.001.
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The number of wild type and transgenic conceptuses observed at each 
developmental stage was compared to the number that would be expected 
according to Mendelian ratios using the Chi-squared ( x 2) test. P values for each 
analysis are shown in Table 3.2. At all stages examined the probability value was 
less than the critical value of 3.841, thus indicating that there was no difference 
between the expected number and observed frequency. The observed n values 
include litters in which there were fewer than 2 individuals of each genotype, and 
thus were excluded from weight analysis.
Stage
Wild i 
Observed n
type 
Expected n
Trans 
Observed n
genic 
Expected n
P ( x 2)
E12.5 43 44 45 44 0.046
E13.5 28 34 40 34 2.120
E14.5 39 41 43 41 0.195
E16.5 43 39 35 39 0.821
E18.5 48 44.5 41 44.5 0.551
Table 3.2: P-values for Chi-squared test
A factor to be considered when investigating transgenic mouse models is an 
unexpected effect on embryonic viability, resulting in a reduced number of 
transgenic progeny compared to the expected frequency. The Chi-squared 
test was performed to determine if the observed frequency of wild type and 
transgenic progeny at each stage during gestation differed significantly from 
the expected frequency predicted by Mendelian inheritance. At the five stages 
examined, there was no deviation from the expected frequency of transgenic 
progeny.
3.2.3 Reduced spongiotrophoblast in transgenic placentae
In Phlda2 null placentae, the ratio of spongiotrophoblast to labyrinth cross- 
sectional area was increased by approximately 50% at E16.5, as a consequence 
of the disproportionate expansion of the spongiotrophoblast, with a slight 
increase in labyrinth area (Frank et al. 2002). Over-expression of Phlda2 has 
indirectly been shown to restrict development of the spongiotrophoblast. Mice 
that inherit a paternal deletion of Kvdmrl, and thus over-express Phlda2 in 
addition to Cdknlc, Ascl2 and others (Fitzpatrick et al. 2002), exhibit a 24% 
reduction in the spongiotrophoblast to labyrinth ratio at E14.5. When Phlda2 
expression levels were restored to normal by maternal inheritance of a Phlda2
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null allele in addition to the paternally inherited Kvdmrl null, the 
spongiotrophoblast to labyrinth ratio was almost entirely rescued, with a 6 % 
reduction compared to wild type placentae observed at E14.5 (Salas et al. 2004). 
Thus, over-expression of Phlda2 accounts for around 75% of the alteration to the 
spongiotrophoblast to labyrinth ratio at this stage. A similar pattern of results was 
reported at E16.5, however the margins were greatly reduced and thus statistical 
significance was not achieved between the comparisons as above.
The gross morphology of placentae between E10.5 and E18.5 was 
examined from H&E stained midline sagittal sections (Fig 3.5). Transgenic 
placentae were visibly smaller from as early as E10.5, although accurate weight 
data could not be obtained at this early stage. At this stage, the ectoplacental 
cone and extraembryonic ectoderm regions could not be distinguished 
morphologically at low magnification. At E12.5, the spongiotrophoblast and 
labyrinth regions of the placentae could be distinguished under low magnification 
on a light microscope. At E14.5, H&E staining enabled the spongiotrophoblast 
and labyrinth regions to be readily distinguished under low magnification on a 
dissection scope. The spongiotrophoblast was generally more darkly stained and 
exhibited large maternal blood lacunae in wild type placentae, which were 
markedly reduced or absent in transgenic placentae. Wild type placentae at 
E16.5 were essentially the same as E14.5, although with a larger labyrinth layer 
at the expense of a smaller spongiotrophoblast with reduced maternal blood 
spaces. Similarly, transgenic placentae exhibited a reduced spongiotrophoblast 
with smaller maternal blood spaces. At E18.5, the size of the spongiotrophoblast 
was reduced in wild type placentae, and was generally more compact than at 
earlier stages. In transgenic placentae, the spongiotrophoblast region was barely 
distinguishable at E18.5.
Spongiotrophoblast and labyrinth regions were previously quantified at 
E14.5 and E16.5 from Kvdmrl null and Kvdmrl/Phlda2 null placentae. Similarly, 
these regions were quantified at these stages in wild type and transgenic 
placentae from line 10-15. At E14.5, the volume of both regions was determined 
and compared to areas measured from midline sections to assess whether 
midline area measurements provided an adequate approximation of volume. 
Midline areas were also measured at E16.5.
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Figure 3.5: H&E staining of midline placental sections
Gross placental morphology was assessed from H&E stained midline 
sections of wild type (left panels) and transgenic (right panels) at (from top) 
E10.5, E12.5, E14.5, E16.5 and E18.5. Placentae were from line 10-15 on 
a pure 129/Sv background. Dashed lines denote boundary of 
spongiotrophoblast, which was overtly reduced in transgenic placentae. 
Scale bar = 500 i^m.
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Spongiotrophoblast and labyrinth volumes were measured as described in 
Section 2.10, with the total volume representing a separate measurement 
encompassing both spongiotrophoblast and labyrinth regions. Volume 
measurements for each region are displayed in Figure 3.6A. At E14.5, the mean 
spongiotrophoblast volume of transgenic placentae was 60.4% less than that of 
wild type (3.44 mm3 ± 0.60 versus 1.36 mm3 ± 0.34; 1 litter; n = 8 ; p = 0.029), 
whereas a 10 .3% reduction in labyrinth volume was observed, although this did 
not reach statistical significance (9.21 mm3 ± 0.77 versus 8.26 mm3 ± 1.13; 1 
litter; n = 8 ; p = 0.200). The combined volume of spongiotrophoblast and labyrinth 
of transgenic placentae was 24.5% smaller than that of wild type (12.81 mm3 ± 
1.20 versus 9.67 mm3 ± 1.40; 1 litter; n = 8 ; p = 0.029). The ratio of 
spongiotrophoblast to labyrinth volume was reduced 2.3-fold in transgenic 
placentae compared to wild type (0.37 ± 0.056 versus 0.16 ± 0.025; 1 litter; n = 8 ; 
p = 0.029).
To determine if area measurements at the placenta midline could be used 
as an estimate of region volume, spongiotrophoblast and labyrinth cross sectional 
areas were measured from midline sections of placentae at E14.5 (Fig 3.6B), and 
compared to volume measurements above (Table 3.3). At E14.5, the mean 
spongiotrophoblast area of transgenic placentae was 59.9% smaller than that of 
wild type (1.35 mm2 ± 0.40 versus 0.54 mm2 ±0.13; 3 litters; n = 18; p = 6.28 x 
10'5), whereas a 2.7% reduction in labyrinth area was observed, although this did 
not reach statistical significance (3.66 mm2 ± 0.36 versus 3.56 mm2 ± 0.59; 3 
litters; n = 18; p = 0.930). The combined area of spongiotrophoblast and labyrinth 
of transgenic placentae was 19% smaller than that of wild type (5.10 mm2 ± 0.41 
versus 4.13 mm2 ± 0.58; 3 litters; n = 1 8 ; p  = 1 . 1 9 x  10'3). The ratio of 
spongiotrophoblast to labyrinth area was reduced by 2.4-fold in transgenic 
placentae compared to wild type (0.38 ±0.13 versus 0.16 ± 0.05; 3 litters; n = 18; 
p = 4.4 x 10'4).
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Figure 3.6: Measurement of spongiotrophoblast and labyrinth at E14.5
Spongiotrophoblast and labyrinth size was quantified at E14.5 by 
measurement of entire volume and midline areas. Graphs show A) raw volume 
and B) raw area of spongiotrophoblast (Sp.), labyrinth (Lab.) and combined 
spongiotrophoblast and labyrinth regions (Total) for wild type and transgenic 
placentae of line 10-15 on a pure 129/Sv background at E14.5. Error bars 
show standard deviation. Significance level calculated by the Mann Whitney 
test is indicated by asterisks: * p < 0.05; ** p < 0.01; *** p < 0.005.
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The two methods for quantification of region size by volume and area 
measurement were compared to determine if area measurements provide an 
adequate estimation of total volume, as shown in Table 3.3. Measurement of both 
volume and area detected a ~60% reduction in spongiotrophoblast size. Although 
slight differences in labyrinth and combined spongiotrophoblast and labyrinth 
were observed between area and volume measurements, the ratio of 
spongiotrophoblast to labyrinth region was consistent between the two methods. 
Measurement of the cross-sectional area of a region at the placental midline 
provides an accurate estimate for the total volume of the placental region.
Proportion of area 
Spongiotrophoblast
in transgenic c 
Labyrinth
compared to area i 
Total
n wild type 
Ratio
Volume 39.6* 89.7 75.5* 2.3*
Area 40.1 *** 97.1 81.0 *** 2 4 ***
Table 3.3: Comparison of volume and area measurements to estimate 
spongiotrophoblast to labyrinth ratio
Spongiotrophoblast to labyrinth ratios were derived from mean area and volume 
measurements and compared to determine if measurement of midline area 
represents an acceptable approximation for volume. Significance level 
calculated by the Mann Whitney test is indicated by asterisks: * p < 0.05; ** p < 
0.01 ; * * * p <  0.005.
Area measurements at E16.5 revealed that the loss of spongiotrophoblast 
observed at E14.5 persists to a similar extent at this later stage. The mean 
spongiotrophoblast area of transgenic placentae was 62.3% smaller than that of 
wild type (1.27 mm2 ± 0.32 versus 0.48 mm2 ±0.15; 3 litters; n = 21; p = 5.67 x 
10'6), whereas a 4.9% reduction in labyrinth area was observed, although this did 
not reach statistical significance (4.51 mm2 ± 0.57 versus 4.29 mm2 ± 0.87; 3 
litters; n = 21; p = 0.349). The combined area of spongiotrophoblast and labyrinth 
of transgenic placentae was 19% smaller than that of wild type (5.67 mm2 ± 0.91 
versus 4.77 mm2 ± 0.87; 3 litters; n = 21; p = 0.043). The ratio of 
spongiotrophoblast to labyrinth volume was reduced 2.4-fold in transgenic 
placentae compared to wild type (0.28 ± 0.06 versus 0.12 ± 0.04; 3 litters; n = 21; 
p = 5 .67x1 O'6).
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Figure 3.7: Measurement of spongiotrophoblast and labyrinth areas
Spongiotrophoblast and labyrinth areas were further quantified at E16.5 to 
confirm the persistence of the phenotype at this stage. Graph shows mean 
raw areas of spongiotrophoblast (Sp.), labyrinth (Lab.) and combined 
spongiotrophoblast and labyrinth regions (Total) of wild type and transgenic 
placentae from line 10-15 on a pure 129/Sv background at E16.5. Error bars 
show standard deviation. Significance level calculated by the Mann Whitney 
test is indicated by asterisks: * p < 0.05; ** p < 0.01; *** p < 0.005.
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Phlda2 is predominantly expressed during early gestation and thus it is 
likely that the loss of spongiotrophoblast observed at E14.5 and E16.5 was a 
consequence of perturbed placental development at earlier gestational stages. It 
was not possible to clearly distinguish spongiotrophoblast and labyrinth on H&E 
stained sections prior to E14.5. Expression of the trophoblast specific protein 
alpha gene (Tpbpa) gene is restricted to cells of the junctional zone in rodent 
placenta and can thus be used to clearly distinguish this region in wild type and 
transgenic placenta (Lescisin et al. 1988). The Tpbpa gene shares homology to 
cathepsin propeptide genes, which encode inhibitors of cathepsin proteases, 
suggesting a role for Tpbpa in also inhibiting these proteases that function in 
various aspects of placentation including proliferation, differentiation and 
vascularisation (Rawn and Cross 2008; Screen et al. 2008)
The expression pattern of Tpbpa was examined by in situ hybridisation of 
midline placental sections at E10.5, E12.5, E14.5, E16.5 and E18.5 in order to 
assess the relative size of the junctional zone at these stages. The extent of 
Tpbpa staining was markedly reduced in transgenic placentae at E10.5 (Fig 3.8 A 
and B), although signal was correctly localised to cells of the ectoplacental cone. 
A similar reduction in signal was observed at E12.5, with the spongiotrophoblast 
appearing as a more compact region in transgenic placentae (Fig 3.8 C and D). 
Analysis of Tpbpa expression by qPCR at E12.5 revealed a statistically 
significant 2.1-fold reduction in transcript level in transgenic placentae (± 0.04; n 
= 8 ; p = 0.014). The extent of Tpbpa staining was similarly reduced at E14.5 and 
E16.5 (Fig 3.8 E - H). At E18.5, the spongiotrophoblast appeared as a distinct 
zone in wild type placentae, albeit reduced in size compared to E16.5, with a 
clear boundary existing between this and the labyrinth region (Fig 3.8 I). In 
transgenic placentae however, this boundary between the two zones was 
completely absent, with only a few Tpbpa positive cells localised in the 
anticipated area, the majority of Tpbpa positive cells were instead dispersed 
throughout the labyrinth region of transgenic placentae (Fig 3.8 J). Tpbpa positive 
cells were observed to mislocalise in the labyrinth layer of three transgenic 
placentae at E18.5, with no such mislocalisation seen in three wild type placentae 
at the same stage. Similarly, a clear spongiotrophoblast boundary was not 
observed at E18.5 in an additional five transgenic placenta stained with H&E.
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Figure 3.8: Spatial and temporal expression pattern of Tpbpa
A direct examination of junctional zone cells was performed throughout 
gestation by hybridisation of placental sections with the spongiotrophoblast- 
specific riboprobe Tpbpa. Figure shows midline placental sections from line 
10-15 on a pure 129/Sv background. Wild type (left panels) and transgenic 
(right panels) at (from top) E10.5, E12.5, E14.5, E16.5 and E18.5 hybridised 
with the Tpbpa riboprobe. Scale bar = 200 urn .
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3.2.4 Reduced glycogen cell staining in transgenic placentae
The developmental origins of the glycogen cell are poorly understood, however 
an alteration to glycogen cell number is often observed in mouse models of 
disrupted placental development. For instance, the number of glycogen cells was 
increased in Phlda2 null placentae, although the effect on glycogen cell number 
was not reported in the Kvdmrl null placenta (Frank et al. 2002; Salas et al. 
2004). Glycogen cells are characterised by large glycogen-filled vacuoles and 
express the spongiotrophoblast marker Tpbpa, leading some to suggest that 
glycogen cells are a sub-type of the spongiotrophoblast lineage. Clusters of 
Tpbpa-positive cells were observed within the labyrinth of transgenic placentae, 
becoming increasingly more prominent towards term. Periodic acid Schiff staining 
was utilised to determine if the mislocalised Tpbpa-positive cells contained stored 
glycogen, and also to assess the relative abundance of glycogen cells in wild 
type and transgenic placentae.
Glycogen cells can be first identified from ~E10.5 by a small accumulation 
of glycogen stores, although the developmental origins of these cells appears to 
be -E7.5, with expression of the glycogen cell marker Pcdh12 first detected at 
this stage (Bouillot et al. 2005). From around E12.5, glycogen cells are 
identifiable by large glycogen stores and their progressive migration to the 
decidua (Coan et al. 2006). The relative abundance of glycogen cells in wild type 
and transgenic placentae was assessed between E10.5 and E18.5 (Fig 3.9). Few 
PAS-positive cells were observed in wild type and transgenic placentae at E10.5, 
consistent with glycogen accumulation beginning from this stage. PAS-positive 
staining was observed in the decidua at this stage (Fig 3.9 A and B). Glycogen 
staining was markedly reduced in transgenic placentae compared to wild type 
throughout gestation from E12.5 to E18.5 (Fig 3.9 C - J). At E16.5, glycogen cell 
staining of transgenic placentae appeared to persist in the spongiotrophoblast 
region, whereas glycogen cells of wild type placentae predominantly appeared in 
the maternal decidua at this stage (Fig 3.9 G and H).
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Figure 3.9: Glycogen staining as examined by Periodic acid Schiff staining
The relative abundance of glycogen cells was examined by PAS staining of 
midline placental sections from line 10-15 on a pure 129/Sv background. 
Figure shows midline placental sections of wild type (left panels) and 
transgenic (right panels) at (from top) E10.5, E12.5, E14.5, E16.5 and E18.5. 
Scale bar =100 \xm. Broken line indicates boundary between labyrinth (lower) 
and spongiotrophoblast (upper).
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At E18.5, Tpbpa positive cells were mislocalised within the labyrinth of 
transgenic placentae (see Fig 3.8 J). Both spongiotrophoblast and the sub­
population of glycogen cells express this marker, and thus to determine whether 
the mislocalised cells were glycogen cells, adjacent sections from E18.5 
placentae were subjected to PAS staining and hybridised with the Tpbpa 
riboprobe (Fig 3.10 A - F). PAS staining was not observed to co-localise with 
Tpbpa positive cell clusters located in the labyrinth of transgenic placentae, 
although some occasional PAS positive cells were observed in the labyrinth of 
both wild type and transgenic placentae.
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Figure 3.10: Spatial expression pattern of Tpbpa compared with glycogen
staining at E18.5
The spatial expression of Tpbpa was compared with PAS staining to 
determine if the mislocalised Tpbpa-positive clusters in the labyrinth of 
transgenic placentae were glycogen cells. Glycogen cells were examined from 
serial midline placental sections of line 10-15 on a pure 129/Sv background. 
H&E stained sections (left panels) of wild type (upper panels) and transgenic 
(lower panels) show a region of labyrinth bounded by the spongiotrophoblast 
to the top (A and D). Adjacent sections hybridised with the Tpbpa riboprobe 
show mislocalisation in the labyrinth region of transgenic placenta (B and E). 
These mislocalised clusters do not co-stain for glycogen when subjected to 
PAS staining (C and F). Broken line indicates boundary between labyrinth 
(lower) and spongiotrophoblast (upper) layers. Scale bar = 100 p irn .
126
High levels of Cdknlc protein are reported to be a marker of glycogen 
cells at E15.5 (Georgiades et al. 2001), although at E17.5 no Cdknlc mRNA was 
detected in glycogen cells (Takahashi et al. 2000). Adjacent sections of E14.5 
midline placenta were stained for glycogen cells and hybridised with a Cdknlc 
riboprobe to assess the co-localisation of staining (Fig 3.11). Cdknlc mRNA 
appeared to co-localise, although was not specific for, glycogen cells at E14.5.
Figure 3.11: Co-localisation of Cdknlc  and PAS staining at E14.5
The spatial expression of Cdknlc was compared with PAS staining to 
determine if the glycogen cells can be identified by Cdknlc expression. 
Glycogen cells were examined from serial midline placental sections of line 
10-15 on a pure 129/Sv background. H&E stained sections (left panels) of wild 
type (upper panels) and transgenic (lower panels) show a region of 
spongiotrophoblast containing glycogen cells. Adjacent sections hybridised 
with the Cdknlc riboprobe and subjected to PAS staining show a co­
localisation of positive signal. Cdknlc expression was also detected in discrete 
cells of the labyrinth. Broken line indicates boundary between labyrinth (lower) 
and spongiotrophoblast (upper) layers. Scale bar = 100 \im.
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3.2.6 Assessment of placental cell type marker expression
In situ hybridisation was utilised to examine expression of a number of placental 
gene expression markers in wild type and transgenic placenta. Several mouse 
models of defective placentation feature an alteration to giant cell abundance. 
Furthermore, there is a defined relationship between the spongiotrophoblast layer 
and giant cells, with giant cell precursors residing in the spongiotrophoblast layer. 
Although no alteration to giant cell number was reported in Phlda2 null placentae, 
Ascl2 null placentae lack spongiotrophoblast cells due to the excess 
differentiation of giant cells from precursors (Frank et al., 2002; Guillemot et al., 
1994). Giant cell distribution was examined by in situ hybridisation of the giant 
cell markers Prl3d (formerly placental lactogen 1) and Prl3b1 (formerly placental 
lactogen 2). Three placental lactogen 1 genes exist in the mouse, placental 
lactogen 1 alpha (Prl3d1), beta (Prl3d2) and gamma (Prl3d3), all of which are 
expressed only in cells of the parietal giant cell layer (Simmons et al. 2008). 
However, due to a large degree of sequence homology, the cDNA probe 
hybridises with all three genes, and thus expression is summarised as Prl3d. The 
placental lactogen 1 (Prl3d) genes exhibit transient expression between E6.5 until 
E11.5. Expression of placental lactogen 2 (Prl3b1\ formerly PI2) is first detected 
at E11.5 and persists until term (Carney et al. 1993; Yamaguchi et al. 1992). 
Prl3b1 expression is first observed in the giant cell layer only, but is later 
observed in all layers of the placenta (Simmons et al. 2007). Prl3b1 is expressed 
by cells of the parietal giant cell layer in addition to the canal trophoblast giant 
cells and sinusoidal giant cells in the labyrinth layer. Additionally, 
spongiotrophoblast but not glycogen cells also express Prl3b1 (Simmons et al. 
2008). Accordingly, relative giant cell distribution was assessed by in situ 
hybridisation of the Prl3d probe at E10.5 and the Prl3b1 probe at E12.5, E14.5 
and E16.5.
There was no overt difference in Prl3d staining at E10.5 (Fig 3.13 A and B) 
with the relative distribution of Prl3b1 staining comparable between wild type and 
transgenic placentae between E12.5 and E16.5 (Fig 3.13 C to H). However, the 
extent of Prl3b1 staining at these stages was visibly reduced within the 
spongiotrophoblast region, likely representing an indirect consequence of the loss 
of cells from the junctional zone.
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Figure 3.12: Spatial and temporal expression pattern Prl3d and Prl3b1
The relative abundance of giant cells was examined in midline placental 
sections from line 10-15 on a pure 129/Sv background by hybridisation with 
probes for Prl3d and Prl3b1. Prl3d expression in wild type (A) and transgenic 
(B) placentae at E10.5. Prl3b1 expression in wild type (C, E, G) and transgenic 
(D, F, H) placentae at E12.5 (C and D), E14.5 (E and F) and E16.5 (G and H). 
Scale bar = 500 pm.
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Ascl2 is expressed in ceils of both the spongiotrophoblast and labyrinth 
regions with expression levels declining from E10.5 such that little Ascl2 
expression is observed at E18.5 (Rossant et al. 1998). At E16.5, microarray 
analysis on a mixed genetic background indicated a 1.7-fold lower expression 
level of Ascl2, although without achieving statistical significance. As endogenous 
Ascl2 expression is relatively low at E16.5 expression was further examined by 
qPCR at E12.5, in addition to in situ hybridisation analysis of the spatial 
expression pattern at E10.5 and E12.5.
Expression of Ascl2 at E12.5 was 1.5-fold (±0.11; n = 8 ; p = 0.014) down 
regulated according to qPCR analysis (Fig 3.14 A). The spatial expression 
pattern of Ascl2 in transgenic placentae at both E10.5 and E12.5 was largely 
comparable with that of wild type placentae at the same stage. The notable 
exception to this was the loss of Ascl2 expression associated with 
spongiotrophoblast region at both stages. At E10.5, Ascl2 expression associated 
with spongiotrophoblast cells was overtly reduced (Fig 3.14 C), whereas at E12.5 
Ascl2 expression was almost entirely absent from this region (Fig 3.14 E).
Ascl2 acts to maintain the spongiotrophoblast population by preventing 
differentiation of giant cells. The basic helix-loop-helix transcription factor 
encoded by Handl acts antagonistically to Ascl2 and is essential for giant cell 
differentiation and marks precursors of this trophoblast sub type (Riley et al., 
1998; Scott et al., 2000). Microarray analysis of Handl expression at E16.5 on a 
mixed genetic background identified a 1.3-fold reduction in Handl expression in 
transgenic placentae, although without achieving statistical significance. At 
E12.5, expression of Handl according to qPCR analysis was reduced by 1.3-fold 
(± 0.18; n = 8 ; p = 0.014) in transgenic placentae (Fig 3.15 A). This correlates 
with the reduced Prl3b1 staining observed in the transgenic placentae and is 
likely an indirect consequence of the loss of spongiotrophoblast. Examination of 
the spatial expression pattern of Handl by in situ hybridisation did not reveal any 
overt differences in Handl mRNA distribution (Fig 3.15 B -  E).
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Figure 3.13: Expression of Ascl2 at E10.5 and E12.5
Ascl2 expression was examined by qPCR at E12.5 (A) and by in situ 
hybridisation at E10.5 and E12.5 (B-E). Graph (A) shows relative fold change 
of Ascl2 expression in transgenic placenta compared to wild type at E12.5. 
Error bar represents standard deviation. Statistical significance calculated by 
the Mann Whitney test is denoted by asterisks: * p < 0.05. Ascl2 mRNA was 
examined by in situ hybridisation of midline placental sections from line 10-15 
on a pure 129/Sv background. Ascl2 expression at E10.5 (B and C) and E12.5 
(D and E) in wild type (B and D) and transgenic (C and E) placentae. Ascl2 
expression associated with the spongiotrophoblast region was reduced or 
absent in transgenic placentae (arrow heads) Scale bar = 200 ^m.
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Handl
Figure 3.14: Spatial expression of Handl at E10.5 and E12.5
Handl expression was examined by qPCR at E12.5 (A) and by in situ 
hybridisation at E10.5 and E12.5 (B-E). Graph (A) shows relative fold change 
of Handl expression in transgenic placenta compared to wild type at E12.5. 
Error bar represents standard deviation. Statistical significance calculated by 
the Mann Whitney test is denoted by asterisks: * p < 0.05. Handl mRNA was 
examined by in situ hybridisation of midline placental sections from line 10-15 
on a pure 129/Sv background. Handl expression at E10.5 (B and C) and 
E12.5 (D and E) in wild type (B and D) and transgenic (C and E) placentae. 
Scale bar = 200 i^m.
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Gcm1 marks branch-points of the labyrinth and is essential for branching 
morphogenesis of this layer of the placenta (Anson-Cartwright et al. 2000). 
Microarray analysis of Gcm1 expression at E16.5 on a mixed genetic background 
indicated that there was no significant alteration to Gcm1 expression. At E12.5, 
expression of Gcm1 according to qPCR analysis was increased by 1.4-fold (± 
0.16; n = 8 ; p = 0.014) in transgenic placentae (Fig 3.16 A). However, 
examination of the spatial expression pattern of Gcm1 by in situ hybridisation did 
not reveal any overt differences in Gcm1 mRNA distribution (Fig 3.16 B -  E).
Kdr (Flk1) encodes the VEGF receptor-2 and marks fetal vasculature in 
the labyrinth layer of the placenta (Breier et al. 1995; Dumont et al. 1995). 
Microarray analysis of Kdr expression at E16.5 on a mixed genetic background 
revealed a statistically significant 1.5-fold elevation in expression levels in 
transgenic placentae. At E12.5, qPCR analysis of Kdr expression reported a 1.4- 
fold increase (± 0.31; n = 8 ; p = 0.014) in expression levels in transgenic 
placentae (Fig 3.17 A). A qualitative analysis of the spatial expression pattern of 
Kdr by in situ hybridisation did not reveal any overt differences in Kdr expression 
at E12.5 (Fig 3.17 B - E ) .
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Figure 3.15: Spatial expression of Gcm1 at E10.5 and E12.5
Gcm1 expression was examined by qPCR at E12.5 (A) and by in situ 
hybridisation at E10.5 and E12.5 (B-E). Graph (A) shows relative fold change 
of Gcm1 expression in transgenic placenta compared to wild type at E12.5. 
Error bar represents standard deviation. Statistical significance calculated by 
the Mann Whitney test is denoted by asterisks: * p < 0.05. Gcm1 mRNA was 
examined by in situ hybridisation of midline placental sections from line 10-15 
on a pure 129/Sv background. Gcm1 expression at E10.5 (B and C) and 
E12.5 (D and E) in wild type (B and D) and transgenic (C and E) placentae. 
Scale bar = 200 i^rn.
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Kdr
Figure 3.16: Spatial expression of Kdr at E12.5
Kdr (Flk1) expression was examined by qPCR at E12.5 (A) and by in situ 
hybridisation at E12.5. Graph (A) shows relative fold change of Ascl2 
expression in transgenic placenta compared to wild type at E12.5. Error bar 
represents standard deviation. Statistical significance calculated by the Mann 
Whitney test is denoted by asterisks: * p < 0.05. Kdr mRNA was examined by 
in situ hybridisation of midline placental sections from line 10-15 on a pure 
129/Sv background. Kdr expression pattern under low (B and C) and higher 
magnification (D and E) at E12.5 in wild type (B and D) and transgenic (C and
E) placentae. Scale bar = 200 |^ m (A and B) 100 i^m (C and D).
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3.3 Discussion
The principal aim of the work presented in this chapter was to further characterise 
the placental phenotype associated with over-expression of Phlda2 and Slc22a18 
from a BAC transgene. Spatial and temporal expression patterns of Phlda2 and 
Slc22a18 were first examined by qPCR and in situ hybridisation techniques. The 
subsequent work builds upon initial observations reported by Salas and 
colleagues (2004), who reported a reduction in placental weight at E14.5 and 
E16.5. A more detailed examination of the placental phenotype was performed, 
with placental structure assessed using various techniques between E10.5 and 
E18.5.
3.3.1 Expression of Phlda2 and Slc22a18 in transgenic placenta
Expression of Phlda2 and Slc22a18 from the transgene as detected by Northern 
blotting was previously reported to be at least 10-fold greater than the level 
observed from the endogenous locus at E14.5 and E16.5 (Salas et al. 2004). In 
contrast, qPCR analysis of gene expression at E12.5 and E16.5 indicated that 
expression of these two genes was consistent with transgene copy number. This 
was further supported by the relative staining intensity of wild type and transgenic 
placental sections hybridised with probes specific for Phlda2 or Slc22a18. 
Interestingly, Phlda2 expression was observed at nearly 4-fold the level of wild 
type in Kvdmr1+I' / PhldaZ,+ placentae, despite the presence of only two active 
copies (Salas et al. 2004). There are a number of potential explanations for the 
variable levels of expression reported for Phlda2 and Slc22a18 in different 
models. One possibility is that Phlda2 acts via a positive feedback mechanism to 
directly promote its own expression. Similarly, Phlda2 may act to maintain 
adjacent cells in a P/?/cfa2-positive state. Although the first possibility could not be 
directly examined in the context of this investigation, in situ hybridisation of 
Phlda2 mRNA at E10.5 or E12.5 did not indicate any alteration to the number of 
P/7/da2 -positive cells in transgenic placentae, indicating instead that elevated 
expression was due to increased expression in the same number of cells. 
Furthermore, such explanations do not address the relatively high expression of 
Slc22a18, which suggests that the observed elevated expression levels are due 
to over-expression of the transgene.
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Another possible explanation for the variable expression levels observed is 
the effect of genetic background. Line 10-15 was generated by pronuclear 
injection of a BAC transgene containing genomic DNA from a 129/Sv genome 
into a C57BL/6 x CBA F1 hybrid. This line was initially bred for approximately four 
generations into the 129/Sv background at which point initial characterisations 
were performed and expression was observed at ~ 10-fold endogenous levels 
(Salas et al. 2004). Following a further four generations of breeding into the 
129/Sv background, expression levels determined by microarray analysis 
revealed Phlda2 was expressed at - 6 .6-fold wild type and Slc22a18 at ~5.4-fold 
wild type levels. At least a further four generations of breeding into the 129/Sv 
background took place prior to beginning this investigation, at which point 
expression levels were found to correlate with transgene copy number. The 
decreasing level of Phlda2 and Slc22a18 expression following successive 
generations of breeding onto the 129/Sv background demonstrates a clear effect 
of genetic background on transgene expression. Perhaps unsurprisingly 
appropriate expression of the transgene is achieved when the genetic 
background of the transgenic line matches the origin of the genomic fragment 
contained within the transgene.
Neither the spatial or temporal expression patterns of Slc22a18 have been 
previously described in detail in the literature, although placental expression has 
been reported at E12.5 and E14.5 (Dao et al. 1998). In situ hybridisation at E12.5 
revealed that Scl22a18 is expressed by a subset of cells within the labyrinth. This 
expression pattern correlates with the predicted role of the Slc22a18 gene 
product in solute transport. No overt difference was observed in the spatial 
expression pattern between wild type and transgenic placentae, with elevated 
expression evidently due to increased expression in a comparable number of 
cells. A comparison of the ACj values between Slc22a18 and the mean of the 
two reference genes from wild type placentae at E12.5 and E16.5 indicated an 
approximate 1.5-fold increase in expression level between these time-points. A 
similar increase in expression level was observed when ACj values were 
compared between transgenic placentae. Thus, assuming that expression of 
Gapdh and /3-actin remains constant between these stages, Slc22a18 expression 
increases moderately between E12.5 and E16.5. A similar comparison of the ACj
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values for Phlda2 revealed a ~20-fold decrease in expression between E12.5 and 
E16.5 in both wild type and transgenic placentae, correlating with the previously 
reported dramatic decline in expression from ~E12.5 (Frank et al. 2002).
Although no overt differences in Phlda2 or Slc22a18 positive cell 
abundance was observed between the wild type and transgenic placenta 
examined, cell number was not directly assessed. Ideally, the protein level of 
both Phlda2 and Slc22a18 could be further investigated using Western blotting to 
directly quantify total protein levels in wild type and transgenic placenta. 
Additionally, the number of cells expressing Phlda2 and Slc22a18 could be 
directly quantified from a number of placental sections to confirm that the number 
of cells expressing the genes is not altered. This will also enable an examination 
of possible ectopic expression to confirm that expression of the genes from the 
transgene is restricted to the cell types that endogenously express these genes.
3.3.2 Placental weight reduction of transgenic placentae
Placental weight of transgenic conceptuses was significantly reduced at all 
gestational stages examined between E12.5 and E18.5. The weight deficit of 
transgenic placentae varied between 15% and 25% from E12.5 to E16.5, with the 
most severe weight deficit of 25% observed at E13.5. The observed effect on 
placental weight was consistent with the previously reported 17% weight 
reduction at E14.5 and the 25% difference at E16.5 (Salas et al. 2004). Similarly, 
the degree of placental weight loss was also comparable to the extent of 
placentomegaly reported in Phlda2 null mice, for which knockout placentae 
weighed on average 22% more than wild type at E12.5 and 27% more at E16.5 
(Frank et al. 2002).
The extent of weight loss in transgenic placentae was greater than 
perhaps would have been predicted from a comparison between Kvdmrl null and 
Kvdmrl /  Phlda2 double null mice. Kvdmrl null mice essentially possess one 
additional copy of each gene in the imprinted domain, although expression of 
Phlda2 was 4-fold wild type levels. Crossing the Kvdmrl null line with the Phlda2 
null line generates double transgenic mice that possess one active copy of 
Phlda2 but retain the two active copies of the other genes in the domain. Thus, a 
comparison of phenotypes between these two genotypes allowed the effect of 
Phlda2 over-expression to be elucidated. Conceptuses that lack the ICR at
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Kvdmrl, and thus exhibit loss of imprinting of all genes in the domain possess 
placentae that are ~18% lighter than wild type at both E14.5 and E16.5. 
Restoration of Phlda2 gene dosage in the double transgenic placenta results in 
an approximate 50% rescue of the weight deficit, indicating that over-expression 
of Phlda2 is associated with a ~9% reduction in placental weight. Loss of 
expression of Cdknlc is associated with significant placentomegaly resulting from 
an approximate doubling of spongiotrophoblast and labyrinth cell number 
(Takahashi et al. 2000). This would suggest that over-expression of Cdknlc, as 
occurs in the Kvdmrl null and Kvdmr / Phlda2 double null placentae, would 
account for a significant proportion of the weight deficit observed. However, the 
presence of a comparable weight deficit between the BAC transgenic mice that 
over-express only Phlda2 and Slc22a18 and the Kvdmrl null placentae, which 
over-express all genes in the domain, suggest that over-expression of Phlda2 
and Slc22a18 are the causative factors.
Alternatively, it is possible that the effect of Phlda2 and/or Slc22a18 over­
expression is dosage dependent, with more severe phenotypes resulting from 
elevated expression levels. The BAC transgenic mice possess three additional 
copies of Phlda2 and Slc22a18, whereas in Kvdmrl null mice, only one additional 
copy of each gene is present. It is also possible that over-expression of Slc22a18 
accounts for the remaining placental weight deficit in Kvdmrl / Phlda2 double null 
conceptuses. Furthermore, the genetic background of the transgenic lines 
examined may also be a contributory factor, with BAC transgenic mice examined 
on a 129/Sv background, whereas the Kvdmrl null mice were maintained on a 
129/Sv x C57BL/6 background (Fitzpatrick et al. 2002) and the Phlda2 null line on 
a C57BL/6 background (Frank et al. 2002). Each of these potential scenarios is 
addressed in Chapter 4.
Comparison of wild type and transgenic placental weights for both raw and 
normalised data sets achieved statistical significance according to the f-test at the 
0.1% significance level for all stages examined between E12.5 and E16.5. At 
E18.5 however, statistical significance was only achieved when comparing 
normalised placental weights, with significance achieved only at the 1% 
significance level. Wild type placenta reached a maximum weight at E14.5, 
whereas the weight of transgenic placentae plateaued between E14.5 and E16.5, 
but subsequently increased by approximately 10% between E16.5 and E18.5.
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Thus, while the difference in weight between wild type and transgenic placentae 
between E12.5 and E16.5 was approximately 20%, at E18.5 this weight deficit 
was only 10%. This late gestation increase in placental weight was only observed 
in transgenic placenta and may be a consequence of the reduction in 
spongiotrophoblast proportion at this stage. The labyrinth region continues to 
expand until term at the expense of the spongiotrophoblast (Coan et al. 2004), 
thus causing a relative decline in the proportion of cells that exhibit a phenotype. 
Alternatively, the modest increase in weight in late gestation may be 
compensatory for the weight deficit that has persisted throughout earlier gestation 
enabling increased efficiency at the time of maximal embryonic demand. The 
absence of a significant weight deficit at E18.5 when examining raw weight data 
correlates with human data in which placentae of low birth weight infants 
exhibited elevated PHLDA2 expression yet did not exhibit a significant weight 
deficit compared to normal (Apostolidou et al. 2007).
3.3.3 Loss of spongiotrophoblast in transgenic placentae
The reduced placental weight observed throughout gestation was evidently due 
to a ~60% loss of spongiotrophoblast area at both E14.5 and E16.5. Although a 
slight reduction in labyrinth area was observed at both stages, this was not 
statistically significant, and is reciprocal to the slight expansion of the labyrinth 
observed in Phlda2 null placentae (Frank et al. 2002). Although not quantified at 
earlier gestational stages, Tpbpa staining was overtly reduced as early as E10.5, 
indicating that the loss of spongiotrophoblast results from an earlier defect. The 
spongiotrophoblast layer comprises two distinct trophoblast sub-types, namely 
spongiotrophoblast cells and glycogen cells. Collectively these cell populations 
are sometimes referred to as the junctional zone, although this classification 
occasionally includes the giant cell layer in addition.
The exact role of the spongiotrophoblast layer has not been defined. 
However, the presence of this region is critical for embryonic survival, as 
exemplified by Ascl2 null conceptuses, which have no spongiotrophoblast layer in 
the placenta and die at E10.5 (Guillemot et al. 1994). Similarly, Birc6 deficient 
mice die between E11.5 and E14.5 due to loss of spongiotrophoblast (Hitz et al. 
2005). The majority of mouse models of defective placentation exhibit perturbed 
labyrinth formation either in isolation or alongside other placental defects. For
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example, placentomegaly associated with Cdknlc null conceptuses is due to 
expansion of both spongiotrophoblast and labyrinth layers. Similarly, loss of 
placenta-specific Igf2 expression causes a placental weight deficit due to loss of 
both spongiotrophoblast and labyrinth layers (Constancia etal. 2002). Even Ascl2 
null placentae exhibit additional labyrinth layer defects and excess giant cell 
abundance, due to the role of Ascl2 in maintaining the spongiotrophoblast and 
preventing giant cell differentiation (Guillemot et al. 1994; Tanaka et al. 1997). 
Phlda2 appears to be the only gene described to date that regulates development 
of only the junctional zone. This is perhaps even more interesting given the 
discrete expression of this gene in a subset of labyrinth cells.
Placentomegaly associated with Phlda2 null placenta was due entirely to a 
disproportionate expansion of the spongiotrophoblast layer, including an 
increased abundance of glycogen cells. Although a marginal increase in labyrinth 
area was observed, this did not achieve statistical significance (Frank et al. 
2002). In this investigation, transgenic placentae expressing Phlda2 and 
Slc22a18 at four-fold wild type levels displayed a weight deficit to a similar 
degree as the placentomegaly of Phlda2 null conceptuses. This weight deficit 
could be directly attributed to a -60%  loss of spongiotrophoblast area in 
transgenic placenta. This was supported by a ~2-fold decrease in Tpbpa levels in 
transgenic placentae at E12.5. Similar to Phlda2 null placentae a marginal 
decrease in labyrinth area was observed, although this did not achieve statistical 
significance. The relative distribution of glycogen cell staining was reduced 
throughout gestation in transgenic placenta. The gross phenotype of the BAC 
transgenic placentae was reciprocal to that observed in Phlda2 null placentae. No 
overt labyrinth phenotype was evident, although this does not eliminate a 
possible phenotype at the cellular level as discussed later.
The most striking phenotype was observed at E18.5, at which stage the 
distinct spongiotrophoblast boundary was entirely absent from transgenic 
placenta, with Tpbpa-positive cells instead dispersed throughout the labyrinth 
layer. Tpbpa expression is specific for spongiotrophoblast and glycogen cell 
populations, leading some to believe that glycogen cells are a sub-type of 
spongiotrophoblast cells (Adamson et al. 2002; Georgiades et al. 2002). 
However, expression of Protocadherinl2 (Pcdh12), a glycogen cell specific 
marker (Rampon et al. 2005), is observed as early as E7.5, suggesting that
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spongiotrophoblast and glycogen cells represent distinct cell populations (Bouillot 
et al. 2005). PAS staining was performed on adjacent sections to those 
hybridised with Tpbpa at E18.5 in an effort to determine which population of 
trophoblast sub-type these mislocalised clusters represented. Although PAS 
staining was reduced at all stages examined, the Tpbpa-positive clusters did not 
also stain with PAS, suggesting that these mislocalised cells were not glycogen 
cells.
Migration of glycogen cells appeared to be perturbed at E16.5 with 
glycogen cells of transgenic placentae observed primarily within the 
spongiotrophoblast layer, whereas those of wild type placenta had migrated to 
the decidua. Additionally, the presence of a relatively intact spongiotrophoblast 
layer at E16.5 followed by a complete disruption and mislocalisation of this layer 
at E18.5 further indicated perturbed cell migration was causative of the 
spongiotrophoblast mislocalisation. However, the absence of PAS staining from 
the 7pbpa-positive clusters in the labyrinth region was somewhat surprising given 
that spongiotrophoblast cells are not inherently a migratory cell type, whereas this 
is a characteristic property of glycogen cells. One possibility is that the 
mislocalised pockets of Tpbpa-positive cells represent an immature glycogen cell 
population. Glycogen cells can be identified from as early as E7.5 by expression 
of the marker Pcdh12, but only begin accumulating glycogen stores between 
E10.5 to E12.5 (Bouillot et al. 2005; Coan et al. 2006). The isolated Tpbpa- 
positive cells may thus represent this immature cell type that has failed to 
accumulate glycogen appropriately. Alternatively, as glycogen cell number rapidly 
declines between E16.5 and E18.5 due to a combination of migration and 
glycogen release (Coan et al. 2006), the mislocalised cells may represent 
glycogen cells that have released their glycogen stores and migrated into the 
labyrinth instead of the decidua.
It is interesting to note that the placentae of cloned mouse conceptuses 
exhibit placentomegaly characterised by an expansion of the spongiotrophoblast 
layer (Tanaka et al. 2001). For example, conceptuses generated by somatic cell 
nuclear transfer (SCNT) possess placenta that have an expanded 
spongiotrophoblast with a disrupted boundary with the labyrinth layer. 
Additionally, the expanded spongiotrophoblast of these placentae contain a 
disproportionate abundance of glycogen cells at E19.5 (Wakisaka et al. 2008).
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Analysis of imprinted gene expression in cloned placentae revealed that 
expression of genes including Igf2, H19 and Cdknlc was appropriate. However, 
expression of the maternally expressed Grb10 and paternally expressed Mest 
were reduced in cloned placentae (Inoue etal. 2002). Interestingly, the expanded 
spongiotrophoblast associated with cloned placenta correlates with the 
placentomegaly of Grb10 null mice (Charalambous et al. 2003), although 
contrasts somewhat with the proportionate reduction in labyrinth and 
spongiotrophoblast of Mest deficient mice (Lefebvre et al. 1998). It will be 
interesting to determine whether expression of Phlda2 is altered in cloned 
conceptuses.
Despite the absence of PAS staining in the Tpbpa-positive clusters in the 
labyrinth of transgenic placentae, it is possible that these cells indeed represent a 
population of glycogen cells as discussed above. Glycogen cells are 
characterised by a number of other markers, including Igf2 (Redline et al. 1993), 
Cdknlc (Georgiades et al. 2001) and Connexin31 (Gjb3) (Coan et al. 2006). 
Although spongiotrophoblast cells do not express Igf2 from mid gestation, Igf2 
expression is maintained in cells of the labyrinth layer (Carter et al. 2006; Redline 
et al. 1993), thus preventing glycogen cells from being specifically identified by 
Igf2 expression. Furthermore, although PAS staining was observed to co-localise 
with Cdknlc mRNA wild type and transgenic placentae at E14.5, Cdknlc 
expression was also observed in other cells of the labyrinth and 
spongiotrophoblast. Furthermore, Takahashi et al. reported that Cdknlc 
expression was not detectable in glycogen cells at E17.5 (Takahashi et al. 2000), 
thus eliminating Cdknlc as a specific marker for glycogen cells at E18.5. 
Connexln31 has recently been reported to specifically identify differentiated 
glycogen cells in the murine placenta (Coan et al. 2006). Expression of this 
marker may therefore be used in future to determine if the mislocalised Tpbpa- 
positive cells represent glycogen cells. Indeed, microarray analysis of gene 
expression revealed a significant 1.7-fold decrease in expression of the gene 
encoding Connexin31 (Gjb3).
3.3.4 Examination of placental marker expression
Expression of a number of markers representing specific trophoblast sub-types 
was examined by microarray and in situ hybridisation to determine if any subtle
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placental phenotype exists that may remain undetected by histological 
examination of placental sections. Ascl2 expression was significantly decreased 
in transgenic placenta. This decrease could be accounted for by the loss of 
spongiotrophoblast cells that express this gene.
A close relationship exists between spongiotrophoblast and giant cells, 
and thus an examination of giant cell abundance was performed by analysing 
expression of the giant cell markers Prl3d and Prl3b1, in addition to the 
transcription factor Handl, which regulates giant cell differentiation. 
Differentiation of trophoblast cells into giant cells appears to be the default 
pathway (Cross 2005), although cell fate is ultimately regulated by expression of 
the transcription factors Ascl2 and Handl. Expression of Handl marks giant cell 
precursors and is promotes giant cell differentiation (Scott et al., 2000), whereas 
Ascl2 maintains potential precursor cells in the spongiotrophoblast lineage, with 
loss of Ascl2 resulting in an abundance of giant cells at the expense of the 
spongiotrophoblast (Guillemot et al. 1994). At E10.5, there was no overt 
difference in Prl3d staining between wild type and transgenic placenta. At later 
stages, giant cell abundance was examined by expression of Prl3b1, the 
distribution of which appeared to be comparable between wild type and 
transgenic placenta. Reduced Prl3b1 staining was observed in the 
spongiotrophoblast, consistent with endogenous expression of this gene in 
spongiotrophoblast cells (Simmons et al. 2007; Simmons et al. 2008), and is 
likely an indirect consequence of the loss of this layer in transgenic placenta.
The two placental VEGF receptors exhibit characteristic expression 
patterns, with Flt1 expressed in the spongiotrophoblast and Kdr (Flk1) expressed 
in the labyrinth layer (Breier et al. 1995; Dumont et al. 1995). Microarray analysis 
of gene expression revealed a 1.7-fold decrease in Flt1 expression, whereas Kdr 
expression was upregulated to a similar degree. Both Flt1 and Kdr mark placental 
vasculature, with the decline in Flt1 likely an indirect consequence of the reduced 
spongiotrophoblast area in transgenic placentae. Kdr expression level was 
confirmed by qPCR although in situ hybridisation did not reveal the cause of the 
apparent increase in expression. The elevated expression of Kdr may represent a 
compensatory mechanism, either in direct response to the reduced Flt1 
expression or as an indirect response to the loss of the spongiotrophoblast. It is 
possible that the increased Kdr level is indicative of increased placental
144
vasculature, potentially increasing the transport efficiency of the placenta. This 
could not be directly determined in the course of this investigation, although one 
approach to examine this possibility is discussed in Section 3.3.6. Alternatively, 
the altered expression of Kdr and Flt1 may be an indirect consequence of the 
altered proportion of labyrinth and spongiotrophoblast cells in transgenic placenta 
compared to wild type.
Two striking alterations to gene expression were a ~7-fold down-regulation 
of Psg18 and a ~9-fold down-regulation of Psg19. These pregnancy specific 
glycoproteins are expressed specifically by cells of the spongiotrophoblast 
(Kromer et al. 1996; Wynne et al. 2006), and thus the reduced expression is likely 
a direct consequence of the disproportionate loss of spongiotrophoblast in 
transgenic placentae. However, the ~7-fold reduction in transcript level does not 
correlate with the approximate 60% loss of spongiotrophoblast area. This 
suggests that the cells that secrete these glycoprotein molecules also display a 
disproportionate reduction in transgenic placenta. Interestingly, expression of 
Cd9, the gene encoding the Psg receptor, exhibited a moderate increase in 
expression according to microarray data (1.3-fold; p = 0.048). However, the 
altered expression of Psg18 and Psg19 reported from the microarray were not 
validated by qPCR and thus the microarray data must be interpreted cautiously. 
This indication of a reduction in the endocrine function of the placenta may prove 
useful in clarifying the function of the spongiotrophoblast layer, as discussed in 
Section 3.3.6.
3.3.5 Summary of main findings
The work presented in this chapter sought to build upon initial observations 
reported by Salas et al. (2004), and involved a more detailed characterisation of 
the placental phenotype of line 10-15 on a pure 129/Sv genetic background. 
Expression of both Phlda2 and Slc22a18 were observed to correlate with 
transgene copy number, in contrast to previous reports of - 10 -fold endogenous 
levels. This over-expression appeared to be due to elevated expression in a 
comparable number of cells. Over-expression of the discrete locus encompassing 
the maternally expressed imprinted genes Phlda2 and Slc22a18 results in a 
severe placental phenotype throughout gestation:
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• Placental weight deficit from at least E12.5 until term, although transgenic 
placenta exhibit a marginal increase in weight between E16.5 and E18.5, 
which was absent in wild type placenta
• Spongiotrophoblast area was reduced from at least E10.5 until term, with a 
reduced relative abundance of glycogen cells
• 7pbpa-positive cells were mislocalised within the labyrinth region at E18.5
3.3.6 Future directions
In this investigation, the placental phenotype was characterised between E10.5 
and E18.5. Although placental weight could not be accurately recorded at E10.5, 
in situ hybridisation of sections at this stage clearly demonstrated a reduced 
expression pattern of the spongiotrophoblast marker Tpbpa. Future investigations 
could thus focus on investigating earlier stages of placental development in order 
to isolate the stage at which a placental phenotype is first apparent. Expression 
of Phlda2 is first detectable in the polar trophectoderm, followed by the 
ectoplacental cone at E5.5, later becoming restricted to a subset of cells in the 
labyrinth layer (Frank et al. 1999). From mid gestation Phlda2 expression is 
restricted to the syncytiotrophoblast bilayer of the labyrinth (Frank et al. 2002), 
yet the phenotypic consequences of Phlda2 over-expression are observed on the 
adjacent spongiotrophoblast layer. It is possible therefore, that the 
spongiotrophoblast defect derives directly from altered expression of Phlda2 in 
the ectoplacental cone at ~E5.5, from which the spongiotrophoblast develops. 
Such a phenotype would be difficult to examine in vivo, and thus the use of in 
vitro cell culture studies could be employed to investigate the developmental 
potential of various trophoblast cell types in which Phlda2 is over-expressed.
As discussed in Section 3.3.3, the identity of the mislocalised Tpbpa- 
positive cells remains unclear. Although the absence of PAS staining indicates 
that these cells are not glycogen cells, the apparent migration of these cell 
clusters between E16.5 and E18.5 does not correlate with the properties of 
spongiotrophoblast cells, which are non-migratory. In contrast, glycogen cells are 
inherently a migratory cell type, albeit invading the maternal decidua from mid 
gestation. Further characterisation of these cell clusters is necessary in order to 
confirm which cell type they represent. The glycogen cell specific marker
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Connexin31/Gjb3 is a potential candidate by which these clusters may be 
identified.
Microarray analysis of the two placental VEGF receptors Flt1 and Kdr 
(Flk1) revealed a striking pattern of altered expression in transgenic placentae. 
Expression of Flt1, which is restricted to the spongiotrophoblast, was significantly 
down regulated, a likely consequence of the disproportionate reduction in this 
region in transgenic placenta. In contrast, expression of the labyrinth-specific 
VEGF receptor Kdr (Flk1) was significantly upregulated. Expression of Kdr 
examined by in situ hybridisation appeared to be widespread and at a relatively 
low level. For this reason, it may be difficult to observe moderate differences in 
vasculature of the labyrinth layer. The alteration to Kdr expression level may 
represent a compensatory mechanism of the placenta of increasing fetal blood 
flow to minimise the impact of the reduced spongiotrophoblast layer on 
embryonic growth. A direct method of examining placental vasculature would be 
to generate resin vascular casts of wild type and transgenic placenta as 
described by Adamson et al. (2002). Vasculature could be examined at various 
stages throughout gestation. If elevated Kdr represents an increase in 
vasculature of the labyrinth as a response to the reduced spongiotrophoblast, 
then this could be directly quantified from the vascular casts. An alternative 
approach to creating vascular casts would be to use stereology examine the 
structure of the labyrinth layer. This would enable a direct quantification of all 
volume, surface area and length measurements in this region of the placenta as 
described by Coan et al. (2004).
Further work may also be directed to further investigating the altered 
expression of the Psg18 and Psg19 genes reported on the microarray. Initially, 
these altered expression levels must be validated by qPCR, with expression 
levels of additional Psg genes also potential targets of qPCR analysis. Such 
dramatically reduced levels of pregnancy-related hormones may be indicative of 
the functional role of the spongiotrophoblast, which to date has not been 
definitively characterised. The spongiotrophoblast is predicted to perform an 
endocrine role through secreting hormones that target maternal physiology to 
favour embryonic growth. However, a definitive role for this region of the mouse 
placenta has not been described to date. The transgenic model described in this 
chapter is unique in only exhibiting a spongiotrophoblast defect, and may thus
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provide an invaluable tool for elucidating the function of the spongiotrophoblast. If 
the spongiotrophoblast secretes hormones that alter maternal physiology, this 
could be investigated in pregnant females containing conceptuses that are all 
hemizygous for the BAC transgene described previously. All such conceptuses 
would have placentae with a significantly reduced spongiotrophoblast layer. This 
would be predicted to result in a reduction in the level of circulating hormones in 
the pregnant dam. These levels could be compared against those of pregnant 
females containing entirely wild type conceptuses in a similar sized litter.
The placental phenotype described in this chapter correlates with the initial 
reports of a placental weight deficit at E14.5 and E16.5. Phlda2 was isolated as 
the likely cause of this phenotype from examination of a Kvdmrl / Phlda2 double 
null placenta. The weight deficit was additionally attributed to a disproportionate 
loss of the spongiotrophoblast (Salas et al. 2004). Although evidence suggests a 
causative role for Phlda2 in the phenotype, the presence of Slc22a18 on the 
transgene means that a role for this gene cannot be ruled out. This scenario is 
addressed in Chapter 4.
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Chapter 4:
Effect of gene dosage and genetic background on
placental phenotype
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4.1 Overview
The effect of over-expressing a discrete imprinted locus containing the maternally 
expressed genes Phlda2 and Slc22a18 was discussed in Chapter 3. These 
characterisations were performed using mice on a pure 129/Sv genetic 
background. An important aspect to consider when investigating mouse models 
that possess a transgene is the indirect effect that integration of this transgene 
may have. For instance, the transgene may integrate within the coding region of 
another gene. Any observed phenotype may therefore be the result of either 
excess expression from the transgene or loss of expression of the gene at the 
site of integration. In order to eliminate the possibility that the placental 
phenotype is a consequence of the site of transgene integration, rather than over­
expression of the genes Phlda2 and/or Slc22a18, an independent transgenic line 
was generated containing the same modified BAC transgene.
This second transgenic line was named 10-10, and was initially maintained 
on a C57BL/6 background, with phenotypic analysis performed on the 129/Sv x 
C57BL/6 background. To enable a direct comparison between the transgenic 
lines 10-15 and 10-10, line 10-15 was also characterised on the 129/Sv x 
C57BL/6 background. The effect of genetic background of mouse models is often 
not a major consideration when performing phenotypic analyses. There is, 
however precedent that genetic background affects the phenotype of mouse 
models of placentation. For instance, the degree of placentomegaly in Phlda2 null 
animals at E16.5 was increased in a pure C57BL/6 background (33% larger than 
wild type) compared with the C57BL/6 x 129/Sv background (27% than wild type) 
(Frank et al. 2002).
A genetic background-dependent placental defect is also observed in 
Myod family inhibitor Mdfi (l-mfa) null mice. Homozygous null mice on a C57BL/6 
background have significantly fewer trophoblast giant cells with embryonic death 
resulting at E10.5. In contrast, the same mutation on the 129/Sv background 
does not cause a placental phenotype although embryos display neurological 
defects (Kraut et al. 1998). Additionally, mice that lack expression of the gene 
encoding the epidermal growth factor receptor (Egfr) have smaller placentae with 
a reduced spongiotrophoblast layer. On a pure 129/Sv background, embryonic
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death occurs around E12.5, whereas some embryos survive to birth on the 
129/Sv x C57BL/6 background (Sibilia and Wagner 1995; Threadgill et al. 1995).
The placental phenotype was also examined in an additional two 
transgenic lines, which possess either one or two copies of the unmodified 
transgene. These animals contain intact copies of Cdknlc on the transgene. 
However, placental-specific enhancer elements are absent and thus Cdknlc is 
only over-expressed in a subset of embryonic tissues (John et al. 2001). Use of 
these transgenic lines, in addition to line 10- 10 , enabled an examination of the 
effect of transgene copy number on the placental phenotype. More importantly, 
line 5D3, which contains a single copy of the unmodified transgene, represents a 
model for LOI at the discrete locus containing the imprinted genes Phlda2 and 
Slc22a18. The placental phenotype observed in lines 10-15 and 10-10 was 
therefore compared with that of line 5D3 to determine whether the multiple copy 
transgenic lines exhibit a similar phenotype.
To elucidate the relative contribution of Phlda2 and Slc22a18 to the 
observed placental phenotype, the placental phenotype was examined in 
placentae in which Phlda2 gene dosage was restored to normal while Slc22a18 
remains elevated. Such “double transgenic” conceptuses were generated by 
mating a hemizygous 5D3 transgenic male with a heterozygous Phlda2 null 
female. A direct comparison of double transgenic placentae with both wild type 
and 5D3 transgenic placentae from the same litter was undertaken to examine 
the effect of restoring Phlda2 gene dosage to normal. A similar approach was 
undertaken to investigate over-expression of Phlda2 by comparing Kvdmrl null 
placentae and double Kvdmrl and Phlda2 null placentae (Salas et al. 2004).
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4.2 Results
4.2.1 Characterising line 10-15 on the 129/Sv x C57BL/6 background
The effect of over-expressing Phlda2 and Slc22a18 was initially examined using 
mice on a pure 129/Sv genetic background (Chapter 3). The placental phenotype 
of line 10-15 was additionally investigated on the 129/Sv x C57BL/6 genetic 
background to determine if there were any differences in the phenotype. This was 
necessary, as further analysis of the placental phenotype would include three 
independent lines maintained on a different genetic background.
Expression levels of Phlda2 and Slc22a18 were consistent with transgene 
copy number in line 10-15 on a pure 129/Sv background (see Section 3.2.1). To 
confirm that similar expression levels were maintained on the 129/Sv x C57BL/6 
background the expression of Phlda2 and Slc22a18 was assessed by qPCR at 
E12.5. Phlda2 was expressed at 3.0-fold (± 0.18) wild type and Slc22a18 was 
expressed at 3.78-fold (± 1.39) wild type levels (Fig 4.1).
On a pure 129/Sv background, mean transgenic placental weight was 
~15% less than that of wild type at E14.5, with an approximate 50%  
compensation in placental weight occurring by E18.5, with transgenic placentae 
-9%  lighter. Placental weight was examined at E14.5 and E18.5 on the 129/Sv x 
C57BL/6 background, with data presented in Figure 4.2. At E14.5, a similar 
weight difference to transgenic placenta on a pure 129/Sv background was 
observed, with transgenic placentae 19.1% lighter than wild type (104.7 mg ± 8.4 
versus 84.7 mg ± 9.0; 5 litters; n = 35; p = 1.07 x 10'7). In contrast to transgenic 
placenta on a 129/Sv background, this degree of weight deficit persisted to 
E18.5, with transgenic placentae 19.6% lighter at this stage (118.9 mg ± 6.2 
versus 95.6 mg ± 8.2; 6 litters; n = 37; p = 2.22 x 10‘11).
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Figure 4.1: Transgene expression at E12.5 in placentae of line 10-15 on the
129/Sv x C57BL/6 background
Expression of Phlda2 and Slc22a18 was examined in E12.5 placentae from 
line 10-15 on the 129/Sv x C57BL/6 background to determine if appropriate 
expression levels were maintained. Graph shows mean fold change for 
Phlda2 and Slc22a18 in transgenic placentae compared to wild type 
placentae from the same litter. Error bars represent standard deviation 
between independent samples.
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Figure 4.2: Placental weights at E14.5 and E18.5 from line 10-15 on the
129/Sv x C57BL/6 background
To confirm that the placental phenotype persists on the 129/Sv x C57BL/6 
background, placental weights were examined at E14.5 and E18.5. The 
graph shows the mean placental weight of wild type and transgenic 
placentae, with error bars representing standard deviation. Percentage 
values indicate the ratio of mean transgenic weight to wild type. Statistical 
significance as determined by t-test is denoted by asterisks *** p < 0 .001 .
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Transgenic placentae of line 10-15 on a pure 129/Sv background exhibit 
a significantly reduced spongiotrophoblast area at E14.5, with a complete loss of 
the spongiotrophoblast-labyrinth boundary and mislocalisation of Tpbpa-positive 
cells in the labyrinth at E18.5. E14.5 and E18.5 placentae from line 10-15 on the 
129/Sv x C57BL/6 background were hybridised with the Tpbpa probe to examine 
the extent of spongiotrophoblast loss and mislocalisation (Fig 4.3). At both E14.5 
and E18.5, the spongiotrophoblast was overtly reduced in size in transgenic 
placenta, with Tpbpa-positive cells observed in the labyrinth of transgenic 
placentae at both stages. Some Tpbpa-positive cells were also detected in the 
labyrinth of wild type placentae at E14.5, although to a lesser extent compared to 
transgenic, and with no such mislocalisation in wild type placentae at E18.5. At 
E18.5, transgenic placentae exhibit a similar pattern of Tpbpa-positive cells in the 
labyrinth, although not to the extent that is seen on the pure 129/Sv background, 
with a relatively intact spongiotrophoblast-labyrinth border existing at this stage 
(Fig 4.3F and H)
The area of placental regions was measured as before at E14.5. 
Spongiotrophoblast area was significantly reduced in transgenic placentae, 
accounting for only 57% of the area in wild type placentae (3.17 mm2 ± 0.76 
versus 1.81 mm2 ± 0.42; 4 litters; n = 22; p = 4.19 x 10'4) (Fig 4.4). No significant 
effect on labyrinth area was observed (4.02 mm2 ± 0.56 versus 3.78 mm2 ± 0.60; 
p = 0.339), with the combined area of the two regions reduced by approximately 
21% (7.16 mm2 ± 0.74 versus 5.63 mm2 ± 0.82; p = 6.84 x 10’4).
To examine the glycogen content of wild type and transgenic placentae, 
PAS staining was performed at E14.5 and E18.5. Similar to transgenic placentae 
on the pure 129/Sv background, PAS staining was markedly reduced in 
transgenic placentae on the 129/Sv x C57BL/6 background at both stages (Fig
4.5 C, D, G and H). Occasional PAS-positive staining was observed in the 
labyrinth, however this was seen in both wild type and transgenic placentae and 
did not consistently co-localise with Tpbpa-positive cells within the labyrinth.
In summary, the placental phenotype of line 10-15 on a pure 129/Sv 
background was maintained on a 129/Sv x C57BL/6 background. Although there 
were two notable variations, with the - 2 0% placental weight deficit persisting to a 
similar degree at E18.5 on the 129/Sv x C57BL/6 background, at which stage the 
spongiotrophoblast mislocalisation defect appeared to be less severe.
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Figure 4.3: Loss of spongiotrophoblast in line 10-15 on the 129/Sv x
C57BL/6 background
To visualise placental structure and determine if spongiotrophoblast was 
reduced in transgenic placentae, placental sections were hybridised with the 
Tpbpa riboprobe. Wild type sections (left column) and transgenic sections 
(right column) were examined at E14.5 (A-D) and E18.5 (E-H). Sections in A, 
B, E and F are shown under higher magnification in C, D, G and H 
respectively. Scale bar = 1 mm (A, B, E, F); and 0.5 mm (C, D, G, H).
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Figure 4.4: Midline placental areas at E14.5 from line 10-15 on the 129/Sv x
C57BL/6 background
Spongiotrophoblast and labyrinth regions were measured at E14.5 to 
determine the extent of spongiotrophoblast loss. Graph shows mean area of 
spongiotrophoblast (Sp.), labyrinth (Lab.) and combined spongiotrophoblast 
and labyrinth regions (Total), with error bars representing standard deviation. 
Percentage values show the ratio of transgenic to wild type area. Statistical 
significance as determined by Mann-Whitney test is denoted by asterisks; *** 
p < 0.05.
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Figure 4.5: Glycogen cells in placentae of line 10-15 on the 129/Sv x
C57BL/6 background
General placental morphology was examined by H&E staining, with relative 
glycogen cell number assessed by PAS staining. Figure shows H&E (A, B, E, 
F) and PAS (C, D, G, H) staining at E14.5 (upper four) and E18.5 (lower four) 
of wild type (left column) and transgenic (right column) placentae. Dashed 
boxes indicate region of section stained for glycogen cells and shown at 
higher magnification below. Broken lines indicate boundaries of placental 
layers; labyrinth at bottom. Scale bar = 500 ^m (H&E) and 200 i^m (PAS).
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4.2.2 Characterising line 10-10 on the 129/Sv x C57BL/6 background
A second transgenic line was also generated that possesses the same modified 
transgene as line 10-15 but at an independent integration site and with an 
unconfirmed copy number. This line was generated by pronuclear injection into 
C57BL/6 x CBA Fi embryos and subsequently bred into the C57BL/6 
background. The placental phenotype was studied on a 129/Sv x C57BL/6 
background thus allowing a direct comparison with placentae from line 10-15 on 
a similar genetic background.
The transgene copy number of line 10-10 was not quantified by Southern 
blotting. However, expression of Phlda2 and Slc22a18 was examined at by qPCR 
E12.5 from placenta on the 129/Sv x C57BL/6 background. Phlda2 was 
expressed at 2.8-fold (± 0.38) wild type and Slc22a18 at 1.8-fold (± 0.56) wild 
type level (Fig 4.6), suggesting that the line contained 1-2 copies of the BAC 
transgene.
Transgenic placentae from line 10-15 on the 129/Sv x C57BL/6 
background were approximately 20% lighter than wild type at both E14.5 and 
E18.5 (see Section 4.2.1). A similar effect on placental weight was observed in 
line 10-10, with transgenic placentae 20.2% lighter than wild type at E14.5 (111.0 
mg ± 9.0 versus 88.6  mg ± 9.8; 7 litters; n = 46; p = 3.12 x 10 10), and 16.9% 
lighter at E18.5 (112.3 mg ± 6.8 versus 93.4 mg ± 9.3; 5 litters; n = 34; p = 1.01 x 
10'7) (Fig 4.7).
Placentae from line 10-10 at E14.5 and E18.5 were hybridised with the 
Tpbpa probe to examine the extent of spongiotrophoblast loss and 
mislocalisation (Fig 4.8). At both E14.5 and E18.5, the spongiotrophoblast was 
overtly reduced in size in transgenic placenta. Although discrete clusters of 
Tpbpa-positive cells were observed in the labyrinth of transgenic placentae at 
both stages, this feature of the phenotype was not as pronounced at E18.5 as for 
line 10-15 on both genetic backgrounds examined at this stage.
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Figure 4.6: Transgene expression at E12.5 in placentae of line 10-10 on the
129/Sv x C57BL/6 background
Expression of Phlda2 and Slc22a18 was examined at E12.5 in placentae 
from line 10-10 on the 129/Sv x C57BL/6 background to estimate the 
transgene copy number and allow a comparison with line 10-15 for which 
transgene copy number was known. Graph shows mean fold change for 
Phlda2 and Slc22a18 in transgenic placentae compared to wild type 
placentae from the same litter. Error bars show standard deviation.
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Figure 4.7: Placental weights at E14.5 and E18.5 from line 10-10 on the
129/Sv x C57BL/6 background
To confirm that the placental phenotype is due to over-expression of the 
imprinted locus, placental weights were examined at E14.5 and E18.5 from 
the independent line 10-10. The graph shows the mean placental weight of 
wild type and transgenic placentae, with error bars representing standard 
deviation. Percentage values indicate the ratio of transgenic weight to wild 
type. Statistical significance as determined by /-test is denoted by asterisks
***p <  0.001.
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Figure 4.8: Loss of spongiotrophoblast in line 10-10 on the 129/Sv x
C57BL/6 background
To visualise placental structure and determine if spongiotrophoblast was 
reduced in transgenic placentae, placental sections from line 10-10 were 
hybridised with the 7pbpa riboprobe. Wild type sections (left column) and 
transgenic sections (right column) were examined at E14.5 (A-D) and E18.5 
(E-H). Sections in A, B, E and F are shown under higher magnification in C, 
D, G and H respectively. Scale bar = 1 mm (A, B, E, F); and 0.5 mm (C, D, 
G, Hj.
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At E14.5, similar to line 10-15 on both a pure 129/Sv and 129/Sv x 
C57BL/6 background, the spongiotrophoblast area was significantly reduced in 
transgenic placentae of line 10-10, accounting for only 54.9% the area in wild 
type placentae (3.17 mm2 ± 0.54 versus 1.74 mm2 ± 0.49; 4 litters; n = 29; p = 
2.10 x 10-5). No significant effect on labyrinth area was observed (3.75 mm2 ± 
0.91 versus 3.39 mm2 ± 1.19; p = 0.511), with the combined area of the two 
regions reduced by approximately 25% (6.91 mm2 ± 1.20 versus 5.17 mm2 ± 
1.46; p = 3 .30x1 O'3) (Fig 4.9).
Glycogen cell staining was overtly reduced in transgenic placentae at both 
stages examined (Fig 4.10). Although some glycogen cells were detected in the 
labyrinth region of transgenic placentae at E14.5, this did not correlate with, the 
number of Tpbpa-positive clusters in the transgenic placentae.
In summary, the placental phenotype of line 10-10 on a 129/Sv x C57BL/6 
genetic background was comparable to that of line 10-15 on a similar genetic 
background. Similar to line 10-15 on the 129/Sv x C57BL/6 background, the 
placental weight deficit observed at E14.5 persisted to a similar degree at E18.5, 
with a similar mislocalisation phenotype apparent at this stage. This comparable 
placental phenotype is despite an apparently lower expression of Phlda2 and 
Slc22a18 in transgenic placentae of line 10-10.
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Figure 4.9: Midline placental areas at E14.5 from line 10-10 on the 129/Sv x
C57BL/6 background
Areas of spongiotrophoblast, labyrinth and combined areas (total) from 
midline placental sections at E14.5 from line 10-10. Graph shows mean 
midline areas of spongiotrophoblast (Sp.), labyrinth (Lab.) and combined 
spongiotrophoblast and labyrinth regions (Total), with error bars representing 
standard deviation. Percentage values indicate the ratio of transgenic area to 
wild type. Statistical significance as determined by Mann-Whitney test is 
denoted by asterisks; ** p < 0.005 *** p < 0.001.
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Figure 4.10: Glycogen cells in placentae of line 10-10 on the 129/Sv x
C57BL/6 background
General placental morphology was examined by H&E staining, with relative 
glycogen cell number assessed by PAS staining. H&E (A, B, E, F) and PAS 
(C, D, G, H) staining at E14.5 (upper four) and E18.5 (lower four) of wild type 
(left column) and transgenic (right column) placentae. Dashed boxes indicate 
region of section stained for glycogen cells and shown at higher 
magnification below. Broken lines indicate boundaries of placental layers; 
labyrinth at bottom. Scale bar = 500 (H&E) and 200 ^m (PAS).
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4.2.3 Effect of genetic background on wild type placenta
Wild type placentae on a pure 129/Sv background were overtly smaller compared 
to wild type placentae on the 129/Sv x C57BL/6 background at both E14.5 and 
E18.5 (Fig 4.11). Normalised wild type placental weights from 129/Sv x C57BL/6 
litters of lines 10-15 and 10-10 were combined and compared to wild type 
placental weights from line 10-15 on a pure 129/Sv background. By weight, wild 
type 129/Sv x C57BL/6 placentae were 38.1% heavier than pure 129/Sv wild type 
placentae at E14.5 (78.7 mg ± 12.5 versus 108.6 mg ± 9.2; wild type placentae 
from 19 litters; n = 73; p = 2.10 x 10'18). A similar difference in weight persisted at 
E18.5, with 129/Sv x C57BL/6 placentae 45.1% heavier than pure 129/Sv wild 
type (79.6 mg ± 6.9 versus 115.4 mg ± 7.2; wild type placentae from 22 litters; n 
= 82; p = 7.22 x 10‘37).
The increased weight of placentae on the 129/Sv x C57BL/6 background 
appears to be due entirely to the presence of a larger spongiotrophoblast area, 
which is 2.34 times larger in placentae of the 129/Sv x C57BL/6 background 
compared to those on the pure 129/Sv background (1.36 mm2 ± 0.40 versus 3.17 
mm2 ± 0.61; wild type placentae from 11 litters; n = 37; p = 3.29 x 10'6). In 
contrast, there was no significant difference in the area of the labyrinth region 
(3.66 mm2 ± 0.36 versus 3.85 mm2 ± 0.79; p = 0.104). The difference in the 
combined area of spongiotrophoblast and labyrinth regions was comparable to 
the weight difference between the two genetic backgrounds, with a 37% 
increased area in placentae of the 129/Sv x C57BL/6 background (5.10 mm2 ± 
0.41 versus 7.00 mm2 ± 1.04; p = 7.17 x 10'5) (Fig 4.12).
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Figure 4.11: Comparison of wild type placental weights at E14.5 and E18.5 
between pure 129/Sv and 129/Sv x C57BL/6 backgrounds
Wild type placental weight was compared between the two genetic 
backgrounds used. Mean normalised weights of wild type placentae are 
shown on the 129/Sv and 129/Sv x C57BL/6 genetic backgrounds at A) 
E14.5 and B) E18.5. Percentage values indicate the ratio of mean placental 
weight on the 129/Sv x C57BL/6 background to that on the 129/Sv 
background. Error bars show standard deviation and asterisks denote 
significance level according to the Student’s f-test: *** p < 0.001.
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Figure 4.12: Comparison of midline placental areas at E14.5 on a pure 
129/Sv and 129/Sv x C57BL/6 genetic background
To determine whether placentae on a 129/Sv x C57BL/6 background were 
proportionately larger than those on a pure 129/Sv background, 
spongiotrophoblast and labyrinth areas were compared. Graph shows mean 
midline areas of spongiotrophoblast (Sp.), labyrinth (Lab.) and combined 
spongiotrophoblast and labyrinth regions (Total), with error bars representing 
standard deviation. Percentage values indicate the ratio of midline area on a 
129/Sv x C57BL/6 background to the area on a pure 129/Sv background. 
Asterisks denote significance level according to the Mann-Whitney test: *** p 
< 0 .001.
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4.2.4 Characterising line 5D3 on the 129/Sv x C57BL/6 background
The effect of over-expressing Phlda2 and Slc22a18 in the mouse placenta was 
characterised in two independent transgenic lines, one possessing three 
additional copies of each gene, and the other with an undetermined transgene 
copy number. The key placental phenotypes of both transgenic lines were 
comparable, indicating that the transgene integration site was not a significant 
contributory factor to the phenotype. Both lines 10-15 and 10-10 possess more 
than one copy of the BAC transgene. Loss of imprinting of the IC2 domain would 
be equivalent to the presence of two active copies of the genes investigated in 
this study. We next examined whether a lower dosage of Phlda2 and Slc22a18 
showed a similarly severe placental phenotype by making use of a single copy 
transgenic line (5D3) and a two-copy transgenic line (5A4). The transgene 
present in these transgenic lines contains an intact Cdknlc gene, but since the 
Cdknlc placenta-specific enhancers are not on the BAC (John et al. 2001), lines 
5D3 and 5A4 can be compared with lines 10-15 and 10-10, as only Phlda2 and 
Slc22a18 are over-expressed in the placenta of all three lines.
Transgene copy number was previously determined by Southern blotting, 
with gene expression further assessed by qPCR. At E12.5, expression of Phlda2 
in transgenic placentae on the 129/Sv x C57BL/6 background was 4.9-fold (± 1.3) 
compared to wild type with Slc22a18 expression elevated by 4.6-fold (± 1.8) (Fig 
4.13A). To examine if the inconsistency between observed gene expression and 
the anticipated expression level predicted by the transgene copy number was 
due to genetic background differences, expression was also assessed from 
generation 7 C57BL/6 placentae by qPCR. Expression of Phlda2 and Slc22a18 
correlated more closely with the predicted expression level, with Phlda2 
upregulated by 2.3-fold (± 0.9) compared to wild type and Slc22a18 expression 
elevated by 1.6-fold (± 0.8) (Fig 4.13B). However, as exemplified by the large 
standard deviations, expression levels remained variable between the individual 
placentae that were compared.
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Figure 4.13: Transgene expression at E12.5 in placentae of line 5D3 on two
genetic backgrounds
Expression from the transgene was first examined on the 129/Sv x C57BL/6 
background, and subsequently from a G7 C57BL/6 mating. Fold change 
between wild type and transgenic placentae of line 5D3 on A) 129/Sv x 
C57BL/6 genetic background and B) G7 C57BL/6 genetic background. Error 
bars show standard deviation.
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The placental phenotype was examined in line 5D3 on the 129/Sv x 
C57BL/6 background. At E13.5 transgenic placentae were approximately 27% 
lighter than wild type (87.1 mg ± 9.8 versus 63.9 mg ± 13.1; 5 litters; n = 40; p = 
1.98 x 10'6), a phenotype which persisted to a similar degree at E14.5 (106.5 mg 
± 8.8 versus 78.3 mg ± 8.4; 3 litters; n = 22; p = 4.40 x 10'7) and E18.5 (110.1 mg 
± 12.3 versus 84.8 mg ± 10.8; 7 litters; n = 59; p = 6.51 x 10'8) (Fig 4.14A). A 
more severe placental weight deficit was observed in transgenic placentae of line 
5A4, which possess two copies of the unmodified BAC transgene. At E13.5 
transgenic placentae were approximately 40% lighter than wild type (90.2 mg ± 
12.9 versus 54.1 mg ± 12.5; 7 litters; n = 50; p = 1.08 x 10'6), with a similar 
difference at E14.5 (107.0 mg ± 3.9 versus 66.2 mg ± 5.5; 4 litters; n = 25; p = 
3.56 x 10'16), and a ~30% weight deficit at E18.5 (115.5 mg ± 10.7 versus 81.5 
mg ± 12.7; 7 litters; n = 54; p = 2.04 x 10'14) (Fig 4.14B).
At E14.5, spongiotrophoblast area was significantly reduced in transgenic 
placentae, accounting for only 40% of the area in wild type placentae (3.18 mm2 
± 0.68 versus 1.28 mm2 ± 0.27; 2 litters; n = 17; p = 7.24 x 10'3) (Fig 4.15B). No 
significant effect on labyrinth area was observed (4.38 mm2 ± 0.65 versus 4.04 
mm2 ± 0.44; 2 litters; n = 17; p = 0.831), with the combined area of the two 
regions reduced by approximately 30% (7.64 mm2 ± 0.97 versus 5.32 mm2 ± 
0.52; 2 litters; n = 13; p = 7.08 x 10'3). Furthermore, the mean spongiotrophoblast 
area of transgenic placentae from line 5D3 was significantly less than that of 
transgenic placentae of lines 10-15 and 10-10 on the 129/Sv x C57BL/6 
background (see Table 4.1). Glycogen staining was reduced although correctly 
localised as seen in transgenic placentae from both lines 10-15 and 10-10 (Fig 
4.17).
In summary, transgenic mice that possess two active copies of Phlda2 and 
Slc22a18 exhibit a placental phenotype that is similar to that of lines 10-15 and 
10-10. Placental weight was reduced to a comparable degree, although the loss 
of spongiotrophoblast area in line 5D3 was more severe than observed in lines 
10-15 and 10-10. Placental weight of transgenic placentae from line 5A4 was 
more severely reduced that observed in lines 10-15, 10-10 and 5D3.
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E18.5E13.5 E14.5
70.6%59.9% 61.8% * * *
E14.5E13.5 E18.5
□  Wild type ■  Transgenic
Figure 4.14: Placental weights from lines 5D3 and 5A4 on the 129/Sv x
C57BL/6 background
Placental weights were compared between lines 5D3 and 5A4 at E13.5, E14.5 
and E18.5. Graphs show mean normalised placental weight of wild type and 
transgenic placentae of A) line 5D3 on the 129/Sv x C57BL/6 background at 
E13.5, E14.5 and E18.5 and B) line 5A4 at E13.5, E14.5 and E18.5. 
Percentage values indicate the ratio of transgenic weight to wild type. Error 
bars represent standard deviation. Statistical significance as determined by t- 
test is denoted by asterisks *** p < 0 .001 .
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Figure 4.15: Loss of spongiotrophoblast in line 5D3 on the 129/Sv x
C57BL/6 background
Placental morphology was examined by H&E staining of wild type (A and C) and 
transgenic (B and D) placentae at E14.5 (A and B) and E18.5 (C and D) from line 
5D3 on the 129/Sv x C57BL/6 background. Dashed lines indicate boundary of 
spongiotrophoblast. Scale bar = 1 mm.
Area (mm2) % of WT area P
5D3 1.28 ±0.27 40% -
10-15 1.81 ±0.42 57% 0.00387
10-10 1.74 ±0.49 55% 0.0190
Combined 10-15 and 10-10 1.77 ±0.45 56% 0.00421
Table 4.1: Comparison of mean spongiotrophoblast area of transgenic 
placentae from lines 10-15, 10-10 and 5D3 on the 129/Sv x C57BL/6
background
The table shows the mean spongiotrophoblast area of transgenic placentae from 
lines 5D3, 10-15, 10-10 and the combined data for lines 10-15 and 10-10. The 
midline spongiotrophoblast area of transgenic placentae from line 5D3 was 
significantly smaller than that of lines 10-15 and 10-10. The p value represents a 
comparison between the spongiotrophoblast area of transgenic placentae of line 
5D3 and the area of the designated line on the 129/Sv x C57BL/6 background.
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□  Wild type 3 Transgenic
Figure 4.16: Midline placental areas in line 5D3 on the 129/Sv x C57BL/6
background
Spongiotrophoblast (Sp.), labyrinth (Lab.) and combined (Total) areas were 
measured from midline placental sections of line 5D3 at E14.5. Percentage 
values indicate the ratio of transgenic area to wild type. Error bars show 
standard deviation. Statistical significance as determined by Mann-Whitney 
test is denoted by asterisks; ** p < 0.005.
Figure 4.17: Glycogen cells in placentae of line 5D3 on the 129/Sv x
C57BL/6 background
H&E (A, B, E, F) and PAS (C, D, G, H) staining at E14.5 (upper four) and 
E18.5 (lower four) of wild type (left column) and transgenic (right column) 
placentae. Dashed box indicates region of section stained for glycogen cells 
and shown at higher magnification below. Broken lines indicate boundaries of 
placental layers; labyrinth at bottom. Scale bar = 500 i^m (H&E) and 200 |jm 
(PAS).
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4.2.5 Restoration of Phlda2 gene dosage to normal to assess the role 
of Slc22a18 in the placental phenotype
All transgenic lines utilised throughout this investigation over-express both 
Phlda2 and Slc22a18 in the placenta. Lines 10-15 and 10-10 contain modified 
BAC transgenes, whereby Cdknlc is inactivated by the presence of a p- 
galactosidase reporter construct. Enhancers required for placental Cdknlc 
expression are not located on the transgene, thus Cdknlc is not over-expressed 
in placentae of lines 5D3 or 5A4 (John et al. 2001).
A consequence of over-expressing two genes is that the resulting 
phenotype cannot be directly attributed to either gene. Previously published 
observations however, indicate that the placental deficit and reduced 
spongiotrophoblast observed in this model are primarily due to over-expression of 
Phlda2. Firstly, the small placenta and reduced spongiotrophoblast characteristic 
of transgenic placentae is the reciprocal to the phenotype of Phlda2 null 
placentae, which exhibit placentomegaly and an increased spongiotrophoblast 
region (Frank et al. 2002). Furthermore, in mice that lack paternal Kvdmrl, and 
thus over express Phlda2 and Slc22a18, the placenta is reduced in size with a 
small spongiotrophoblast. Restoration of Phlda2 gene dosage to normal by 
paternal inheritance of the Kvdmrl null allele with maternal inheritance of the 
Phlda2 null allele rescued both placental weight and spongiotrophoblast 
phenotypes (Salas etal. 2004).
A similar approach was undertaken in an attempt to dissect out the 
contribution of Phlda2 and Slc22a18 to the placental phenotype. Mating a stud 
male from the single copy transgenic line (5D3) with a female Phlda2 null mouse, 
generated progeny that possess both the transgene and the Phlda2 null allele. 
These progeny thus have two active Slc22a18 alleles but only one active Phlda2 
allele, which is located on the transgene. By investigating the effect of restoring 
Phlda2 gene dosage to normal, it was envisaged that the contribution of over­
expression of this gene to the phenotype would be revealed. Utilising both 
heterozygous male and female mice enabled four genotypes to be generated in 
each litter, with an expected Mendelian ratio of 1:1:1:1 (Fig 4.1). In doing so, a 
direct comparison of wild type, transgenic and “rescue” placentae was possible in 
placentae from the same litter.
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Ms
Wild type
iternal
PhldaZ'*
Wild type
Paternal
Wild type PhldaZ
Transgene Transgenic PhldaZ'*with transgene
Punnett Square showing resulting genotypes from a mating between a 
hemizygous 5D3 transgenic male and a heterozygous Phlda2 null female.
Table 4.2: Punnett square showing potential genotypes generated in double 
transgenic matings
The four potential genotypes generated in such a breeding program differ 
according to the number of active alleles of Phlda2, Slc22a18 and Cdknlc  (Table 
4.2). Wild type conceptuses possess a single active allele for each gene, 
whereas transgenic conceptuses possess two active alleles for Phlda2 and 
Slc22a18, and a single active Cdknlc  allele. Phlda2 null conceptuses possess a 
single active allele for Slc22a18 and Cdknlc, but no active Phlda2 allele. The 
combined inheritance of the transgene and Phlda2 null allele results in two copies 
of Slc22a18, while Phlda2 gene dosage is maintained at normal level of one 
active allele.
Phlda2 Slc22a18 Cdknlc
Wild type 1 1 1
Transgenic 2 2 1 +
PhldaZ/+ 0 1 1
PhldaZl+ with transgene 1 2 1 +
Table 4.3: Number of active alleles according to genotype in the placentae 
of conceptuses from double transgenic matings
1 Cdknlc  is represented by the presence of two alleles in these progeny, 
although they are only actively expressed in the embryo, as Cdknlc  is not 
expressed from the transgene in the placenta.
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Phlda2 expression was quantified by qPCR at E12.5 to determine whether 
expression levels were restored to wild type levels in the double transgenic 
placentae. Optimally, a direct comparison of Phlda2 expression would be made 
between double transgenic and wild type placentae. However, this was not 
possible, as none of the four litters collected at E12.5 contained two wild type and 
two double transgenic placentae. Instead, expression of Phlda2 and Slc22a18 
was compared between double transgenic and 5D3 transgenic placentae. 
Assuming that appropriate copy number-dependent Phlda2 expression exists 
from the transgene, such a comparison would be expected to yield a 2-fold 
reduction in Phlda2 levels with Slc22a18 expression remaining comparable 
between the two genotypes. Consistent with this prediction, Phlda2 expression 
was reduced by 2.24-fold (± 0.13) in double transgenics, whereas Slc22a18 
remained unaffected (0.96-fold ± 0.08) (Fig 4.18). Thus, Phlda2 expression was 
reduced in double transgenic placentae compared to 5D3 transgenic placentae.
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Figure 4.18: Relative expression levels of Phlda2 and Slc22a18
Placental expression of Phlda2 and Slc22a18 in double transgenic placenta 
compared with 5D3 transgenic placentae. Graph shows mean fold change with 
error bars representing standard deviation.
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Expression of Phlda2 was also examined at E13.5 by in situ hybridisation 
(Fig 4.17A-D). Comparison of Phlda2 probe hybridisation between wild type, 
transgenic and double transgenic placentae indicated that Phlda2 expression 
was most similar between wild type (Fig 4.19A) and double transgenic placentae 
(Fig 4.19C). Although not a quantitative measure, comparison of signal intensity 
between wild type and single BAC transgenic placentae (Fig 4.19B) indicated that 
Phlda2 expression was greater than two-fold wild-type levels in this individual 
sample. This is consistent with qPCR analysis of expression from placentae of 
line 5D3 on the 129/Sv x C57BL/6 background, which suggests that Phlda2 
expression can vary. Thus, although Phlda2 expression was reduced in double 
transgenic placentae compared to 5D3 transgenic placentae, expression levels 
appear to remain elevated above wild type levels. As anticipated, no signal was 
observed in Phlda2 null placentae (Fig 4.17D).
Figure 4.19: Phlda2 expression atE13.5 in each of the four genotypes 
generated by double transgenic matings
Expression of Phlda2 was examined by in situ hybridisation at E13.5 in 
placentae from double transgenic matings. A) Wild type, B) 5D3 transgenic, C) 
5D3 transgenic and Phlda2 null, D) Phlda2 null. Broken lines indicate 
boundaries of placental layers: labyrinth at bottom. Scale bar = 500 pm.
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Placentae and embryos were dissected at E14.5 and wet weights 
recorded as described previously. Fourteen litters were obtained at E14.5, 
comprising 24 wild type, 24 transgenic, 34 Phlda2 null and 18 double transgenic 
conceptuses. Due to the four potential genotypes arising in each litter, only nine 
of the 14 litters contained at least two wild-type conceptuses. All data collected 
were first analysed as raw data (Fig 4.20 A). Consistent with results reported in 
Section 4.2.3, transgenic placentae were 20% lighter than wild type at E14.5 
(106.0 mg ± 18.71 versus 84.1 mg ± 13.88; 14 litters; n = 48; p = 3.22 x 10'5). 
Furthermore, and consistent with previously published results, Phlda2 null 
placentae were significantly heavier than wild type (106.0 mg ± 18.71 versus
132.1 mg ± 24.21; 14 litters; n = 58; p = 4.36 x 10‘5). The double transgenic 
placentae were 8% lighter than wild type placentae, but this result was not 
statistically significant at the 5% significance level (106.0 mg ± 18.71 versus 97.7 
mg ± 14.86; 14 litters; n = 42; p = 0.128). In contrast, the mean weight of double 
transgenic placentae was significantly greater than that of 5D3 transgenic 
placentae (84.1 mg ± 13.88 versus 97.7 mg ± 14.86; 14 litters; n = 42; p = 4.1 x 
10'3).
The weights obtained from the nine litters with at least two wild type 
conceptuses were normalised and analysed separately. A similar pattern of 
results was observed; transgenic placentae were 15.2% lighter than wild type 
(104.0 mg ± 16.5 versus 83.8 mg ± 21.4; 9 litters; n = 33; p = 0.0167), and 
Phlda2 null placentae were significantly heavier than wild type (104.0 mg ± 16.5 
versus 118.8 mg ± 25.9; 9 litters; n = 43; p = 5.37 x 10'3). Double transgenic 
placentae appeared to be 10.5% lighter than wild type, although this failed to 
achieve statistical significance (104.0 mg ± 16.5 versus 93.1 mg ± 12.2; 9 litters; 
n = 21; p = 0.0741). In contrast to analysis of raw data however, there was no 
significant difference between the mean weights of 5D3 transgenic or double 
transgenic placentae (87.2 mg ± 21.4 versus 93.1 mg ± 12.2; 9 litters; n = 22; p = 
0.446).
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Figure 4.20: Placental weights from double transgenic matings at E14.5
Mean (A) raw and (B) normalised placental weights from each genotype at 
E14.5 from a cross between 5D3 and Phlda2',+. Graphs show mean weight, 
with error bars denoting standard deviation. Percentage values indicate the 
weight ratio relative to wild type. Significance level calculated by the f-test is 
indicated by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.005.
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Sections from placentae representing each of the four genotypes were 
hybridised with the Tpbpa probe at E14.5 and E18.5 to examine the relative 
spongiotrophoblast area in each genotype (Fig 4.21). The mislocalisation of 
Tpbpa-positive cells in the labyrinth, which was a prominent feature of transgenic 
placentae at both E14.5 and E18.5, was comparably less severe in transgenic 
placentae examined from double transgenic matings. Spongiotrophoblast of 
rescue placentae appeared larger than that of transgenic placentae. To 
determine the extent of this apparent return to the wild type state, 
spongiotrophoblast area was measured from midline sections of placentae from a 
number of litters (Fig 4.22).
As anticipated, spongiotrophoblast area was significantly reduced in 
transgenic placentae, representing approximately 44% the spongiotrophoblast 
area observed in wild type (3.52 mm2 ± 0.57 versus 1.58 mm2 ± 0.49; 5 litters; n 
= 19; p = 2.80 x 10-4). Spongiotrophoblast area in rescue placentae was 
approximately 70% that of wild type (3.52 mm2 ± 0.57 versus 2.40 mm2 ± 0.20; 5 
litters; n = 20; p = 1.09 x 10"3), although this represented a significant ~50% 
increase over the transgenic placentae (1.58 mm2 ± 0.49 versus 2.40 mm2 ±
0.20; 5 litters; n = 21; p = 2.87 x 10"4). In agreement with previously published 
results, the spongiotrophoblast area of Phlda2 null placentae was approximately 
40% larger (3.52 mm2 ± 0.57 versus 4.77 mm2 ± 1.18; 5 litters; n = 18; p = 5.02 x 
10‘3). The extent of glycogen staining at E14.5 and E18.5 appeared to correlate 
with spongiotrophoblast area (Figs 4.23 and 4.24). Increased glycogen staining 
was observed in double transgenic placentae in comparison to 5D3 transgenic 
placentae, although visibly less than wild type placentae at the same stage. As 
expected, glycogen staining was overtly stronger in Phlda2 null placentae.
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Figure 4.21: Assessment of spongiotrophoblast in placenta from double
transgenic matings
Spongiotrophoblast in placentae from double transgenic matings. E14.5 (A-D) 
and E18.5 (E-H). A and E) Wild type, B and F) 5D3 transgenic, C and G) 5D3 
transgenic and Phlda2 null, D and H) Phlda2 null. Scale bar = 500 i^m.
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Figure 4.22: Spongiotrophoblast area from double transgenic matings
Spongiotrophoblast area was measured from midline placental sections at 
E14.5. Error bars show standard deviation. Percentage values indicate the 
weight ratio relative to wild type. Statistical significance as determined by 
Mann-Whitney test is denoted by asterisks; ** p < 0.005 *** p < 0.001.
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Figure 4.23: Glycogen staining at E14.5 in double transgenic matings
Placental morphology was examined from H&E stained sections at E14.5 (upper 
panels) and glycogen cells detected by PAS staining (lower panels). A and E) 
Wild type, B and F) 5D3 transgenic, C and G) 5D3 transgenic and Phlda2 null, 
D and H) Phlda2 null. Broken lines indicate boundaries between placental 
layers: labyrinth at bottom. Scale bar = 500 pm for A-D and 200 pm for E-H.
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Figure 4.24: Glycogen staining at E18.5 in double transgenic matings
Placental morphology was examined from H&E stained sections at E18.5 (upper 
panels) and glycogen cells detected by PAS staining (lower panels). A and E) 
Wild type, B and F) 5D3 transgenic, C and G) 5D3 transgenic and Phlda2 null, 
D and H) Phlda2 null. Broken lines indicate boundaries between placental 
layers: labyrinth at bottom. Scale bar = 500 pirn for A-D and 200 pm for E-H.
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4.3 Discussion
There were three primary aims to the work presented in this chapter:
1. To confirm the key placental phenotypes of line 10-15 in an independent 
transgenic line
2. To determine if the placental phenotype associated with three additional 
copies of Phlda2 and Slc22a18 is affected by dosage of these genes
3. To dissect the relative contributions of Phlda2 and Slc22a18 to the 
placental phenotype
4.3.1 Confirmation of phenotype in an independent line
As transgenic males from the second transgenic line (10-10) were initially bred 
into the C57BL/6 genetic background, the placental phenotype of this line could 
only be examined on the 129/Sv x C57BL/6 background. To enable a direct 
comparison of the placental phenotype between lines 10-15 and 10-10, the 
phenotype of line 10-15 was first examined on the 129/Sv x C57BL/6 
background. In addition to enabling a direct comparison of phenotypes between 
lines 10-15 and 10-10, this also provided an opportunity to assess the effect of 
genetic background on placental phenotype.
The placental phenotype of line 10-15 on the 129/Sv x C57BL/6 
background at E14.5 was comparable to that of line 10-15 on a pure 129/Sv 
background. At this stage, transgenic placentae were -20%  lighter due to the 
disproportionate loss of spongiotrophoblast area, including an overt reduction in 
glycogen cell staining. No compensatory weight gain was observed in transgenic 
placentae on the 129/Sv x C57BL/6 background between E14.5 and E18.5. At 
E18.5, transgenic placentae on the pure 129/Sv background displayed a -50%  
restoration of the weight towards the wild type mean, with a weight deficit of -9%  
persisting to this stage. In contrast, the -20%  weight deficit of transgenic 
placentae on the 129/Sv x C57BL/6 background persisted until E18.5. A striking 
mislocalisation of Tpbpa-positive cells was observed in transgenic placentae on a 
129/Sv background at E18.5, with a distinct spongiotrophoblast boundary absent 
at this stage. This phenotype was somewhat less severe on the 129/Sv x 
C57BL/6 genetic background, with a clear spongiotrophoblast-labyrinth border 
observed at E18.5. Occasional Tpbpa-positive cells were observed within the
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labyrinth of transgenic placentae at both E14.5 and E18.5, although to a lesser 
extent than in placentae on a pure 129/Sv background. Additionally, Tpbpa- 
positive cells were observed in the labyrinth of wild type 129/Sv x C57BL/6 
placentae at E14.5, although this appeared to occur at a lower frequency than in 
transgenic placentae, and was not observed in wild type placentae at E18.5. In 
contrast, Tpbpa positive cells were not observed to this extent in the labyrinth of 
wild type placenta on a pure 129/Sv background. This may represent another 
genetic background effect, with Tpbpa positive cells previously observed in the 
labyrinth of wild type placenta on an ICR x 129/Sv genetic background. However, 
in this same genetic background, placentae lacking Parpl expression exhibit a 
reduced spongiotrophoblast layer with an absence of Tpbpa positive cells in the 
labyrinth layer (Hemberger et al. 2003). This contrasts with this study in which 
mutant placenta displayed increased Tpbpa expression in distinct clusters of the 
labyrinth layer. Similar to transgenic placentae on a pure 129/Sv background, 
glycogen cell staining was visibly reduced at both E14.5 and E18.5 in placentae 
on the 129/Sv x C57BL/6 background. Additionally, glycogen staining did not co- 
localise with Tpbpa-positive cell clusters in the labyrinth in either wild type or 
transgenic placentae.
Despite the small variations in the phenotype described above, the 
placental consequences of over-expressing Phlda2 and Slc22a18 were 
comparable between a pure 129/Sv background and the 129/Sv x C57BL/6 
background. The phenotype initially appeared to be more severe on the 129/Sv x 
C57BL/6 background, with the placental weight deficit persisting until term. 
However, histological examination of placental structure revealed that the 
mislocalisation of spongiotrophoblast was less severe in comparison to the 
129/Sv placentae. These phenotypic variations underline the importance of 
characterising line 10-15 on the 129/Sv x C57BL/6 background in order to allow a 
direct comparison with line 10-10, which could only be investigated on the 129/Sv 
x C57BL/6 background.
Line 10-10 was generated during the course of this investigation and was 
initially bred into the C57BL/6 genetic background. Backcrossing of this line to the 
129/Sv background has commenced, however due to time restraints, only 
transgenic animals on a C57BL/6 background were available to begin the 
characterisation of the placental phenotype. The transgene copy number of line
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10-15 was previously determined by Southern blotting, and although this is a 
long-term aim for 10-10, it was not deemed necessary to accurately determine 
transgene copy number in this way. Instead, given the apparently stable 
expression of the transgene in line 10-15 on the 129/Sv x C57BL/6 background 
as determined by qPCR, this technique was also utilised to estimate copy 
number in line 10-10. Data from a comparison of two wild type and two 
transgenic placentae from the same litter suggest that line 10-10 contains 1-2 
copies of the transgene. The primary objective for line 10-10 was to provide an 
independent transgenic line possessing the same transgene as line 10-15 in 
which to confirm a causative role for the genes located on the transgene. Further 
to this, line 10-10 additionally provided a line with an alternative transgene copy 
number to line 10-15 in which gene dosage effects could be investigated, which 
is discussed in Section 4.3.3.
The placental phenotype of line 10-10 was comparable to that of line IQ- 
15 on the 129/Sv x C57BL/6 background. Transgenic placentae were ~20% 
lighter at E14.5, a deficit that persisted until E18.5, similar to line 10-15 on the 
129/Sv x C57BL/6 genetic background. Furthermore, as for line 10-15 on the 
129/Sv x C57BL/6 background, a distinct spongiotrophoblast boundary existed at 
both stages examined. Occasional Tpbpa-positive clusters of cells were observed 
in the labyrinth of transgenic placentae at E18.5, with varying frequency of these 
cells at E14.5 in wild type and transgenic placentae. The placental phenotypes of 
lines 10-15 and 10-10 were largely equivalent when examined on a similar 
129/Sv x C57BL/6 background.
The development of similar placental phenotypes in two independently 
generated transgenic lines carrying the same transgene effectively excluded the 
possibility that the placental defect was a consequence of the site of transgene 
integration. A causative role for the site of transgene integration was considered 
an unlikely contributory factor to the placental phenotype given the previously 
reported results directly implicating Phlda2. Firstly, the phenotype of line 10-15 
was reciprocal to that of the Phlda2m\\ line, in which placentomegaly occurs due 
to an expansion of the spongiotrophoblast. Furthermore, the placental weight 
deficit and loss of spongiotrophoblast associated with Kvdmr1+I~ placentae was 
rescued by restoring Phlda2 gene dosage to normal in Kvdmr1+I~ / Phlda2',+ 
double transgenic conceptuses (Salas et al. 2004). Nonetheless, the presence of
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comparable phenotypes in two independent lines demonstrates a causative role 
for Phlda2 and/or Slc22a18.
A striking visual difference was observed between wild type 129/Sv 
placentae and wild type placentae on the 129/Sv x C57BL/6 background. Those 
on a pure 129/Sv background appeared to have a smaller diameter and were 
more robust to handle prior to fixation. Wild type placentae from 129/Sv x 
C57BL/6 matings appeared to have a larger diameter and were considerably less 
rigid when handled prior to fixation. These initial visual characterisations of the 
two placentae prompted a comparison of weight and area data collected from 
wild type placentae on the two genetic backgrounds. At both E14.5 and E18.5, 
wild type placentae on the 129/Sv x C57BL/6 background were around ~40% 
heavier in comparison to those on a pure 129/Sv background. This increased 
weight was apparently due entirely to the presence of a larger spongiotrophoblast 
area in placentae on the 129/Sv x C57BL/6 background. The midline area of the 
spongiotrophoblast of these placentae was ~2.5 times greater than that seen in 
pure 129/Sv placentae, with no overt difference in the cross-sectional area of the 
labyrinth. Interestingly, perhaps due to the inherently larger spongiotrophoblast 
area of placentae on the 129/Sv x C57BL/6 background, transgenic placenta on 
this background possessed a larger spongiotrophoblast midline area than wild 
type placenta on a pure 129/Sv background (1.35 ± 0.40 versus 1.77 ± 0.45; n = 
36; p = 0.0122). A summary of the mean midline spongiotrophoblast area is 
presented in Table 4.3.
To our knowledge, the striking structural differences between Mus 
musculus placentae on different genetic backgrounds discussed above have not 
been previously described, although Fi hybrid placentae of a C57BL/6 x C3H 
cross were ~20% heavier than those of an inbred C57BL/6 cross (McLaren 
1965). However, genetic background is known to impact upon phenotype 
severity, as demonstrated by the increased placentomegaly associated with 
Phlda2 null mice on a pure C57BL/6 background compared with those on a 
C57BL/6 x 129/Sv background (Frank et al. 2002). The underlying cause of such 
genetic background effects remains uncertain. An awareness of the effect that 
genetic background may have on placental phenotype will be an important 
consideration for future investigation of the mouse placenta.
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WT area (mm2) Tg area (mm2) P
10-15 (129/Sv) 1.35 ±0.40 0.54 ±0.13 -
10-15 (129/Sv XC57BL/6) 3.17 ±0.76 1.81 ±0.42 0.0153
10-10 (129/Sv XC57BL/6) 3.17 ±0.54 1.74 ±0.49 0.0497
Combined 10-10 and 10-15 
(129/Sv x C57BL/6)
3.17 ±0.61 1.77 ±0.45 0.0122
Table 4.4: Comparison of spongiotrophoblast midline area according to
genetic background
Mean spongiotrophoblast midline area is presented for wild type and transgenic 
placenta of line 10-15 on a pure 129/Sv and the 129/Sv x C57BL/6 genetic 
backgrounds, line 10-10 on the 129/Sv x C57BL/6 genetic background, and the 
combined data for lines 10-15 and 10-10 on the 129/Sv x C57BL/6 background. 
Transgenic placentae of lines 10-15 and 10-10 on the 129/Sv x C57BL/6 
background possess a larger midline spongiotrophoblast area than wild type 
placentae on a pure 129/Sv genetic background. The p value according to the 
Student’s f-test represents a comparison between area on a pure 129/Sv 
background and area on the 129/Sv x C57BL/6 background.
Furthermore, abnormal placental development has been described in 
interspecific hybrids between different species of the genus Mus. For instance, 
hyperplasia was observed in placenta of a Mus spretus x Mus musculus cross, 
whereas the reciprocal Mus musculus x Mus spretus cross was associated with 
placental hypoplasia. Placental hyperplasia in these crosses was characterised 
by an expanded and disrupted spongiotrophoblast layer, whereas hypotrophic 
placenta were characterised by a reduction or complete loss of this layer 
(Zechner et al. 1996). The paternally expressed Igf2 and the X-linked imprinted 
gene Esx1 have been implicated in the placental dysplasia observed in 
interspecific hybrids (Zechner et al. 2002).
4.3.3 Effect of gene dosage on phenotype
Initial attempts to investigate the effect of gene dosage on phenotype focused on 
attempting to generate homozygous transgenic conceptuses of line 10-15 by 
mating hemizygous males with hemizygous females. Eleven litters were obtained 
at E14.5, comprising 19 wild type and 57 transgenic conceptuses, of which 7 
were dying and an additional 20 conceptuses were at various stages of 
resorption. Although no statistical analysis was performed, the level of embryonic 
lethality observed was greater than seen in hemizygous matings with wild type
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females, and thus it was decided not to proceed with this line of investigation. 
Instead, the alternative transgenic lines 10-10, 5D3 and 5A4 were used to 
examine the effect of gene dosage.
Analysis of gene expression by qPCR indicated the presence of 1-2 copies 
of the transgene in line 10-10. However, as discussed previously the placental 
phenotype of line 10-10 was comparable to that of line 10-15 (3 copies) on a 
similar genetic background, suggesting that dosage of Phlda2 and Slc22a18 did 
not impact the severity of the phenotype. To further investigate the effect of 
dosage on the phenotype a further two transgenic lines that possess similar 
transgenes to lines 10-15 and 10-10 were characterised. Lines 5D3 and 5A4 
possess one and two copies of an unmodified BAC transgene respectively. The 
Cdknlc gene is intact on these transgenes, although it is expressed only in a 
subset of embryonic tissues, with no placental expression from the transgene 
(John et al. 2001). Both lines were investigated on a similar 129/Sv x C57BL/6 
genetic background to lines 10-15 and 10-10.
The placental phenotype observed in line 5D3 was similar to that seen in 
lines 10-15 and 10-10, with transgenic placentae -27%  lighter at E14.5 and 
-23%  lighter at E18.5. This placental weight deficit could be attributed to a 
disproportionate loss of the spongiotrophoblast layer. However, the extent of 
spongiotrophoblast loss in line 5D3 was more severe than in lines 10-15 and 10- 
10 on the 129/Sv x C57BL/6 background, with a 60% reduction in 
spongiotrophoblast area in transgenic placentae of line 5D3, compared to a 
-45%  reduction in area of lines 10-15 and 10-10. Furthermore, transgenic 
placentae of line 5A4 were -40% lighter at E14.5 and -30%  lighter at E18.5, 
suggesting that the placental weight deficit in a transgenic line possessing two 
copies of an unmodified transgene is more severe than that of a line possessing 
a single copy of the same transgene.
There are two potential explanations to account for the increased severity 
of the placental phenotype observed in line 5A4 and to some extent in line 5D3. 
One possible explanation is that expression of the transgene is not copy number 
dependent in lines 5D3 and 5A4, with expression of Phlda2 and Slc22a18 
actually greater than the two or three-fold wild type levels that would be expected 
in lines 5D3 and 5A4 respectively. Indeed, expression of these genes in line 5D3 
on the 129/Sv x C57BL/6 genetic background was more than twice the
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anticipated level. Thus, the more severe placental phenotype could be directly 
attributed to elevated Phlda2 and Slc22a18 expression. However, this seems 
unlikely, as the phenotype of line 10-15 has remained relatively constant despite 
initial reports of greater than 10-fold endogenous levels of Phlda2 and Slc22a18 
(Salas et al. 2004).
An alternative explanation for the more severe placental phenotype seen 
in lines 5A4 and 5D3 is to consider the effect of Cdknlc over-expression in the 
embryo. As a consequence of excess Cdknlc in a subset of tissues, transgenic 
embryos from lines 5D3 and 5A4 were intrinsically growth restricted in a dosage 
dependent manner (Andrews et al. 2007). It can be presumed that such 
inherently smaller embryos place less demand on the placenta compared to wild 
type embryos. Consequently, the placenta of transgenic embryos from lines 5D3 
and 5A4 would not need to be as large as normal in order to deliver the nutrients 
required for the embryos to reach their genetic growth potential. In contrast, 
embryos from lines 10-15 and 10-10 can be considered to have a normal growth 
potential and thus place greater demand on their associated placentae. The 
consequences of this scenario are addressed in Chapter 5. It is possible that the 
transgenic placenta of lines 5D3 and 5A4 in which Phlda2 and Slc22a18 are 
over-expressed would exceed the size required by the intrinsically small embryo. 
This relatively lower embryonic demand on the placenta may thus account for the 
more severe weight deficit of placentae from these lines and the greater 
reduction in spongiotrophoblast area observed. A potential method to investigate 
this theory would be to generate chimeric conceptuses comprising transgenic 
5A4 or 5D3 embryos and wild type tetraploid embryos that contribute only to 
extraembryonic tissue (Nagy et al. 1990). In this way, if transgenic embryos 
directly limit the size of their associated placenta, then the mean weight of 
placentae from such chimeric animals would be significantly smaller than that of 
placentae from chimeric conceptuses consisting of wild type and tetraploid wild 
type cells. The potential for interaction between the embryo and placenta is 
discussed further in Chapter 5.
4.3.4 Attributing the phenotype to Slc22a18 or Phlda2
The relative contribution of Phlda2 to the placental phenotype was examined in a 
cross between the Phlda2 null line and the single copy transgenic line 5D3. The
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aim of this cross was to generate double transgenic conceptuses with a normal 
gene dosage of Phlda2 but with two copies of Slc22a18 and which could be 
compared to both wild type and 5D3 transgenic conceptuses. The basic 
principles of this experiment were similar to that described in Salas et al. (2004), 
in which the role of Phlda2 in the Kvdmrl null phenotype was isolated by 
restoring Phlda2 dosage to normal by crossing lines Kvdmr1+I' and Phlda2'l+. A 
comparison between Kvdmr+I~ and Kvdmr1+I' / Phlda2',+ placenta revealed that 
restoring Phlda2 gene dosage to normal entirely rescued the spongiotrophoblast 
deficit with a 50% rescue of the weight deficit at both E14.5 and E16.5 (Salas et 
al. 2004). Interestingly, Phlda2 mRNA levels were somewhat variable in both 
Kvdmr+I’ and Kvdmr1+I' / PhldaZl+ placenta, with Phlda2 expression apparently 
failing to completely normalise in some Kvdmr1+I~ / Phlda2',+ placenta.
In this investigation, the mean placental weight of double transgenic 
placentae was restored to within the normal range at E14.5, with no significant 
difference existing between placental weight of wild type and double transgenic 
placentae. In contrast, only a 50% rescue in spongiotrophoblast area was 
achieved at this stage, with the area of double transgenic placentae significantly 
larger than that of 5D3 transgenic placentae but remaining significantly smaller 
than that of wild type. This could be because Phlda2 gene expression was not 
restored to wild type levels. However, this seems unlikely, as data presented in 
this chapter suggests that gene dosage does not affect phenotype severity, with 
lines 10-15 and 10-10 exhibiting a comparable placental phenotype despite 
different levels of Phlda2 expression. Furthermore, the phenotype of line 10-15 
has remained comparable to the previously published report despite a -2 .5  fold 
reduction in Phlda2 expression levels (Salas et al. 2004).
Alternatively, the reduced spongiotrophoblast area may be attributed to an 
effect of Cdknlc over-expression in the embryo. Transgenic embryos of line 5D3 
are intrinsically growth restricted due to excess embryonic Cdknlc expression in 
a subset of tissues (Andrews et al. 2007). Additionally, embryos of the Phlda2 
null line used in this investigation were also reported to be 13% lighter than wild 
type at E16.5 (Frank et al. 2002). As described in Section 4.3.3, the extent of 
spongiotrophoblast loss in line 5D3 was more severe than observed in lines IQ- 
15 and 10-10. One possible explanation for the reduced spongiotrophoblast of 
double transgenic placentae is that the growth potential of the embryo may be
194
linked to the volume and functional capacity of the placenta. Thus, restoring 
Phlda2 gene dosage to normal would be unable to entirely rescue the 
spongiotrophoblast loss, with the remaining phenotype instead attributable to the 
effect of an intrinsically small embryo exerting reduced demand on the placenta.
One way in which to determine whether excess placental Phlda2 is 
causative of the remaining spongiotrophoblast deficit would be to measure 
spongiotrophoblast area only from placenta in which Phlda2 expression is 
restored to wild type levels. This would be achieved by determining gene 
expression and spongiotrophoblast area from opposite halves of the same 
placenta. This approach assumes that Phlda2 expression will be restored to wild 
type levels in some placenta. However, this assumption seems reasonable given 
that Phlda2 expression is variable even in wild type placenta, with expression 
levels in individual placenta previously observed to range between 0.5 and 1.5 
times the mean wild type level (Salas et al. 2004).
Although these results do not fully exclude a role for excess Slc22a18 in 
the placental phenotype described, it seems unlikely that Slc22a18 plays a 
significant causative role for several reasons. Firstly, the phenotype of placenta 
that over-express Phlda2 and Slc22a18 is reciprocal to that observed in Phlda2 
null placenta, thus solely implicating a role for Phlda2. Secondly, the Phlda2 and 
Slc22a18 gene products have distinct functions, with Slc22a18 being a putative 
organic cation transporter (Dao et al. 1998), and Phlda2 implicated in 
phosphatidyl inositol phosphate signalling (Frank et al. 2002; Saxena et al. 2002). 
These diverse functions do not implicate excess Slc22a18 in altering placental 
structure or spongiotrophoblast size. Thirdly, introduction of the targeted Phlda2 
null allele to the single copy BAC line is able to restore an almost normal 
phenotype. Confidently excluding a role for Slc22a188 in the described placental 
defect will require the generation of new transgenic lines in which either Phlda2 
or Slc22a18 are over-expressed in isolation.
4.3.5 Summary of main findings
Two of the three primary objectives to this work were achieved in full. The 
independent transgenic line 10-10 was characterised at two key stages, 
demonstrating a comparable phenotype to line 10-15, and thus confirming a 
causative role for Phlda2 and/or Slc22a18 in the placental phenotype. The effect
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of gene dosage was investigated in four transgenic lines possessing between 
one and three copies of either a modified or unmodified transgene. Similar 
placental phenotypes were observed in transgenic lines possessing a single copy 
of the unmodified transgene and lines possessing two or three copies of the 
modified transgene demonstrating that there was no overt gene dosage effect on 
phenotype severity. Furthermore, these results indicate that lines 10-15 and 10- 
10 may be used as a model for LOI of Phlda2 and Slc22a18. This will prove 
particularly useful in embryonic and post-natal investigations due to the absence 
of excess Cdknlc that persists in line 5D3.
To attempt to dissect the relative contributions of Phlda2 and Slc22a18 to 
the placental phenotype, the single copy transgenic line was crossed with the 
Phlda2',+ line to generate conceptuses possessing a single active copy of Phlda2 
but maintaining two active copies of Slc22a18. However, despite the presence of 
only one active copy of Phlda2, expression level of this gene failed to normalise 
in such conceptuses. It was therefore not possible to entirely exclude a role for 
Slc22a18 in the placental phenotype, although as discussed above it seems 
unlikely that both Phlda2 and Slc22a18 would have similar functions. Potential 
approaches for examining the contribution of Slc22a18 are discussed below.
4.3.6 Future directions
A number of opportunities exist for pursuing further work based upon the findings 
reported in this chapter. A clear effect of genetic background on the phenotype 
was demonstrated between placentae on a pure 129/Sv background and those 
on the 129/Sv x C57BL/6 background. Line 10-10 is currently being bred onto the 
129/Sv background with the intention of characterising the phenotype at E14.5 
and E18.5, enabling a future comparison with line 10-15 on a pure 129/Sv 
background. Further interest may also lie in characterising the placental 
phenotype on a pure C57BL/6 background. This is due to the intended future use 
of adult mice on a pure C57BL/6 background in post-natal studies. To 
complement the characterisation of the above transgenic lines on both pure 
129/Sv and 129/Sv x C57BL/6 genetic backgrounds, future work could also focus 
entirely on describing the development and structure of the mouse placenta 
across different genetic backgrounds. For example, Coan et al. (2004)
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characterised placental development in the pure C57BL/6 strain, although a 
comparison with other genetic backgrounds was not performed.
An important aspect remains unresolved in that a role for Slc22a18 in the 
placental phenotype could not be entirely excluded based on the results 
obtained. The failure to restore Phlda2 expression to wild type levels may reflect 
the variable expression of Phlda2 from the transgene (Salas et al. 2004). This 
persistent expression of Phlda2 above the anticipated level may be restored 
following further generations of breeding line 5D3 onto the C57BL/6 background. 
Thus, additional material will be generated using transgenic 5D3 animals that 
have been bred further into the C57BL/6 background. After weighing, each 
placenta will be cut approximately in half, with one side of the placenta used for 
RNA isolation and the other side fixed and paraffin embedded for sectioning. 
Following genotyping, Phlda2 expression will be examined and only double 
transgenic placenta in which ACt values are restored to wild type levels will be 
analysed. This is clearly a more labour intensive and time-consuming approach, 
and assumes that the failure to rescue the phenotype can be attributed to 
variable Phlda2 levels in double transgenic placenta. A more direct approach 
would be to generate a new transgenic line, of which several possibilities exist. 
The existing transgene could be modified to disrupt either Phlda2 or Slc22a18 
thus enabling the effect of over-expressing only one of these genes to be 
examined in isolation. The preferred option would be to target Slc22a18 thus 
creating a transgenic line in which the placental, embryonic and post-natal 
consequences of over-expression of Phlda2 could be studied. A third potential 
option would be to create an Slc22a18 null model. This model would reveal 
Slc22a18 gene function, however it would not provide a tool in which to examine 
the imprinting of this gene.
Finally, and perhaps most intriguingly, data presented in this chapter could 
suggest an interaction between Cdknlc dosage in the embryo and Phlda2 
dosage in the placenta in order to achieve a balance between embryonic demand 
and placental supply of nutrients. Generation of a transgenic line possessing a 
single copy of the modified BAC transgene would enable a direct comparison 
with line 5D3 and further investigation of this hypothesis.
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Chapter 5:
Embryonic and post-natal consequences of excess
Phlda2 and Slc22a18
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5.1 Overview
Work presented in chapters 3 and 4 characterised the placental defects 
associated with increased dosage of Phlda2 and Slc22a18. The consequence of 
such over-expression was a significant reduction in placental weight due to the 
restricted expansion of the spongiotrophoblast layer. Initial results indicated that 
embryonic growth on a mixed genetic background remained normal until E14.5 
but was significantly impaired at E16.5 (Salas et al. 2004). The placental defect 
and associated late gestation embryonic growth deficit is consistent with 
placental insufficiency negatively restricting growth of the embryo.
In the Western world, placental insufficiency is predicted to be the primary 
causative factor of IUGR (Henriksen and Clausen 2002), affecting up to 7% of all 
births (Brodsky and Christou 2004; Vandenbosche and Kirchner 1998). Placental 
insufficiency is generally associated with asymmetric IUGR with the growth- 
restricting factor affecting growth during the third trimester (Lin and Santolaya- 
Forgas 1998; Sifianou 2006). Approximately 70-80% of IUGR cases are 
classified as asymmetric, characterised by an increased head circumference to 
abdominal circumference (HC/AC) ratio. This disproportionate growth restriction 
is a consequence of the relative sparing of brain and skeletal development at the 
expense of liver and subcutaneous fat development (reviewed in Fay and 
Ellwood 1993; Platz and Newman 2008; Valsamakis et al. 2006). The immediate 
risk of asymmetric IUGR is a significantly increased risk of perinatal mortality 
(Fay and Ellwood 1993; Kok et al. 1998; Mclntire et al. 1999; Sifianou 2006). 
Flowever, individuals that survive the neonatal period exhibit catch-up growth, 
which is not generally observed in infants with symmetric IUGR, with these 
individuals remaining small throughout life (Fay and Ellwood 1993).
Numerous epidemiological studies in humans have reported a correlation 
between low birth weight and the development of metabolic syndrome in 
adulthood. Low birth weight has been associated with increased rates of CVD 
(Barker et al. 1993; Barker and Osmond 1986; Osmond et al. 1993) hypertension 
(Barker et al. 1990; Law et al. 1993) and impaired glucose tolerance (Hales et al. 
1991). The association of birth weight with obesity tends to follow a U-shaped 
relation, with both low and high birth weights associated with increased rates of 
adult obesity. Contrastingly, high birth weight tends to predict an increased body
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mass index (BMI) in adulthood, whereas low birth weight is specifically 
associated with central obesity (Parsons et al. 2001; Ravelli et al. 1999; Te Velde 
et al. 2003). Furthermore, catch-up growth has been identified as an additional 
contributory factor, with low birth weight infants that displayed catch up growth by 
two years of age more likely to be obese at five years of age (Ong et al. 2000). 
Indeed, the risk of developing other aspects of metabolic syndrome was 
increased in individuals with a low birth and subsequent post-natal catch up 
growth (Eriksson et al. 2000; Eriksson et al. 1999; Forsen et al. 2000; Forsen et 
al. 1999).
The “developmental origins of adult disease” hypothesis proposes that the 
risk of developing aspects of metabolic syndrome is modified by poor growth in 
utero manifesting as a low birth weight (Barker 1995; Hales and Barker 1992). 
This predisposition to development of disease in adulthood is proposed to occur 
through “fetal programming”, whereby an undernourished fetus adapts to a low 
nutrient environment in utero. These adaptations irreversibly alter the 
metabolism, subsequently resulting in a mismatch between the perceived low 
nutrient environment predicted in utero, and the actual nutrient rich environment. 
The altered metabolism is thus unable to adapt to the nutrient rich environment 
causing a predisposition to metabolic syndrome (Barker 1997). It has been 
proposed that there are two critical windows involved in the programming of 
metabolic syndrome. Poor in utero growth followed by rapid postnatal catch up 
growth are proposed to represent the greatest risk, with prevention of catch-up 
growth affording some protection (reviewed in Jimenez-Chillaron and Patti 2007).
The initial association between low birth weight and metabolic disease was 
identified from human epidemiological studies. However, such studies are 
inherently long-term, and provide little insight into the underlying mechanisms. 
Animal models provide useful tools for elucidating the mechanisms that may 
underlie fetal programming associated with IUGR. Indeed, a number of animal 
models of IUGR have been developed that are associated with various aspects of 
metabolic syndrome in adulthood. One of the most extensively studied rodent 
models of IUGR is the maternal low protein model. Feeding pregnant rats a low 
protein diet during gestation and lactation predisposes -animals to developing 
insulin resistance (Fernandez-Twinn et al. 2005; Petry et al. 2001). Similarly, 
calorie restriction of pregnant rats from day 10 of gestation resulted in IUGR with
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catch up growth displayed by animals suckled by ad libitum fed dams. These 
animals became heavier than control animals with increased fat mass and 
reduced lean mass at 9 months of age. However, in this instance, continued 
exposure to food restriction during the lactation period delayed catch up growth 
and prevented the alteration of lean and fat mass proportions (Desai et al. 2005). 
Additionally, calorie restriction during the last week of gestation in mice was
associated with post-natal catch up growth, glucose intolerance and p-cell
dysfunction (Jimenez-Chillaron et al. 2005). Continuation of calorie restriction 
during lactation protected against glucose intolerance (Jimenez-Chillaron et al. 
2006). However, a genetic model of IUGR that recapitulates known conditions in 
human patients has not been reported to date.
Data presented in Chapters 3 and 4 described the placental defect
associated with over-expression of Phlda2 and Slc22a18 in the mouse placenta. 
Recent reports from human studies have described elevated levels of PHLDA2 in 
the placentae of IUGR and lower birth weight infants (Apostolidou et al. 2007; 
McMinn et al. 2006). Transgenic embryos on a mixed genetic background 
displayed reduced embryonic growth at E16.5 (Salas et al. 2004), although no 
weight difference was observed at 3 weeks of age (Andrews et al. 2007). 
Embryonic growth of line 10-15 was further characterised on a pure 129/Sv 
genetic background to determine if similar growth restriction was observed on this 
genetic background. Similarly, embryonic growth was examined in lines 10-15 
and 10-10 on the 129/Sv x C57BL/6 background to assess the effect of genetic 
background on embryonic growth.
As described above, placental insufficiency is associated with asymmetric 
IUGR, which is similarly associated with post-natal catch up growth and a 
predisposition to metabolic syndrome. Further work was performed to ascertain 
whether the placental defect of line 10-15 was responsible for the reported IUGR, 
and whether this was associated with metabolic syndrome in adult animals. This 
characterisation included the examination of placental transporter expression 
levels to determine if transgenic placenta displayed a compensatory increase in 
transport potential, which would be indicative of placental insufficiency. Two key 
features of metabolic syndrome, reduced glucose tolerance and increased 
adiposity, were examined in adult animals.
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5.2 Results
5.2.1 The placental defect is linked to embryonic growth restriction
Previous work reported that at E14.5, transgenic embryos were slightly larger by 
weight, although without achieving statistical significance, whereas at E16.5, 
transgenic embryos were 10% lighter, but with only marginal statistical 
significance (Salas et al. 2004). The effect of excess Phlda2 and Slc22a18 on 
embryonic growth was further investigated by generating additional litters at 
these time-points in addition to earlier and later stages in development on a pure 
129/Sv genetic background. At least six litters with a minimum of two transgenic 
and two wild type animals each were collected at each developmental stage. 
Raw mean wet weights of wild type and transgenic placentae are presented in 
Figure 5.1.
At E12.5, transgenic embryos weighed approximately 9% less than wild 
type, with marginal statistical significance (76.0 mg ± 11.6 versus 69.3 mg ± 12.6; 
9 litters; n = 74; p = 0.019). At E13.5 transgenic embryos were no different by 
weight compared to wild type (124.9 mg ± 16.2 versus 125.7 mg ± 10.1; 6 litters; 
n = 41; p = 0.846). At E14.5, transgenic embryos were 3.6% lighter, although 
again without statistical significance (222.5 mg ± 35.4 versus 214.6 mg ± 19.9; 7 
litters; n = 53; p = 0.346). Transgenic embryos at E16.5 were 5.8% lighter (600.0 
mg ± 63.5 versus 565.1 mg ± 50.3; 8 litters; n = 58; p = 2.48 x 10'2). Further to 
previous work, embryonic weights were also examined at E18.5, representing the 
most advanced stage that can be characterised prior to birth. At this stage, 
transgenic embryos were found to be 11 .1% lighter than wild type animals 
(1212.8 mg ± 143.4 versus 1078.0 mg ± 149.2; 10 litters; n = 6 8 ; p = 6.16 x 10‘4). 
At all gestational stages examined, wild type and transgenic conceptuses were 
observed at the expected frequencies (see Section 3.2.2 for %2 values).
Individual raw weights of wild type embryos exhibited a standard deviation 
of up to 18% the mean weight for each gestational stage. Such variations in 
weight may be caused by a number of factors that could not be controlled for, 
such as litter size, exact gestational age, position of the conceptus in the uterine 
horn, maternal health and other environmental factors. To prevent such factors 
from potentially disguising or introducing apparent growth phenotypes, individual 
weights of both wild type and transgenic embryos were adjusted by the ratio of
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the mean wild type weight for the gestational stage to the mean wild type weight 
for the litter, as described in Section 2.19.4. Such manipulation did not alter the 
mean wild type weight, but adjusts the mean transgenic weight accordingly and 
reduces the standard deviation of both wild type and transgenic data sets. Mean 
normalised embryonic weights of wild type and transgenic embryos are 
presented in Fig 5.1B, with error bars representing standard deviation of 
normalised data. The average transgenic weight is also presented as a 
percentage of mean wild type weight for each gestational stage.
At E12.5, transgenic embryos weighed approximately 6 % less than wild 
type, although without reaching statistical significance (76.0 mg ± 7.5 versus 71.6 
mg ± 12.8; 9 litters; n = 74; p = 7.13 x 10'2). At E13.5 transgenic were no different 
by weight compared to wild type (124.9 mg ± 11.8 versus 126.4 mg ± 10.3; 6 
litters; n = 41; p = 0.664). At E14.5, transgenic embryos were 2.8% lighter, again 
without statistical significance (222.5 mg ± 17.4 versus 216.2 mg ± 26.1; 7 litters; 
n = 53; p = 0.293). Transgenic embryos at E16.5 were 6 .6 % lighter (600.0 mg ± 
48.3 versus 560.5 mg ± 40.3; 8 litters; n = 58; p = 1.39 x 10'3). At E18.5 
transgenic embryos were 13.2% lighter than wild type animals (1226.8 mg ± 58.6 
versus 1068.6 mg ± 88 .6 ; 10 litters; n = 6 8 ; p = 8.66  x 10'15).
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Figure 5.1: Weights of wild type and transgenic embryos from line 10-15
between E12.5 and E18.5
Graphs showing mean A) raw and B) normalised embryonic weights for wild 
type and transgenic embryos of line 10-15 on a pure 129/Sv background at 
the indicated gestational stages. Error bars show standard deviation. 
Percentage figures indicate the relative weight of transgenic embryos 
compared to wild type embryos at each stage. Significance level according 
to the Student’s /-test indicated by asterisks: * p < 0.05; ** p < 0.01; *** p < 
0 .001 .
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Embryonic growth was also examined at E14.5 and E18.5 for embryos 
from line 10-15 on the 129/Sv x C57BL/6 genetic background, in addition to 
embryos from line 10-10 on a similar genetic background. Figure 5.2 shows the 
normalised mean weights of wild type and transgenic embryos from line 10-15 on 
a 129/Sv background, and from lines 10-15 and 10-10 on the 129/Sv x C57BL/6 
background at E14.5 and. E18.5. At E14.5, transgenic embryos from line 10-15 on 
a pure 129/Sv background were 2.8% lighter, although without achieving 
statistical significance. Similarly, transgenic embryos from the same line on the 
129/Sv x C57BL/6 genetic background were not significantly different in weight 
(261.7 mg ± 22.7 versus 259.8 mg ± 24.8; 4 litters; n = 35; p = 0.822). Transgenic 
embryos from line 10-10 were also no different by weight (241.2 mg ± 11.9 
versus 241.9 mg ± 27.2; 6 litters; n = 46; p = 0.909). At E18.5, transgenic 
embryos from line 10-15 on a pure 129/Sv background were 13.2% lighter. In 
contrast, transgenic embryos of line 10-15 on the 129/Sv x C57BL/6 background 
were only 4.4% lighter than wild type (1327.6 mg ± 64.2 versus 1269.1 mg ± 
86.9; 6 litters; n = 37; p = 0.0278), whereas those from line 10-10 were 5.4% 
lighter (1322.9 mg ± 57.7 versus 1246.2 mg ± 79.9; 4 litters; n = 26; p = 0.0089).
The growth restriction of transgenic embryos at E18.5 apparent on the 
129/Sv x C57BL/6 background was less than half of that observed on the pure 
129/Sv background. Interestingly, as observed for placentae, wild type embryos 
on the 129/Sv x C57BL/6 genetic background were significantly heavier than wild 
type embryos on a pure 129/Sv background at both gestational stages examined 
(Fig 5.3). At E14.5, wild type embryos on the 129/Sv x C57BL/6 background were 
11.9% heavier than those on a pure 129/Sv background (222.5 mg ± 35.4 versus
249.0 mg ± 19.4; wild type weights from 19 litters; n = 73; p = 1.13 x 10"4), with a 
similar difference in weight of 8.5% at E18.5 (1215.7 mg ± 54.9 versus 1318.6 mg 
± 60.7; wild type data from 22 litters; n = 82; p = 6.57 x 10'12).
In summary, embryonic weight of transgenic animals was significantly less 
than wild type littermates at E18.5 for line 10-15 on both a pure 129/Sv and 
129/Sv x C57BL/6 genetic background and also for line 10-10. However, the 
extent of the weight deficit was more severe on a pure 129/Sv genetic 
background (~13%), with only a ~5% weight deficit observed for transgenic 
embryos of lines 10-15 and 10-10 on the 129/Sv x C57BL/6 background.
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Figure 5.2: Embryonic growth in lines 10-15 and 10-10
Normalised mean weights of wild type and transgenic embryos are shown 
for lines 10-15 on a pure 129/Sv background and lines 10-15 and 10-10 on 
the 129/Sv x C57BL/6 background at A) E14.5 and B) E18.5. Percentage 
figures indicate the relative weight of transgenic embryos compared to wild 
type. Error bars show standard deviation; asterisks denote significance level 
according to the Student’s t-test: * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 5.3: Comparison of wild type embryonic weights at E14.5 and E18.5 
between pure 129/Sv and 129/Sv x C57BL/6 backgrounds
Normalised mean weights of wild type embryos are shown on the 129/Sv 
and 129/Sv x C57BL/6 genetic backgrounds at A) E14.5 and B) E18.5. 
Percentage figures indicate the ratio of mean embryonic weight on the 
129/Sv x C57BL/6 background to that on the pure 129/Sv background. Error 
bars show standard deviation; asterisks denote significance level according 
to the Student’s /-test: *** p < 0.001.
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5.2.2 Transgenic animals exhibit rapid post-natal catch-up growth
The effect of over-expression of Phlda2 on post-natal growth has not previously 
been directly investigated. However, a comparison between Kvdmrl null mice (all 
genes in the IC2 domain are over-expressed) and Phlda2 / Kvdmrl double null 
mice (Phlda2 levels returned to normal), revealed a marginal increase in weight 
at P14 in Phlda2 / Kvdmrl double null animals, although this was not statistically 
significant (Salas et al. 2004). We recently reported that at three weeks of age, 
there was no significant difference in weight between transgenic and wild type 
animals of line 10-15 on a mixed genetic background (Andrews etal. 2007).
The extent of growth restriction immediately following birth and in the 
subsequent neo-natal period was investigated by the removal and sacrifice of 
entire litters on the day of birth and the following day; post-natal day 0 (P0) and 
P1 respectively. Data was normalised as described in Section 2.19.4, and further 
divided into groups according to the estimated time of birth. Litters that were born 
during the night were not discovered until 9 am, whereas some litters were born 
during daylight hours, and were removed immediately upon discovery. These 
groups are referred to as “P0 fed” and “P0 unfed” respectively, whereas “P0 
combined” represents the pooled data of both groups. Mean normalised weights 
of transgenic and wild type animals for each group are presented in Figure 5.4, 
with error bars representing the standard deviation.
A substantial number of litters were obtained at P0, and were initially 
studied as a single set of data, with the birth weight of transgenic animals 11.3% 
less than wild type (1.41 g ± 0.08 versus 1.25 g ± 0.13; 22 litters; n = 154; p = 
3.29 x 10'17). In comparison, those litters that were born during the day, and thus 
had little time to begin feeding, the birth weight of transgenic animals was 13.1% 
less than wild type (1.39 g ± 0.5 versus 1.21 g ± 0.15; 7 litters; n = 63; p = 5.14 x 
10'9). In contrast, transgenic animals from litters born during the night, which had 
thus begun feeding, were only 10.1% lighter than wild type (1.42 g ± 0.10 versus 
1.28 g ± 0.11; 15 litters; n = 96; p = 1.39 x 10'9). By P1, the weight difference 
between transgenic and wild type animal weights was reduced to 7.3% (1.62 g ± 
0.11 versus 1.51 g ± 0.11; 6 litters; n = 49; p = 3.9 x 10’4).
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Figure 5.4: Neo-natal weights of mice from line 10-15
Mean normalised weights for wild type and transgenic embryos of line 10-15 
on a pure 129/Sv background at PO and P1. Data at PO is divided according 
to time of birth, PO fed (births during night), PO unfed (births during day), and 
displayed collectively as PO. Error bars show standard deviation. Percentage 
figures indicate the relative weight of transgenic embryos compared to wild 
type embryos at each stage. Asterisks denote significance level according to 
the Student’s f-test: *** p < 0.001.
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The 13% difference between transgenic and wild type birth-weight was 
approximately halved to 7% within one day of birth. A cohort of animals was 
generated to examine growth over the course of a year from one week of age. All 
animals used in the weighing study were born within a two-week period and were 
weaned exactly 28 days following birth. A minimum litter size of 6 was accepted 
for the study, with littermates of the same sex co-housed after weaning. Animals 
of different litters were not mixed together, and no animals were housed alone. 
Mice from the cohort were not used for breeding and had ad libitum access to 
food and water.
Mean raw weights are presented in Figure 5.5 for animals up to weaning 
age. At one week of age, although transgenic animals appear to be 
approximately 5% lighter than wild type animals, there was no significant 
difference in weight for either male (3.57 g ± 0.52 versus 3.35 g ± 0.62; n = 47; p 
= 0.203) or female animals (3.47 g ± 0.62 versus 3.35 g ± 0.55; n = 57; p = 
0.425). At two weeks of age, there was no discernable difference in weight for 
either males (6.51 g ± 0.85 versus 6.42 g ± 0.81; n = 69 p = 0.672) or females 
(6.40 g ± 0.92 versus 6.47 g ± 0.94; n = 78 p = 0.747). No significant difference in 
weight was detected for either male (8.07 g ± 1.40 versus 8.12 g ± 1.35; n = 69 p 
= 0.672) or female animals (8.05 g ± 1.43 versus 8.06 g ± 1.34; n = 78 p = 0.954) 
at three weeks of age. The same was also observed at four weeks of age in both 
males (13.09 g ± 2.27 versus 13.45 g ± 2.11; n = 66  p = 0.516) and females 
(12.36 g ± 2.25 versus 12.39 g ± 1.78; n = 78 p = 0.945). Although data are 
presented separately for male and female animals, no significant difference in 
weight between wild type male and female animals was observed until 6 weeks 
of age.
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Figure 5.5: Weights of mice from line 10-15 prior to weaning
Mean raw weights of wild type and transgenic males (A) and females (B) 
from line 10-15 on a pure 129/Sv background from one week of age until 
weaning. Error bars denote standard deviation. Statistical significance was 
not achieved for any comparison examined by f-test.
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5.2.3 Asymmetric growth restriction of transgenic mice
Rapid catch-up growth in the neo-natal period suggests that transgenic animals 
may be growth restricted due to placental insufficiency. Such growth phenotypes 
are characteristic of type II (asymmetric) IUGR, where the head and brain are 
proportionately larger in comparison to the growth-restricted body. Organ size 
was measured from PO pups in order to determine whether growth restriction was 
symmetric or asymmetric.
Organ weights were measured in a subset of eight litters, which were born 
during the night over a five-day period. Entire litters were removed from the cage 
immediately prior to dissection and maintained at a warm temperature under a 
lamp. Transgenic animals within the cohort were 11.4% lighter than wild type 
(1.36 g ± 0.12 versus 1.20 g ± 0.12; n = 55; p = 8.34 x 10"6), and appeared to be 
asymmetrically growth restricted, with relatively large heads in comparison to 
body size. Organs were dissected, fixed in 4% PFA and equilibrated in 70% 
EtOH prior to weighing. Individual organ weights were normalised as described 
previously, and the mean weight for each organ in wild type and transgenic pups 
is presented in Figure 5.6. All organs were observed to be lighter in transgenic 
animals compared to wild type. The extent of this weight difference varied 
between approximately 5% and 20%. The brain of transgenic animals was 5.5% 
lighter than wild type (49.1 mg ± 2.68 versus 46.4 mg ± 3.00; n = 55; p = 9.04 x 
10'4). Heart, liver and kidneys of transgenic animals were 12.1% (5.7 mg ± 0.57 
versus 5.0 mg ± 0.94; n = 55; p = 1.68 x 10"3), 11.6% (41.1 mg ± 3.97 versus
36.7 mg ± 5.02; n = 55; p = 7.74 x 10'4) and 12.3% (4.1 mg ± 0.59 versus 3.6 mg 
± 0.47; n = 110; p = 2.76 x 10'6) lighter than wild type respectively, exhibiting a 
similar degree of weight reduction compared to body weight. Lungs and pancreas 
of transgenic pups were 15.1% (32.2 mg ± 4.77 versus 27.3 mg ± 6.50; n = 55; p 
= 2.49 x 10'3) and 20.7% lighter than wild type respectively (8.7 mg ± 1.82 versus 
6.9 mg ± 2.17; n = 55; p = 1.57 x 10'3).
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Figure 5.6: P0 organ weights from line 10-15
Neonatal pups of line 10-15 on a pure 129/Sv background were dissected 
and organ weights obtained post-fixation to determine the relative growth 
restriction of each organ. Percentage figures indicate the relative weight of 
transgenic organs compared to wild type. Error bars show standard 
deviation; asterisks denote significance level according to the Student’s t- 
test: * p < 0.05, ** p < 0.01, *** p < 0.001.
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All organs examined displayed a significantly reduced weight in transgenic 
pups compared to wild type. However, by expressing organ weight as a 
proportion of body weight, the relative extent of growth restriction can be  more 
directly observed. Data are presented in this format in Figure 5.7. Transgenic 
pups display a 6 .6% increase in brain proportion compared to wild type, (3 .65%  ± 
0.36 versus 3.89% ± 0.36; n = 55; p = 0.017). Heart, liver and kidneys exhibit a 
0.9% decrease (0.42% ± 0.04 versus 0.42% ± 0.07; n = 55; p = 0.815), 0.6% 
increase (3.04% ± 0.25 versus 3.06% ± 0.30; n = 55; p = 0.799) and 0.5% 
decrease (0.30% ± 0.03 versus 0.30% ± 0.03; n = 110; p = 0.799) in body weight 
proportion respectively, without statistical significance. Lungs and pancreas were 
4.2% lighter (2.37% ± 0.25 versus 2.27% ± 0.48; n = 55; p = 0.334) and 10.9%  
lighter (0.64% ± 0.11 versus 0.57% ± 0.16; n = 55; p = 0.071) as a proportion of 
body weight respectively, although both failed to achieve statistical significance.
We recently reported that transgenic embryos of line 5D3 display 
embryonic growth restriction from at least E13.5, with this weight deficit persisting 
into adulthood (Andrews et al. 2007). This transgenic line may potentially 
represent a model of symmetric IUGR, characterised by onset of IUGR during 
early gestation with an absence of post-natal catch up growth. Organ weights 
were also examined in neonatal animals from line 5D3 to examine if brain-sparing 
growth was present.
Brain sparing growth was not observed in transgenic neonates of line 5D3, 
with brain weight representing a comparable proportion of body weight in wild 
type and transgenic animals (3.00% ± 0.22 versus 2.92% ± 0.28; 6 litters; n = 38; 
p = 0.333) (Fig 5.8A). Similarly, no significant difference in body weight proportion 
was observed for lungs (2.47% ± 0.34 versus 2.66% ± 0.42; 6 litters; n = 38; p = 
0.152), liver (3.13% ± 0.22 versus 3.13% ± 0.36; 6 litters; n = 38; p = 0.124), 
heart (0.43% ± 0.03 versus 0.45% ± 0.06; 6 litters; n = 38; p = 0.185), kidneys 
(0.29% ± 0.02 versus 0.30% ± 0.04; 6 litters; n = 76; p = 0.137) or pancreas 
(0.59% ± 0.06 versus 0.54% ± 0.13; 6 litters; n = 38; p = 0.124).
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Figure 5.7: P0 organ weights relative to body weight from line 10-15
Organ weights were also examined as a proportion of body weight to assess 
the presence of brain-sparing growth. Normalised weights as a proportion of 
normalised body weight. Percentage figures indicate the relative proportion 
of transgenic organs compared to wild type. Error bars show standard 
deviation; asterisks denote significance level according to the f-test: * p < 
0.05.
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Figure 5.8: Organ weights relative to body weight from line 5D3
Organ weights were compared between wild type and transgenic neonates 
from line 5D3 on the 129/Sv x C57BL/6 background to determine if growth 
restriction was symmetric. Normalised weights as a proportion of normalised 
body weight. Percentage figures indicate the relative proportion of transgenic 
organs compared to wild type. Error bars show standard deviation.
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5.2.4 Weight of adult transgenic animals is comparable to wild type
Asymmetric IUGR with catch-up growth has been linked with metabolic syndrome 
and obesity in humans (Eriksson et a/. 1999; Forsen et al. 2000). A cohort of 
animals was weighed weekly from one week until ten weeks of age, and 
thereafter every fifth week until approximately one year of age. No significant 
difference in weight was observed between wild type and transgenic females at 
any age. Transgenic males were 16.2% larger than wild type males at 5 weeks 
(16.57 g ± 3.96 versus 19.26 g ± 3.05; n = 56; p = 5.89 x 10*3) , 7.5% larger at 6 
weeks (21.14 g ± 2.44 versus 22.72 g ± 1.84; n = 54; p = 9.09 x 10'3), 4.4% larger 
at 7 weeks (23.84 g ± 1.78 versus 24.89 g ± 1.65; n = 54; p = 0.0295) and 6.3%  
larger at 8 weeks of age (24.47 g ± 2.25 versus 26.00 g ± 1.82; n = 43; p = 
0.0189). At 9 weeks of age, transgenic males were 3.5% larger than wild type, 
although this failed to achieve statistical significance (26.15 g ± 1.43 versus 27.06 
g ± 1.80; n = 34; p = 0.141). There was subsequently no significant difference in 
weight observed between transgenic and wild type male mice between 10 weeks 
and one year of age. Growth of male and female animals between 5 and 50 
weeks of age is shown in Figure 5.9.
Further to weighing a cohort of mice up to one year of age, a subset of 
animals were sacrificed at 10 weeks, 6 months and one year of age. Tibia bone 
lengths were measured from these animals to determine if transgenic and wild 
type animals achieved comparable growth rates. Average tibia lengths for male 
and female animals are presented in Figure 5.10. At all ages examined, female 
transgenic mice were comparable to wild type, with no significant difference in 
tibia length at 10 weeks (1.77 cm ± 0.060 versus 1.76 ± 0.049; n = 6 ; p = 0.513), 
6 months (1.84 cm ± 0.045 versus 1.85 ± 0.036; n = 8 ; p = 0.773) or 1 year (1.83 
cm ± 0.036 versus 1.83 ± 0.036; n = 12; p = 0.570) of age. Similarly, male 
transgenic animals showed no difference in tibia length at 10 weeks (1.78 cm ± 
0.030 versus 1.80 ± 0.038; n = 6 ; p = 0.275) or 6 months (1.83 cm ± 0.023 versus 
1.80 ± 0.031; n = 8 ; p = 0.134) of age, although at one year of age, transgenic 
male mice had slightly shorter tibia compared to wild type (1.89 cm ± 0.032 
versus 1.84 ± 0.032; n = 12; p = 0.028).
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Figure 5.9: Adult weights of male and female mice from line 10-15
Adult mice from line 10-15 on a pure 129/Sv background were weighed 
every fifth week over the course of a year to assess weight gain of wild type 
and transgenic animals. Mean raw weights are presented separately for A) 
males and B) females. Error bars show standard deviation; asterisks denote 
significance level according to the Mann-Whitney test: ** p < 0.01.
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Figure 5.10: Tibia length of adult animals from line 10-15
Tibia length of adult mice from line 10-15 on a pure 129/Sv background was 
determined at the ages shown to examine if wild type and transgenic 
animals are proportionate in length. Mean raw tibia lengths are shown for A) 
male and B) female wild type and transgenic mice at 10 weeks, 6 months 
and 1 year of age. Error bars show standard deviation; asterisks denote 
significance level according to the Mann-Whitney test: * p < 0.05.
219
5.2.5 Fat deposition is increased in female transgenic mice
No overt sustained difference in weight was observed in transgenic mice of either 
sex compared to wild type animals over the course of one year. To specifically 
examine adipose mass, the retroperitoneal and mesenteric fat depots were 
dissected from mice sacrificed at 10 weeks, 6 months and 1 year of age. These 
fat deposits were weighed and morphology examined by H&E staining. Mean 
weights of the individual fat depots and the combined weight of the two fat depots 
are presented in Figures 5.11 (females) and 5.12 (males).
No significant weight difference was observed between wild type and 
transgenic mesenteric (402.2 mg ± 66.6  versus 370.6 mg ± 61.2; n = 14; p = 
0.338) or retroperitoneal (68.3 mg ± 19.7 versus 69.4 mg ± 18.3; n = 14; p = 
0.898) fat depots in females at 10 weeks of age. The mesenteric fat of transgenic 
females was slightly lighter than wild type, resulting in a ~7.5% reduction in 
combined fat weight (470.5 mg ± 76.3 versus 440.0 mg ± 58.7; n = 14; p = 
0.406), although this did not reach significance. At 6 months, there was no 
difference in weight of mesenteric fat depots (324.3 mg ± 25.7 versus 321.8 mg ± 
44.8; n = 8 ; p = 0.773), and a ~30% increase in the weight of retroperitoneal 
adipose tissue (69.0 mg ± 9.4 versus 90.3 mg ± 18.9; n = 8 ; p = 0.083), although 
this failed to reach statistical significance. Due to the relatively heavier 
mesenteric fat exhibiting no increase in mean weight, the combined fat weight 
was no different in transgenic females (393.3 mg ± 33.6 versus 412.0 mg ± 56.3; 
n = 8 ; p = 0.564). At one year of age, the mean weight of mesenteric fat of 
females was ~70% greater (228.3 mg ± 64.8 versus 382.3 mg ± 242.4; n = 12; p 
= 0.223), with a ~60% increase in the weight of retroperitoneal fat (96.0 mg ± 
12.2 versus 150.3 mg ± 93.5; n = 12; p = 0.062), although neither result achieved 
statistical significance. The weight of the combined fat pads achieved marginal 
statistical significance, with a ~65% increase in weight of transgenic adipose 
tissue compared to wild type (324.3 mg ± 60.2 versus 532.6 mg ± 332.0; n = 12; 
p = 0.042). The standard deviation of individual and combined fat pad weights in 
transgenic females at one year of age represented up to ~70% of the mean 
weight, whereas all other standard deviations were a maximum of 25% of the 
mean weight.
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A similar pattern of weight gain was observed in transgenic male animals 
between 10 weeks and 6 months, although at 1 year of ag e  transgenic fat pads 
were lighter than wild type, generally due to a large variation o f wild type fat pad 
weights at this age. At 10 weeks of age, there was no significant difference in 
mesenteric fat (354.0 mg ± 104.4 versus 355.4 mg ± 94.2; n = 14; p = 0.468), 
with a -14%  reduction in retroperitoneal weight (72.9 mg ± 17 .7  versus 63.0 mg ± 
18.2; n = 14; p = 0.366), although this failed to reach statistical significance. 
There was no difference in combined fat pad weight (426.9  mg ± 106.2 versus
418.3 mg ± 85.9; n = 14; p = 0.897). At six months, transgenic animals exhibited 
a 17% increase in weight of both mesenteric (216.0 mg ± 4 6 .6  versus 251.8 mg ± 
54.6; n = 8 ; p = 0.881) and retroperitoneal (76.0 mg ± 3 7 .3  versus 89.0 mg ± 
31.6; n = 8 ; p = 0.655) fat pads, with a similar increase observed when these 
results were combined (292.0 mg ± 78.6 versus 340.8 mg ± 81.4; n = 8 ; p = 
0.881), although again statistical significance was not achieved. At one year of 
age there was a -25%  reduction in mesenteric (368.1 mg ±  154.1 versus 278.4 
mg ± 70.9; n = 12; p = 0.416) and retroperitoneal (174.9 mg ±  118.7 versus 134.6 
mg ± 78.2; n = 12; p = 0.685) adipose depots of transgenic animals. A similar 
difference was observed when the combined data was analysed (543.0 mg ±
265.7 versus 413.0 mg ± 108.3; n = 12; p = 0.570). In contrast to females, at one 
year of age the male animals displayed greater variability in individual fat pad 
weights.
A comparison of raw fat pad weights may be complicated by variations in 
body weight between individual animals, and thus fat pad weights were also 
examined as a proportion of body weight. The mean results o f this comparison 
are presented in Figures 5.13 (females) and 5.14 (males).
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Figure 5.11: Fat pad weight of female mice from line 10-15
Weight of A) mesenteric, B) retroperitoneal and C) 
combined mesenteric and retroperitoneal fat from male 
mice at 10 weeks, 6 months and 1 year from line 10-15 on 
a pure 129/Sv background. Statistical significance 
calculated by the Mann-Whitney test is denoted by 
asterisks: * p < 0.05.
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Figure 5.12: Fat pad weight of male mice from line 10-15
Weight of A) mesenteric, B) retroperitoneal and C) 
combined mesenteric and retroperitoneal fat from male 
mice at 10 weeks, 6 months and 1 year from line 10-15 on 
a pure 129/Sv background.
At 10 weeks of age, there was no significant difference in proportion of 
mesenteric (1.77% ± 0.29 versus 1.65% ± 0.31; n = 14; p = 0.406) or 
retroperitoneal (0.30% ± 0.07 versus 0.30% ± 0.06; n = 14; p = 0.949) fat in 
female animals, consistent with the combined data (2.07% ± 0.31 versus 1.95% ± 
0.28; n = 14; p = 0.338). At 6 months of age there was no difference in the 
proportion of mesenteric fat pad (1.15% ± 0 .1 0  versus 1.18% ± 0.23; n = 8 ; p = 
0.773), with a ~34% increase in the proportion of retroperitoneal fat (0.24% ± 
0.04 versus 0.33% ± 0.06; n = 8 ; p = 0.083), although this did not achieve 
statistical significance. No difference was observed in fat pad proportion of the 
combined fat pad weight (1.39% ± 0.14 versus 1.51% ± 0.26; n = 8 ; p = 0.386). 
At one year of age, mesenteric fat pad proportion was ~60% greater in 
transgenics (0.77% ± 0.21 versus 1.21% ± 0.57; n = 8 ; p = 0.062), with a ~50%  
increase observed for retroperitoneal fat (0.32% ± 0.03 versus 0.47% ± 0.21; n = 
8 ; p = 0.062). The combined proportion of mesenteric and retroperitoneal fat in 
transgenic females was ~55% more (1.09% ± 0 .1 8  versus 1.68% ± 0.76; n = 8 ; p 
= 0.042). Normalisation of fat pad weight according to individual body weight did 
not affect the standard deviation of transgenic fat pad proportions at one year of 
age, suggesting that fat pad weight was not necessarily correlated with body 
weight.
Male animals at 10 weeks of age did not exhibit any difference in fat pad 
proportion of mesenteric (1.35% ± 0.38 versus 1.38% ± 0.30; n = 14; p = 0.698), 
retroperitoneal (0.28% ± 0.07 versus 0.25% ± 0.70; n = 14; p = 0.271), or 
combined (1.63% ± 0.39 versus 1.63% ± 0.25; n = 14; p = 0.796). At six months 
of age, fat pad proportions of mesenteric (0.75% ± 0 .1 6  versus 0.84% ± 0.16; n = 
8 ; p = 0.881), retroperitoneal (0.26% ± 0 .1 3  versus 0.30% ± 0.10; n = 8 ; p = 
0.881) and combined (1.01% ± 0.27 versus 1.14% ± 0.25; n = 8 ; p = 0.655) fat 
pads were increased by approximately 12%. At one year of age, fat pad 
proportions were reduced by approximately 20% for mesenteric (1.06% ± 0.37 
versus 0.83% ± 0.23; n = 12; p = 0.570), retroperitoneal (0.49% ± 0.28 versus 
0.39% ± 0.20; n = 12; p = 0.465) and combined (1.55% ± 0.61 versus 1.22% ± 
0.30; n = 12 ; p = 0.291) fat pads, although statistical significance was not 
achieved in any instance. Interestingly, the large standard deviation associated 
with fat pad weight in wild type animals was reduced when corrected for body 
weight, suggesting that male fat pad weight is directly correlated with body mass.
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Figure 5.13: Fat pad weight as proportion of body weight 
in female mice from line 10-15
Fat pad proportion of body weight for A) mesenteric, B) 
retroperitoneal and C) combined mesenteric and 
retroperitoneal fat from female mice at 10 weeks, 6 months 
and 1 year from line 10-15 on a pure 129/Sv background. 
Statistical significance calculated by the Mann-Whitney test 
is denoted by asterisks: * p < 0.05.
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Figure 5.14: Fat pad weight as proportion of body weight 
in male mice from line 10-15
Fat pad proportion of body weight for A) mesenteric, B) 
retroperitoneal and C) combined mesenteric and 
retroperitoneal fat from female mice at 10 weeks, 6 months 
and 1 year from line 10-15 on a pure 129/Sv background.
The modest increase in fat pad weight observed in transgenic females at 
one year of age may result from an increase in either cell size or cell number, or 
a combination of both. Adipocyte cell diameter was measured according to the 
method of Ashwell and colleagues (1976), which was modified as described in 
Section 2.15.2. Mean cell diameter was calculated from the number of cells 
counted in a defined region. Three wild type and three transgenic animals were 
examined at 10 weeks and 1 year of age, with three regions of retroperitoneal fat 
measured from each individual. H&E stained sections representative of each 
genotype at both stages are shown in Figure 5.15 A-D. The mean cell diameter at 
each stage is shown in Figure 5.15 E, with error bars representing the standard 
deviation. No significant difference was observed in adipocyte size between wild 
type and transgenic animals at 10 weeks (52.1 pm ± 3.0 versus 53.1 pm ± 2.8; n 
= 6 ; p = 0.773) or one year of age (67.9 pm ± 2.3 versus 65.6 pm ± 1.9; n = 6 ; p 
= 0.439).
The hormone leptin is secreted by adipose tissue, with circulating serum 
leptin concentration tending to correlate with the degree of adiposity. Plasma 
leptin concentration of female animals at 6 months and one year of age was 
determined by ELISA. Blood was taken at the terminal end-point of the same 
animals from which fat pads were dissected. Mice were not fasted prior to 
dissection, and thus the plasma concentration represents mice in a fed state. 
Individual serum leptin concentrations are presented in Figure 5.16 A. At 6 
months of age, there was no difference in serum leptin concentration between 
wild type and transgenic animals (80.8 pM ± 42.1 versus 87.0 pM ± 33.1; n = 8 ; p 
= 0.773), whereas at one year of age, despite a large degree of variation, 
transgenic females exhibited a significantly elevated plasma leptin concentration 
(43.9 pM ± 28.1 versus 236.6 pM ± 277.7; n = 11; p = 0.028). Leptin 
concentration was also normalised according to the combined fat pad weight of 
the individual and analysed separately (Fig. 5.16 B). A similar pattern of results 
was observed, with no discernable difference between wild type and transgenic 
animals at 6 months (0.207 pM/mg ± 0.117 versus 0.212 pM/mg ± 0.073; n = 8 ; 
p = 0.564), and a marginally significant difference at 1 year of age (0.152 pM/mg 
± 0.124 versus 0.323 pM/mg ± 0.164; n = 11; p = 0.045).
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Figure 5.15: Morphological analysis of retroperitoneal adipose tissue
H&E stained retroperitoneal adipose depots of wild type and transgenic 
females from line 10-15 on a pure 129/Sv background at 10 weeks (A and B 
respectively) and 1 year (C and D respectively) of age. Scale bar =100 i^rn. 
Graph in E shows the average adipose cell diameter. Error bars represent 
standard deviation.
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Figure 5.16: Serum leptin concentration in females
Scatter plots showing A) the serum leptin concentration in females at six 
months and one year of age; and B) the serum leptin concentration 
normalised to fat pad weight at the same stages in animals from line 10-15 
on a pure 129/Sv background. Significance levels as calculated by the Mann 
Whitney test are denoted by asterisks; * p < 0.05.
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One possible explanation for the increased adiposity observed in 
transgenic animals is that Phlda2 and/or Slc22a18 are over-expressed in adipose 
tissue. Semi-quantitative PCR was initially used to determine if either gene was 
endogenously expressed in wild type adipose tissue or if transcripts could be 
detected in adipose tissue of transgenic animals. No transcript could be detected 
for Phlda2, with relatively low levels of Slc22a18  expression in white adipose 
tissue. C dkn lc  was also expressed in both wild type and transgenic adipose 
tissue (Fig 5.17). Transcripts for Slc22a18  and Phlda2  could not be detected by 
qPCR, despite the amplification of both reference gene transcripts with C j values 
of between 18 and 20, indicating that Phlda2  is not expressed in white adipose 
tissue and that Slc22a 18 expression is minimal.
A
B
C
Figure 5.17: Analysis of gene expression in retroperitoneal adipose tissue
Expression of A) Phlda2, B) C dkn lc  and C) Slc22a18  in adult retroperitoneal 
adipose depots of wild type (lanes 2 and 3) and transgenic animals (lanes 4 
and 5) from line 10-15 on a pure 129/Sv background. Lane 1 shows a 100 bp 
ladder and lane 6 is a negative (water) control.
2 3 0
There are several of disadvantages of assessing adiposity from dissecting 
the tissue from animals and weighing it. Primarily this approach requires a larger 
cohort of animals than would be required if fat deposition could be measured 
without needing to sacrifice the animals. Additionally, the approach is limited by 
the accuracy of dissection and access to various sites of adipose tissue. An 
alternative method to dissecting fat pads at various stages is to use Magnetic 
Resonance Imaging (MRI) to directly quantify adipose tissue in live animals. In 
order to establish this technique for use in future experiments, a small cohort of 
animals was subjected to MRI scanning. Due to restrictions of our current Home 
Office licensing, animals used in this study were sacrificed immediately prior to 
scanning. However, future use of this technique would enable the use of 
anaesthetised animals such that fat deposition could be investigated in a 
longitudinal study utilising the same cohort of animals, in which glucose and 
insulin tolerance testing would also be performed.
A cohort of fourteen females at 14 months of age, consisting of four 
transgenics and 10 wild type were selected for this study, with total body fat 
volume calculated from MRI scan images as described in Section 2.17, and 
combined adipose to body weight proportions calculated from dissection of fat 
pads immediately following MRI scan. As observed previously, no significant 
difference was observed in body weight of transgenic mice compared to wild type 
(31.1 g ± 3.2 versus 31.1 mg ± 1.9; n = 14; p = 0.733). As a proportion of body 
weight, the combined fat pad weight was not significantly different in transgenic 
animals compared to wild type (1.69% ± 0.54 versus 1.76% ± 0.12; n = 14; p = 
0.540). Similarly, following analysis of MRI scan images, fat volume as a 
proportion of total body volume was also not significantly different in transgenic 
animals compared to wild type (20.6% ± 4.2 versus 22.2% ± 6.39; n = 14; p = 
0.945). The relative volume of adipose tissue determine by MRI scanning was 
greater than the proportion indicated by dissection as the MRI enables analysis of 
total body fat, whereas only two adipose depots were examined by dissection.
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Figure 5.18: Comparison of adiposity determined by weight and MRI scans
Analysis of adiposity by MRI scans was compared with weights obtained by 
dissection from a cohort of 14 female mice from line 10-15 on a pure 129/Sv 
background. A) Combined retroperitoneal and mesenteric adipose tissue 
weights as a proportion of body weight and B) Total adipose tissue volume as a 
proportion of body volume
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5.2.6 Female transgenic mice develop glucose intolerance
Increased visceral adiposity is a major risk factor for type 2 diabetes. Fasting 
glucose tolerance tests were performed on the same cohort of male and female 
mice at 10 weeks, 6 months and 1 year of age. Glucose tolerance tests were 
performed as described in Section 2.16. Mice were fasted overnight, in order to 
eliminate the possibility that recently consumed food would interfere with the test, 
and a baseline blood glucose measurement obtained. Each mouse was then 
injected with 2 mg/g glucose and blood glucose measured every thirty minutes 
thereafter. A normal insulin response would result in an initial peak blood-glucose 
concentration immediately after injection, followed by a steady decline in blood 
glucose as the metabolism responds to insulin. Glucose intolerance, or insulin 
insensitivity, was indicated by a delayed response to glucose injection, with blood 
glucose concentration remaining elevated in comparison to wild type animals of 
the same age.
Fasting blood glucose levels were no different in transgenic females at 10 
weeks (3.46 mM ± 0.40 versus 3.64 mM ± 0.46; n = 12; p = 0.626) or 6 months 
(4.30 mM ± 1.06 versus 3.74 mM ± 0.54; n = 12; p = 0.086) of age. At one year of 
age, transgenic females exhibited slightly reduced fasting blood glucose levels 
(4.46 mM ± 0.65 versus 3.70 mM ± 0.43; n = 12; p = 0.051), although this failed 
to achieve statistical significance. The response to glucose challenge at 10 
weeks was comparable between wild type and transgenic females, with no 
difference in blood glucose concentration 30 minutes (11.52 mM ± 1.01 versus 
10.99 mM ± 1.23; n = 12; p = 0.370), 60 minutes (8.20 mM ± 0.88 versus 8.46 
mM ± 1.44; n = 12; p = 0.870), 90 minutes (7.00 mM ± 0.76 versus 7.16 mM ± 
0.50; n = 12; p = 0.515) or 120 minutes (6.06 mM ± 0.52 versus 6.41 mM ± 0.40; 
n = 12; p = 0.740) following glucose injection. A similar scenario was observed at 
6 months of age, with no alteration to blood glucose concentration 30 minutes 
(9.28 mM ± 1.10 versus 9.56 mM ± 1.24; n = 12; p = 0.807), 60 minutes (7.38 
mM ± 0.58 versus 7.84 mM ± 0.88; n = 12; p = 0.166), 90 minutes (6.52 mM ± 
0.68 versus 6.39 mM ± 0.76; n = 12; p = 0.988) or 120 minutes (6.10 mM ± 0.46 
versus 5.63 mM ± 0.92; n = 12; p = 0.566) following injection. In contrast, at one 
year of age, transgenic females displayed significantly elevated blood glucose 
concentration 30 minutes (7.88 mM ± 0.50 versus 8.89 mM ± 1 .1 3 ;n  = 12;p =
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0.042) and 60 minutes (6.68  mM ± 0.59 versus 8.17 mM ± 2.03; n = 12; p = 
0.041) following injection. Blood glucose concentration remained elevated 90 
minutes (5.96 mM ± 1.05 versus 7.13 mM ± 1.14; n = 12; p = 0.057) and 120 
minutes (5.50 mM ± 1.15 versus 6.36 mM ± 1.22; n = 12; p = 0.416) after 
injection, although without reaching statistical significance.
Fasting blood glucose levels were no different in transgenic males at 10 
weeks (3.96 mM ± 0.92 versus 3.07 mM ± 0.80; n = 12; p = 0.106), 6 months 
(3.98 mM ± 0.75 versus 3.29 mM ± 0.25; n = 12; p = 0.106) or 1 year (3.86 mM ± 
0.29 versus 3.93 mM ± 1.12; n = 12; p = 0.223). The response to glucose 
challenge at 10 weeks was comparable between wild type and transgenic males, 
with no difference in blood glucose concentration 30 minutes (12.24 mM ± 2.38 
versus 11.57 mM ± 1.47; n = 12; p = 0.998) 60 minutes (11.38 mM ± 1.26 versus
12.69 mM ± 1.99; n = 12; p = 0.202) 90 minutes (9.74 mM ± 0.76 versus 11.03 
mM ± 2.31; n = 12; p = 0.432) or 120 minutes (8.08 mM ± 0.80 versus 9.16 mM ± 
1.54; n = 12; p = 0.343) following injection of glucose. At 6 months, there was 
also no difference in blood glucose concentration 30 minutes (12.46 mM ± 2.86 
versus 10.94 mM ± 1.61; n = 12; p = 0.530) 60 minutes (13.66 mM ± 2.31 versus 
12.31 mM ± 2.10; n = 12; p = 0.432) 90 minutes (11.56 mM ± 1.29 versus 10.61 
mM ± 1.82; n = 12; p = 0.343) or 120 minutes (9.88 mM ± 0.90 versus 9.17 mM ± 
1.50; n = 12; p = 0.202) after injection. Whereas at one year of age, transgenic 
females exhibited prolonged elevation of blood glucose, this was not observed in 
transgenic males, with no significant difference observed 30 minutes (9.84 mM ±
1.69 versus 10.10 mM ± 1.62; n = 12; p = 0.957), 60 minutes (9.28 mM ± 1.18 
versus 9.70 mM ± 1.63; n = 12; p = 0.731), 90 minutes (8.50 mM ± 0.98 versus 
8.57 mM ± 1.55; n = 12; p = 0.782) or 120 minutes (8.00 mM ± 0.54 versus 7.89 
mM ± 1.49; n = 12; p = 0.554) after injection.
A measure of the efficiency of glucose clearance is the area under the 
curve (AUC) of the glucose tolerance test measured in arbitrary area units (AAU). 
No significant difference was observed for the area under the curve of glucose 
tolerance test for males at 10 weeks (1181.4 ± 128.6 versus 1242.0 ± 176.0; n = 
12; p = 0.465), 6 months (1338.3 ± 185.8 versus 1203.0 ± 186.0; n = 12; p = 
0.291) or 1 year (1006.5 ± 104.6 versus 1028.4 ± 158.6; n = 12; p = 0.935).
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Figure 5.19: Glucose tolerance of female mice from line 10-15
Glucose tolerance tests were performed at A) 10 weeks, B)
6 months and C) 1 year of age to compare the ability of wild 
type and transgenic mice to respond to a glucose 
challenge. Graphs show mean blood glucose concentration 
I  at the indicated time following injection of glucose. Error 
bars show standard deviation. Statistical significance 
calculated by the Mann-Whitney test is denoted by 
asterisks; * p < 0.05.
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Figure 5.20: Glucose tolerance of male mice from line 10-15
Glucose tolerance tests were performed at A) 10 weeks, B)
6 months and C) 1 year of age to compare the ability of wild 
type and transgenic mice to respond to a glucose 
challenge. Graphs show mean blood glucose concentration 
at the indicated time following injection of glucose. Error 
bars show standard deviation.
Blood glucose levels are regulated primarily by the hormones insulin and 
glucagon. Insulin is released from the pancreas in response to elevated blood 
glucose, causing cells to take up glucose and store it as glycogen, thus reducing 
the circulating glucose concentration. Glucagon is secreted by the pancreas in 
response to low blood sugar levels, and causes the liver to convert stored 
glycogen into glucose, which is released into the blood. Type 2 diabetes is 
associated with reduced insulin sensitivity (insulin resistance) and impaired p-cell 
function. Insulin resistance means that normal levels of insulin do no elicit a 
sufficient insulin response, thus blood glucose levels remain elevated. 
Hyperinsulinemia often occurs in early stages of Type 2 diabetes as the pancreas 
continues to secrete insulin in an attempt to reduce blood glucose levels. Non­
fasted serum insulin and glucagon concentrations were assessed by ELISA in 
females of 6 months and 1 year of age.
No difference was observed between wild type and transgenic non-fasted 
females for serum insulin concentration at 6 months (37.0 pM ± 28.9 versus 28.9 
pM ± 13.7; n = 8 ; p = 0.886) or 1 year of age (33.0 pM ± 16.4 versus 46.8 pM ± 
57.6; n = 11; p = 0.662) (Fig 5.21 A). Similarly, no difference was observed for 
serum glucagon concentration at 6 months (6.2 pM ± 2.2 versus 5.5 pM ± 2.6; n = 
8 ; p = 0.486) or 1 year of age (118.3 pM ±151.0 versus 61.0 pM ±40.0; n = 11; p 
= 0.792) (Fig 5.21 B).
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Figure 5.21: Insulin and glucagon serum concentrations
Serum insulin and glucagon concentration was quantified by ELISA at 6 months 
and 1 year of age from animals of line 10-15 on a pure 129/Sv background. 
Scatter graphs show individual serum hormone concentrations from female 
animals at the indicated ages.
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5.2.7 Indication of perinatal lethality in transgenic anim als
Low birth weight is associated with increased perinatal lethality (Mclntire et al. 
1999), whereas obesity and diabetes are known risk factors for reduced longevity 
in humans. There was no difference between the number of wild type and 
transgenic animals at any stage during gestation (Section 3.2.2). The number of 
wild type and transgenic animals observed at PO, P1 and weaning age were 
compared using the Chi-squared test to determine if the observed number 
differed from the expected number. At both PO and P1 the calculated p value was 
< 3.841 (Table 5.1), thus indicating no difference in the number of wild type and 
transgenic animals. At weaning, the number of transgenic animals was 
significantly less than the number of wild type animals (136 versus 102 ; p = 
4.857), although when the number of wild type and transgenic animals was 
compared by sex, no significant difference was observed for either females (73 
versus 53; p = 3.175) or males (63 versus 49; p = 1.750). Furthermore, there was 
no difference in the number of male or female animals observed at P28 (112 
versus 126; p = 0.824).
WT Tg P
P0 79 75 0.104
P1 26 23 0.184
P28 males and females 136 102 4.857
P28 (females) 73 53 3.175
P28 (males) 63 49 1.750
Table 5.1: Analysis of number of wild type and transgenic neonates
Table shows P values for Chi-squared test for comparison of number of wild 
type and transgenic animals at PO, P1 and P28 from line 10-15 on a pure 
129/Sv background.
Females Males P
P28 112 126 0.824
Table 5.2: Analysis of number of male and females at weaning
Table shows P  value for Chi-squared test for comparison of number of male and 
female animals at P28 from line 10-15 on a pure 129/Sv background.
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5.2.8 Transgenic placentae exhibit elevated expression levels of 
nutrient transporters
Evidence presented thus far suggests that over-expression of Phlda2 and 
Slc22a18 in the mouse placenta causes placental insufficiency resulting in 
asymmetric IUGR of transgenic embryos with post-natal catch up growth 
complete within two weeks of birth. A similar growth profile is observed in mice 
that lack expression of placenta-specific Ig12 (l’gf2P0 null,). Placental insufficiency 
results in onset of IUGR between E15.5 and E18.5, with transgenic animals born 
30% lighter than wild type littermates. Transgenic animals display catch up 
growth that is complete by 3 months of age. The reduced size of lgf2P0 null 
placentae impairs the passive permeability, thus limiting the nutrient supply to 
mutant embryos (Constancia et al. 2002). However, mutant placentae are able to 
compensate for their reduced size by upregulating expression of genes that 
encode nutrient transporter molecules. Slc2a3, which encodes a glucose 
transporter, and the 4-kb transcript from the imprinted gene Slc38a4, which 
encodes a member of the System A amino acid transporter family, are both 
upregulated in lgf2P0 null placentae at E15.5. Upregulation of these genes 
results in increased transport efficiency of miutant placentae, which is able to 
meet the nutrient demands of the embryo at this stage. However, System A 
transport was no longer upregulated at E18.5, and thus combined with the 
reduced passive permeability of the mutant placenta resulted in late gestation 
IUGR (Constancia et al. 2005; Constancia et al. 2002; Sibley et al. 2004).
Microarray analysis of gene expression for wild type and transgenic 
placentae of line 10-15 was performed by Ben Tycko. Gene expression was 
compared between three wild type and three transgenic placentae at E16.5. Eight 
genes encoding nutrient transporters were significantly upregulated in transgenic 
placentae and one transporter Slc22a5 was significantly downregulated by nearly 
5-fold (Table 5.4). Similar to the lgf2P0 null placentae, Slc2a3 was upregulated, 
with one probe reporting a 1.7 fold upregulation and a second probe indicating a 
2.9-fold upregulation. In contrast to the lgf2P0 model, no significant effect on 
expression level of Slc38a4 was detected although it is unknown whether the 
probe was specific for the 4-kb transcript.
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G ene Fold Change
Slc2a3 1.7*
Slc2a3 2.9*
Slc3a2 1.5*
S/c19a2 2 .0 *
Slc22a5 - 4 . 8 *
Slc22a3 2.5*
Scl25a3 1.7*
Slc38a 1 - 1.1
Slc38a2 2.0  *
Slc38a4 1.3 Nb
Slc40a 1 2.1 *
Slc41 a 1 1.7*
Table 5.3: Relative expression levels of genes encoding placental 
transporters in transgenic placentae of line 10-15
Fold change of transporter expression in transgenic placentae at E16.5 
determined by microarray. Statistical significance determined by Mann 
Whitney test is denoted by asterisks; * p < 0.05, NS = not significant.
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Mice that completely lack expression of Igf2 are inherently growth 
restricted, and do not exhibit altered placental gene expression, presumably as 
the mutant placenta is able to supply the lower nutrient demand of the mutant 
embryo (Constancia et al. 2005). It is possible that the altered gene expression 
observed in transgenic placentae of line 10-15 is a direct result of the perturbed 
placental structure, and does not represent upregulation of gene expression to 
compensate for reduced placental function. In order to eliminate this possibility, 
gene expression was examined by qPCR in placentae of line 5D3. Results 
presented in Chapter 4 show that transgenic placentae of lines 5D3 and 5A4 
exhibit a similar placental defect to line 10-15. Transgenic embryos of these lines 
additionally over-express the growth-inhibitory Cdknlc in the embryo, resulting in 
intrinsic embryonic growth restriction from at least E13.5. Transgenic embryos of 
line 5D3 on a mixed 129/Sv x MF1 background were 14% lighter at E13.5, 
whereas no effect on embryonic growth was observed in line 10-15 at this stage 
(Andrews et al. 2007). Transgenic embryos of line 5A4 possess two copies of the 
unmodified transgene, and expresses Cdknlc at greater levels than line 5D3 in 
the embryo. Embryonic weights were compared for lines 10-15, 5D3 and 5A4 at 
E13.5 and E18.5 (Fig 5.21).
As presented in Figure 5.1, no difference in embryonic weight was 
observed at E13.5 in line 10-15 on a pure 129/Sv background. Transgenic 
embryos of line 5D3 on a mixed 129/Sv x C57BL/6 genetic background were 4% 
lighter than wild type at E13.5, although without reaching statistical significance 
(151.5 mg ± 14.1 versus 145.3 mg ± 16.1; 5 litters; n = 47; p = 0.171), whereas 
previously they had been shown to be ~20% lighter (Andrews et al. 2007). 
Transgenic embryos of line 5A4 on a similar mixed genetic background were 
20.5% lighter than wild type (146.5 mg ± 15.3 versus 116.4 mg ± 14.6; 7 litters; n 
= 50; p = 1.43 x 10"4). At E18.5, transgenic embryos of line 10-15 were 13.4% 
lighter than wild type, whereas those from line 5D3 were 8 .6 % lighter (1300.8 mg 
± 67.4 versus 1188.6 mg ± 51.5; 7 litters; n = 59; p = 2.09 x 10"5), and those of 
line 5A4 were 17.1% lighter (1295.8 mg ± 54.1 versus 1074.6 mg ± 138.2; 7 
litters; n = 54; p = 1.18 x 10*9).
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Figure 5.22: Embryonic growth restriction in transgenic lines 5D3 and 5A4
Graphs show embryonic growth of wild type and transgenic embryos in line 
10-15 on a pure 129/Sv genetic background and lines 5D3 and 5A4 on the 
129/Sv x C57BL/6 background at A) E13.5, and B) E18.5. Error bars 
represent standard deviation, with significance as determined by the f-test 
denoted by asterisks; * p < 0.05.
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Expression of the glucose transporter Slc2a3, and the System A amino 
acid transporter Slc38a4 was altered in lgf2P0 null placentae, whereas 
expression of another System A transporter Slc38a2 was altered in Igf2 null 
placenta. Expression of these three genes was thus also examined in placentae 
of lines 10-15 and 5D3. Additionally, expression of another molecule involved in 
amino acid transport, Slc3a2, was also compared between lines 10-15 and 5D3. 
Slc3a2 (formerly Cd98) encodes a type II transmembrane protein that forms the 
heavy chain of a group of heterodimeric amino acid transporters (HATs) (Verrey 
et al. 1999; Verrey et al. 2000). Slc3a2 dimerises with members of the Slc7 family 
of light or catalytic chain HATs to mediate cationic and glycoprotein-associated 
amino acid transport (Verrey et al. 2004). Similar to the comparison of gene 
expression between the lgf2P0 null line and the Igf2 null line, genes displaying 
similarly altered expression in both lines 10-15 and 5D3 lines were predicted to 
represent a direct effect of the disrupted placental structure. In contrast, those 
genes displaying upregulated expression only in transgenic placentae of line 10- 
15, and not line 5D3, were predicted to be a consequence of altered gene 
expression in order to compensate for reduced placental size.
Microarray analysis indicated that Slc2a3 was upregulated by between 
1.7- and 2.9-fold in transgenic placentae of line 10-15. Analysis of expression by 
qPCR confirmed that the fold change was around 1.7-fold wild type levels in line 
10-15, with a similar degree of upregulation (1.6-fold) observed in line 5D3. 
Slc3a2 expression was reported to be 1.5-fold wild type levels in microarray data, 
with qPCR analysis verifying this upregulation. In transgenic placentae of line 
5D3, Slc3a2 was expressed at 1.3-fold wild type levels. However, a direct 
comparison between fold change in line 10-15 and fold change in line 5D3 did not 
achieve statistical significance, indicating that there was no difference in the 
expression of Slc3a2 in transgenic placentae of lines 10-15 and 5D3. A 2-fold 
increase in expression of Slc38a2 was reported by microarray, with a 1.7 fold 
increase by qPCR. No significant difference in expression was found between 
transgenic and wild type placentae of line 5D3, with a significant difference 
between the fold change in line 10-15 and the fold change in line 5D3. Consistent 
with microarray data, no alteration to expression was observed for Slc38a4 in line 
10-15, whereas a 1.3-fold increase was observed for line 5D3, although this did 
not achieve statistical significance.
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Slc38a4
Figure 5.23: Relative expression levels of nutrient transporters in
transgenic placentae
Graph shows the mean relative fold change of nutrient transporters in 
transgenic placenta of line 10-15 (yellow) and line 5D3 (green) compared to 
wild type at E16.5. Broken line indicates arbitrary expression level in wild 
type. Significance as determined by the Mann Whitney test is denoted by 
asterisks; * p < 0.05.
10-15 5D3 P
Slc2a3 1.7 ± 0.08 (p  = 0.014) 1.6 ±0.21 (p  = 0.037) 0.593
Slc3a2 1.5 ± 0.24 (p  = 0.014) 1.3 ± 0.22 (p  = 0.034) 0.154
Slc38a2 1.7 ± 0.07 (p  = 0.037) 1 .2 ± 0.16 (p  = 0.121) 0.042
Slc38a4 1.0 ± 0.15 (p  = 1.00) 1.3 ± 0.37 (p  = 0.487) 0.439
Table 5.4: Relative expression levels of nutrient transporters in transgenic
placentae
The table shows the mean values relating to the graph above, with the 
associated p value for the Mann Whitney test. The third column labelled “F ’ 
shows the p value for a comparison between fold change in transgenic 
placentae of lines 10-15 and 5D3.
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5.3 Discussion
The primary aim of the work presented in this final experimental chapter was to 
ascertain the long-term consequences of the placental defect in transgenic mice 
that over-express Phlda2 and Slc22a18. These investigations focused primarily 
on mice on a pure 129/Sv genetic background, as backcrossing of line 10-15 on 
to the C57BL/6 background had not progressed to generation six at the onset of 
the study. Embryonic growth was examined during gestation from the same litters 
that were used to investigate placental development. Neonatal animals were 
dissected on the day of birth (PO) to determine if organ weights of wild type and 
transgenic animals were proportional. A cohort of animals was weighed 
throughout the course of one year, with a subset of these animals used to 
ascertain fat pad weights and glucose tolerance at 10 weeks, 6 months and 1 
year of age. Morphology of key organs, including adipose tissue and pancreas, 
was examined at 10 weeks and 6 months. Gene expression was also examined 
in transgenic placentae to assess whether the small placenta responded to 
embryonic nutrient demands by upregulating nutrient transporters as observed in 
lgf2P0 nullconceptuses.
5.3.1 Placental defect and asymmetric IUGR is indicative of placental 
insufficiency restricting embryonic growth
Transgenic placentae from line 10-15 were significantly lighter than wild type at 
all gestational stages examined between E12.5 and E18.5. Previously published 
data reported a 10% weight deficit for transgenic embryos compared to wild type 
at E16.5, with no weight difference evident at E14.5 (Salas et al. 2004). Data 
presented in this investigation demonstrate a late onset and progressive 
embryonic growth restriction on a pure 129/Sv genetic background. No significant 
weight difference was observed at E14.5, whereas transgenic embryos were 
~6 % lighter at E16.5 and -13%  lighter at E18.5. Such late onset impaired 
embryonic growth is characteristic of placental insufficiency, whereby embryonic 
growth is adversely affected by an inability of the placenta to supply the required 
nutrients inlate gestation (Brodsky and Christou 2004). This is consistent with the 
presence of a placental phenotype from at least E10.5 in line 10-15, with 
embryonic growth adversely affected in late gestation. This pattern of embryonic
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growth indicates that the slow down in embryonic growth is not an intrinsic 
embryonic phenotype but is rather an indirect consequence of the placental 
defect. A similar placental defect and delayed embryonic growth phenotype exists 
in the lgf2P0 null mouse. Mutant placentae lack expression of placenta-specific 
Igf2, resulting in a significantly lighter placenta from at least E11.5. However, 
embryonic growth was only adversely affected after E15.5, with mutant embryos 
exhibiting a marginal weight deficit at this stage, a -20%  weight deficit at E18.5 
and a -30%  weight deficit at birth (Constancia et al. 2002). In this instance, only 
Igf2 expression directed by the placental-specific PO promoter was disrupted with 
normal embryonic Igf2 expression maintained. This model clearly demonstrates 
the role of placental insufficiency in the resulting embryonic growth restriction.
The transgenic line utilised in this investigation possesses three additional 
copies of the maternally expressed Phlda2 and Slc22a18 imprinted genes. 
Although these genes are primarily expressed in the extraembryonic lineages, 
low-level expression of both genes also occurs in some embryonic tissues. For 
instance, Phlda2 is expressed in the embryonic lungs, liver, kidney and limbs 
(Qian et al. 1997), whereas Slc22a18 exhibits expression in embryonic liver, 
kidney and intestine (Dao et al. 1998). Due to the complication of elevated 
embryonic expression of the genes present on the transgene, it is not possible to 
eliminate an intrinsic effect for these genes on embryonic growth. However, 
considering the limited expression pattern, and the predicted functions of the 
genes, it seems unlikely that over-expression of these genes in a subset of 
embryonic tissues would cause such an overt embryonic growth deficit. Indeed, it 
seems more likely that the observed embryonic growth deficit observed in this 
transgenic line is a consequence of placental insufficiency. Prior to -E 14.5  the 
defective transgenic placenta is sufficient to support normal embryonic growth. 
However, from this stage, as embryonic nutrient demands surge in the final 
trimester of pregnancy, the transgenic placenta becomes unable to support the 
rapidly growing embryo. The placental insufficiency thus results in a moderate 
reduction in transgenic embryo weight at E16.5 progressing to a significant 
embryonic growth restriction effect with a -13%  weight deficit existing at E18.5.
Given that the spongiotrophoblast is not directly involved in nutrient 
transport and there is no overt labyrinth defect in the transgenic placenta, it 
seems unlikely that the reduced embryonic growth is directly attributable to
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reduced placental nutrient transfer which occurs in the labyrinth layer. 
Considering the endocrine function of the spongiotrophoblast in releasing 
hormones to alter maternal physiology it is plausible that embryonic growth is 
restricted due to an inadequate modulation of maternal physiology by the 
transgenic placenta. As described in Chapter 3, there is an indication of reduced 
pregnancy specific glycoprotein transcription in transgenic placenta. Thus, the 
loss of spongiotrophoblast results in a reduction in pregnancy-related hormone 
secretion and a failure of the normal maternal adaptations that support late 
gestation embryonic growth. This may result in an insufficient blood supply to the 
placenta, thus limiting the availability of nutrient and gas exchange and indirectly 
restricting embryonic growth. This may also explain the elevated expression of 
Slc38a2 that is observed in transgenic placenta at E16.5 (discussed in Section 
5.3.4).
Additional support for the role of placental insufficiency in the observed 
embryonic growth restriction derives from recent reports of human IUGR data. 
Two recent publications have identified upregulated PHLDA2 in the placenta of 
human IUGR and low birth weight infants (Apostolidou et al. 2007; McMinn et al.
2006). Furthermore, hypoxia induces down-regulation of PHLDA2 in human term 
trophoblast cells, indicating that PHLDA2 is a hypoxia responsive gene. This 
response to hypoxia of reducing PHLDA2 expression would be predicted to allow 
increased placental growth thus minimising the effect of hypoxia (Kim et al.
2007). However, a failure of this hypoxia-responsive mechanism could cause 
placental insufficiency as an indirect consequence of inappropriate PHLDA2 
expression.
Transgenic pups were born approximately 11% lighter than wild type pups. 
However, considering the additional 10% weight deficit accrued by lgf2P0 null 
pups between E18.5 and birth, the absence of any additional weight deficit 
between these stages for this line seemed unusual. It was noted that some 
pregnant dams gave birth during the night as expected, with these litters 
collected at approximately 9 am. Other pregnant dams however gave birth during 
the day (E19.5), with these litters collected within a relatively shorter timeframe. 
Analysing the complete data set of P0 pups as two different data sets according 
to the time of birth revealed an interesting trend. The weight deficit of transgenic 
pups born during the night was relatively smaller than that of transgenic pups
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born during the day (89% versus 87% respectively), although there was no 
statistically significant difference when transgenic weights were compared from 
the two data sets. Furthermore, the weight deficit of transgenic pups at P1 was 
reduced further (93%). By just one week of age, there was no statistically 
significant difference in weight between wild type and transgenic pups. This rapid 
post-natal catch up growth was further indicative of embryonic growth restriction 
due to placental insufficiency. Following the removal of the growth-limiting factor 
(the defective placenta) the transgenic embryo was able to re-establish and 
continue along its genetic growth trajectory. The post-natal catch up growth 
observed in this transgenic line was significantly more rapid than that seen in the 
lgf2P0 null line. lgf2P0 mutant embryos exhibit catch up growth that is complete 
within 3 months of birth (Constancia et al. 2002), although the growth deficiency 
of both the placenta and embryo were more severe in the /gf2P0 null line.
Considering the evidence implicating placental insufficiency as the 
causative factor of the observed IUGR, organ weights of wild type and transgenic 
embryos were examined at PO to determine if brain-sparing growth was present. 
Brain-sparing growth is characteristic of type II (asymmetric) IUGR, which would 
be predicted to occur in embryos whose growth has been restricted due to 
placental insufficiency in late gestation. In the cohort of animals for which organ 
weight was assessed, the degree of embryonic growth restriction affecting 
transgenic pups was ~11% at PO. A similar degree of growth restriction was 
observed on the liver, heart and kidneys of transgenic animals. In contrast, brain 
weight was only 5.5% less than wild type, whereas lungs were ~15% lighter and 
the pancreas ~20% lighter in transgenic pups. Expressing organ weights as a 
proportion of body weight revealed that the brain to body weight proportion of 
transgenic animals was nearly 7% larger than that of wild type animals. The ratio 
of organ to body weight for liver, heart and kidneys was not affected in transgenic 
pups, whereas the lungs and pancreas appeared to represent a smaller 
proportion of the body weight, although without achieving statistical significance. 
These data indicate that brain-sparing growth was evident in transgenic animals 
of line 10-15, thus suggesting the presence of asymmetric growth restriction.
Organ weights were also examined from embryos of line 5D3, which in 
addition to possessing a similar placental defect to line 10-15 also over-express 
Cdknlc in a subset of embryonic tissues. As a consequence of this embryonic
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over-expression of Cdknlc, transgenic animals are intrinsically growth restricted, 
being born 10-30% lighter, depending upon genetic background, with no post­
natal catch up growth evident (Andrews et al. 2007). Due to the inherently 
reduced growth potential of transgenic embryos of line 5D3, it is proposed that 
embryonic growth is not adversely affected by the presence of the placental 
defect. Consequently, transgenic embryos of line 5D3 would not be expected to 
exhibit asymmetric growth restriction. In contrast, transgenic embryos of this line 
would be predicted to be symmetrically growth restricted, due to the presence of 
a growth restrictive factor directly limiting embryonic growth. No significant 
difference in organ to body weight proportion was observed for any of the six 
organs examined from line 5D3, indicating the presence of symmetric growth 
restriction. However, the anticipated embryonic growth retardation of line 5D3 at 
PO was less severe than predicted, with transgenic embryos only -5 %  lighter 
than wild type at this stage.
This apparent loss of the embryonic growth phenotype in line 5D3 may be 
due to genetic background, with this experimental cohort generated on a mixed 
129/Sv x C57BL/6 background, utilising transgenic males that were G7 C57BL/6. 
However, the embryonic growth phenotype was observed in line 5D3 at E18.5 on 
a mixed 129/Sv x C57BL/6 background, although utilising transgenic males that 
were from G6 C57BL/6. Additionally, the embryonic phenotype persists in line 
5A4 on a similar mixed genetic background. Such evidence indicates that the 
loss of the embryonic growth phenotype is not attributable to the genetic 
background, but may instead be due to epigenetic inactivation of the transgene. 
Transgene inactivation is common in mice, with reports of inactivation of 
transgenes containing the globin genes (Robertson et al. 1995) or a p- 
galactosidase reporter (Montoliu et al. 2000), with this silencing apparently 
attributable to the CpG content of the inserted sequence (Chevalier-Mariette et al. 
2003). Alternatively, the entire transgene may not be the subject of silencing, with 
Phlda2 and Slc22a18 remaining appropriately expressed from the transgene. 
Instead, the copy of Cdknlc present on the transgene may be actively targeted 
and methylated in transgenic mice, thus silencing only this gene. Indeed, 
endogenous Cdknlc accumulates post-fertilisation methylation of the promoter 
sequence in the paternal germline, which maintains monoallelic expression of this 
gene (Bhogal et al. 2004). Such a scenario would result in the persistence of the
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placental phenotype indicating apparent integrity of expression from the 
transgene whereas no embryonic growth deficit would be seen. In an attempt to 
reverse the potential epigenetic modification of the transgene, the transgene will 
be passed through the female germline to re-establish transgenic males from 
which to generate experimental animals. In these animals, the presence of 
embryonic growth retardation will be examined in addition to an evaluation of 
gene expression levels in the embryo and placenta. If this approach fails, it may 
be necessary to introduce a degree of genetic heterogeneity by backcrossing for 
one generation onto the 129/Sv genetic background. However, this would prevent 
the subsequent generation of transgenic animals from line 5D3 on a pure 
C57BL/6 background.
5.3.2 Effect of genetic background on embryonic growth
Embryonic growth was examined on the 129/Sv x C57BL/6 genetic background 
for lines 10-15 and 10-10 at E14.5 and E18.5. At E14.5, no significant weight 
difference existed in either line 10-15 or 10-10 on this genetic background. At 
E18.5, transgenic embryos of lines 10-15 and 10-10 on the 129/Sv x C57BL/6 
genetic background were significantly smaller than wild type. However, the 
degree of weight deficit was less than 50% of that observed on a pure 129/Sv 
genetic background. Transgenic embryos of line 10-15 were ~4% lighter and 
those of line 10-10 were ~6 % lighter than wild type littermates at this E18.5, in 
contrast with the ~13% weight deficit of transgenic embryos from line 10-15 on a 
pure 129/Sv background.
Similar to wild type placenta on the 129/Sv x C57BL/6 genetic background, 
wild type embryos on this genetic background were significantly heavier than wild 
type embryos on a pure 129/Sv background. Although the extent of this weight 
difference was not as great as for placenta. Wild type embryos on the 129/Sv x 
C57BL/6 genetic background were ~10% heavier at E14.5 and - 8% heavier at 
E18.5. Whether the inherently heavier nature of embryos on this genetic 
background accounts for the reduced severity of the embryonic weight deficit is 
unclear. Alternatively, the less severe growth restriction may be due to the 
presence of an inherently larger spongiotrophoblast in placentae on the 129/Sv x 
C57BL/6 background. As discussed in Chapter 4, the midline spongiotrophoblast 
area of transgenic placenta from lines 10-15 and 10-10 on the 129/Sv x C57BL/6
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genetic background was significantly larger than the midline spongiotrophoblast 
area of wild type placenta on a pure 129/Sv genetic background. Thus, a similar 
degree of spongiotrophoblast loss may not exhibit such an adverse effect on 
embryonic growth on the 129/Sv x C57BL/6 genetic background.
5.3.3 Asymmetric IUGR is associated with development of some 
aspects of metabolic syndrome
The immediate concern for human IUGR infants is the increased rate of neonatal 
lethality (Kok et al. 1998; Mclntire et al. 1999). No embryonic lethality was 
observed for line 10-15, with the number of wild type and transgenic animals 
observed at PO and P1 not deviating from the anticipated frequency. However, at 
weaning age there appeared to be significantly fewer transgenic animals than 
wild type animals from the combined numbers of males and females (136 wild 
type versus 102 transgenic; x2 = 4.857). When these numbers were examined 
separately for males and females, although fewer transgenic animals appeared to 
be present in both instances, statistical significance was not achieved. Similarly, 
there was no significant difference in the number of male and female animals at 
PO or P1. These data indicate a possible low frequency of neonatal lethality 
associated with this transgenic line.
In humans, IUGR followed by post-natal catch up growth is considered a 
risk factor for the development of metabolic syndrome in adulthood (Eriksson et 
al. 2000; Eriksson et al. 1999; Forsen et al. 2000; Forsen et al. 1999). 
Development of obesity and type 2 diabetes, two of the key factors of metabolic 
syndrome (reviewed in Alberti et al. 2005), were examined in a small cohort of 
mice from line 10-15. The glucose tolerance test was utilised to assess the ability 
of wild type and transgenic animals to respond to an elevated blood glucose 
concentration. Development of obesity was assessed by weighing a larger cohort 
of animals throughout the course of a year and by directly weighing adipose 
depots in a subset of animals at three time-points.
Transgenic mice did not develop overt obesity within one year of age, with 
no statistically significant weight difference between wild type and transgenic 
animals of either gender at this age. Although transgenic males were slightly 
heavier than wild type between 5 and 9 weeks of age, this weight difference did 
not persist and the biological significance remains unclear, possibly representing
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an over-compensation of catch-up growth. No overt weight difference was 
observed between wild type and transgenic animals up to one year of age. 
However, transgenic females exhibited a progressive increase in adiposity, with a 
significant increase in the combined retroperitoneal and mesenteric adipose 
tissue weight at one year of age. No significant difference in adipocyte cell 
diameter was observed, suggesting instead a possible increase in cell number. 
However, adipose tissue from obese individuals may be composed of pockets of 
small adipocytes within regions of larger adipocytes (Ashwell et al. 1975). 
Although this was not immediately apparent from the sections examined, a more 
detailed examination of sections from a greater number of individuals would be 
needed in order to exclude this possible scenario.
In addition to the increased adiposity observed in female transgenic 
animals at one year of age, serum leptin levels were also significantly elevated in 
this cohort. Leptin is primarily produced from white adipose tissue (WAT) and 
acts to signal satiety and thus prevent excess food intake (hyperphagia). Mice 
lacking function leptin production are overtly obese, as are those with a disruption 
of the leptin receptor (Pelleymounter et al. 1995; Tartaglia et al. 1995). Leptin 
resistance may play a role in development of obesity, with mice unable to 
respond appropriately to the leptin produced by the adipose tissue (Frederich et 
al. 1995). To examine whether transgenic females of line 10-15 exhibit leptin 
resistance, it will be necessary to compare food intake with wild type mice over a 
period of time. Leptin resistance would present as hyperphagia, thus indicating 
an inability to respond appropriately to leptin signalling.
Glucose tolerance testing indicated a significantly impaired ability to 
respond to an elevated blood glucose level and may be indicative of Type 2 
diabetes. Type 2 Diabetes may result from insulin resistance, impaired (3-cell 
function or more usually a combination of both. Insulin tolerance testing may be 
performed to assess insulin response at similar stages to glucose tolerance 
testing. Similarly, p-cell function could be assessed by immunohistochemical 
staining of pancreas sections for insulin. Alternatively, pancreatic explant cultures 
could be utilised to assess insulin response in vivo.
It is clear that the experimental setup utilised in this investigation was not 
optimised to induce obesity, however the modest increase in adiposity observed
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for some individuals is promising for future investigations. There are two general 
factors that must be considered when designing future experiments to further 
investigate development of obesity in these mice, these are the genetic 
background of the mice and the dietary provisions for the animals. Firstly, the 
adult phenotype was investigated using mice on a pure 129/Sv genetic 
background. This is generally considered to be genetically resistant to weight 
gain and glucose intolerance in comparison to more susceptible strains such as 
C57BL/6 (Leiter 1989). Backcrossing of line 10-15 to the C57BL/6 background is 
underway, with the intention of using mice of at least generation 12 on this 
background. Secondly, it is clear that obesity can only occur if energy intake 
exceeds energy expenditure. This can occur through numerous mechanisms, 
including increased food intake, reduced physical activity, altered metabolism or 
a combination of several factors. One of the most widely used animal models of 
obesity is the high fat diet (HFD) fed mouse. This model utilised wild type 
C57BL/6 mice fed a diet that contains five times as much fat and twice the calorie 
content of standard chow (Sorhede Winzell and Ahren 2004; Surwit et al. 1988).
A potential complication to further characterising the post-natal phenotype 
on a pure C57BL/6 genetic background is the apparently reduced severity of 
embryonic growth restriction on the 129/Sv x C57BL/6 background. Transgenic 
animals on a pure 129/Sv genetic background are born ~13% lighter and display 
only a modest increase in adiposity and decrease in glucose tolerance. Whether 
such phenotypes would manifest in animals that were born only ~4-6% lighter is 
unlikely. Therefore, prior to characterising the post-natal phenotype of line 10-15 
on a pure C57BL/6 background, it will be necessary to determine the extent of 
growth restriction at birth on this genetic background. If the severity of embryonic 
growth restriction on the pure C57BL/6 background is not comparable to that on a 
pure 129/Sv background, it may be necessary to re-evaluate the use of the pure 
C57BL/6 background. Instead, the post-natal characterisation could be continued 
using mice on a pure 129/Sv genetic background, but fed a high fat, highly 
palatable diet as described above.
Investigation of the embryonic and post-natal phenotypes were 
complicated by the endogenous expression of Phlda2 and Slc22a18 in embryonic 
and adult tissues. For instance, both Phlda2 and Slc22a18 are expressed in adult 
kidney (Dao et al. 1998; Qian et al. 1997), with qPCR analysis of gene
254
expression showing over-expression of both genes in the kidney of transgenic 
animals (data not shown). The increased adiposity and reduced glucose 
tolerance reported here are indicative of aspects of metabolic syndrome 
occurring as a consequence of IUGR and catch-up growth. However, a direct 
causative role for the over-expression of Phlda2 and/or Slc22a18 in embryonic or 
adult tissues cannot be excluded at this stage. Such a role seems unlikely, given 
the restricted expression of these genes in embryonic and adult tissues. 
Furthermore, preliminary characterisation of line 5A4 found that a similar effect 
on adiposity and glucose tolerance was not observed in transgenic animals of 
line 5A4 (data not shown). Both Phlda2 and Slc22a18 remain over-expressed in 
the relevant tissues of transgenic embryos and adults of line 5A4, with these 
animals differing only in the presence of an intact Cdknlc gene on the two copies 
of the transgene present. Thus, the absence of such a post-natal phenotype in 
line 5A4 suggests that over-expression of Phlda2 and/or Slc22a18 in embryonic 
or adult tissues is not directly causative of the observed post-natal phenotype.
5.3.4 Compensation for reduced placental size by upregulation of 
transporter expression
Placental transport efficiency was examined in lgf2P0 null conceptuses, which 
comprise an embryo with a normal growth potential but with severely reduced 
placental growth. Although the passive diffusion of mutant placentae was 
decreased, active transport of amino acids and glucose was increased at E15.5 
due to upregulation of genes encoding a glucose transporter (Slc2a3) and a 
member of the System A amino acid transporter (Slc38a4) (Constancia et al. 
2002; Sibley et al. 2004). However, Slc38a4 expression was no longer elevated 
at E18.5 and System A transport efficiency was reduced (Constancia et al. 2005). 
The apparent compensatory upregulation of Slc2a3 and Slc38a4 at E15.5 was 
predicted to allow relatively normal growth of the mutant embryos up to this 
stage. The inability to maintain this increased transport efficiency to term 
combined with the reduced passive permeability of lgf2P0 null placenta resulted 
in embryonic growth restriction at E18.5 (Constancia et al. 2005; Constancia et 
al. 2002). In contrast, mice that lack embryonic Igf2 expression in addition to the 
loss of placenta-specific Igf2, do not exhibit this compensatory increase in active 
transport capacity. This is predicted to be due to the reduced nutrient demand of
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the Igf2 null embryo, which is met, and possibly exceeded by the mutant 
placenta. Indeed at E18.5, expression of a second System A amino acid 
transporter gene Slc38a2 was downregulated in Igf2 null placenta (Constancia et 
al. 2005; Constancia et al. 2002).
The presence of a similar compensatory upregulation of nutrient transport 
associated genes was examined in transgenic placenta of line 10-15 at E16.5. 
Transgenic conceptuses of this line exhibit a comparable growth phenotype to 
lgf2P0 null conceptuses, with placental weight deficit evident from early gestation 
and late gestation embryonic growth restriction from -E 16 .5  (Constancia et al. 
2002). Similarly, conceptuses of line 5D3 exhibit a comparable growth phenotype 
to Igf2 null conceptuses, with an early gestation placental weight deficit and an 
intrinsic embryonic growth deficit (Andrews et al. 2007). Placental gene 
expression was compared between lines 10-15 and 5D3 at E16.5 to establish if 
any genes encoding nutrient transporters were upregulated potentially as a 
compensatory response to placental insufficiency. Those genes exhibiting 
increased expression in line 10-15 but remaining unaltered in line 5D3 were 
presumed to be altered in response to placental insufficiency. In contrast, those 
genes exhibiting similar expression patterns in transgenic placentae of lines 10- 
15 and 5D3 were presumed to exhibit perturbed expression due to the disrupted 
placental structure common to both lines. As established in Chapter 4, the 
placental phenotype of line 5D3 is comparable to that of line 10-15, thus allowing 
a comparison of gene expression between the two lines.
Initial microarray analysis of gene expression analysis was performed on 
placentae of line 10-15 at E16.5. A number of nutrient transporter genes were 
included on this array, the majority of which displayed significantly upregulated 
expression in transgenic placentae. Expression of Slc2a3, Slc38a2 and Slc38a4 
was further assessed by qPCR from placentae of lines 10-15 and 5D3 at E16.5. 
In addition to these genes, which displayed perturbed expression in either the 
lgf2P0 null or Igf2 null models, expression of Slc3a2, which encodes a further 
amino acid transporter, was also assessed by qPCR.
Similar to lgf2P0 null placentae, expression of the glucose transporter 
Slc2a3 was upregulated in transgenic placentae of line 10-15. However, a similar 
degree of upregulation was also observed in transgenic placenta of line 5D3, with 
no significant difference between expression levels in transgenic placentae of
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lines 10-15 and 5D3. This suggests that upregulation of Slc2a3 is either an 
indirect consequence of the disrupted placental structure or that placental 
glucose transport is insufficient to meet the needs of transgenic 5D3 embryos.
The amino acid transporter Slc38a4 was upregulated in lgf2P0 null 
placentae at E15.5 but not at E18.5 (Constancia et al. 2005; Constancia et al. 
2002). However, no significant difference in expression of Slc38a2 was detected 
by microarray analysis of placentae from line 10-15. Two transcripts exist for 
Slc38a4; one of 2-kb and the other of 4-kb in length, differing only in the extent of 
the 3’-UTR. In lgf2P0 null placenta, only expression of the 4-kb transcript was 
elevated, with expression of the 2-kb transcript unaffected. It is not known 
whether the microarray probe was specific to the 4-kb transcript or whether this 
probe detected both transcripts. Primers were designed to amplify a region of the 
3’-UTR that is present only in the 4-kb transcript such that the expression of this 
mRNA could be specifically assessed by qPCR. However, no significant 
difference in expression was observed for transgenic placentae of either line IQ- 
15 or 5D3.
Slc3a2 was upregulated 1.5-fold in line 10-15, with a 1.3-fold increase 
observed in line 5D3. However, similar to expression of Slc2a3, there was no 
significant difference between expression of Slc3a2 in transgenic placentae of 
lines 10-15 and line 5D3. In contrast, expression of Slc38a2, a second member of 
the System A amino acid transporter complex, was upregulated in transgenic 
placentae of line 10-15 but unaltered in those of line 5D3. This pattern is 
somewhat in contrast to the altered expression in the two Igf2 deficient models, 
with expression of Slc38a2 unaltered in lgf2P0 null placentae but significantly 
downregulated in Igf2 null placenta. Nonetheless, the upregulation of Slc38a2 in 
line 10-15 but no effect in line 5D3 indicates that Slc38a2 may be involved in the 
compensatory mechanism to alleviate the effect of placental insufficiency.
Four nutrient transporters were selected for further analysis of gene 
expression based upon the altered expression of three of these genes in lgf2P0 
null placentae (Constancia et al. 2005). Of these four genes, only Slc38a2 was 
upregulated in transgenic placentae of line 10-15 with no effect on expression in 
transgenic placentae of line 5D3. This observation contrasts with the lgf2P0 null 
model in which expression of Slc38a2 was unaltered, whereas expression of 
Slc2a3 and Slc38a4 was elevated at a similar stage of gestation. It cannot be
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concluded as to whether the upregulation of Slc38a2 occurs to compensate for 
reduced placental transport capacity. In order to further investigate this, it would 
be necessary to examine the active transport capacity of placentae from both 
lines 10-15 and 5D3 by using similar experiments to those described by 
Constancia et al. (2005; 2002).
The apparently different effects on gene expression between the BAC 
transgenic mice described in this study and the lgf2P0 null mice reported 
previously may be due to the morphological differences between the placental 
defects of each line. lgf2P0 null placentae exhibit a proportionate reduction of 
both spongiotrophoblast and labyrinth layers (Constancia et al. 2002), whereas 
over-expression of Phlda2 and Slc22a18 in the BAC transgenic mice is 
associated with a disproportionate loss of the spongiotrophoblast region. The 
different functions of these two layers may thus result in embryonic growth 
restriction through different mechanisms, and may therefore invoke alternative 
responses to alleviate placental deficiency. For instance, the labyrinth layer 
mediates nutrient transport, whereas the spongiotrophoblast is predicted to have 
a role in secreting hormones that alter maternal physiology. As discussed in 
Section 5.3.1, the disproportionate loss of the spongiotrophoblast layer in the 
BAC transgenic mice described in this investigation may be associated with an 
insufficient modulation of maternal physiology. This may indirectly restrict 
embryonic growth by reduced blood flow to the placenta, which may respond by 
upregulation of genes encoding nutrient transporters, such as Slc38a2. 
Interestingly, in contrast to the proportional loss of labyrinth and 
spongiotrophoblast layers of lgf2P0 null placentae, there is a disproportionate 
loss of the labyrinth layer in Igf2 null placentae (Coan et al. 2008).
5.3.5 Summary of main findings
The primary aim of the work presented in this Chapter was to characterise 
embryonic growth and the post-natal consequences associated with the placental 
defect of line 10-15 described in Chapter 3. Transgenic embryos were 
significantly growth restricted from E16.5 with a birth weight ~13% less than that 
of wild type littermates. Embryonic growth restriction at E18.5 was less severe on 
a mixed 129/Sv x C57BL/6 background, possibly due to the presence of a larger 
spongiotrophoblast area in the associated placentae. Brain-sparing and rapid
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post-natal catch up growth was evident in transgenic animals of line 10-15 on a 
pure 129/Sv background, with no significant weight difference between wild type 
and transgenic adult mice. Transgenic female mice displayed a progressive 
increase in adiposity over the course of a year with a significant reduction in 
glucose tolerance at one year of age. However, these symptoms were not 
observed in transgenic males.
Gene expression was examined in placentae of lines 10-15 and 5D3 at 
E16.5 to determine if any compensatory increase in nutrient transporter 
expression was present. Although expression of Slc2a3 and Slc3a2 was 
increased in transgenic placentae of line 10-15, a similar level of expression was 
observed in placentae of line 5D3, indicating that the altered expression was not 
to compensate for placental insufficiency. In contrast, expression of Slc38a2 was 
upregulated in transgenic placentae of line 10-15, with no upregulation in line 
5D3, indicating that at least one nutrient transporter molecule exhibits 
upregulated expression in line 10-15. In summary, the embryonic and post-natal 
phenotype associated with transgenic animals of line 10-15 were:
• Asymmetric growth restriction and rapid post-natal catch up growth
• Increased adiposity and decreased glucose tolerance at one year of age in 
female mice
• Upregulation of Slc38a2 in transgenic placentae at E16.5
While these data suggest that this is a model of placental insufficiency, a 
role for embryonic expression of Phlda2 and/or Slc22a18 cannot be excluded 
without generating additional transgenic models.
5.3.6 Future directions
The post-natal characterisation performed as part of this investigation utilised 
only a small cohort of animals on the 129/Sv genetic background. Although an 
indication of increased adiposity and reduced glucose tolerance was observed in 
female transgenic mice at one year of age, similar results were not observed for 
male animals at this age. Similarly, adiposity was not significantly altered in the 
four transgenic animals examined by MRI. Nonetheless, the manifestation of 
such symptoms in some transgenic animals warrants further investigation. As 
discussed in Section 5.3.3, the experimental set-up was not optimally designed to 
invoke the most severe phenotype. Future characterisation of the post-natal
259
phenotype of line 10-15 will be investigated on a pure C57BL/6 genetic 
background, which displays increased susceptibility to development of diabetes 
and obesity. Furthermore, to further induce weight gain, both wild type and 
transgenic animals will be fed a high fat, highly palatable diet, such as that 
described by Ozanne et al. (2004). Development of metabolic syndrome in 
transgenic animals of line 10-15 could also be further examined in line 10-10. 
Additionally, glucose tolerance and adiposity could be investigated in lines 5A4 
and 5D3, although the over-expression of Cdknlc in a subset of tissues would 
need to be considered in such characterisation. Indeed, preliminary data 
indicates that such aspects of metabolic syndrome are absent from transgenic 
animals of line 5A4. This observation may potentially exclude a role for 
embryonic or adult expression of Phlda2 and/or Slc22a18 in the post-natal 
phenotype reported for line 10-15. Although it is possible that the excess 
embryonic Cdknlc in line 5A4 may obscure the effects of excess Phlda2 and 
Slc22a18.
A further opportunity for future investigation is the altered gene expression 
of transgenic placentae. Microarray analysis revealed a large number of genes 
encoding nutrient transporter molecules that displayed altered expression at 
E16.5 in line 10-15. Expression of each could be further assessed by qPCR in 
line 10-15 and additionally in line 5D3 based upon the same principles described 
in Section 5.2.8. A comparison with expression in placentae of line 5A4
could also be performed, embryos of which are more severely growth
retarded than those of line 5D3 but with a similar placental phenotype to line IQ- 
15. Embryos of line 5A4 would thus be predicted to exert further reduced nutrient 
demand on the placenta than those of line 5D3. Furthermore, although identifying 
nutrient transporter genes that are upregulated in 10-15 but not in 5D3 or 5A4 
may indicate increased transport efficiency, this cannot be concluded from such 
analysis. Instead, to confirm that the altered gene expression indeed results in an 
increase in transport efficiency, solute transport would need to be directly 
measured as described previously (Constancia et al. 2005; Constancia et al. 
2002).
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Chapter 6: 
Final discussion
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6.1.1 Summary of phenotypic consequences of over-expression of 
Phlda2 and Slc22a18 in the mouse placenta
The effect of excess expression of imprinted genes has not been extensively 
studied. However, such models are useful in attempting to elucidate the potential 
advantages of imprinting and monoallelic expression of particular genes. This 
work utilised a novel transgenic mouse model to characterise the consequences 
of excess expression of Phlda2 and Slc22a18 on mouse development. 
Previously, transgenic placentae were investigated on a mixed genetic 
background. Expression levels of both Phlda2 and Slc22a18 were more than 10- 
fold greater than endogenous levels, with transgenic placenta significantly lighter 
at E14.5 and E16.5. A comparison of the placental phenotype between Kvdmrl 
null and Kvdmrl / Phlda2 double null conceptuses revealed that the placental 
weight deficit was due to a disproportionate loss of the spongiotrophoblast layer 
(Salas et al. 2004). This placental weight deficit of transgenic placenta was 
reciprocal to that of Phlda2 null placenta, which exhibited placentomegaly due to 
an expansion of the spongiotrophoblast (Frank et al. 2002).
This work sought to build upon the published work by performing a more 
detailed characterisation of placentae from line 10-15 on a pure 129/Sv 
background. In contrast to the 10-fold wild type expression of Phlda2 and 
Slc22a18 reported for this line on a 129/Sv x C57BL/6 genetic background, 
expression levels were found to correlate with transgene copy number on a pure 
129/Sv background. Despite this relative decrease in Phlda2 and Slc22a18 
expression, placental stunting persisted to a similar degree. Transgenic 
placentae were 10-25% lighter than wild type from E12.5 until term, with the least 
severe weight deficit observed at E18.5. Transgenic placentae were 
characterised by a disproportionate loss of the spongiotrophoblast layer 
throughout gestation, with a complete mislocalisation of Tpbpa-positive cells at 
E18.5. Glycogen cell staining was reduced throughout gestation, with an 
apparent failure of glycogen cell migration at E16.5.
The placental phenotype of line 10-15 was also examined on the 129/Sv x 
C57BL/6 genetic background. Expression of Phlda2 and Slc22a18 remained 
consistent with transgene copy number on this genetic background. Additionally, 
the placental weight deficit observed at E14.5 on a pure 129/Sv genetic
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background was comparable to that observed on the 129/Sv x C57BL/6 genetic 
background. However, this weight deficit persisted to a similar degree at E18.5 
on the 129/Sv x C57BL/6 background, whereas the weight deficit was reduced to 
less than 10% on a pure 129/Sv background. Transgenic placentae were 
characterised by a disproportionate loss of the spongiotrophoblast region, 
although the mislocalisation of Tpbpa-positive cells at E18.5 appeared to be less 
severe than on the pure 129/Sv genetic background. The difference in expression 
levels observed reported from the previous study on a mixed genetic background 
and the current data using the 129/Sv x C57BL/6 genetic background cannot be 
easily explained. However, it is possible that the variable genetic background of 
line 10-15 over this time period had an effect. Line 10-15 was initially generated 
by pronuclear injection into F-i C57BL/6 x CBA embryos and subsequently bred 
onto the 129/Sv genetic background. Initial characterisation of this line was 
performed following approximately 6 generations of breeding into the 129/Sv 
background with a further 6 generations of breeding performed prior to beginning 
this investigation.
The placental phenotype of a second, independent transgenic line was 
also characterised. Line 10-10 was generated as part of this investigation with 
qPCR analysis of gene expression suggesting the presence of 1-2 copies of the 
transgene. Line 10-10 was characterised only on the 129/Sv x C57BL/6 genetic 
background. The placental phenotype of line 10-10 was comparable to that of line 
10-15 on a similar genetic background, with a comparable degree of placental 
stunting observed at both E14.5 and E18.5. Similarly, a disproportionate loss of 
the spongiotrophoblast layer was observed, with the mislocalisation of Tpbpa- 
positive cells within the labyrinth comparable to line 10-15 on the 129/Sv x 
C57BL/6 background.
The placental phenotype was examined in two additional transgenic lines 
that possess either one or two copies of an unmodified version of the transgene. 
Transgenic mice of these two lines possess active transgenic copies of Cdknlc. 
Enhancer elements required for placental and embryonic expression in some 
tissues were absent from this transgene, thus isolating the consequences of 
excess Phlda2 and Slc22a18 in the placenta but not the embryo (John et al.
2001). These transgenic lines were characterised on the 129/Sv x C57BL/6 
genetic background, and showed a comparable placental defect to lines 10-15
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and 10-10 on a similar genetic background. However, the placental weight deficit 
of the two-copy line was more severe than that of the single copy line, which was 
itself slightly more severe than the weight deficit of lines 10-15 and 10- 10 .
The single copy unmodified BAC transgenic line was crossed with the 
Phlda2 null line in an attempt to assess the relative contribution of over­
expressing Slc22a18 to the observed placental phenotype. Despite Phlda2 
expression remaining slightly elevated relative to wild type placentae, placental 
weight of double Phlda2 null / 5D3 transgenic placentae was restored to within 
the normal range at E14.5. Similarly, spongiotrophoblast area was significantly 
increased in double transgenic placentae compared to 5D3 transgenic placentae, 
although remaining somewhat reduced in comparison to wild type. This may be 
because Phlda2 expression was not fully restored to wild type levels or due to the 
difficulty of isolating placentae of a similar developmental stage when Phlda2 
expression is rapidly down regulated. Alternatively, as discussed previously, this 
may reflect an effect of the intrinsically small 5D3 transgenic embryo on 
restricting placental development.
Embryonic growth was significantly reduced from E16.5, with transgenic 
animals born approximately 13% lighter than wild type littermates. These animals 
displayed asymmetric growth restriction, characterised by relative sparing of brain 
growth and subsequently exhibiting rapid post-natal catch up growth that was 
complete within two weeks of birth. In contrast, transgenic animals of line 5D3 
were intrinsically small and displayed no brain sparing or post-natal catch up 
growth. This late gestation embryonic growth restriction associated with a severe 
placental weight deficit from early gestation was indicative of IUGR as a 
consequence of placental insufficiency.
Based on epidemiological investigations in humans, low birth weight that is 
associated with rapid post-natal catch up growth is considered a risk factor for the 
development of aspects of metabolic syndrome in adult life (Eriksson et al. 1999; 
Forsen et al. 2000). Development of obesity and diabetes was monitored in a 
small cohort of animals from line 10-15 over the course of one year. Although 
known contributory factors such as a high fat diet were excluded from the 
investigation, female transgenic mice displayed increased adiposity and reduced 
glucose tolerance at one year of age. Transgenic animals from line 10-15 thus 
appear to undergo asymmetric IUGR as a consequence of an early gestation
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placental defect. These animals display rapid post-natal catch up growth and 
display evidence of metabolic syndrome in adulthood. This investigation 
describes preliminary evidence that may establish line 10-15 as a potential 
genetic model of IUGR in which to further study fetal programming of metabolic 
syndrome.
6.1.2 Identifying the role of Phlda2 in placental development
There are two possible approaches that may be taken in the characterisation of 
imprinted genes. The first is to generate loss of expression models by specifically 
disrupting the actively expressed allele. Such models provide insight as to the 
function of an imprinted gene product. For instance, loss of Phlda2 results in 
placentomegaly as a consequence of a disproportionate expansion of the 
spongiotrophoblast layer, thus identifying a definitive role for Phlda2 in regulating 
placental development (Frank et al. 2002). An alternative approach is to 
characterise over-expression models, in which expression of an imprinted gene is 
restored to or above the biallelic level. Such models provide additional insight as 
to the rationale for imprinting a particular gene. BAC transgenic mice possessing 
additional copies of the imprinted genes Phlda2 and Slc22a18 were 
characterised in this investigation. These mice displayed a severe placental 
defect that was evident from as early as E10.5. A major role for Slc22a18 was 
excluded following the rescue of the placental phenotype after restoration of 
Phlda2 gene dosage to normal. Over-expression of Phlda2 was associated with a 
disproportionate loss and late gestation mislocalisation of the spongiotrophoblast 
layer. Furthermore, glycogen cell staining was significantly reduced throughout 
gestation, with an apparent failure of glycogen cell migration at E16.5. Microarray 
analysis of gene expression at E16.5 revealed a significant reduction in the 
glycogen cell marker Gjb3. Additionally, a reduction in the expression level of 
genes encoding enzymes involved in the synthesis and turnover of glycogen 
including Gpil and Pygl was also observed (data not shown). In contrast, 
expression of genes including Prl2b1, Prl2c2} Prl7a2, Prl8a6 and Prl8a8, which 
specifically mark the spongiotrophoblast sub-population of cells (Simmons et al. 
2008), was unaffected (data not shown). It therefore seems that Phlda2 directly 
regulates the glycogen cell population, with over-expression of Phlda2 apparently 
associated with a marked decrease in this specific sub-population of cells. In
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order to confirm this hypothesis it will be necessary to quantify the abundance of 
both spongiotrophoblast sub-populations in wild type and transgenic placentae of 
line 10-15.
A comparable placental phenotype was observed in transgenic lines 
possessing between one and three copies of the transgene, thus indicating that 
the severity of the placental phenotype was unaffected by a gene dosage above 
two-fold. Biallelic expression of Phlda2 would thus be associated with a lighter 
placenta with a smaller spongiotrophoblast and a reduced abundance of 
glycogen cells. Imprinting and monoallelic expression of Phlda2 would be 
predicted to enable the formation of a larger placenta with an increased 
abundance of glycogen cells. The exact function of glycogen cells is unclear, 
although it has been proposed that they may serve as an energy source for 
embryonic growth during late gestation (Coan et al. 2006). Thus, a placenta that 
contains an increased abundance of glycogen cells may be better able to support 
increased embryonic growth. However, as discussed in the subsequent section, 
an increased placental capacity does not necessarily impart any growth 
advantage to the embryo, thus explaining the imprinting of the IC2 sub-domain 
rather than Phlda2 in isolation.
6.1.3 Genomic imprinting and nutrient supply and demand
The majority of imprinted genes described to date are critically involved in the 
regulation of placental development (reviewed in Coan et al. 2005). Indeed, 
evolution of the eutherian placenta and the phenomenon of genomic imprinting 
appear to be phylogentically linked (Kaneko-lshino et al. 2003). For instance, 
imprinting has not been described in monotremes, whereas Igf2 is paternally 
expressed and Igf2r is maternally expressed in both eutheria and marsupials 
(Killian et al. 2000; Nolan et al. 2001; Suzuki et al. 2005). In contrast, the Kvdmrl 
locus appears to have become imprinted following the divergence of eutheria 
from marsupials, with Cdknlc biallelically expressed in marsupials (Ager et al. 
2008; Suzuki et al. 2005). The key difference between marsupials and eutherian 
mammals is the ability to support longer gestation periods and give birth to 
mature progeny (Killian et al. 2001; Renfree et al. 2008). The ability to support 
increased gestation and produce developmental^ advanced progeny is linked 
with the evolution of an invasive placenta in eutherian mammals compared with
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the more primitive non-invasive marsupial placenta (John and Surani 2000). Thus 
parental imprinting of specific genes appears central to the development of the 
eutherian placenta and consequently the ability to give birth to developmentally 
mature progeny.
The primary role of most imprinted genes appears to be in the control of 
embryogenesis, whether through regulation of the development of the embryo, 
placenta or both (Coan et al. 2005; Isles and Holland 2005; Tycko and Morison
2002). The placental conflict hypothesis suggests that imprinting arose due to the 
conflicting interests of the parental genomes during embryogenesis, with paternal 
interests lying solely in producing large, healthy and viable offspring whereas the 
mother must additionally maintain sufficient resources for her own survival and 
that of future progeny (Moore and Haig 1991). Thus, the maternal genome would 
favour the repression of growth promoting genes and the expression of growth 
restrictive genes whereas the paternal genome would favour expression of 
growth promoting genes and repression of growth restrictive genes. Indeed, the 
majority of imprinted genes investigated to date correlate with this prediction, with 
paternally expressed imprinted genes tending to be growth promoting and 
maternally expressed imprinted genes growth restrictive (Isles and Holland 2005; 
Tycko and Morison 2002).
Imprinted genes are proposed to play an important role in regulating 
embryonic demand for nutrients in addition to controlling the potential placental 
supply of these nutrients. Thus, imprinting of specific genes achieves a balance 
between fetal demand and placental supply of nutrients in order to achieve 
optimal embryonic growth. If there is an imbalance between the supply and 
demand of nutrients, then optimal embryonic growth can not achieved (Angiolini 
et al. 2006) For instance, loss of expression of Phlda2 results in placentomegaly 
but no growth advantage is conferred to the embryo (Frank et al. 2002). This is 
likely due to the absence of an increased embryonic demand such that even with 
the potential increase in placental function, Phlda2 null embryos do not benefit, 
as their genetic growth potential remains unaltered. The inverse relationship 
exists in the lgf2P0 null mouse, in which placental growth is severely reduced 
and indirectly restricts embryonic growth (Constancia et al. 2002). In this case, 
the embryonic growth potential is unaltered, but the inability of the placenta to 
deliver the required nutrients results in growth restriction during late gestation.
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The transient increase in placental transport efficiency and post-natal catch up 
growth of these mice supports the proposal that the mutant placenta is the 
growth-limiting factor. In contrast, additional loss of Igf2 expression in the embryo 
is associated with a reduction in the genetic growth potential of the embryo that 
places fewer demands on the placenta, which thus does not increase transport 
efficiency and adult mice remain significantly smaller than wild type (Constancia 
et al. 2005; Constancia et al. 2002). Interestingly, maternal inheritance of a H19 
deletion results in embryonic and placental overgrowth. This is likely a 
consequence of the elevated placental and embryonic Igf2 expression, which 
increases the genetic growth potential of the embryo in addition to the supply 
capacity of the placenta (Angiolini et al. 2006; Leighton et al. 1995).
As described above, embryonic growth is only enhanced if the placental 
supply capacity is associated with an increased embryonic growth potential. In 
the absence of increased embryonic demand, a larger placenta has no obvious 
benefit to the embryo. Likewise, an embryonic growth potential that exceeds the 
potential transport capacity of the placenta confers no advantage. However, in 
such instances the placenta may be able to adapt and transiently increase its 
transport efficiency, although this appears to be insufficient to support the growth 
potential of the embryo. Thus, imprinting of specific loci would only confer an 
embryonic growth advantage if the result were to increase placental transport 
capacity in addition to the genetic growth potential of the embryo.
The IC2 sub-domain of mouse distal 7 contains a number of maternally 
expressed imprinted genes in addition to the paternally expressed Kcnq1ot1, 
which is associated with repression of these genes on the paternal chromosome 
(Mancini-Dinardo et al. 2006; Thakur et al. 2004). The IC2 sub-domain is a major 
regulator of embryonic and placental development. Paternal deletion of Kvdmrl 
results in biallelic expression of the maternally expressed imprinted genes within 
the domain and as predicted by the parental conflict hypothesis is associated with 
reduced embryonic and placental growth (Fitzpatrick et al. 2002; Salas et al.
2004). Similarly, mice that lack expression of Cdknlc  exhibit placentomegaly with 
a proportionate expansion of labyrinth and spongiotrophoblast layers (Takahashi 
et al. 2000a). Embryonic growth was enhanced at E13.5 (Andrews et al. 2007), 
although was severely disrupted towards term, with few animals surviving the 
neonatal period, indicating the crucial role of Cdknlc in proper embryonic
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development (Takahashi et al. 2000b; Yan et al. 1997; Zhang et al. 1997). Mice 
lacking expression of Phlda2 also displayed placentomegaly, with a 
disproportionate expansion of the spongiotrophoblast (Frank et al. 2002). In 
contrast, loss of Ascl2 expression results in a smaller placenta due to a loss of 
the spongiotrophoblast layer, with precursor cells instead differentiating into giant 
cells (Guillemot et al. 1994). Examination of the phenotype of mice deficient for a 
specific gene product provides insight as to the role of a specific gene. However, 
it is also important to consider the phenotype associated with over-expression of 
imprinted genes. Such models can provide insight as to the scenario prior to 
imprinting of a specific locus and thus identify potential advantages for favouring 
monoallelic expression of these genes.
We recently reported the intrinsic embryonic growth restriction associated 
with over-expression of Cdknlc in only a subset of embryonic tissues (Andrews 
et al. 2007). Similarly, as reported previously (Salas et al. 2004) and further 
characterised in this investigation, over-expression of Phlda2 is associated with a 
placental defect that is associated with embryonic growth restriction. Thus, 
biallelic expression of Cdknlc  and Phlda2 would be predicted to be associated 
with smaller, less efficient placenta, and in the case of Cdknlc, a reduced 
embryonic growth potential.
The structural organisation of the mouse distal 7/human 11 p15.5 domain 
predates imprinting of this locus (Paulsen et al. 2005), with imprinting evidently 
established following the divergence of eutheria and marsupial (Suzuki et al.
2005). Biallelic expression of genes in the mouse IC2 sub-domain results in a 20- 
25% reduction in embryonic and placental growth (Fitzpatrick et al. 2002; Salas 
et al. 2004), clearly demonstrating a role for imprinting this domain in achieving 
increased placental and embryonic growth.
Figure 6.1 depicts the rationale for imprinting the entire IC2 sub-domain 
rather than Phlda2 in isolation. Prior to imprinting at the domain, biallelic 
expression of Phlda2 and Cdknlc meant that embryonic growth was genetically 
limited with sufficient nutrients supplied by a similarly small placenta. In this 
scenario, embryonic demand and placental supply for nutrients was balanced, 
resulting in the development of a genetically small embryo that achieved its 
growth potential. The theoretical imprinting and the subsequent monoallelic 
expression of Phlda2 in isolation would result in the development of a larger
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placenta, but have no growth advantage on the embryo due to the lack of 
increased nutrient demand. Similarly, imprinting and monoallelic expression of 
Cdknlc in isolation would also theoretically result in a larger placenta. However, 
in this scenario the genetic growth potential of the embryo would also be 
enhanced. It is plausible that the increased placental capacity achieved by 
imprinting of Cdknlc would be insufficient to meet the increased embryonic 
growth potential associated with monoallelic expression of Cdknlc. Indeed, 
Cdknlc null embryos are not significantly heavier than wild type at birth 
(Takahashi et al. 2000b; Yan et al. 1997; Zhang et al. 1997). A similar situation is 
observed in the maternal inheritance of a H19  deletion. In these conceptuses, the 
resulting ~30% increase in placental weight is only associated with a ~12% 
increase in embryonic growth (Angiolini et al. 2006; Leighton et al. 1995). Thus, a 
larger placenta would be required in order for embryos with monoallelic 
expression of Cdknlc  to achieve their genetic growth potential. This would be 
achieved by imprinting of the IC2 sub-domain, with monoallelic expression of 
Phlda2 and Cdknlc increasing the genetic growth potential of the embryo and 
additionally providing a placenta sufficient to support such growth.
It will be interesting to identify the enhancers required for placenta-specific 
Cdknlc expression and generate BAC transgenic mice that over-express Cdknlc 
in the placenta in addition to the full complement of embryonic tissues. 
Additionally, it may be possible to specifically disrupt the embryonic enhancer 
elements thus generating transgenic mice that over-express Cdknlc in the 
placenta only. Such mice would be predicted to be comparable to the Igf2 and 
lgf2P0 null models respectively. Embryonic and placental over-expression of 
Cdknlc would be predicted to result in a balanced reduction of embryonic and 
placental growth, whereas over-expression of Cdknlc in the placenta alone 
would create an imbalance, with only placental growth directly reduced.
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Figure 6.1: Theoretical effects of imprinting Phlda2 and Cdknlc in isolation and together
The diagram depicts the theoretical growth advantage of imprinting Phlda2 and Cdknlc in isolation and 
together. Biallelic expression of the maternally expressed Phlda2 and Cdknlc was growth restrictive in the 
ancestral embryo. Monoallelic expression of Phlda2 in isolation would provide a larger placenta, but in the 
absence of increased embryonic demand, would impart no growth advantage. Monoallelic expression of 
Cdknlc would increase the inherent growth potential of the embryo and theoretically increase placental size 
also, thus resulting in a moderate growth advantage. However, imprinting of both Phlda2 and Cdknlc would 
increase embryonic demand and placental supply of nutrients, thus imparting maximum growth advantage to 
the embryo.
6.1.4 Metabolic syndrome and fetal programming
In addition to identifying the rationale for imprinting of Phlda2, the BAC transgenic 
mice also provided a model to investigate the consequences of loss of imprinting 
at the discrete locus encompassing Phlda2 and Slc22a18. Imprinting of the IC2 
sub-domain is associated with the maternal methylation of Kvdmrl and paternal 
expression of the ncRNA Kcnq1ot1, which renders the paternal alleles of genes 
including Phlda2, Slc22a18 and Cdknlc silent (Smilinich et al. 1999). Loss of 
transcription of the paternal Kcnq1ot1 transcript results in biallelic expression of 
the associated genes (Fitzpatrick et al. 2002; Mancini-Dinardo et al. 2006; Thakur 
et al. 2004). True LOI at distal 7 would therefore be associated with upregulation 
of genes including Cdknlc and Ascl2 in addition to Phlda2 and Slc22a18. 
Nonetheless, the BAC transgenic mice enabled the relative contribution of Phlda2 
and Scl22a18 to be investigated. Additionally, PHLDA2 was found to be 
specifically upregulated in Dicer knockdown HEK293 cells as a result of altered 
chromatin structure with Cdknlc expression remaining monoallelic (Tang et al. 
2007). This observation suggests that over-expression of Phlda2 alone is 
possible in vitro.
As discussed previously, the placental defect associated with the BAC 
transgenic mice can be largely attributed to over-expression of Phlda2. The 
consequence of such over-expression is a significantly lighter placenta from at 
least E12.5, with embryonic growth adversely affected from E16.5. Transgenic 
embryos exhibit brain-sparing growth and display rapid post-natal catch up 
growth. These observations are consistent with the presence of placental 
insufficiency negatively impacting on embryonic growth. Such individuals are 
thought to be subject to “fetal programming”, such that the embryo adapts to the 
low-nutrient environment in utero and cannot subsequently adapt to a relatively 
nutrient rich post-natal environment. The consequence of fetal programming is 
the onset of metabolic syndrome in adulthood, characterised by central obesity, 
type 2 diabetes, hypertension and cardiovascular disease. The presence of 
increased adiposity and reduced glucose tolerance in transgenic females at one 
year of age was indicative of a predisposition to metabolic syndrome, consistent 
with the placental insufficiency and metabolic programming of transgenic 
embryos. However, a role for embryonic expression of Phlda2 and Slc22a18 in
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the observed adult phenotypes cannot be excluded at present. Interestingly, 
preliminary data indicates that such aspects of metabolic syndrome are absent 
from transgenic animals of line 5A4. Phlda2 and Slc22a18 are over-expressed in 
line 5A4 similar to line 10-15 but Cdknlc is additionally over-expressed in the 
embryo, thus intrinsically restricting embryonic growth. This suggests that Phlda2 
and Slc22a18 do not directly affect adult metabolism. Transgenic animals of line 
10-15 exhibit asymmetric growth restriction followed by rapid post-natal catch up 
growth and an association with increased adiposity and reduced glucose 
tolerance. In contrast, the additional over-expression of Cdknlc  in the embryo of 
line 5A4 intrinsically restricts embryonic growth, such that post-natal catch up 
growth is absent and this appears to protect against the onset of metabolic 
syndrome as summarised in Table 6.1.
In addition to providing further insight into the consequences of imprinting 
the IC2 domain, these data has important implications for human health. Indeed, 
elevated PHLDA2 has been reported in human placentae of IUGR and lower birth 
weight infants, despite the preserved paternal methylation of Kvdmrl 
(Apostolidou et al. 2007; McMinn et al. 2006). This data suggests that the ratio of 
Phlda2 and Cdknlc expression may be an important diagnostic marker for 
human IUGR infants. Elevated but balanced Phlda2 and Cdknlc expression 
would be associated with reduced embryonic growth but no long-term metabolic 
consequences. Similarly, an increased Cdknlc to Phlda2 ratio would indicate an 
intrinsically small individual with no long-term metabolic consequences. In 
contrast, an increased Phlda2 to Cdknlc expression ratio would predict placental 
insufficiency and asymmetric IUGR, which may be indicative of a predisposition 
to metabolic syndrome in later life. Elevated Phlda2 and Cdknlc  expression 
could result from LOI of the domain, although this would result in a balanced 
over-expression of both Phlda2 and Cdknlc. However, excess expression of 
Phlda2 independent of loss of Kcnq1ot1 has been demonstrated in a Dicer 
deficient human cell line (Tang et al. 2007). Furthermore, maintenance of 
monoallelic expression of Cdknlc requires additional methylation of the Cdknlc 
promoter on the paternal chromosome (Bhogal et al. 2004). This methylation is 
dependent upon the chromatin remodelling protein Hells/Lsh (helicase, lymphoid 
specific), with biallelic expression of Cdknlc  observed in Hells deficient mice 
despite appropriate methylation of Kvdmrl (Fan et al. 2005). Hells deficient mice
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are born approximately ~20% lighter, although they die soon after birth (Geiman 
et al. 2001). Deregulated expression of both Phlda2 and Cdknlc has thus been 
demonstrated to occur independent of domain-wide LOI, identifying potential 
mechanisms through which unbalanced Phlda2 and Cdknlc expression may 
result.
One potential complication associated with the BAC transgenic mice 
utilised in this investigation is the expression of Phlda2 and Slc22a18 in a subset 
of embryonic and adult tissues. The observed adult phenotypes cannot therefore 
be directly attributed to placental insufficiency, as a direct role for excess 
expression of these genes in contributing to the adult phenotypes cannot be 
excluded. However, it is possible that excess Phlda2 in human placentae is also 
associated with elevated expression in all tissues in which the gene is 
endogenously expressed. Whether such expression is directly linked with a 
predisposition to metabolic syndrome or this is an indirect consequence of 
placental insufficiency and the associated fetal programming remains unclear. It 
will be interesting to examine the level of Phlda2 expression in the kidney of adult 
human IUGR individuals.
274
Phlda2 Cdknlc Consequences
Monoallelic Monoallelic
Large placenta 
Intrinsically large embryo 
Embryonic growth potential is achieved
Biallelic Monoallelic
Small placenta 
Intrinsically large embryo 
Embryonic growth potential is not achieved 
Asymmetric IUGR  
Predisposition to metabolic syndrome
Monoallelic Biallelic
Intermediate placenta 
Intrinsically small embryo 
Embryonic growth potential is achieved
Biallelic Biallelic
Small placenta 
Intrinsically small embryo 
Embryonic growth potential is achieved 
Resistance to metabolic syndrome
Table 6.1: Consequences of unbalanced Phlda2 and Cdknlc  expression
The table summarises the consequences of unbalanced Phlda2 and Cdknlc  
expression. Balanced Phlda2 and Cdknlc  expression is not associated with 
any long-term consequences, with the level of expression associated with 
embryonic growth potential. Similarly, increased Cdknlc  to Phlda2 
expression ratio intrinsically restricts embryonic growth, but has no long-term 
health consequences. In contrast, an elevated Phlda2 to Cdknlc  ratio would 
cause placental insufficiency associated with asymmetric IUGR and a 
predisposition to metabolic syndrome.
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6.1.5 Concluding remarks
In summary, over-expression of Phlda2 in the mouse placenta is associated with 
a significant reduction in placental growth due to a disproportionate loss and 
disruption of the spongiotrophoblast layer. Transgenic embryos display 
asymmetric growth restriction, are born significantly smaller than wild type and 
exhibit rapid post-natal catch up growth. This placental and embryonic growth 
pattern is consistent with the presence of placental insufficiency. Additionally, 
transgenic adult female mice display increased adiposity and reduced glucose 
tolerance, indicative of a predisposition to metabolic syndrome.
A number of conclusions can be drawn from the data presented in this 
investigation. Firstly, these data have identified a possible rationale for imprinting 
Phlda2, with reduced expression levels associated with enhanced placental 
function in order to support the increased embryonic growth potential driven by 
imprinting of Cdknlc. Secondly, this work has identified Phlda2 as a potential 
regulator of the glycogen cell population of the placenta, which represents a 
novel finding. Thirdly, this work has characterised a progressive and asymmetric 
embryonic growth restriction phenotype, suggesting a role for deregulated 
expression of this locus in human IUGR. Finally, there is evidence of an adult 
metabolic phenotype in transgenic mice of line 10-15. Whether this is due to 
placental insufficiency or excess expression of Phlda2 and/or Slc22a18 in the 
embryo, or indeed the adult, is currently unknown. Regardless of the cause, this 
data identifies these mice as a novel genetic model in which both adiposity and 
glucose tolerance is modified. Further investigations may provide insight into the 
developmental origins of these potentially life-threatening disorders that are 
particularly associated with those born with a low birth weight and show catch up 
growth.
276
Bibliography
Adair, L. S. 1989. Low birth weight and intrauterine growth retardation in Filipino 
infants. Pediatrics 84(4), pp. 613-622.
Adamson, S. L., Lu, Y., Whiteley, K. J., Holmyard, D., Hemberger, M., Pfarrer, C. 
and Cross, J. C. 2002. Interactions between trophoblast cells and the maternal 
and fetal circulation in the mouse placenta. Dev Biol 250(2), pp. 358-373.
Ager, E. I., Pask, A. J., Gehring, H. M., Shaw, G. and Renfree, M. B. 2008. 
Evolution of the CDKN1C-KCNQ1 imprinted domain. BMC Evoi Biol 8 , p. 163.
Ainscough, J. F., John, R. M. and Surani, M. A. 1998. Mechanism of imprinting 
on mouse distal chromosome 7. Genet Res 72(3), pp. 237-245.
Alberti, K. G., Zimmet, P. and Shaw, J. 2005. The metabolic syndrome-a new 
worldwide definition. Lancet 366(9491), pp. 1059-1062.
Alders, M., Hodges, M., Hadjantonakis, A. K., Postmus, J., van Wijk, I., Bliek, J., 
de Meulemeester, M., Westerveld, A., Guillemot, F., Oudejans, C., Little, P. and 
Mannens, M. 1997. The human Achaete-Scute homologue 2 (ASCL2,HASH2) 
maps to chromosome 11 p15.5, close to IGF2 and is expressed in extravillus 
trophoblasts. Hum Mol Genet 6(6), pp. 859-867.
Altshuller, Y., Copeland, N. G., Gilbert, D. J., Jenkins, N. A. and Frohman, M. A. 
1996. Gcm1, a mammalian homolog of Drosophila glial cells missing. FEBS Lett 
393(2-3), pp. 201-204.
Andrews, S. C., Wood, M. D., Tunster, S. J., Barton, S. C., Surani, M. A. and 
John, R. M. 2007. Cdknlc (p57Kip2) is the major regulator of embryonic growth 
within its imprinted domain on mouse distal chromosome 7. BMC Dev Bioi 7, p. 
53.
Angiolini, E., Fowden, A., Coan, P., Sandovici, I., Smith, P., Dean, W., Burton, G., 
Tycko, B., Reik, W., Sibley, C. and Constancia, M. 2006. Regulation of placental 
efficiency for nutrient transport by imprinted genes. Placenta 27 Suppl, pp. 98- 
102.
Anson-Cartwright, L., Dawson, K., Holmyard, D., Fisher, S. J., Lazzarini, R. A. 
and Cross, J. C. 2000. The glial cells missing-1 protein is essential for branching 
morphogenesis in the chorioallantoic placenta. Nat Genet 25(3), pp. 311-314.
Antonazzo, P., Alvino, G., Cozzi, V., Grati, F. R., Tabano, S., Sirchia, S., Miozzo, 
M. and Cetin, I. 2008. Placental IGF2 expression in normal and intrauterine 
growth restricted (IUGR) pregnancies. Placenta 29(1), pp. 99-101.
Apostolidou, S., Abu-Amero, S., O'Donoghue, K., Frost, J., Olafsdottir, O., 
Chavele, K. M., Whittaker, J. C., Loughna, P., Stanier, P. and Moore, G. E. 2007.
277
Elevated placental expression of the imprinted PHLDA2 gene is associated with 
low birth weight. J Mol Med 85(4), pp. 379-387.
Arman, E., Haffner-Krausz, R., Chen, Y., Heath, J. K. and Lonai, P. 1998. 
Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role 
for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci 
U S A  95(9), pp. 5082-5087.
Ashwell, M., Priest, P., Bondoux, M., Sowter, C. and McPherson, C. K. 1976. 
Human fat cell sizing-a quick, simple method. J Lipid Res 17(2), pp. 190-192.
Ashwell, M. A., Priest, P. and Sowter, C. 1975. Importance of fixed sections in the 
study of adipose tissue cellularity. Nature 256(5520), pp. 724-725.
Avner, P. and Heard, E. 2001. X-chromosome inactivation: counting, choice and 
initiation. Nat Rev Genet 2(1), pp. 59-67.
Baker, J., Liu, J. P., Robertson, E. J. and Efstratiadis, A. 1993. Role of insulin-like 
growth factors in embryonic and postnatal growth. Ce//75(1), pp. 73-82.
Bamberg, C. and Kalache, K. D. 2004. Prenatal diagnosis of fetal growth 
restriction. Semin Fetal Neonatal Med 9(5), pp. 387-394.
Barker, D. J. 1995. Fetal origins of coronary heart disease. BMJ 311(6998), pp. 
171-174.
Barker, D. J. 1997. Maternal nutrition, fetal nutrition, and disease in later life. 
Nutrition 13(9), pp. 807-813.
Barker, D. J., Bull, A. R., Osmond, C. and Simmonds, S. J. 1990. Fetal and 
placental size and risk of hypertension in adult life. Bmj 301 (6746), pp. 259-262.
Barker, D. J., Gluckman, P. D., Godfrey, K. M., Harding, J. E., Owens, J. A. and 
Robinson, J. S. 1993. Fetal nutrition and cardiovascular disease in adult life. 
Lancet 341(8850), pp. 938-941.
Barker, D. J. and Osmond, C. 1986. Infant mortality, childhood nutrition, and 
ischaemic heart disease in England and Wales. Lancet 1(8489), pp. 1077-1081.
Barker, M., Robinson, S., Osmond, C. and Barker, D. J. 1997. Birth weight and 
body fat distribution in adolescent girls. Arch Dis Child 77(5), pp. 381-383.
Barlow, D. P. 1993. Methylation and imprinting: from host defense to gene 
regulation? Science 260(5106), pp. 309-310.
Barlow, D. P. 1995. Gametic imprinting in mammals. Science 270(5242), pp. 
1610-1613.
278
Barlow, D. P., Stoger, R., Herrmann, B. G., Saito, K. and Schweifer, N. 1991. The 
mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to 
the Tme locus. Nature 349(6304), pp. 84-87.
Barton, S. C., Surani, M. A. and Norris, M. L. 1984. Role of paternal and maternal 
genomes in mouse development. Nature 311(5984), pp. 374-376.
Basyuk, E., Cross, J. C., Corbin, J., Nakayama, H., Hunter, P., Nait-Oumesmar,
B. and Lazzarini, R. A. 1999. Murine Gcm1 gene is expressed in a subset of 
placental trophoblast cells. Dev Dyn 214(4), pp. 303-311.
Bell, A. C. and Felsenfeld, G. 2000. Methylation of a CTCF-dependent boundary 
controls imprinted expression of the Igf2 gene. Nature 405(6785), pp. 482-485.
Bell, A. C., West, A. G. and Felsenfeld, G. 1999. The protein CTCF is required for 
the enhancer blocking activity of vertebrate insulators. Cell 98(3), pp. 387-396.
Bestor, T. H. 2000. The DNA methyltransferases of mammals. Hum Mol Genet 
9(16), pp. 2395-2402.
Bhogal, B., Arnaudo, A., Dymkowski, A., Best, A. and Davis, T. L. 2004. 
Methylation at mouse Cdknlc is acquired during postimplantation development 
and functions to maintain imprinted expression. Genomics 84(6), pp. 961-970.
Bieswal, F., Ahn, M. T., Reusens, B., Holvoet, P., Raes, M., Rees, W. D. and 
Remade, C. 2006. The importance of catch-up growth after early malnutrition for 
the programming of obesity in male rat. Obesity (Silver Spring) 14(8), pp. 1330- 
1343.
Bininda-Emonds, O. R., Cardillo, M., Jones, K. E., MacPhee, R. D., Beck, R. M., 
Grenyer, R., Price, S. A., Vos, R. A., Gittleman, J. L. and Purvis, A. 2007. The 
delayed rise of present-day mammals. Nature 446(7135), pp. 507-512.
Birchler, J. A., Bhadra, M. P. and Bhadra, U. 2000. Making noise about silence: 
repression of repeated genes in animals. CurrOpin Genet Dev 10(2), pp. 211- 
216.
Bird, A. 1992. The essentials of DNA methylation. Ce//70(1), pp. 5-8.
Blair, E. 1994. The myth of fetal growth retardation at term. B rJ Obstet Gynaecol 
101(9), pp. 830-831.
Bouillot, S., Rampon, C., Tillet, E. and Huber, P. 2005. Tracing the Glycogen 
Cells with Protocadherin 12 During Mouse Placenta Development. Placenta.
Branco, M. R., Oda, M. and Reik, W. 2008. Safeguarding parental identity: Dnmtl 
maintains imprints during epigenetic reprogramming in early embryogenesis. 
Genes Dev 22(12), pp. 1567-1571.
279
Breier, G., Clauss, M. and Risau, W. 1995. Coordinate expression of vascular 
endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine 
regulation of murine vascular development. Dev Dyn 204(3), pp. 228-239.
Brodsky, D. and Christou, H. 2004. Current concepts in intrauterine growth 
restriction. J Intensive Care Med 19(6), pp. 307-319.
Brown, S. W. and Nur, U. 1964. Heterochromatic Chromosomes In The Coccids. 
Science 145, pp. 130-136.
Buck, G. M., Cookfair, D. L., Michalek, A. M., Nasca, P. C., Standfast, S. J.,
Sever, L. E. and Kramer, A. A. 1989. Intrauterine growth retardation and risk of 
sudden infant death syndrome (SIDS). Am J Epidemiol 129(5), pp. 874-884.
Burdge, G. C., Hanson, M. A., Slater-Jefferies, J. L. and Lillycrop, K. A. 2007. 
Epigenetic regulation of transcription: a mechanism for inducing variations in 
phenotype (fetal programming) by differences in nutrition during early life? B rJ  
Nutr 97(6), pp. 1036-1046.
Campbell, S. and Thoms, A. 1977. Ultrasound measurement of the fetal head to 
abdomen circumference ratio in the assessment of growth retardation. B rJ  
Obstet Gynaecol 84(3), pp. 165-174.
Carney, E. W., Prideaux, V., Lye, S. J. and Rossant, J. 1993. Progressive 
expression of trophoblast-specific genes during formation of mouse trophoblast 
giant cells in vitro. Mol Reprod Dev 34(4), pp. 357-368.
Carter, A. M., Nygard, K., Mazzuca, D. M. and Han, V. K. 2006. The Expression 
of Insulin-like Growth Factor and Insulin-like Growth Factor Binding Protein 
mRNAs in Mouse Placenta. Placenta 27(2-3), pp. 278-290.
Caspary, T., Cleary, M. A., Baker, C. C., Guan, X. J. and Tilghman, S. M. 1998. 
Multiple mechanisms regulate imprinting of the mouse distal chromosome 7 gene 
cluster. Mol Cell Biol 18(6), pp. 3466-3474.
Caspary, T., Cleary, M. A., Perlman, E. J., Zhang, P., Elledge, S. J. and 
Tilghman, S. M. 1999. Oppositely imprinted genes p57(Kip2) and igf2 interact in a 
mouse model for Beckwith-Wiedemann syndrome. Genes Dev 13(23), pp. 3115- 
3124.
Cattanach, B. M. and Beechey, C. 1997. Genomic imprinting in the mouse: 
possible final analysis. In: Reik, W. and Surani, A. eds. Genomic Imprinting. 
Oxford University Press, pp. 118-141.
Cattanach, B. M. and Beechey, C. V. 1990. Autosomal and X-chromosome 
imprinting. DevSuppI, pp. 63-72.
Cattanach, B. M., Beechey, C. V. and Peters, J. 2004. Interactions between 
imprinting effects in the mouse. Genetics 168(1), pp. 397-413.
280
Cattanach, B. M. and Kirk, M. 1985. Differential activity of maternally and 
paternally derived chromosome regions in mice. Nature 315(6019), pp. 496-498.
Chapman, D. D., Shivji, M. S., Louis, E., Sommer, J., Fletcher, H. and Prodohl, P.
A. 2007. Virgin birth in a hammerhead shark. Biol Lett 3(4), pp. 425-427.
Charalambous, M., Smith, F. M., Bennett, W. R., Crew, T. E., Mackenzie, F. and 
Ward, A. 2003. Disruption of the imprinted Grb10 gene leads to disproportionate 
overgrowth by an Igf2-independent mechanism. Proc Natl Acad Sci U S A  
100(14), pp. 8292-8297.
Chazaud, C., Yamanaka, Y., Pawson, T. and Rossant, J. 2006. Early lineage 
segregation between epiblast and primitive endoderm in mouse blastocysts 
through the Grb2-MAPK pathway. Dev Cell 10(5), pp. 615-624.
Chess, A., Simon, I., Cedar, H. and Axel, R. 1994. Allelic inactivation regulates 
olfactory receptor gene expression. Cell 78(5), pp. 823-834.
Chevalier-Mariette, C., Henry, I., Montfort, L., Capgras, S., Forlani, S., Muschler, 
J. and Nicolas, J. F. 2003. CpG content affects gene silencing in mice: evidence 
from novel transgenes. Genome Biol 4(9), p. R53.
Clark, L., Wei, M., Cattoretti, G., Mendelsohn, C. and Tycko, B. 2002. The Tnfrhl 
(Tnfrsf23) gene is weakly imprinted in several organs and expressed at the 
trophoblast-decidua interface. BMC Genet 3, p. 11.
Coan, P. M., Burton, G. J. and Ferguson-Smith, A. C. 2005a. Imprinted genes in 
the placenta--a review. Placenta 26 Suppl A, pp. S10-20.
Coan, P. M., Conroy, N., Burton, G. J. and Ferguson-Smith, A. C. 2006. Origin 
and characteristics of glycogen cells in the developing murine placenta. Dev Dyn 
235(12), pp. 3280-3294.
Coan, P. M., Ferguson-Smith, A. C. and Burton, G. J. 2004. Developmental 
dynamics of the definitive mouse placenta assessed by stereology. Biol Reprod 
70(6), pp. 1806-1813.
Coan, P. M., Ferguson-Smith, A. C. and Burton, G. J. 2005b. Ultrastructural 
changes in the interhaemal membrane and junctional zone of the murine 
chorioallantoic placenta across gestation. J Anat 207(6), pp. 783-796.
Coan, P. M., Fowden, A. L., Constancia, M., Ferguson-Smith, A. C., Burton, G. J. 
and Sibley, C. P. 2008. Disproportional effects of Igf2 knockout on placental 
morphology and diffusional exchange characteristics in the mouse. J Physiol 
586(Pt 20), pp. 5023-5032.
Constancia, M., Angiolini, E., Sandovici, I., Smith, P., Smith, R., Kelsey, G.,
Dean, W., Ferguson-Smith, A., Sibley, C. P., Reik, W. and Fowden, A. 2005. 
Adaptation of nutrient supply to fetal demand in the mouse involves interaction
281
between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S 
A 102(52), pp. 19219-19224.
Constancia, M., Dean, W., Lopes, S., Moore, T., Kelsey, G. and Reik, W. 2000. 
Deletion of a silencer element in Igf2 results in loss of imprinting independent of 
H19. Nat Genet 26(2), pp. 203-206.
Constancia, M., Hemberger, M., Hughes, J., Dean, W., Ferguson-Smith, A., 
Fundele, R., Stewart, F., Kelsey, G., Fowden, A., Sibley, C. and Reik, W. 2002. 
Placental-specific IGF-II is a major modulator of placental and fetal growth.
Nature 417(6892), pp. 945-948.
Constancia, M., Pickard, B., Kelsey, G. and Reik, W. 1998. Imprinting 
mechanisms. Genome Res 8(9), pp. 881-900.
Cooper, P. R., Smilinich, N. J., Day, C. D., Nowak, N. J., Reid, L. H., Pearsall, R. 
S., Reece, M., Prawitt, D., Landers, J., Housman, D. E., Winterpacht, A., Zabel,
B. U., Pelletier, J., Weissman, B. E., Shows, T. B. et al. 1998. Divergently 
transcribed overlapping genes expressed in liver and kidney and located in the 
11 p15.5 imprinted domain. Genomics 49(1), pp. 38-51.
Copp, A. J. 1979. Interaction between inner cell mass and trophectoderm of the 
mouse blastocyst. II. The fate of the polar trophectoderm. J Embryol Exp Morphol 
51, pp. 109-120.
Corcoran, A. E. 2005. Immunoglobulin locus silencing and allelic exclusion.
Semin Immunol 17(2), pp. 141-154.
Cross, J. C. 2000. Genetic insights into trophoblast differentiation and placental 
morphogenesis. Semin Cell Dev Biol 11 (2), pp. 105-113.
Cross, J. C. 2005. How to make a placenta: mechanisms of trophoblast cell 
differentiation in mice—a review. Placenta 26 Suppl A, pp. S3-9.
Cross, J. C., Baczyk, D., Dobric, N., Hemberger, M., Hughes, M., Simmons, D.
G., Yamamoto, H. and Kingdom, J. C. 2003a. Genes, development and evolution 
of the placenta. Placenta 24(2-3), pp. 123-130.
Cross, J. C., Flannery, M. L., Blanar, M. A., Steingrimsson, E., Jenkins, N. A., 
Copeland, N. G., Rutter, W. J. and Werb, Z. 1995. Hxt encodes a basic helix- 
loop-helix transcription factor that regulates trophoblast cell development. 
Development 121 (8), pp. 2513-2523.
Cross, J. C., Simmons, D. G. and Watson, E. D. 2003b. Chorioallantoic 
morphogenesis and formation of the placental villous tree. Ann N Y Acad Sci 995, 
pp. 84-93.
Cross, J. C., Werb, Z. and Fisher, S. J. 1994. Implantation and the placenta: key 
pieces of the development puzzle. Science 266(5190), pp. 1508-1518.
282
Crouse, H. V. 1960. The Controlling Element in Sex Chromosome Behavior in 
Sciara. Genetics 45(10), pp. 1429-1443.
Curley, J. P., Barton, S., Surani, A. and Keverne, E. B. 2004. Coadaptation in 
mother and infant regulated by a paternally expressed imprinted gene. Proc Biol 
Sci 271(1545), pp. 1303-1309.
Dao, D., Frank, D., Qian, N., O'Keefe, D., Vosatka, R. J., Walsh, C. P. and Tycko,
B. 1998. IMPT1, an imprinted gene similar to polyspecific transporter and multi­
drug resistance genes. Hum Mol Genet 7(4), pp. 597-608.
DeChiara, T. M., Efstratiadis, A. and Robertson, E. J. 1990. A growth-deficiency 
phenotype in heterozygous mice carrying an insulin-like growth factor II gene 
disrupted by targeting. Nature 345(6270), pp. 78-80.
DeChiara, T. M., Robertson, E. J. and Efstratiadis, A. 1991. Parental imprinting of 
the mouse insulin-like growth factor II gene. Cell 64(4), pp. 849-859.
Delaval, K. and Feil, R. 2004. Epigenetic regulation of mammalian genomic 
imprinting. CurrOpin Genet Dev 14(2), pp. 188-195.
Desai, M., Crowther, N. J., Lucas, A. and Hales, C. N. 1996. Organ-selective 
growth in the offspring of protein-restricted mothers. Br J Nutr 76(4), pp. 591-603.
Desai, M., Gayle, D., Babu, J. and Ross, M. G. 2005. Programmed obesity in 
intrauterine growth-restricted newborns: modulation by newborn nutrition. Am J 
Physiol Regul Integr Comp Physiol 288(1), pp. R91-96.
Devriendt, K. 2005. Hydatidiform mole and triploidy: the role of genomic 
imprinting in placental development. Hum Reprod Update 11(2), pp. 137-142.
Dhar, M. S., Sommardahl, C. S., Kirkland, T., Nelson, S., Donnell, R., Johnson,
D. K. and Castellani, L. W. 2004. Mice heterozygous for Atp10c, a putative 
amphipath, represent a novel model of obesity and type 2 diabetes. J Nutr 
134(4), pp. 799-805.
Dobson, P. C., Abell, D. A. and Beischer, N. A. 1981. Mortality and morbidity of 
fetal growth retardation. Aust N Z J  Obstet Gynaecol 21(2), pp. 69-72.
Downs, K. M. and Gardner, R. L. 1995. An investigation into early placental 
ontogeny: allantoic attachment to the chorion is selective and developmentally 
regulated. Development 121(2), pp. 407-416.
Dumont, D. J., Fong, G. H., Puri, M. C., Gradwohl, G., Alitalo, K. and Breitman,
M. L. 1995. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and 
vascular endothelial growth factor expression during development. Dev Dyn 
203(1), pp. 80-92.
283
Dunwoodie, S. L. and Beddington, R. S. 2002. The expression of the imprinted 
gene Ipl is restricted to extra-embryonic tissues and embryonic lateral mesoderm 
during early mouse development. IntJ Dev B/'o/46(4), pp. 459-466.
Dytham, C. 2003a. The basics. In: Dytham, C. ed. Choosing and Using Statistics: 
A Biologists Guide. Second ed. Blackwell Publishing.
Dytham, C. 2003b. Hypothesis testing, sampling and experimental design. In: 
Dytham, C. ed. Choosing and Using Statistics: A Biologists Guide. Second ed. 
Blackwell Publishing.
Dytham, C. 2003c. Statistics, variables and distributions. In: Dytham, C. ed. 
Choosing and Using Statistics: A Biologists Guide. Second ed. Blackwell 
Publishing.
Dytham, C. 2003d. The tests 1: tests to look at differences. In: Dytham, C. ed. 
Choosing and Using Statistics: A Biologists Guide. Second ed. Blackwell 
Publishing.
Eden, S., Constancia, M., Hashimshony, T., Dean, W., Goldstein, B., Johnson, A.
C., Keshet, I., Reik, W. and Cedar, H. 2001. An upstream repressor element 
plays a role in Igf2 imprinting. Embo J 20(13), pp. 3518-3525.
Edwards, C. A. and Ferguson-Smith, A. C. 2007. Mechanisms regulating 
imprinted genes in clusters. CurrOpin Cell Biol 19(3), pp. 281-289.
Efstratiadis, A. 1995. Epigenetics. A new whiff of monoallelic expression. Curr 
Biol 5(1), pp. 21-24.
Eggenschwiler, J., Ludwig, T., Fisher, P., Leighton, P. A., Tilghman, S. M. and 
Efstratiadis, A. 1997. Mouse mutant embryos overexpressing IGF-II exhibit 
phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel 
syndromes. Genes Dev 11(23), pp. 3128-3142.
Engel, N., Thorvaldsen, J. L. and Bartolomei, M. S. 2006. CTCF binding sites 
promote transcription initiation and prevent DNA methylation on the maternal 
allele at the imprinted H19/lgf2 locus. Hum Mol Genet 15(19), pp. 2945-2954.
Engemann, S., Strodicke, M., Paulsen, M., Franck, O., Reinhardt, R., Lane, N., 
Reik, W. and Walter, J. 2000. Sequence and functional comparison in the 
Beckwith-Wiedemann region: implications for a novel imprinting centre and 
extended imprinting. Hum Mol Genet 9(18), pp. 2691-2706.
Eriksson, J., Forsen, T., Tuomilehto, J., Osmond, C. and Barker, D. 2000. Fetal 
and childhood growth and hypertension in adult life. Hypertension 36(5), pp. 790- 
794.
Eriksson, J. G., Forsen, T., Tuomilehto, J., Winter, P. D., Osmond, C. and Barker,
D. J. 1999. Catch-up growth in childhood and death from coronary heart disease: 
longitudinal study. Bmj 318(7181), pp. 427-431.
284
Falls, J. G., Pulford, D. J., Wylie, A. A. and Jirtle, R. L. 1999. Genomic imprinting: 
implications for human disease. Am J Pathol 154(3), pp. 635-647.
Fan, T., Hagan, J. P., Kozlov, S. V., Stewart, C. L. and Muegge, K. 2005. Lsh 
controls silencing of the imprinted Cdknlc gene. Development 132(4), pp. 635- 
644.
Fay, R. A. and Ellwood, D. 1993. Categories of intrauterine growth retardation. 
Fetal and Maternal Medicine Review 5, pp. 203-212.
Feil, R. and Berger, F. 2007. Convergent evolution of genomic imprinting in 
plants and mammals. Trends Genet 23(4), pp. 192-199.
Feil, R., Walter, J., Allen, N. D. and Reik, W. 1994. Developmental control of 
allelic methylation in the imprinted mouse Igf2 and H19 genes. Development 
120(10), pp. 2933-2943.
Feldman, B., Poueymirou, W., Papaioannou, V. E., DeChiara, T. M. and 
Goldfarb, M. 1995. Requirement of FGF-4 for postimplantation mouse 
development. Science 267(5195), pp. 246-249.
Ferguson-Smith, A. C., Cattanach, B. M., Barton, S. C., Beechey, C. V. and 
Surani, M. A. 1991. Embryological and molecular investigations of parental 
imprinting on mouse chromosome 7. Nature 351(6328), pp. 667-670.
Ferguson-Smith, A. C., Sasaki, H., Cattanach, B. M. and Surani, M. A. 1993. 
Parental-origin-specific epigenetic modification of the mouse H19 gene. Nature 
362(6422), pp. 751-755.
Ferguson-Smith, A. C. and Surani, M. A. 2001. Imprinting and the epigenetic 
asymmetry between parental genomes. Science 293(5532), pp. 1086-1089.
Fernandez-Twinn, D. S., Wayman, A., Ekizoglou, S., Martin, M. S., Hales, C. N. 
and Ozanne, S. E. 2005. Maternal protein restriction leads to hyperinsulinemia 
and reduced insulin-signaling protein expression in 21-mo-old female rat 
offspring. Am J Physiol Regul Integr Comp Physiol 288(2), pp. R368-373.
Fisher, A. M., Thomas, N. S., Cockwell, A., Stecko, O., Kerr, B., Temple, I. K. and 
Clayton, P. 2002. Duplications of chromosome 11 p15 of maternal origin result in 
a phenotype that includes growth retardation. Hum Genet 111(3), pp. 290-296.
Fitzpatrick, G. V., Soloway, P. D. and Higgins, M. J. 2002. Regional loss of 
imprinting and growth deficiency in mice with a targeted deletion of KvDMRI. Nat 
Genet 32(3), pp. 426-431.
Font de Mora, J., Esteban, L. M., Burks, D. J., Nunez, A., Garces, C., Garcia- 
Barrado, M. J., Iglesias-Osma, M. C., Moratinos, J., Ward, J. M. and Santos, E. 
2003. Ras-GRF1 signaling is required for normal beta-cell development and 
glucose homeostasis. Embo J 22(12), pp. 3039-3049.
285
Forsen, T., Eriksson, J., Tuomilehto, J., Reunanen, A., Osmond, C. and Barker,
D. 2000. The fetal and childhood growth of persons who develop type 2 diabetes. 
Ann Intern Med  133(3), pp. 176-182.
Forsen, T., Eriksson, J. G., Tuomilehto, J., Osmond, C. and Barker, D. J. 1999. 
Growth in utero and during childhood among women who develop coronary heart 
disease: longitudinal study. Bmj 319(7222), pp. 1403-1407.
Fowden, A. L. 2003. The insulin-like growth factors and feto-placental growth. 
Placenta 24(8-9), pp. 803-812.
Frank, D., Fortino, W., Clark, L., Musalo, R., Wang, W., Saxena, A., Li, C. M., 
Reik, W., Ludwig, T. and Tycko, B. 2002. Placental overgrowth in mice lacking 
the imprinted gene Ipl. Proc Natl Acad Sci U S A  99(11), pp. 7490-7495.
Frank, D., Mendelsohn, C. L., Ciccone, E., Svensson, K., Ohlsson, R. and Tycko,
B. 1999. A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, 
TDAG51, and Tih1: tissue-specific expression, chromosomal location, and 
parental imprinting. Mamm Genome 10(12), pp. 1150-1159.
Frederich, R. C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B. B. and Flier, 
J. S. 1995. Leptin levels reflect body lipid content in mice: evidence for diet- 
induced resistance to leptin action. Nat Med 1(12), pp. 1311-1314.
Gale, C. R., Martyn, C. N., Kellingray, S., Eastell, R. and Cooper, C. 2001. 
Intrauterine programming of adult body composition. J Clin Endocrinol Metab 
86(1), pp. 267-272.
Geiman, T. M., Tessarollo, L., Anver, M. R., Kopp, J. B., Ward, J. M. and 
Muegge, K. 2001. Lsh, a SNF2 family member, is required for normal murine 
development. Biochim Biophys Acta 1526(2), pp. 211-220.
Georgiades, P., Ferguson-Smith, A. C. and Burton, G. J. 2002. Comparative 
developmental anatomy of the murine and human definitive placentae. Placenta 
23(1), pp. 3-19.
Georgiades, P., Watkins, M., Burton, G. J. and Ferguson-Smith, A. C. 2001.
Roles for genomic imprinting and the zygotic genome in placental development. 
Proc Natl Acad Sci U S A  98(8), pp. 4522-4527.
Georgiades, P., Watkins, M., Surani, M. A. and Ferguson-Smith, A. C. 2000. 
Parental origin-specific developmental defects in mice with uniparental disomy for 
chromosome 12. Development 127(21), pp. 4719-4728.
Gicquel, C., Rossignol, S., Cabrol, S., Houang, M., Steunou, V., Barbu, V., 
Danton, F., Thibaud, N., Le Merrer, M., Burglen, L., Bertrand, A. M., Netchine, I. 
and Le Bouc, Y. 2005. Epimutation of the telomeric imprinting center region on 
chromosome 11 p15 in Silver-Russell syndrome. Nat Genet 37(9), pp. 1003-1007.
286
Gilbert, S. F. 2003. Early Embryonic Development from Developmental Biology. 
7th ed. Sunderland, Massachusetts: Sinauer Associates, Inc.
Glenn, C. C., Driscoll, D. J., Yang, T. P. and Nicholls, R. D. 1997. Genomic 
imprinting: potential function and mechanisms revealed by the Prader-Willi and 
Angelman syndromes. Mol Hum Reprod 3(4), pp. 321-332.
Gluckman, P. D., Hanson, M. A. and Beedle, A. S. 2007. Non-genomic 
transgenerational inheritance of disease risk. Bioessays 29(2), pp. 145-154.
Gnarra, J. R., Ward, J. M., Porter, F. D., Wagner, J. R., Devor, D. E., Grinberg,
A., Emmert-Buck, M. R., Westphal, H., Klausner, R. D. and Linehan, W. M. 1997. 
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient 
mice. Proc Natl Acad Sci U S A  94(17), pp. 9102-9107.
Godfrey, K. M., Lillycrop, K. A., Burdge, G. C., Gluckman, P. D. and Hanson, M. 
A. 2007. Epigenetic mechanisms and the mismatch concept of the developmental 
origins of health and disease. Pediatr Res 61(5 Pt 2), pp. 5R-10R.
Goldmit, M. and Bergman, Y. 2004. Monoallelic gene expression: a repertoire of 
recurrent themes. Immunol Rev 200, pp. 197-214.
Graham, C. F. 1974. The production of parthenogenetic mammalian embryos 
and their use in biological research. Biol Rev Camb Philos Soc 49(3), pp. 399- 
424.
Guillemot, F., Caspary, T., Tilghman, S. M., Copeland, N. G., Gilbert, D. J., 
Jenkins, N. A., Anderson, D. J., Joyner, A. L., Rossant, J. and Nagy, A. 1995. 
Genomic imprinting of Mash2, a mouse gene required for trophoblast 
development. Nat Genet 9(3), pp. 235-242.
Guillemot, F., Nagy, A., Auerbach, A., Rossant, J. and Joyner, A. L. 1994. 
Essential role of Mash-2 in extraembryonic development. Nature 371(6495), pp. 
333-336.
Hadchouel, M., Farza, H., Simon, D., Tiollais, P. and Pourcel, C. 1987. Maternal 
inhibition of hepatitis B surface antigen gene expression in transgenic mice 
correlates with de novo methylation. Nature 329(6138), pp. 454-456.
Haffner-Krausz, R., Gorivodsky, M., Chen, Y. and Lonai, P. 1999. Expression of 
Fgfr2 in the early mouse embryo indicates its involvement in preimplantation 
development. Mech Dev 85(1-2), pp. 167-172.
Hagan, J. P., Kozlov, S. V., Chiang, Y., Sewell, L. and Stewart, C. L. 2004. 
Intraspecific mating with Czechll/Ei mice rescue lethality associated with loss of 
function mutations of the imprinted genes, Igf2r and Cdknlc. Genomics 84(5), pp. 
836-843.
Haig, D. 1994. Refusing the ovarian time bomb. Trends Genet 10(10), pp. 346- 
347; author reply 348-349.
287
Haig, D. and Graham, C. 1991. Genomic imprinting and the strange case of the 
insulin-like growth factor II receptor. Cell 64(6), pp. 1045-1046.
Hales, C. N. and Barker, D. J. 1992. Type 2 (non-insulin-dependent) diabetes 
mellitus: the thrifty phenotype hypothesis. Diabetologia 35(7), pp. 595-601.
Hales, C. N. and Barker, D. J. 2001. The thrifty phenotype hypothesis. Br Med 
Bull 60, pp. 5-20.
Hales, C. N., Barker, D. J., Clark, P. M., Cox, L. J., Fall, C., Osmond, C. and 
Winter, P. D. 1991. Fetal and infant growth and impaired glucose tolerance at 
age 64. Bmj 303(6809), pp. 1019-1022.
Hall, J. G. 1990. Genomic imprinting: review and relevance to human diseases. 
Am J Hum Genet 46(5), pp. 857-873.
Hart, A. H., Hartley, L., Ibrahim, M. and Robb, L. 2004. Identification, cloning and 
expression analysis of the pluripotency promoting Nanog genes in mouse and 
human. Dev Dyn 230(1), pp. 187-198.
Haslam, R. J., Koide, H. B. and Hemmings, B. A. 1993. Pleckstrin domain 
homology. Nature 363(6427), pp. 309-310.
Hata, K., Okano, M., Lei, H. and Li, E. 2002. Dnmt3L cooperates with the Dnmt3 
family of de novo DNA methyltransferases to establish maternal imprints in mice. 
Development 129(8), pp. 1983-1993.
Hatada, I. and Mukai, T. 1995. Genomic imprinting of p57KIP2, a cyclin- 
dependent kinase inhibitor, in mouse. Nat Genet 11(2), pp. 204-206.
Hatada, I., Ohashi, H., Fukushima, Y., Kaneko, Y., Inoue, M., Komoto, Y., Okada, 
A., Ohishi, S., Nabetani, A., Morisaki, H., Nakayama, M., Niikawa, N. and Mukai, 
T. 1996. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann 
syndrome. Nat Genet 14(2), pp. 171-173.
Hediger, M. L., Overpeck, M. D., Kuczmarski, R. J., McGlynn, A., Maurer, K. R. 
and Davis, W. W. 1998. Muscularity and fatness of infants and young children 
born small- or large-for-gestational-age. Pediatrics 102(5), p. E60.
Hemberger, M. 2008. IFPA award in placentology lecture - characteristics and 
significance of trophoblast giant cells. Placenta 29 Suppl A, pp. S4-9.
Hemberger, M., Nozaki, T., Winterhager, E., Yamamoto, H., Nakagama, H., 
Kamada, N., Suzuki, H., Ohta, T., Ohki, M., Masutani, M. and Cross, J. C. 2003. 
Parpl-deficiency induces differentiation of ES cells into trophoblast derivatives. 
Dev Biol 257(2), pp. 371-381.
288
Henriksen, T. and Clausen, T. 2002. The fetal origins hypothesis: placental 
insufficiency and inheritance versus maternal malnutrition in well-nourished 
populations. Acta Obstet Gynecol Scand 81(2), pp. 112-114.
Henry, I., Bonaiti-Pellie, C., Chehensse, V., Beldjord, C., Schwartz, C., Utermann,
G. and Junien, C. 1991. Uniparental paternal disomy in a genetic cancer- 
predisposing syndrome. Nature 351(6328), pp. 665-667.
Hirasawa, R., Chiba, H., Kaneda, M., Tajima, S., Li, E., Jaenisch, R. and Sasaki,
H. 2008. Maternal and zygotic Dnmtl are necessary and sufficient for the 
maintenance of DNA methylation imprints during preimplantation development. 
Genes Dev 22(12), pp. 1607-1616.
Hitz, C., Vogt-Weisenhorn, D., Ruiz, P., Wurst, W. and Floss, T. 2005. 
Progressive loss of the spongiotrophoblast layer of Birc6/Bruce mutants results in 
embryonic lethality. Genesis 42(2), pp. 91-103.
Hokken-Koelega, A. C., De Ridder, M. A., Lemmen, R. J., Den Hartog, H., De 
Muinck Keizer-Schrama, S. M. and Drop, S. L. 1995. Children born small for 
gestational age: do they catch up? Pediatr Res 38(2), pp. 267-271.
Hu, J. F., Oruganti, H., Vu, T. H. and Hoffman, A. R. 1998. Tissue-specific 
imprinting of the mouse insulin-like growth factor II receptor gene correlates with 
differential allele-specific DNA methylation. Mol Endocrinol 12(2), pp. 220-232.
Hu, R. J., Lee, M. P., Johnson, L. A. and Feinberg, A. P. 1996. A novel human 
homologue of yeast nucleosome assembly protein, 65 kb centromeric to the 
p57KIP2 gene, is biallelically expressed in fetal and adult tissues. Hum Mol 
Genet 5(11), pp. 1743-1748.
Hurst, L. 1997. Evolutionary theories of genomic imprinting.
Hurst, L. D. and McVean, G. T. 1998. Do we understand the evolution of genomic 
imprinting? CurrOpin Genet Dev 8(6), pp. 701-708.
Inoue, K., Kohda, T., Lee, J., Ogonuki, N., Mochida, K., Noguchi, Y., Tanemura, 
K., Kaneko-lshino, T., Ishino, F. and Ogura, A. 2002. Faithful expression of 
imprinted genes in cloned mice. Science 295(5553), p. 297.
Isles, A. R. and Holland, A. J. 2005. Imprinted genes and mother-offspring 
interactions. Early Hum Dev 81(1), pp. 73-77.
Jay, P., Rougeulle, C., Massacrier, A., Moncla, A., Mattei, M. G., Malzac, P., 
Roeckel, N., Taviaux, S., Lefranc, J. L., Cau, P., Berta, P., Lalande, M. and 
Muscatelli, F. 1997. The human necdin gene, NDN, is maternally imprinted and 
located in the Prader-Willi syndrome chromosomal region. Nat Genet 17(3), pp. 
357-361.
Jelinic, P. and Shaw, P. 2007. Loss of imprinting and cancer. J Pathol 211(3), pp. 
261-268.
289
Jimenez-Chillaron, J. C., Hernandez-Valencia, M., Lightner, A., Faucette, R. R., 
Reamer, C., Przybyla, R., Ruest, S., Barry, K., Otis, J. P. and Patti, M. E. 2006. 
Reductions in caloric intake and early postnatal growth prevent glucose 
intolerance and obesity associated with low birthweight. Diabetologia 49(8), pp. 
1974-1984.
Jimenez-Chillaron, J. C., Hernandez-Valencia, M., Reamer, C., Fisher, S., Joszi, 
A., Hirshman, M., Oge, A., Walrond, S., Przybyla, R., Boozer, C., Goodyear, L. J. 
and Patti, M. E. 2005. Beta-cell secretory dysfunction in the pathogenesis of low 
birth weight-associated diabetes: a murine model. Diabetes 54(3), pp. 702-711.
Jimenez-Chillaron, J. C. and Patti, M. E. 2007. To catch up or not to catch up: is 
this the question? Lessons from animal models. Curr Opin Endocrinol Diabetes 
Obes 14(1), pp. 23-29.
John, R. M., Ainscough, J. F., Barton, S. C. and Surani, M. A. 2001. Distant cis- 
elements regulate imprinted expression of the mouse p57( Kip2) (Cdknlc) gene: 
implications for the human disorder, Beckwith—Wiedemann syndrome. Hum Mol 
Genet 10(15), pp. 1601-1609.
John, R. M. and Surani, M. A. 2000. Genomic imprinting, mammalian evolution, 
and the mystery of egg-laying mammals. Cell 101(6), pp. 585-588.
Jollie, W. P. 1990. Development, morphology, and function of the yolk-sac 
placenta of laboratory rodents. Teratology 41(4), pp. 361-381.
Kagitani, F., Kuroiwa, Y., Wakana, S., Shiroishi, T., Miyoshi, N., Kobayashi, S., 
Nishida, M., Kohda, T., Kaneko-lshino, T. and Ishino, F. 1997. Peg5/Neuronatin 
is an imprinted gene located on sub-distal chromosome 2 in the mouse. Nucleic 
Acids Res 25(17), pp. 3428-3432.
Kajii, T. and Ohama, K. 1977. Androgenetic origin of hydatidiform mole. Nature 
268(5621), pp. 633-634.
Kanduri, C., Pant, V., Loukinov, D., Pugacheva, E., Qi, C. F., Wolffe, A., Ohlsson, 
R. and Lobanenkov, V. V. 2000. Functional association of CTCF with the 
insulator upstream of the H19 gene is parent of origin-specific and methylation- 
sensitive. Curr Biol 10(14), pp. 853-856.
Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E. and Sasaki, H. 
2004. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and 
maternal imprinting. Nature 429(6994), pp. 900-903.
Kaneko-lshino, T., Kohda, T. and Ishino, F. 2003. The regulation and biological 
significance of genomic imprinting in mammals. J Biochem (Tokyo) 133(6), pp. 
699-711.
Kaneko-lshino, T., Kuroiwa, Y., Miyoshi, N., Kohda, T., Suzuki, R., Yokoyama,
M., Viville, S., Barton, S. C., Ishino, F. and Surani, M. A. 1995. Peg1/Mest
290
imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. 
Nat Genet 11(1), pp. 52-59.
Kato, Y., Kaneda, M., Hata, K., Kumaki, K., Hisano, M., Kohara, Y., Okano, M.,
Li, E., Nozaki, M. and Sasaki, H. 2007. Role of the Dnmt3 family in de novo 
methylation of imprinted and repetitive sequences during male germ cell 
development in the mouse. Hum Mol Genet 16(19), pp. 2272-2280.
Kaufman, M. H., Barton, S. C. and Surani, M. A. 1977. Normal postimplantation 
development of mouse parthenogenetic embryos to the forelimb bud stage. 
Nature 265(5589), pp. 53-55.
Kermicle, J. L. 1970. Dependence of the R-Mottled Aleurone Phenotype in Maize 
on Mode of Sexual Transmission. Genetics 66(1), pp. 69-85.
Khatib, H. 2007. Is it genomic imprinting or preferential expression? Bioessays 
29(10), pp. 1022-1028.
Khatib, H., Zaitoun, I. and Kim, E. S. 2007. Comparative analysis of sequence 
characteristics of imprinted genes in human, mouse, and cattle. Mamm Genome 
18(6-7), pp. 538-547.
Killian, J. K., Buckley, T. R., Stewart, N., Munday, B. L. and Jirtle, R. L. 2001. 
Marsupials and Eutherians reunited: genetic evidence for the Theria hypothesis 
of mammalian evolution. Mamm Genome 12(7), pp. 513-517.
Killian, J. K., Byrd, J. C., Jirtle, J. V., Munday, B. L., Stoskopf, M. K., MacDonald, 
R. G. and Jirtle, R. L. 2000. M6P/IGF2R imprinting evolution in mammals. Mol 
Cell 5(4), pp. 707-716.
Kim, H. S., Roh, C. R., Chen, B., Tycko, B., Nelson, D. M. and Sadovsky, Y.
2007. Hypoxia regulates the expression of PHLDA2 in primary term human 
trophoblasts. Placenta 28(2-3), pp. 77-84.
Kingdom, J., Huppertz, B., Seaward, G. and Kaufmann, P. 2000. Development of 
the placental villous tree and its consequences for fetal growth. EurJ Obstet 
Gynecol Reprod Biol 92(1), pp. 35-43.
Kinoshita, T., Yadegari, R., Harada, J. J., Goldberg, R. B. and Fischer, R. L.
1999. Imprinting of the MEDEA polycomb gene in the Arabidopsis endosperm. 
Plant Cell 11(10), pp. 1945-1952.
Kishino, T., Lalande, M. and Wagstaff, J. 1997. UBE3A/E6-AP mutations cause 
Angelman syndrome. Nat Genet 15(1), pp. 70-73.
Knoll, J. H., Nicholls, R. D., Magenis, R. E., Graham, J. M., Jr., Lalande, M. and 
Latt, S. A. 1989. Angelman and Prader-Willi syndromes share a common 
chromosome 15 deletion but differ in parental origin of the deletion. Am J Med 
Genet 32(2), pp. 285-290.
291
Koch, C. A. and Platt, J. L. 2007. T cell recognition and immunity in the fetus and 
mother. Cell Immunol 248(1), pp. 12-17.
Kok, J. H., den Ouden, A. L., Verloove-Vanhorick, S. P. and Brand, R. 1998. 
Outcome of very preterm small for gestational age infants: the first nine years of 
life. B rJ Obstet Gynaecol 105(2), pp. 162-168.
Kono, T. 2006. Genomic imprinting is a barrier to parthenogenesis in mammals. 
Cytogenet Genome Res 113(1-4), pp. 31-35.
Kono, T., Obata, Y., Wu, Q., Niwa, K., Ono, Y., Yamamoto, Y., Park, E. S., Seo,
J. S. and Ogawa, H. 2004. Birth of parthenogenetic mice that can develop to 
adulthood. Nature 428(6985), pp. 860-864.
Kono, T., Sotomaru, Y., Katsuzawa, Y. and Dandolo, L. 2002. Mouse 
parthenogenetic embryos with monoallelic H19 expression can develop to day 
17.5 of gestation. Dev Biol 243(2), pp. 294-300.
Kraut, N., Snider, L., Chen, C. M., Tapscott, S. J. and Groudine, M. 1998. 
Requirement of the mouse l-mfa gene for placental development and skeletal 
patterning. Embo J 17(21), pp. 6276-6288.
Kromer, B., Finkenzeller, D., Wessels, J., Dveksler, G., Thompson, J. and 
Zimmermann, W. 1996. Coordinate expression of splice variants of the murine 
pregnancy-specific glycoprotein (PSG) gene family during placental development. 
EurJBiochem  242(2), pp. 280-287.
Kunath, T., Strumpf, D. and Rossant, J. 2004. Early trophoblast determination 
and stem cell maintenance in the mouse--a review. Placenta 25 Suppl A, pp. 
S32-38.
Lalande, M. 1997. Parental imprinting and human disease. Annu Rev Genet 30, 
pp. 173-195.
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., 
Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., 
Heaford, A., Howland, J. et al. 2001. Initial sequencing and analysis of the human 
genome. Nature 409(6822), pp. 860-921.
Lau, M. M., Stewart, C. E., Liu, Z., Bhatt, H., Rotwein, P. and Stewart, C. L. 1994. 
Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor 
results in fetal overgrowth and perinatal lethality. Genes Dev 8(24), pp. 2953- 
2963.
Law, C. M., Barker, D. J., Osmond, C., Fall, C. H. and Simmonds, S. J. 1992. 
Early growth and abdominal fatness in adult life. J Epidemiol Community Health 
46(3), pp. 184-186.
292
Law, C. M., de Swiet, M., Osmond, C., Fayers, P. M., Barker, D. J., Cruddas, A. 
M. and Fall, C. H. 1993. Initiation of hypertension in utero and its amplification 
throughout life. BMJ 306(6869), pp. 24-27.
Lawler, S. D., Povey, S., Fisher, R. A. and Pickthall, V. J. 1982. Genetic studies 
on hydatidiform moles. II. The origin of complete moles. Ann Hum Genet 46(Pt 
3), pp. 209-222.
Lawson, K. A. and Pedersen, R. A. 1987. Cell fate, morphogenetic movement 
and population kinetics of embryonic endoderm at the time of germ layer 
formation in the mouse. Development 101(3), pp. 627-652.
Lee, M. H., Reynisdottir, I. and Massague, J. 1995. Cloning of p57KIP2, a cyclin- 
dependent kinase inhibitor with unique domain structure and tissue distribution. 
Genes Dev 9(6), pp. 639-649.
Lee, M. P., Brandenburg, S., Landes, G. M., Adams, M., Miller, G. and Feinberg, 
A. P. 1999a. Two novel genes in the center of the 11 p15 imprinted domain 
escape genomic imprinting. Hum Mol Genet 8(4), pp. 683-690.
Lee, M. P., DeBaun, M. R., Mitsuya, K., Galonek, H. L., Brandenburg, S., 
Oshimura, M. and Feinberg, A. P. 1999b. Loss of imprinting of a paternally 
expressed transcript, with antisense orientation to KVLQT1, occurs frequently in 
Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II 
imprinting. Proc Natl Acad Sci U S A  96(9), pp. 5203-5208.
Lefebvre, L., Viville, S., Barton, S. C., Ishino, F., Keverne, E. B. and Surani, M. A. 
1998. Abnormal maternal behaviour and growth retardation associated with loss 
of the imprinted gene Mest. Nat Genet 20(2), pp. 163-169.
Leger, J., Limoni, C. and Czernichow, P. 1997. Prediction of the outcome of 
growth at 2 years of age in neonates with intra-uterine growth retardation. Early 
Hum D e v 48(3), pp. 211-223.
Leighton, P. A., Ingram, R. S., Eggenschwiler, J., Efstratiadis, A. and Tilghman,
S. M. 1995a. Disruption of imprinting caused by deletion of the H19 gene region 
in mice. Nature 375(6526), pp. 34-39.
Leighton, P. A., Saam, J. R., Ingram, R. S., Stewart, C. L. and Tilghman, S. M. 
1995b. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 
9(17), pp. 2079-2089.
Leiter, E. H. 1989. The genetics of diabetes susceptibility in mice. FASEB J 
3(11),’pp. 2231-2241.
Lemmon, M. A. and Ferguson, K. M. 2000. Signal-dependent membrane 
targeting by pleckstrin homology (PH) domains. Biochem J 350 Pt 1, pp. 1-18.
293
Lescisin, K. R., Varmuza, S. and Rossant, J. 1988. Isolation and characterization 
of a novel trophoblast-specific cDNA in the mouse. Genes Dev 2(12A), pp. 1639- 
1646.
Lewis, A. and Reik, W. 2006. How imprinting centres work. Cytogenet Genome 
Res 113(1-4), pp. 81-89.
Li, E., Beard, C. and Jaenisch, R. 1993. Role for DNA methylation in genomic 
imprinting. Nature 366(6453), pp. 362-365.
Li, Y. and Behringer, R. R. 1998. Esx1 is an X-chromosome-imprinted regulator 
of placental development and fetal growth. Nat Genet 20(3), pp. 309-311.
Lin, C. C. and Santolaya-Forgas, J. 1998. Current concepts of fetal growth 
restriction: part I. Causes, classification, and pathophysiology. Obstet Gynecol 
92(6), pp. 1044-1055.
Lin, C. C., Su, S. J. and River, L. P. 1991. Comparison of associated high-risk 
factors and perinatal outcome between symmetric and asymmetric fetal 
intrauterine growth retardation. Am J Obstet Gynecol 164(6 Pt 1), pp. 1535-1541; 
discussion 1541-1532.
Livak, K. J. and Schmittgen, T. D. 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25(4), pp. 402-408.
Loos, R. J., Beunen, G., Fagard, R., Derom, C. and Vlietinck, R. 2001. Birth 
weight and body composition in young adult m en-a prospective twin study. IntJ 
Obes Relat Metab Disord 25(10), pp. 1537-1545.
Lopez, M. F., Dikkes, P., Zurakowski, D. and Villa-Komaroff, L. 1996. Insulin-like 
growth factor II affects the appearance and glycogen content of glycogen cells in 
the murine placenta. Endocrinology 137(5), pp. 2100-2108.
Lubchenco, L. O., Hansman, C., Dressier, M. and Boyd, E. 1963. Intrauterine 
Growth As Estimated From Liveborn Birth-Weight Data At 24 To 42 Weeks Of 
Gestation. Pediatrics 32, pp. 793-800.
Luedi, P. P., Hartemink, A. J. and Jirtle, R. L. 2005. Genome-wide prediction of 
imprinted murine genes. Genome Res 15(6), pp. 875-884.
Lumbers, E. R., Yu, Z. Y. and Gibson, K. J. 2001. The selfish brain and the 
barker hypothesis. Clin Exp Pharmacol Physiol 28(11), pp. 942-947.
Lyon, M. F. 1961. Gene action in the X-chromosome of the mouse (Mus 
musculus L.). Nature 190, pp. 372-373.
Ma, D., Shield, J. P., Dean, W., Leclerc, I., Knauf, C., Burcelin, R. R., Rutter, G.
A. and Kelsey, G. 2004. Impaired glucose homeostasis in transgenic mice
294
expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin 
Invest 114(3), pp. 339-348.
Maeda, N. and Hayashizaki, Y. 2006. Genome-wide survey of imprinted genes. 
Cytogenet Genome Res 113(1-4), pp. 144-152.
Malassine, A., Frendo, J. L. and Evain-Brion, D. 2003. A comparison of placental 
development and endocrine functions between the human and mouse model. 
Hum Reprod Update 9(6), pp. 531-539.
Mancini-Dinardo, D., Steele, S. J., Levorse, J. M., Ingram, R. S. and Tilghman, S. 
M. 2006. Elongation of the Kcnq1ot1 transcript is required for genomic imprinting 
of neighboring genes. Genes Dev 20(10), pp. 1268-1282.
Mandruzzato, G., Antsaklis, A., Botet, F., Chervenak, F. A., Figueras, F., 
Grunebaum, A., Puerto, B., Skupski, D. and Stanojevic, M. 2008. Intrauterine 
restriction (IUGR). J Perinat Med 36(4), pp. 277-281.
Mann, J. R. 2001. Imprinting in the germ line. Stem Cells 19(4), pp. 287-294.
Mann, J. R. and Lovell-Badge, R. H. 1984. Inviability of parthenogenones is 
determined by pronuclei, not egg cytoplasm. Nature 310(5972), pp. 66-67.
Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, 
J. W. and Elledge, S. J. 1995. p57KIP2, a structurally distinct member of the 
p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 
9(6), pp. 650-662.
McGrath, J. and Solter, D. 1984. Completion of mouse embryogenesis requires 
both the maternal and paternal genomes. Cell 37(1), pp. 179-183.
Mclntire, D. D., Bloom, S. L., Casey, B. M. and Leveno, K. J. 1999. Birth weight in 
relation to morbidity and mortality among newborn infants. N Engl J Med 340(16), 
pp. 1234-1238.
McLaren, A. 1965. Genetic and Environmental Effects on Foetal and Placental 
Growth in Mice. J Reprod Fertil 9, pp. 79-98.
McLaughlin, K. J., Szabo, P., Haegel, H. and Mann, J. R. 1996. Mouse embryos 
with paternal duplication of an imprinted chromosome 7 region die at 
midgestation and lack placental spongiotrophoblast. Development 122(1), pp. 
265-270.
McMillen, I. C. and Robinson, J. S. 2005. Developmental origins of the metabolic 
syndrome: prediction, plasticity, and programming. Physiol Rev 85(2), pp. 571- 
633.
McMinn, J., Wei, M., Schupf, N., Cusmai, J., Johnson, E. B., Smith, A. C., 
Weksberg, R., Thaker, H. M. and Tycko, B. 2006. Unbalanced placental
295
expression of imprinted genes in human intrauterine growth restriction. Placenta 
27(6-7), pp. 540-549.
McNeely, M. J., Fujimoto, W. Y., Leonetti, D. L., Tsai, E. C. and Boyko, E. J.
2007. The association between birth weight and visceral fat in middle-age adults. 
Obesity (Silver Spring) 15(4), pp. 816-819.
Miyamoto, T., Hasuike, S., Jinno, Y., Soejima, H., Yun, K., Miura, K., Ishikawa,
M. and Niikawa, N. 2002. The human ASCL2 gene escaping genomic imprinting 
and its expression pattern. J Assist Reprod Genet 19(5), pp. 240-244.
Miyoshi, N., Kuroiwa, Y., Kohda, T., Shitara, H., Yonekawa, H., Kawabe, T., 
Hasegawa, H., Barton, S. C., Surani, M. A., Kaneko-lshino, T. and Ishino, F.
1998. Identification of the Meg1/Grb10 imprinted gene on mouse proximal 
chromosome 11, a candidate for the Silver-Russell syndrome gene. Proc Natl 
AcadSci U S A  95(3), pp. 1102-1107.
Mochizuki, A., Takeda, Y. and Iwasa, Y. 1996. The evolution of genomic 
imprinting. Genetics 144(3), pp. 1283-1295.
Monk, D., Arnaud, P., Apostolidou, S., Hills, F. A., Kelsey, G., Stanier, P., Feil, R. 
and Moore, G. E. 2006. Limited evolutionary conservation of imprinting in the 
human placenta. Proc Natl Acad Sci U S A  103(17), pp. 6623-6628.
Monk, D. and Moore, G. E. 2004. Intrauterine growth restriction-genetic causes 
and consequences. Semin Fetal Neonatal Med 9(5), pp. 371-378.
Montoliu, L., Chavez, S. and Vidal, M. 2000. Variegation associated with lacZ in 
transgenic animals: a warning note. Transgenic Res 9(3), pp. 237-239.
Moore, T. 1994. Refusing the ovarian time bomb. Trends Genet 10(10), pp. 347- 
349.
Moore, T. 2001. Genetic conflict, genomic imprinting and establishment of the 
epigenotype in relation to growth. Reproduction 122(2), pp. 185-193.
Moore, T., Constancia, M., Zubair, M., Bailleul, B., Feil, R., Sasaki, H. and Reik, 
W. 1997. Multiple imprinted sense and antisense transcripts, differential 
methylation and tandem repeats in a putative imprinting control region upstream 
of mouse Igf2. Proc Natl Acad Sci U S A  94(23), pp. 12509-12514.
Moore, T. and Haig, D. 1991. Genomic imprinting in mammalian development: a 
parental tug-of-war. Trends Genet 7(2), pp. 45-49.
Morison, I. M., Ramsay, J. P. and Spencer, H. G. 2005. A census of mammalian 
imprinting. Trends Genet 21(8), pp. 457-465.
Morison, I. M. and Reeve, A. E. 1998. A catalogue of imprinted genes and 
parent-of-origin effects in humans and animals. Hum Mol Genet 7(10), pp. 1599- 
1609.
296
Mostoslavsky, R., Alt, F. W. and Rajewsky, K. 2004. The lingering enigma of the 
allelic exclusion mechanism. Cell 118(5), pp. 539-544.
Murrell, A., Heeson, S. and Reik, W. 2004. Interaction between differentially 
methylated regions partitions the imprinted genes Igf2 and H19 into parent- 
specific chromatin loops. Nat Genet 36(8), pp. 889-893.
Nagahama, H., Hatakeyama, S., Nakayama, K., Nagata, M., Tomita, K. and 
Nakayama, K. 2001. Spatial and temporal expression patterns of the cyclin- 
dependent kinase (CDK) inhibitors p27Kip1 and p57Kip2 during mouse 
development. Anat Embryol (Berl) 203(2), pp. 77-87.
Nagy, A., Gocza, E., Diaz, E. M., Prideaux, V. R., Ivanyi, E., Markkula, M. and 
Rossant, J. 1990. Embryonic stem cells alone are able to support fetal 
development in the mouse. Development 110(3), pp. 815-821.
Nicholls, R. D., Knoll, J. H., Glatt, K., Hersh, J. H., Brewster, T. D., Graham, J.
M., Jr., Wurster-Hill, D., Wharton, R. and Latt, S. A. 1989. Restriction fragment 
length polymorphisms within proximal 15q and their use in molecular 
cytogenetics and the Prader-Willi syndrome. Am J Med Genet 33(1), pp. 66-77.
Niswander, L. and Martin, G. R. 1992. Fgf-4 expression during gastrulation, 
myogenesis, limb and tooth development in the mouse. Development 114(3), pp. 
755-768.
Nolan, C. M., Killian, J. K., Petitte, J. N. and Jirtle, R. L. 2001. Imprint status of 
M6P/IGF2R and IGF2 in chickens. Dev Genes Evol 211(4), pp. 179-183.
O'Neill, M. J. 2005. The influence of non-coding RNAs on allele-specific gene 
expression in mammals. Hum Mol Genet 14 Spec No 1, pp. R113-120.
Oakey, R. J. and Beechey, C. V. 2002. Imprinted genes: identification by 
chromosome rearrangements and post-genomic strategies. Trends Genet 18(7), 
pp. 359-366.
Okano, M., Bell, D. W., Haber, D. A. and Li, E. 1999. DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian 
development. Cell 99(3), pp. 247-257.
Ong, K. K., Ahmed, M. L., Emmett, P. M., Preece, M. A. and Dunger, D. B. 2000. 
Association between postnatal catch-up growth and obesity in childhood: 
prospective cohort study. Bmj 320(7240), pp. 967-971.
Ono, R., Kobayashi, S., Wagatsuma, H., Aisaka, K., Kohda, T., Kaneko-lshino, T. 
and Ishino, F. 2001. A retrotransposon-derived gene, PEG10, is a novel 
imprinted gene located on human chromosome 7q21. Genomics 73(2), pp. 232- 
237.
297
Ono, R., Nakamura, K., Inoue, K., Naruse, M., Usami, T., Wakisaka-Saito, N., 
Hino, T., Suzuki-Migishima, R., Ogonuki, N., Miki, H., Kohda, T., Ogura, A., 
Yokoyama, M., Kaneko-lshino, T. and Ishino, F. 2006. Deletion of Peg10, an 
imprinted gene acquired from a retrotransposon, causes early embryonic 
lethality. Nat Genet 38(1), pp. 101-106.
Orr, H. A. 1995. Somatic mutation favors the evolution of diploidy. Genetics 
139(3), pp. 1441-1447.
Osmond, C., Barker, D. J., Winter, P. D., Fall, C. H. and Simmonds, S. J. 1993. 
Early growth and death from cardiovascular disease in women. Bmj 307(6918), 
pp. 1519-1524.
Otto, S. P. and Goldstein, D. B. 1992. Recombination and the evolution of 
diploidy. Genetics 131(3), pp. 745-751.
Ozanne, S. E. and Hales, C. N. 2004. Lifespan: catch-up growth and obesity in 
male mice. Nature 427(6973), pp. 411-412.
Ozanne, S. E., Lewis, R., Jennings, B. J. and Hales, C. N. 2004. Early 
programming of weight gain in mice prevents the induction of obesity by a highly 
palatable diet. Clin Sci (Lond) 106(2), pp. 141-145.
Ozcelik, T., Leff, S., Robinson, W., Donlon, T., Lalande, M., Sanjines, E., 
Schinzel, A. and Francke, U. 1992. Small nuclear ribonucleoprotein polypeptide 
N (SNRPN), an expressed gene in the Prader-Willi syndrome critical region. Nat 
Genet 2(4), pp. 265-269.
Palmieri, S. L., Peter, W., Hess, H. and Scholer, H. R. 1994. Oct-4 transcription 
factor is differentially expressed in the mouse embryo during establishment of the 
first two extraembryonic cell lineages involved in implantation. Dev Biol 166(1), 
pp. 259-267.
Parsons, T. J., Power, C. and Manor, O. 2001. Fetal and early life growth and 
body mass index from birth to early adulthood in 1958 British cohort: longitudinal 
study. BMJ 323(7325), pp. 1331-1335.
Pauler, F. M. and Barlow, D. P. 2006. Imprinting mechanisms--it only takes two. 
Genes Dev 20(10), pp. 1203-1206.
Pauler, F. M., Koerner, M. V. and Barlow, D. P. 2007. Silencing by imprinted 
noncoding RNAs: is transcription the answer? Trends Genet 23(6), pp. 284-292.
Paulsen, M., Davies, K. R., Bowden, L. M., Villar, A. J., Franck, O., Fuermann,
M., Dean, W. L., Moore, T. F., Rodrigues, N., Davies, K. E., Hu, R. J., Feinberg, 
A. P., Maher, E. R., Reik, W. and Walter, J. 1998. Syntenic organization of the 
mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann 
syndrome region in chromosome 11p15.5. Hum Mol Genet 7(7), pp. 1149-1159.
298
Paulsen, M., El-Maarri, O., Engemann, S., Strodicke, M., Franck, O., Davies, K., 
Reinhardt, R., Reik, W. and Walter, J. 2000. Sequence conservation and 
variability of imprinting in the Beckwith-Wiedemann syndrome gene cluster in 
human and mouse. Hum Mol Genet 9(12), pp. 1829-1841.
Paulsen, M., Khare, T., Burgard, C., Tierling, S. and Walter, J. 2005. Evolution of 
the Beckwith-Wiedemann syndrome region in vertebrates. Genome Res 15(1), 
pp. 146-153.
Pedersen, R. A. 1986. Potency, lineage and allocation in preimplantation mouse 
embryos from Experimental approaches to mammalian embryonic development. 
Cambridge University Press.
Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, 
T. and Collins, F. 1995. Effects of the obese gene product on body weight 
regulation in ob/ob mice. Science 269(5223), pp. 540-543.
Peters, J. and Beechey, C. 2004. Identification and characterisation of imprinted 
genes in the mouse. Brief Fund Genomic Proteomic 2(4), pp. 320-333.
Petry, C. J., Dorling, M. W., Pawlak, D. B., Ozanne, S. E. and Hales, C. N. 2001. 
Diabetes in old male offspring of rat dams fed a reduced protein diet. IntJ Exp 
Diabetes Res 2(2), pp. 139-143.
Pfeifer, K. 2000. Mechanisms of genomic imprinting. Am J Hum Genet 67(A), pp. 
777-787.
Ping, A. J., Reeve, A. E., Law, D. J., Young, M. R., Boehnke, M. and Feinberg, A. 
P. 1989. Genetic linkage of Beckwith-Wiedemann syndrome to 11 p15. Am J Hum 
Genet 44(5), pp. 720-723.
Plagge, A., Isles, A. R., Gordon, E., Humby, T., Dean, W., Gritsch, S., Fischer- 
Colbrie, R., Wilkinson, L. S. and Kelsey, G. 2005. Imprinted Nesp55 influences 
behavioral reactivity to novel environments. Mol Cell Biol 25(8), pp. 3019-3026.
Platz, E. and Newman, R. 2008. Diagnosis of IUGR: traditional biometry. Semin 
Perinatol 32(3), pp. 140-147.
Prawitt, D., Enklaar, T., Klemm, G., Gartner, B., Spangenberg, C., Winterpacht, 
A., Higgins, M., Pelletier, J. and Zabel, B. 2000. Identification and 
characterization of MTR1, a novel gene with homology to melastatin (MLSN1) 
and the trp gene family located in the BWS-WT2 critical region on chromosome 
11 p15.5 and showing allele-specific expression. Hum Mol Genet 9(2), pp. 203- 
216.
Qian, N., Frank, D., O'Keefe, D., Dao, D., Zhao, L., Yuan, L., Wang, Q., Keating, 
M., Walsh, C. and Tycko, B. 1997. The IPL gene on chromosome 11 p15.5 is 
imprinted in humans and mice and is similar to TDAG51, implicated in Fas 
expression and apoptosis. Hum Mol Genet 6( 12), pp. 2021-2029.
299
Rainier, S., Johnson, L. A., Dobry, C. J., Ping, A. J., Grundy, P. E. and Feinberg, 
A. P. 1993. Relaxation of imprinted genes in human cancer. Nature 362(6422), 
pp. 747-749.
Rampon, C., Prandini, M. H., Bouillot, S., Pointu, H., Tillet, E., Frank, R., Vernet, 
M. and Huber, P. 2005. Protocadherin 12 (VE-cadherin 2) is expressed in 
endothelial, trophoblast, and mesangial cells. Exp Cell Res 302(1), pp. 48-60.
Ravelli, A. C., van Der Meulen, J. H., Osmond, C., Barker, D. J. and Bleker, O. P.
1999. Obesity at the age of 50 y in men and women exposed to famine 
prenatally. Am J Clin Nutr 70(5), pp. 811-816.
Rawn, S. M. and Cross, J. C. 2008. The evolution, regulation, and function of 
placenta-specific genes. Annu Rev Cell Dev Biol 24, pp. 159-181.
Redline, R. W., Chernicky, C. L., Tan, H. Q., Man, J. and llan, J. 1993. Differential 
expression of insulin-like growth factor-ll in specific regions of the late (post day 
9.5) murine placenta. Mol Reprod Dev 36(2), pp. 121-129.
Reik, W., Collick, A., Norris, M. L., Barton, S. C. and Surani, M. A. 1987.
Genomic imprinting determines methylation of parental alleles in transgenic mice. 
Nature 328(6127), pp. 248-251.
Reik, W., Constancia, M., Fowden, A., Anderson, N., Dean, W., Ferguson-Smith,
A., Tycko, B. and Sibley, C. 2003. Regulation of supply and demand for maternal 
nutrients in mammals by imprinted genes. J Physiol 547(Pt 1), pp. 35-44.
Reik, W., Dean, W. and Walter, J. 2001. Epigenetic reprogramming in 
mammalian development. Science 293(5532), pp. 1089-1093.
Reik, W. and Walter, J. 2001a. Evolution of imprinting mechanisms: the battle of 
the sexes begins in the zygote. Nat Genet 27(3), pp. 255-256.
Reik, W. and Walter, J. 2001b. Genomic imprinting: parental influence on the 
genome. Nat Rev Genet 2(1), pp. 21-32.
Renfree, M. B., Ager, E. I., Shaw, G. and Pask, A. J. 2008. Genomic imprinting in 
marsupial placentation. Reproduction 136(5), pp. 523-531.
Richardus, J. H., Graafmans, W. C., Verloove-Vanhorick, S. P. and Mackenbach, 
J. P. 2003. Differences in perinatal mortality and suboptimal care between 10 
European regions: results of an international audit. Bjog 110(2), pp. 97-105.
Riley, P., Anson-Cartwright, L. and Cross, J. C. 1998. The Handl bHLH 
transcription factor is essential for placentation and cardiac morphogenesis. Nat 
Genet 18(3), pp. 271-275.
Ripoche, M. A., Kress, C., Poirier, F. and Dandolo, L. 1997. Deletion of the H19 
transcription unit reveals the existence of a putative imprinting control element. 
Genes Dev 11(12), pp. 1596-1604.
300
Robertson, G., Garrick, D., Wu, W., Kearns, M., Martin, D. and Whitelaw, E.
1995. Position-dependent variegation of globin transgene expression in mice. 
Proc Natl Acad Sci U S A  92(12), pp. 5371-5375.
Rodriguez, T. A., Sparrow, D. B., Scott, A. N., Withington, S. L., Preis, J. I., 
Michalicek, J., Clements, M., Tsang, T. E., Shioda, T., Beddington, R. S. and 
Dunwoodie, S. L. 2004. Cited 1 is required in trophoblasts for placental 
development and for embryo growth and survival. Mol Cell Biol 24(1), pp. 228- 
244.
Rossant, J. and Cross, J. C. 2001. Placental development: lessons from mouse 
mutants. Nat Rev Genet 2(7), pp. 538-548.
Rossant, J., Guillemot, F., Tanaka, M., Latham, K., Gertenstein, M. and Nagy, A.
1998. Mash2 is expressed in oogenesis and preimplantation development but is 
not required for blastocyst formation. Mech Dev 73(2), pp. 183-191.
Rougier, N. and Werb, Z. 2001. Minireview: Parthenogenesis in mammals. Mol 
Reprod Dev  59(4), pp. 468-474.
Saba-EI-Leil, M. K., Vella, F. D., Vernay, B., Voisin, L., Chen, L., Labrecque, N., 
Ang, S. L. and Meloche, S. 2003. An essential function of the mitogen-activated 
protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4(10), pp. 
964-968.
Salas, M., John, R., Saxena, A., Barton, S., Frank, D., Fitzpatrick, G., Higgins, M. 
J. and Tycko, B. 2004. Placental growth retardation due to loss of imprinting of 
Phlda2. Mech Dev 121(10), pp. 1199-1210.
Sapienza, C., Peterson, A. C., Rossant, J. and Balling, R. 1987. Degree of 
methylation of transgenes is dependent on gamete of origin. Nature 328(6127), 
pp. 251-254.
Saxena, A., Morozov, P., Frank, D., Musalo, R., Lemmon, M. A., Skolnik, E. Y. 
and Tycko, B. 2002. Phosphoinositide binding by the pleckstrin homology 
domains of Ipl and Tih 1. J Biol Chem 277(51), pp. 49935-49944.
Schoenherr, C. J., Levorse, J. M. and Tilghman, S. M. 2003. CTCF maintains 
differential methylation at the Igf2/H19 locus. Nat Genet 33(1), pp. 66-69.
Schulz, R., Menheniott, T. R., Woodfine, K., Wood, A. J., Choi, J. D. and Oakey, 
R. J. 2006. Chromosome-wide identification of novel imprinted genes using 
microarrays and uniparental disomies. Nucleic Acids Res 34(12), p. e88.
Scott, I. C., Anson-Cartwright, L., Riley, P., Reda, D. and Cross, J. C. 2000. The 
HAND1 basic helix-loop-helix transcription factor regulates trophoblast 
differentiation via multiple mechanisms. Mol Cell Biol 20(2), pp. 530-541.
301
Screen, M., Dean, W., Cross, J. C. and Hemberger, M. 2008. Cathepsin 
proteases have distinct roles in trophoblast function and vascular remodelling. 
Development 135(19), pp. 3311-3320.
Searle, A. G. and Beechey, C. V. 1990. Genome imprinting phenomena on 
mouse chromosome 7. Genet Res 56(2-3), pp. 237-244.
Sekita, Y., Wagatsuma, H., Nakamura, K., Ono, R., Kagami, M., Wakisaka, N., 
Hino, T., Suzuki-Migishima, R., Kohda, T., Ogura, A., Ogata, T., Yokoyama, M., 
Kaneko-lshino, T. and Ishino, F. 2008. Role of retrotransposon-derived imprinted 
gene, RtH, in the feto-maternal interface of mouse placenta. Nat Genet 40(2), pp. 
243-248.
Sibilia, M. and Wagner, E. F. 1995. Strain-dependent epithelial defects in mice 
lacking the EGF receptor. Science 269(5221), pp. 234-238.
Sibley, C. P., Coan, P. M., Ferguson-Smith, A. C., Dean, W., Hughes, J., Smith, 
P., Reik, W., Burton, G. J., Fowden, A. L. and Constancia, M. 2004. Placental- 
specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange 
characteristics of the mouse placenta. Proc Natl Acad Sci U S A  101(21), pp. 
8204-8208.
Sifianou, P. 2006. Small and growth-restricted babies: drawing the distinction. 
ActaPaediatr 95(12), pp. 1620-1624.
Simmons, D. G. and Cross, J. C. 2005. Determinants of trophoblast lineage and 
cell subtype specification in the mouse placenta. Dev Biol 284(1), pp. 12-24.
Simmons, D. G., Fortier, A. L. and Cross, J. C. 2007. Diverse subtypes and 
developmental origins of trophoblast giant cells in the mouse placenta. Dev Biol 
304(2), pp. 567-578.
Simmons, D. G., Natale, D. R., Begay, V., Hughes, M., Leutz, A. and Cross, J. C. 
2008a. Early patterning of the chorion leads to the trilaminar trophoblast cell 
structure in the placental labyrinth. Development 135(12), pp. 2083-2091.
Simmons, D. G., Rawn, S., Davies, A., Hughes, M. and Cross, J. C. 2008b. 
Spatial and temporal expression of the 23 murine Prolactin/Placental Lactogen- 
related qenes is not associated with their position in the locus. BMC Genomics 9, 
p. 352.
Simmons, R. A., Templeton, L. J. and Gertz, S. J. 2001. Intrauterine growth 
retardation leads to the development of type 2 diabetes in the rat. Diabetes 
50(10), pp. 2279-2286.
Smilinich, N. J., Day, C. D., Fitzpatrick, G. V., Caldwell, G. M., Lossie, A. C., 
Cooper, P. R., Smallwood, A. C., Joyce, J. A., Schofield, P. N., Reik, W.,
Nicholls, R. D., Weksberg, R., Driscoll, D. J., Maher, E. R., Shows, T. B. et at
1999. A maternally methylated CpG island in KvLQTI is associated with an
302
antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann 
syndrome. Proc Natl Acad Sci U S A  96(14), pp. 8064-8069.
Smith, R. J., Dean, W., Konfortova, G. and Kelsey, G. 2003. Identification of 
novel imprinted genes in a genome-wide screen for maternal methylation. 
Genome Res 13(4), pp. 558-569.
Solter, D. 1994. Refusing the ovarian time bomb. Trends Genet 10(10), pp. 346; 
author reply 348-349.
Sorhede Winzell, M. and Ahren, B. 2004. Glucagon-like peptide-1 and islet 
lipolysis. Horm Metab Res 36(11-12), pp. 795-803.
Spahn, L. and Barlow, D. P. 2003. An ICE pattern crystallizes. Nat Genet 35(1),
pp. 11-12.
Strumpf, D., Mao, C. A., Yamanaka, Y., Ralston, A., Chawengsaksophak, K., 
Beck, F. and Rossant, J. 2005. Cdx2 is required for correct cell fate specification 
and differentiation of trophectoderm in the mouse blastocyst. Development 
132(9), pp. 2093-2102.
Sturm, K. S., Flannery, M. L. and Pedersen, R. A. 1994. Abnormal development 
of embryonic and extraembryonic cell lineages in parthenogenetic mouse 
embryos. Dev Dyn 201(1), pp. 11-28.
Sun, F. L., Dean, W. L., Kelsey, G., Allen, N. D. and Reik, W. 1997. 
Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome. 
Nature 389(6653), pp. 809-815.
Surani, M. A. 1998. Imprinting and the initiation of gene silencing in the germ line. 
Cell 93(3), pp. 309-312.
Surani, M. A., Barton, S. C. and Norris, M. L. 1984. Development of reconstituted 
mouse eggs suggests imprinting of the genome during gametogenesis. Nature 
308(5959), pp. 548-550.
Surani, M. A., Barton, S. C. and Norris, M. L. 1986. Nuclear transplantation in the 
mouse: heritable differences between parental genomes after activation of the 
embryonic genome. Ce//45(1), pp. 127-136.
Surani, M. A., Barton, S. C. and Norris, M. L. 1987. Influence of parental 
chromosomes on spatial specificity in androgenetic— parthenogenetic chimaeras 
in the mouse. Nature 326(6111), pp. 395-397.
Surwit, R. S., Kuhn, C. M., Cochrane, C., McCubbin, J. A. and Feinglos, M. N. 
1988. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37(9), pp. 1163- 
1167.
Suzuki, S., Renfree, M. B., Pask, A. J., Shaw, G., Kobayashi, S., Kohda, T., 
Kaneko-lshino, T. and Ishino, F. 2005. Genomic imprinting of IGF2, p57(KIP2)
303
and PEG1/MEST in a marsupial, the tammar wallaby. Mech Dev 122(2), pp. 213- 
222 .
Swain, J. L., Stewart, T. A. and Leder, P. 1987. Parental legacy determines 
methylation and expression of an autosomal transgene: a molecular mechanism 
for parental imprinting. Cell 50(5), pp. 719-727.
Szabo, P., Tang, S. H., Rentsendorj, A., Pfeifer, G. P. and Mann, J. R. 2000. 
Maternal-specific footprints at putative CTCF sites in the H19 imprinting control 
region give evidence for insulator function. Curr Biol 10(10), pp. 607-610.
Szabo, P. E. and Mann, J. R. 1995. Biallelic expression of imprinted genes in the 
mouse germ line: implications for erasure, establishment, and mechanisms of 
genomic imprinting. Genes Dev 9(15), pp. 1857-1868.
Takagi, N. and Sasaki, M. 1975. Preferential inactivation of the paternally derived 
X chromosome in the extraembryonic membranes of the mouse. Nature 
256(5519), pp. 640-642.
Takahashi, K., Kobayashi, T. and Kanayama, N. 2000a. p57(Kip2) regulates the 
proper development of labyrinthine and spongiotrophoblasts. Mol Hum Reprod 
6(11), pp. 1019-1025.
Takahashi, K., Nakayama, K. and Nakayama, K. 2000b. Mice lacking a CDK 
inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J 
Biochem (Tokyo) 127(1), pp. 73-83.
Tanaka, M., Gertsenstein, M., Rossant, J. and Nagy, A. 1997. Mash2 acts cell 
autonomously in mouse spongiotrophoblast development. Dev Biol 190(1), pp. 
55-65.
Tanaka, S., Oda, M., Toyoshima, Y., Wakayama, T., Tanaka, M., Yoshida, N., 
Hattori, N., Ohgane, J., Yanagimachi, R. and Shiota, K. 2001. Placentomegaly in 
cloned mouse concepti caused by expansion of the spongiotrophoblast layer. Biol 
Reprod 65(6), pp. 1813-1821.
Tang, K. F., Wang, Y., Wang, P., Chen, M., Chen, Y., Hu, H. D., Hu, P., Wang,
B., Yang, W. and Ren, H. 2007. Upregulation of PHLDA2 in Dicer knockdown 
HEK293 cells. Biochim Biophys Acta.
Tarkowski, A. K., Witkowska, A. and Nowicka, J. 1970. Experimental 
partheonogenesis in the mouse. Nature 226(5241), pp. 162-165.
Tartaglia, L. A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., 
Richards, G. J., Campfield, L. A., Clark, F. T., Deeds, J., Muir, C., Sanker, S., 
Moriarty, A., Moore, K. J., Smutko, J. S. etal. 1995. Identification and expression 
cloning of a leptin receptor, OB-R. Cell 83(7), pp. 1263-1271.
304
Te Velde, S. J., Twisk, J. W., Van Mechelen, W. and Kemper, H. C. 2003. Birth 
weight, adult body composition, and subcutaneous fat distribution. Obes Res
11(2), pp. 202-208.
Thakur, N., Tiwari, V. K., Thomassin, H., Pandey, R. R., Kanduri, M., Gondor, A., 
Grange, T., Ohlsson, R. and Kanduri, C. 2004. An antisense RNA regulates the 
bidirectional silencing property of the Kcnql imprinting control region. Mol Cell 
Biol 24(18), pp. 7855-7862.
Thomson, J. A. and Solter, D. 1988. The developmental fate of androgenetic, 
parthenogenetic, and gynogenetic cells in chimeric gastrulating mouse embryos. 
Genes Dev  2(10), pp. 1344-1351.
Thorvaldsen, J. L., Duran, K. L. and Bartolomei, M. S. 1998. Deletion of the H19 
differentially methylated domain results in loss of imprinted expression of H19 
and Igf2. Genes Dev 12(23), pp. 3693-3702.
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, 
D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C. and et al. 1995. Targeted 
disruption of mouse EGF receptor: effect of genetic background on mutant 
phenotype. Science 269(5221), pp. 230-234.
Tremblay, K. D., Duran, K. L. and Bartolomei, M. S. 1997. A 5' 2-kilobase-pair 
region of the imprinted mouse H19 gene exhibits exclusive paternal methylation 
throughout development. Mol Cell Biol 17(8), pp. 4322-4329.
Tsang, P., Gilles, F., Yuan, L., Kuo, Y. H., Lupu, F., Samara, G., Moosikasuwan, 
J., Goye, A., Zelenetz, A. D., Selleri, L. and et al. 1995. A novel L23-related gene 
40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal 
and adult human tissues. Hum Mol Genet 4(9), pp. 1499-1507.
Tucker, K. L., Beard, C., Dausmann, J., Jackson-Grusby, L., Laird, P. W., Lei, H., 
Li, E. and Jaenisch, R. 1996. Germ-line passage is required for establishment of 
methylation and expression patterns of imprinted but not of nonimprinted genes. 
Genes Dev 10(8), pp. 1008-1020.
Tycko, B. 2006. Imprinted genes in placental growth and obstetric disorders. 
Cytogenet Genome Res 113(1-4), pp. 271-278.
Tycko, B. and Morison, I. M. 2002. Physiological functions of imprinted genes. J 
Cell Physiol 192(3), pp. 245-258.
Tzortzaki, E. G., Yang, M., Glass, D., Deng, L., Evan, A. P., Bledsoe, S. B., 
Stambrook, P. J., Sahota, A. and Tischfield, J. A. 2003. Impaired expression of 
an organic cation transporter, IMPT1, in a knockout mouse model for kidney 
stone disease. Urol Res 31(4), pp. 257-261.
Valsamakis, G., Kanaka-Gantenbein, C., Malamitsi-Puchner, A. and Mastorakos,
G. 2006. Causes of intrauterine growth restriction and the postnatal development 
of the metabolic syndrome. Ann N Y Acad Sci 1092, pp. 138-147.
305
Vandenbosche, R. C. and Kirchner, J. T. 1998. Intrauterine growth retardation. 
Am Fam Physician 58(6), pp. 1384-1390, 1393-1384.
Varmuza, S. and Mann, M. 1994. Genomic imprinting-defusing the ovarian time 
bomb. Trends Genet 10(4), pp. 118-123.
Verrey, F., Closs, E. I., Wagner, C. A., Palacin, M., Endou, H. and Kanai, Y.
2004. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 
447(5), pp. 532-542.
Verrey, F., Jack, D. L., Paulsen, I. T., Saier, M. H., Jr. and Pfeiffer, R. 1999. New 
glycoprotein-associated amino acid transporters. J Membr Biol 172(3), pp. 181- 
192.
Verrey, F., Meier, C., Rossier, G. and Kuhn, L. C. 2000. Glycoprotein-associated 
amino acid exchangers: broadening the range of transport specificity. Pflugers 
Arch 440(4), pp. 503-512.
Vickers, M. H., Breier, B. H., Cutfield, W. S., Hofman, P. L. and Gluckman, P. D.
2000. Fetal origins of hyperphagia, obesity, and hypertension and postnatal 
amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab 279(1), pp. 
E83-87.
Villar, J., Smeriglio, V., Martorell, R., Brown, C. H. and Klein, R. E. 1984. 
Heterogeneous growth and mental development of intrauterine growth-retarded 
infants during the first 3 years of life. Pediatrics 74(5), pp. 783-791.
Vinkenoog, R., Bushell, C., Spielman, M., Adams, S., Dickinson, H. G. and Scott, 
R. J. 2003. Genomic imprinting and endosperm development in flowering plants. 
Mol Biotechnol 25(2), pp. 149-184.
Wakisaka, N., Inoue, K., Ogonuki, N., Miki, H., Sekita, Y., Hanaki, K., Akatsuka, 
A., Kaneko-lshino, T., Ishino, F. and Ogura, A. 2008. Ultrastructure of placental 
hyperplasia in mice: comparison of placental phenotypes with three different 
etiologies. Placenta 29(8), pp. 753-759.
Walsh, C., Glaser, A., Fundele, R., Ferguson-Smith, A., Barton, S., Surani, M. A. 
and Ohlsson, R. 1994. The non-viability of uniparental mouse conceptuses 
correlates with the loss of the products of imprinted genes. Mech Dev 46(1), pp. 
55-62.
Wang, X., Sun, Q., McGrath, S. D., Mardis, E. R., Soloway, P. D. and Clark, A. G.
2008. Transcriptome-wide identification of novel imprinted genes in neonatal 
mouse brain. PLoS ONE  3(12), p. e3839.
Watanabe, D. and Barlow, D. P. 1996. Random and imprinted monoallelic 
expression. Genes Cells 1(9), pp. 795-802.
306
Watson, E. D. and Cross, J. C. 2005. Development of structures and transport 
functions in the mouse placenta. Physiology (Bethesda) 20, pp. 180-193.
Watts, P. C., Buley, K. R., Sanderson, S., Boardman, W., Ciofi, C. and Gibson, R. 
2006. Parthenogenesis in Komodo dragons. Nature 444(7122), pp. 1021-1022.
Weksberg, R., Shen, D. R., Fei, Y. L., Song, Q. L. and Squire, J. 1993. Disruption 
of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat 
Genet 5(2), pp. 143-150.
West, J. D., Frels, W. I., Chapman, V. M. and Papaioannou, V. E. 1977. 
Preferential expression of the maternally derived X chromosome in the mouse 
yolk sac. Cell 12(4), pp. 873-882.
Westbury, J., Watkins, M., Ferguson-Smith, A. C. and Smith, J. 2001. Dynamic 
temporal and spatial regulation of the cdk inhibitor p57(kip2) during embryo 
morphogenesis. Mech Dev 109(1), pp. 83-89.
Westerman, B. A., Poutsma, A., Looijenga, L. H., Wouters, D., van Wijk, I. J. and 
Oudejans, C. B. 2001. The Human Achaete Scute Homolog 2 gene contains two 
promotors, generating overlapping transcripts and encoding two proteins with 
different nuclear localization. Placenta 22(6), pp. 511-518.
Wu, Q., Ohsako, S., Ishimura, R., Suzuki, J. S. and Tohyama, C. 2004. Exposure 
of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
alters the methylation status of imprinted genes H19 and Igf2. Biol Reprod 70(6), 
pp. 1790-1797.
Wynne, F., Ball, M., McLellan, A. S., Dockery, P., Zimmermann, W. and Moore,
T. 2006. Mouse pregnancy-specific glycoproteins: tissue-specific expression and 
evidence of association with maternal vasculature. Reproduction 131(4), pp. 721- 
732.
Xie, T., Plagge, A., Gavrilova, O., Pack, S., Jou, W., Lai, E. W., Frontera, M., 
Kelsey, G. and Weinstein, L. S. 2006. The alternative stimulatory G protein alpha- 
subunit XLalphas is a critical regulator of energy and glucose metabolism and 
sympathetic nerve activity in adult mice. J Biol Chem 281(28), pp. 18989-18999.
Xin, Z., Soejima, H., Higashimoto, K., Yatsuki, H., Zhu, X., Satoh, Y., Masaki, Z., 
Kaneko, Y., Jinno, Y., Fukuzawa, R., Hata, J. and Mukai, T. 2000. A novel 
imprinted gene, KCNQ1DN, within the WT2 critical region of human chromosome 
11 p15.5 and its reduced expression in Wilms' tumors. J Biochem 128(5), pp. 847- 
853.
Yamaguchi, M., Ogren, L., Endo, H., Thordarson, G., Bigsby, R. M. and 
Talamantes, F. 1992. Production of mouse placental lactogen-l and placental 
lactogen-ll by the same giant cell. Endocrinology 131(4), pp. 1595-1602.
307
Yan, Y., Frisen, J., Lee, M. H., Massague, J. and Barbacid, M. 1997. Ablation of 
the CDK inhibitor p57Kip2 results in increased apoptosis and delayed 
differentiation during mouse development. Genes Dev 11(8), pp. 973-983.
Yoder, J. A., Walsh, C. P. and Bestor, T. H. 1997. Cytosine methylation and the 
ecology of intragenomic parasites. Trends Genet 13(8), pp. 335-340.
Yoshihashi, H., Maeyama, K., Kosaki, R., Ogata, T., Tsukahara, M., Goto, Y., 
Hata, J., Matsuo, N., Smith, R. J. and Kosaki, K. 2000. Imprinting of human 
GRB10 and its mutations in two patients with Russell-Silver syndrome. Am J 
Hum Genet 67(2), pp. 476-482.
Yu, S., Gavrilova, O., Chen, H., Lee, R., Liu, J., Pacak, K., Parlow, A. F., Quon,
M. J., Reitman, M. L. and Weinstein, L. S. 2000. Paternal versus maternal 
transmission of a stimulatory G-protein alpha subunit knockout produces opposite 
effects on energy metabolism. J Clin Invest 105(5), pp. 615-623.
Zechner, U., Hemberger, M., Constancia, M., Orth, A., Dragatsis, I., Luttges, A., 
Hameister, H. and Fundele, R. 2002. Proliferation and growth factor expression in 
abnormally enlarged placentas of mouse interspecific hybrids. Dev Dyn 224(2), 
pp. 125-134.
Zechner, U., Reule, M., Orth, A., Bonhomme, F., Strack, B., Guenet, Hameister,
H. and Fundele, R. 1996. An X-chromosome linked locus contributes to abnormal 
placental development in mouse interspecific hybrid. Nat Genet 12(4), pp. 398- 
403.
Zhang, P., Liegeois, N. J., Wong, C., Finegold, M., Hou, H., Thompson, J. C., 
Silverman, A., Harper, J. W., DePinho, R. A. and Elledge, S. J. 1997. Altered cell 
differentiation and proliferation in mice lacking p57KIP2 indicates a role in 
Beckwith-Wiedemann syndrome. Nature 387(6629), pp. 151-158.
Ziomek, C. A., Johnson, M. H. and Handyside, A. H. 1982. The developmental 
potential of mouse 16-cell blastomeres. J Exp Zool 221 (3), pp. 345-355.
Zubair, M., Hilton, K., Saam, J. R., Surani, M. A., Tilghman, S. M. and Sasaki, H. 
1997. Structure and expression of the mouse L23mrp gene downstream of the 
imprinted H19 gene: biallelic expression and lack of interaction with the H19 
enhancers. Genomics 45(2), pp. 290-296.
Zwart, R., Sleutels, F., Wutz, A., Schinkel, A. H. and Barlow, D. P. 2001. 
Bidirectional action of the Igf2r imprint control element on upstream and 
downstream imprinted genes. Genes Dev 15(18), pp. 2361-2366.
308
